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Introduction and outline of the thesis 

Ch pit ι 1 
General Introduction 
Microorganisms constantly challenge us When mechanical barriers such as the skin and 
mucosa fail in their role of keeping microorganisms outside the body, pathogenic 
microorganisms have a chance to invade the tissue and multiply When this occurs, host 
defense mechanisms that recognize the microorganisms are activated and these 
subsequently induce an optimal immune response to eliminate or control the pathogens 
Tailored immune responses are to be initiated, since infections with various microbes 
require different host defense strategies for defeating the invaders At the tissue level, 
resident macrophages are among the first types of cells that have to accomplish this task 
When they come in contact with pathogens and recognize them as dangerous, several 
actions are triggered they ingest and kill the microorganisms, they release activating 
cytokines, but probably most important, they will attract more cells of the innate immune 
system such as neutrophils and monocytes (which become exsudate macrophages) to the 
site of infection Together these cells orchestrate an effective response that will ultimately 
be able to clear the invading microorganisms If the innate immune response is not capable 
to control the microbiological threat, the adaptive immune response will come into play 
Adaptive immunity consists of humoral (B lymphocytes) and cellular (T lymphocytes) 
responses These responses are activated during a complex process of antigen presentation 
by immune cells (especially dendritic cells) When this stage is entered, there will be an 
intensive interplay between lymphocytes and other immune cells This interplay is heavily 
dependent on cytokines that shape and direct the immune response (Figure 1) 
Candida albicans is a commensal fungal microorganism that is often part of the flora residing 
in the human oral cavity and genital tract Under normal conditions Candida albicans will not 
cause disease However, when mucosal or skin barriers are damaged and/or the immune 
system is compromised, Candida albicans is able to cause disseminated infections that are 
associated with a high mortality, despite the availability of novel and effective antifungal 
drugs (1) 
In addition to these disseminated infections, a large number of patients suffer from mucosal 
Candida infections such as oropharyngeal or vaginal candidiasis In order to develop new 
strategies in the fight against Candida infection, a better understanding of the anti-Cand/da 
host defense is needed The aim of the present thesis is to elucidate the innate and adaptive 
defense mechanisms against Candida in order to provide insights that might contribute to 
the development of adjunctive immunomodulatory treatment options m patients with 
candidiasis 
Outline of the thesis 
The first section of the thesis focuses on "Innate pattern recognition of Candida albicans" 
and comprises the Chapters 2-4 In Chapter 2 we provide a general overview of host and 
fungal pathogen interactions and try to answer the question how innate immunity has 
achieved a certain degree of specificity and delivers a tailored response to various 
pathogens In 1989, the late Charles Janeway Jr argued that the early phases of host defense 
are regulated by receptors and ligands that in evolution preceded the development of 
clonally distributed receptors, encoded by rearrangement of genes (e g Τ- cell receptors and 
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Figure 1. Pathogenesis of host defense against Candida. 
The epithelia of the skin and mucous membranes form the first line of defense by posing primarily a 
mechanical barrier against the fungus, when Candida invades the tissues, professional phagocytic cells 
(neutrophils and mononuclear phagocytes) will phagocytose and kill the fungus. This Innate immune response 
can be followed by an adaptive response, which is initiated by cells (dendritic cells, macrophages and Β cells) 
that present antigen of the fungus. Memory Τ cells and naive Τ cells will be recruited and activated, and the 
cytokine profile that is present in the micro-environment will polarize the Τ helper lymphocyte response 
towards a predominant Thl , Th2 or Thl7 response. IL=lnterleukin; IFN=lnterferon. 
B-cell receptors), and that engagement of these receptors by microbial ligands would trigger 
innate non-clonal responses (2). The first molecules that were identified as such were the 
Toll-like receptors (TLRs), which now belong to the most studied classes of pattern 
recognition receptors (PRRs).They are named Toll like, because of their homology to Toll, a 
receptor identified in the fruit fly Drosophila melanogaster. Lemaitre et al. discovered in 
1996 that Toll had an essential role in the fly's immunity to fungal infection (3). There are 10 
Toll-like receptors expressed in humans and each of them has its own specificity of 
10 
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recognition of components of microorganisms. In the host defense against Candida, the role 
of TLR2,and TLR4 is well established, also based on research performed in our laboratory (4). 
In Chapters we investigated the importance of TLR9 in disseminated candidiasis, asking the 
question whether TLR9-/- mice would be more susceptible to invasive candidiasis, and if 
TLR9 plays a key role in cytokine responses against C. albicans. Similar questions were 
tackled in Chapter 4, in which we investigated the role of TLR1 and TLR6 in antifungal host 
defense in a murine model of invasive candidiasis. 
The second part of the thesis "The role of the inflammasome in host defense against 
Candida albicans" includes the Chapters 5-8. Activation of many TLRs results in de-novo 
production and subsequent intracellular accumulation of the inactive pro-form of the potent 
pro-inflammatory cytokine IL-lß. A second signal through a nucleotide-binding domain and 
leucine-rich repeat-containing protein (NLR) receptor activates a cascade of proteins (a 
'protein platform') called the inflammasome, which results in caspase-1 activation and 
subsequently processing of the TLR-induced pro-interleukin (IL)-lß into mature, bioactive IL-
lß. Dual triggering of TLR and NLR is believed to be necessary for the tight regulation of 
proinflammatory cytokines such as IL-lß (5). In Chapter 5 we give an introduction on the 
inflammasome and describe the differences in the regulation of IL-lß processing between 
monocytes and macrophages. Since IL-lß plays an important role in anti-Candida host 
defense (6), we wanted to dissect the pathways that are important for IL-lß production in 
response to Candida albicans, and we hypothesized that the inflammasome would play an 
important role in antifungal host defense. We addressed these issues in human monocytes 
in Chapter 6 and in a murine model of disseminated candidiasis in Chapter 7 and Chapter 8. 
The third part of the thesis "T helperl? lymphocytes and antifungal host defense" consists of 
the Chapters 8-13. Τ helper (Th) 17 lymphocytes have recently been described as a third 
subset of Τ helper lymphocytes, and these cells are important for both antimicrobial host 
defense and for the development of autoimmune diseases (7). In general, Thl7 responses 
are critical for mucosal production of defensins in response to Candida and for epithelial 
host defense against extracellular bacteria and fungi. This is discussed in detail in Chapter 9. 
In Chapter 10 we have addressed the question which components of Candida albicans and 
which receptors are important for the induction of a Thl7 response. Since it had been 
described that prostaglandins have synergistic effects together with IL-23 to induce Thl7 
responses (8), we investigated in Chapter 11 whether prostaglandin E2 also played an 
important role in the induction of the Thl7 response induced by a fungal pathogen such as 
C. albicans. Both protective and deleterious effects have been attributed to the Thl7 
response during fungal infection (9,10). We have explored whether this is true for the Thl7 
response in a murine model of disseminated candidiasis and in a murine model of 
inflammation-driven multi-organ failure in Chapter 12. In Chapter 13, we investigated the 
question to what extent the host defense against Aspergillus fumigatus, another important 
fungal pathogen, relies on the Thl7 response. 
The final part of the thesis "The inflammasome/Thl7 axis in clinical syndromes" is outlined in 
the Chapters 14-19. Patients with chronic granulomatous disease have a defect in NADPH-
oxidase of phagocytic cells and therefore are unable to generate reactive oxygen species 
(ROS) in these cells (11). It had been claimed that NADPH-dependent ROS are critical for 
inflammasome activation (12). In Chapter 14, we challenged this claim and investigated the 
11 
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activation of the mflammasome in patients with chronic granulomatous disease that are 
deficient in NADPH-dependent ROS 
The Thl7 response is associated with autoimmune diseases, such as multiple sclerosis (MS) 
and rheumatoid arthritis (RA) (7) Studies demonstrated a beneficial effect of rituximab, an 
anti-CD20 antibody that depletes Β cells Such an effect was completely unanticipated in 
these two Thl7 mediated diseases in which Β lymphocytes are not considered to play a role 
(13, 14) We hypothesized however that Β cells do have a key role in Thl7 responses and 
investigated this hypothesis in Chapter 15. 
In Chapter 16, we investigated the role of the Thl7 response m patients with the 
immunodefciency disorder hyper-lgE syndrome, since these patients are especially 
susceptible to mucocutaneous Candida infection and S aureus skin abscesses pneumonia 
(15), and these two pathogens are potent inducers of the Thl7 response m-vitro In Chapter 
17 we investigated five families that suffered from severe forms of autosomal chronic 
mucocutaneous candidiasis (CMC), a clinical syndrome in which the genetic background has 
been enigmatic We used a systematic functional approach to pinpoint the defects in the 
immunological pathways m CMC by integrating the knowledge that was obtained from the 
experiments performed during this thesis and from earlier work from our group 
As outlined m the introduction, new approaches are needed to improve the outcome of 
patients suffering from Candida infections In Chapter 18, I present an overview of novel 
strategies for the prevention and treatment of infections caused by Candida, with emphasis 
on the potential of novel immunotherapeutic approaches 
A summary of the findings and conclusions of this thesis is presented in Chapter 19. 
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Chapter 2 
Summary 
The recognition of fungi is mediated by germline pattern recognition receptors (PRRs) such 
as Toll-like receptors (TLRs) and C-type lectin receptors (CLRs) that interact with conserved 
structures of the microorganisms, the pathogen-associated molecular patterns (PAMPs). 
Subsequently, PRRs activate intracellular signals that collaborate for the efficient activation 
of the host defense. The specificity of these responses is achieved through the activation of a 
particular mosaic of PRRs, that is determined by the available fungal PAMPs and the innate 
immune cells involved. This will determine a divergence of the final type of reaction, and in 
this way the innate host defense has the capability to deliver tailored responses to each 
pathogen. 
Introduction 
The essence of the innate defense mechanism is the ability to recognize and eliminate 
microbial pathogens. This is mediated by a limited arsenal of pattern recognition receptors 
(PRRs) that are able to recognize conserved structures of microorganisms called pathogen-
associated molecular patterns (PAMPs). Several classes of PRRs have been described, among 
which Toll-like receptors (TLRs), C-type lectin receptors (CLRs), NOD-like receptors, and Rigl-
helicases. It is especially the first two classes of these receptors that have been suggested to 
play an important role in antifungal immunity. 
Fungal PAMPs 
Most components of the fungal cell wall are not found in mammals, and therefore, 
represent an ideal target for recognition as nonself. The fungal cell wall can be described as a 
dynamic, highly organized organelle that determines both the shape of the fungus and its 
viability. In general, the core structure of the fungal cell wall, as exemplified by the structure 
of Candida albicans cell wall, is composed of a skeleton of polysaccharide fibrils com- posed 
of ß-(l,3)-glucan that is covalently linked to ß-(l,6)-glucan and chitin (a ß-(l,4)-linked 
polymer of N- acetyl glucosamine), and is designed to function as a scaffold for the external 
protein layer. This outer layer consists of proteins that are mainly glycosylated through N-
linked (1) or O-linked mannosylation (2) (also called mannans). Although this basic model of 
the fungal cell wall is shared by many fungi, at the molecular level these structures differ 
between fungal species. In Aspergillus species an important component of the skeleton of 
the cell wall is galactomannan, while the outermost cell wall layer is composed of rodlet 
fascicles of hydrophobic proteins (hydrophobins) that contribute to the shielding properties 
of the cell wall (3). In Cryptococcus, a thick capsule of mannoproteins, galactoxylomannan 
and glucoronoxylomannan plays a crucial role for inhibiting recognition and activation of 
host defense mechanisms (4). This diversity will result in different qualities of PRR-ligand 
interactions and the activation of different sets of PRRs, leading to specific host responses. 
The role of PRRs in antifungal host defense 
When the host encounters live pathogenic fungi, the initial response by the innate immune 
system will be determined by the recognition of fungal cell wall components. Neutrophils, 
monocytes, and macrophages represent the first line of defense against fungal pathogens. 
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Later on, recognition of fungal structures by dendritic cells leads to the activation of specific 
immunity, especially T-cell-mediated. These various cell populations differ in their expression 
of TLRs and CLRs on the cell membrane, and are therefore capable of initiating different 
responses. 
TLRs 
The first suggestion for a role for TLRs in antifungal host defense was made by Lemaltre et 
al., who observed that Drosophila flies deficient in the Toll receptor rapidly succumbed to 
Aspergillus fumigatus infection, because of defective synthesis of the drosomycin defensin 
(5). Ligand recognition by the functionally equivalent TLRs induces the activation of kinase 
cascades in mammalian cells, and the nuclear translocation of transcription factors such as 
NF-KB, NF-AT, and IRF3, that induce gene expression and production of various chemokines 
and cytokines (6). Moreover, recently a human homolog of drosomycin called drosomycin-
like defensin has been described, that has activity against a variety of filamentous fungi, and 
is expressed mainly in the skin (7). Shortly after the discovery of TLRs, TLR2 and TLR6 were 
shown to be involved in the recognition of the fungal structure zymosan derived from 
Saccharomyces cerevisiae (8). Moreover, the adaptor molecule MyD88, that is shared by 
most TLRs, has proven to be crucial for antifungal defense by several in vivo studies (9-11), 
strongly suggesting that TLRs play a crucial role in host defense against fungi. 
TLR4 
TLR4 is one of the best studied PRRs, because of its role as the main receptor of bacterial 
lipopolysaccharides. In a murine experimental infection model of disseminated C. albicans 
infection, it has been shown that the absence of TLR4-mediated signaling resulted in 
increased susceptibility to the infection, decreased chemokine production, and impaired 
neutrophil recruitment (12). The effects on survival were challenged by a later study (13). 
Wang et al. suggested for the first time a role for TLR4 in the recognition of A. fumigatus 
(14), and subsequent studies have shown that TLR4 is involved in signaling and cytokine 
production in response to Aspergillus (9,15). These data were supported by a study showing 
that TLR4-/- mice died significantly sooner when they were infected with A. fumigatus 
conidia (9). TLR4 is also involved in the susceptibility to Pneumocystis pneumonia, with mice 
deficient in TLR4 having a defective cytokine production by alveolar macrophages leading to 
increased susceptibility to Pneumocystis infection (16). By contrast, the C. neoformans 
component glucuronoxylomannan binds to TLR4 and leads to translocation of NF-kB, but not 
to induction of cytokine production (17), and these findings were supported by the fact that 
TLR4 does not play a major role in cryptococcal host defense (18). 
Only limited knowledge exists regarding the nature of the fungal PAMPs that are recognized 
by TLR4. In addition to the work described above reporting the recognition of 
glucuronoxylomannan by TLR4, another study reported that TLR4 recognizes mannans from 
S. cerevisiae and C. albicans (19). A subsequent study found that short linear O-bound 
mannans of C. albicans are recognized by TLR4 and induce proinflammatory cytokines such 
as TNF (20). Overall, TLR4 appears to participate in antifungal host defense by recognizing 
mannan structures and mediating proinflammatory responses. 
20 
Chapter 2 
TLR2 
One of the first studies that investigated TLR2 in fungal host defense reported that blocking 
of TLR2 by specific antibodies resulted in decreased production of TNF and IL-lß after 
stimulation of monocytes by C. albicans (12). 
An additional study showed that TLR2-/- mice have a decreased production of TNF and MIP-
2, and reduced neutrophil recruitment after a challenge with Candida (21). However, two 
other studies found that TLR2-/-mice showed an increased resistance to disseminated 
candidiasis that was accompanied by decreased production of IL-10, and increased IL-12 and 
INFy production (9,22). In line with this, TLR2-deficient macrophages have shown to have an 
increased ability to contain C albicans (23). This immunomodulatory effects induced by TLR2 
were found to be mediated through the generation of T-regulatory cells with 
immunosuppressive potential (22,24). Evidence for an anti-inflammatory role for TLR2 in 
antifungal host defense is further supported by a recent study reporting that zymosan can 
tolerize DCs through a TLR2-mediated and dectin-1-mediated pathway involving MAPK/ERK 
(25). A limited role for TLR1 and especially TLR6, two receptors known for forming 
heterodimers with TLR2, has been recently reported in case of C. albicans recognition (26). 
In addition to recognition of C. albicans, TLR2 has been suggested to be involved in the 
recognition of A. fumigatus (15). However, TLR2-/-mice do not have an increased 
susceptibility to aspergillosis (9), and Wang et al. reported no role for TLR2 in the recognition 
of Aspergillus hyphae (14). The role of TLR2 in the recognition of C. neoformans is still not 
clear, because of differences in the results by the various investigators: one study reported 
that TLR2 can bind cryptococcal glucuronoxylomannan, but this does not lead to 
translocation of NF-KB (17); an additional study found that TLR2 can mediate cytokine 
production in response to C. neoformans (10); by contrast, Yauch et al. found that TLR2 was 
not involved in cryptococcal-induced cytokine production (11). In conclusion, TLR2 seems to 
be involved in the recognition of fungal pathogens, though disagreement persists regarding 
the precise components recognized, and the amplitude of the effects. Overall, TLR2 ligands 
seem to induce weaker proinflammatory effects than TLR4 ligands, and TLR2 has also been 
shown to have immunosuppressive effects, particularly in C. albicans host defense, through 
promoting environments that favor Th2-type or T-reg-type responses (22,24). 
TLR9 
Unmethylated CpG sequences are the natural ligands forTLR9, and several reports have now 
suggested that TLR9 can recognize fungal DNA. Blocking of TLR9 in human monocytes and 
TLR9-deficient mouse macrophages stimulated with C. albicans leads to a reduced 
production of cytokines, mainly IL-10 (27). Another study showed that TLR9 detects A. 
fumigatus DNA, resulting in the secretion of proinflammatory cytokines (28). The same 
observation has been made for C. neoformans DNA, which was able to trigger IL-12p40 and 
expression of CD40 upon stimulation in murine DCs (29). This study also found that 
cryptococcal DNA activated NF-kB in TLR9-transfected HEK239 cells. However, Bellocchio et 
al. have reported that TLR9-/- mice produced less IL-12 and more IL-4 and IL-10, but this had 
little effects on the overall mortality of the animals (9). In conclusion, most of the data 
available at this time suggest a role for TLR9 for the recognition of fungal DNA, but the 
magnitude of this effect for the overall antifungal defense is likely to be overshadowed by 
redundant signals induced by other PRRs. 
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CLRs 
CLRs comprise a large family of receptors, including dectin-1, the macrophage mannose 
receptor (MR), the dendritic cell-specific ICAM3-grabbing nonintegrin (DC-SIGN), dectin-2, 
and the circulating mannose binding lectin (MBL). These receptors share one or more 
carbohydrate recognition domains that were originally found in the mannose binding lectin 
and are evolutionary conserved. Importantly, over the recent years these receptors have 
been shown to be involved in fungal recognition and the modulation of the innate immune 
response. 
Dectin-1 
Dectin-1 recognizes ß-(l,3)-glucans through which mediates ligand uptake and phagocytosis, 
and is able to trigger production of both proinflammatory and anti-inflammatory cytokines 
(30). Dectin-1 signals through the kinase Syk and the adaptor CARD9, and this pathway has 
been shown to induce IL-2 and IL-10 in DCs (31). It has also been demonstrated that 
infection with C albicans induces CARD9-dependentThl7 cells (31), and cytokine production 
induced by C. albicans by both human peripheral blood mononuclear cells and murine 
macrophages is dependent on dectin-1 (32). Although dectin-1 signaling alone is sufficient to 
induce responses upon fungal recognition, several studies have emphasized that it is also 
able to cooperate with TLRs leading to synergistic proinflammatory responses. Two 
independent studies have shown that dectin-1 in collaboration with TLR2 triggers 
proinflammatory responses upon stimulation with C. albicans and zymosan (33,34), and 
recently dectin-1 has been found to amplify TLR4-dependent pathways in a Syk-dependent 
manner (35). Furthermore, dectin-1 and TLR2 collaborate for the phagocytosis of Aspergillus 
conidia (36), and A. fumigatus can activate the transcription factor AP-1 through a dectin-
1/Syk-dependent pathway (37). The first in vivo evidence that dectin-1 plays an important 
role in innate fungal host defense was reported by a study showing that blocking dectin-1 
leads to increased A. fumigatus fungal burden in the lung (38). Dectin-l-/-mice are more 
susceptible to infection with C. albicans, resulting in lower survival and increased fungal 
burdens (39). However, another study using a different strain of dectin-1-knockout mice 
could not confirm this for C. albicans infection, but found an increased susceptibility to 
Pneumocystis infection (40). No role for dectin-1 for the host defense to C neoformans has 
been observed (41). The adaptor molecule CARD9, involved in the dectin-1-signaling 
pathway, has also been shown to have a crucial role in the survival during disseminated 
candidiasis (42). These data suggest an important role for dectin-1 in antifungal immunity, 
either directly or through collaborative signaling with TLR2 and/or TLR4. 
Macrophage mannose receptor (MR) 
MR has various domains that can recognize oligosaccharides terminating in GlcNAc (chitin is 
a polymer of GlcNAc), fucose, and mannose. The MR has been implicated in the recognition 
of several fungi, including C. neoformans, C. albicans, and Pneumocystis. Recently, the role of 
the MR in C. albicans has been investigated using mutant Candida strains defective in 0-
linked and /V-linked mannans (20). This study showed that the MR recognizes branched N-
bound mannans from C. albicans and this extended the previous observation that the MR 
preferentially recognizes branched α-linked oligomannosides (43). In response to 
22 
Chapter 2 
Pneumocystis and C. neoformans, the MR activates NF-κΒ and leads to proinflammatory 
cytokine production (44,45). However, in the case of Pneumocystis the mannose receptor is 
also capable of inhibiting INF production, illustrating that the MR can act as a double-edged 
sword (44). 
In vivo data in mice defective for the MR are limited. Although one study suggested only a 
minor role for MR for the host defense against Candida infections (46), this study employed 
an intraperitoneal model of infection with relatively little relevance to the clinical situation. 
Another in vivo study on Pneumocystis infection in MR-/-mice also showed no difference in 
survival and only small defects in fungal resistance (47). 
Other CLRs 
DC-SIGN is primarily expressed on mature DCs and recognizes high-mannose structures in a 
calcium-dependent way. Recognition has been reported for the pathogenic fungi C. albicans 
(48) and A. fumigatus (49) and it mediates uptake and phagocytosis of fungal particles (48). 
A recent study suggests an immunosuppressive effect through stimulation of IL-10 
production. Dectin-2 is also a member of the CLR family and is mainly present on myeloid 
cells and maturing inflammatory monocytes, which recognizes high-mannose structures (50) 
and interacts with the FcyR to induce TNF in response to C albicans hyphae (51). Dectin-2 
can also recognize Trichophyton rubrum and Microsporum audouinii with preference to their 
hyphal components. Therefore, dectin-2 mainly seems to play a role in hyphal recognition, 
and is the first receptor described to produce proinflammatory cytokines in response to 
fungal hyphae (51). Galectin-3 is a receptor mainly expressed by macrophages, and it has 
been shown to be crucial for the recognition of the ß-mannosides of C. albicans, in close 
collaboration with TLR2 (52). Mannose binding lectin (MBL) is a soluble CLR that is secreted 
by the liver, which can bind to C. albicans (53) and A. fumigatus (54). MBL can also bind to 
acapsular cryptococcal strains at the level of the budding scar (55). MBL is mainly involved in 
fungal host defense because of its ability to opsonize fungal yeasts by activating the 
complement system (56). However, MBL-deficient mice do not show decreased survival to 
infection with C. albicans (57) or A. fumigatus (58), though a recent study has demonstrated 
that MBL administration in a murine model of invasive pulmonary aspergillosis can be 
protective (59). Recently, a new C-type lectin, Mincie, has been shown to participate in the 
recognition of C. albicans by macrophages. This receptor localizes to the phagocytic cup, but 
was not essential for phagocytosis. However, knockout mice that lacked this receptor were 
hypersusceptible to Candida infection, and macrophages in which the Mincie receptor was 
blocked generated significantly reduced levels of TNF when stimulated by Candida yeast 
cells. The nature of the PAMP that binds to this LR is not yet known (60). 
Interactions between PRRs 
Initial studies already appreciated that fungi are able to recruit different PRRs to activate 
specific arms of innate host defense (12). For example, recognition of C. albicans by 
monocytes and macrophages has been shown to be mediated by at least four recognition 
systems that sense fungal PAMPs of the C. albicans cell wall: recognition of /V-linked 
mannans by MR, recognition of O-linked mannans by TLR4, recognition of ß-glucans by 
dectin-1/ TLR2, and recognition of ß-mannosides by galectin-3/ TLR2 complexes (20). If the 
fungal cell wall is able to trigger many different PRRs at the same, it is important to realize 
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that it is a complex interaction between the various pathways that ultimately leads to the 
host response. 
Several interactions between PRRs are well documented. As mentioned earlier, dectin-1 is 
able to augment the TLR2-mediated MARK and NF-kB pathways leading to proinflammatory 
responses (33,34), and to amplify TLR4 responses through a Syk-dependent pathway (35). 
Galectin-3, a PRR which recognizes ß-(l,2)-mannosides, has recently been shown to 
associate with TLR2, and this leads to the ability to discriminate between the pathogenic C. 
albicans and the nonpathogenic S. cerevisiae (52). In addition, the TLR2 pathway itself is able 
to inhibit TLR4-mediated production of IL-12 through stabilization of c-Fos (61). Another 
study demonstrated that when TLRs activate NF-κΒ, C. albicans can induce DC-SIGN-
dependent signals which subsequently lead to acetylation of the NF-κΒ subunit p65 (62). 
This results in prolonged and increased IL-10 production that shifts the proinflammatory 
response induced by TLRs to a more anti-inflammatory response (62). All these observations 
imply that crosstalk between PRRs is essential to the complexity and flexibility of the innate 
immune response against fungi (Figure 1). 
Convergence and specificity shape the fungal innate immune response 
Although we are still at the beginning of elucidating the combinatorial use of innate defense 
mechanisms that define the initial host response, a general concept of the innate antifungal 
defense can be proposed. In order to recognize and respond to the many different fungi the 
organism encounters, the host evolved germline PRRs that can identify conserved fungal cell 
wall components - the fungal PAMPs. In this way, specific recognition of fungal nonself is 
reduced to a handful of specific pathways that interact with each other: the various mannan 
structures are recognized by TLR4, MR, DC-SIGN, dectin-2, and galectin-3, while the ß-
glucans are detected by dectin-1, TLR2, and CR3 (63). These pathways converge into a 
limited set of shared adaptor molecules and transcription factors (Figure 2). One such 
example is that of TLRs and CLRs sharing NF-κΒ during stimulation of proinflammatory 
cytokines. However, despite converging into certain pathways, the innate immune response 
still maintains its specificity through the activation of a specific mosaic of PRRs that is 
determined by the available fungal PAMPs and the innate immune cells involved. In addition, 
specificity is also preserved by the interactions between the PRR pathways (Figure 1). This 
response will eventually lead to nuclear translocation of transcription factors that have the 
competence to activate specific genes. The specificity insured by these mechanisms will 
determine a divergence of the final type of response. In this way, the innate host response 
has the capability of transforming converging pathways into tailored responses (Figure 2). 
Conclusions 
In this review, we have presented a synthesis of the current knowledge on the recognition of 
fungal pathogens by the innate immune system of the mammalian host. The very active 
research of the past few years has greatly improved our understanding of how the fungal 
pathogens are recognized as nonself by the host defense. Our understanding how TLRs and 
CLRs contribute and collaborate for the recognition of fungi permitted us to propose an 
integrated model of innate pattern recognition of these important human pathogens. We 
have also discussed and speculated how the signals induced by these receptors are 
integrated to bring about efficient activation of the host innate response. This model that is 
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pertinent conceptually to many host-fungal interactions, may permit in the near future the 
design of new therapeutic strategies to improve the outcome of patients suffering from 
these life- threatening infections. 
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Figure 1. The major pattern recognition pathways of fungal pathogens. 
Activation of host response by fungal pathogens at the level of the cell membrane is mediated by Toll-like 
receptors (TLRs) and C-type lectin receptors (CLRs). TLR4 mainly induces proinflammatory signals through the 
MyD88-Mal- mediated NF-kB and MARK pathways, while stimulating type I interferons through IRF3. TLR2 has 
weaker proinflammatory effects, but induces strong stimulation of the anti-inflammatory cytokines IL-10 and 
TGFß and can lead to immunological tolarization in DCs through an ERK/MAPK-dependent mechanism. On the 
contrary, proinflammatory responses induced by TLR2 can be amplified by dectin-1 and galectin-3. Dectin-1 can 
also induce cytokine production independently of TLR2, and can lead to Thl7 responses through the Syk-
CARD9 pathway. The MR induces proinflammatory cytokines such as IL-lß and TNF. DC-SIGN can modulate TLR 
responses and induces production of IL-10 in DCs. Dectin-2 mainly recognizes mannans from hyphae and leads 
to the production of TNF. 
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Figure 2. A general model of fungal pattern recognition. 
The recognition of the many fungal species is mediated by the interaction between conserved fungal PAMPs 
and a limited number of PRRs from the TLR and CLR families. These signals further converge because of the use 
of common adaptor molecules, intracellular pathways, and transcription factors. However, the specificity of the 
host response is maintained by the different mosaic of receptors stimulated by certain fungi, as well as by the 
complex interactions between the various pathways. This will determine a divergence of the final type of 
response elicited by each pathogenic microorganism, and in this way the innate host response has the 
capability of transforming converging pathways into tailored responses. 
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Chcipter 3 
Summary 
The role of Toll-like receptor 9 (TLR9) in the recognition of Candida albicans and anti-
Candida host defense was investigated in a murine model of disseminated candidiasis and in 
human peripheral blood mononuclear cells (PBMC). Blocking TLR9 by a specific inhibitor of 
human TLR9 or stimulation of cells isolated from TLR9-deficient (TLR9-/-) mice resulted in a 
20-30% reduction in cytokine production induced by C albicans. However, this defect was 
not accompanied by differences in mortality and organ fungal growth between TLR9-/- and 
TLR9+/+ mice. In conclusion, TLR9 is a pathogen-recognition receptor for C. albicans, and 
TLR9 is involved in the induction of cytokines in response to C. albicans. However, the 
cytokine defect in TLR9-/- mice is compensated by alternative pathways, and the TLR9-
dependent pathway seems to be redundant in the disseminated candidiasis model in mice. 
Introduction 
Invasive infection caused by the fungus Candida albicans is a serious threat to hospitalized 
patients, with a mortality reaching 30-40% (1). New strategies to overcome these infections 
may include vaccination against Candida species. To that purpose, understanding the 
mechanisms through which the immune response recognizes and responds to this pathogen 
has become increasingly important. The innate immune response occurs within minutes or 
hours after infection or vaccination. Cells of the innate immune system sense components of 
microorganisms through so-called pattern recognition receptors (PRR) of which Toll-like 
receptors (TLR) are probably the most important (2,3). Earlier studies by our group and 
others have described a role for TLR4 (2,4,5) and TLR2 (6,7) in the recognition of cell wall 
components of C. albicans. In addition, TLR6 has recently been shown to be involved in the 
recognition of C. albicans (8). 
TLR9 recognizes unmethylated CpG dinucleotides, which are common in most bacteria and 
DNA viruses, but not in vertebrate DNA (9). Its involvement in fungal infections has yet to be 
determined. The stimulation of TLR9 with CpG DNA leads to the activation of MyD88-
dependent cellular signaling pathways, resulting in predominantly Thl-type innate and 
adaptive immune responses. The strong proinflammatory effects of TLR9 towards activation 
of cellular responses make CpG oligodeoxynucleotides of considerable interest for use in 
human medicine, especially as vaccine adjuvants (9-11). Considering the importance of TLR9 
for recognition of microbial DNA, we investigated in the present study the role of TLR9 in the 
recognition of C. albicans and the activation of antifungal host defense. 
Materials and methods 
Animals 
TLR9-deficient C57BL/6J (TLR9-/-) mice were kindly provided by Dr. S. Akira (Tokyo 
University, Tokyo, Japan) (12). TLR9-/- mice and control littermates that weighed 20-25g and 
were 6-8 weeks old were used for the experiments. The mice were fed sterilized laboratory 
chow (Hope Farms, Woerden, The Netherlands) and water ad libitum. The experiments were 
approved by the Ethics Committee on Animal Experiments of Radboud University Nijmegen. 
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C. albicans and growth conditions 
C. albicans ATCC MYA-3573 (UC 820), a strain well described elsewhere (13), was used in all 
experiments. Candida was grown overnight in Sabouraud broth at 370C, cells were harvested 
by centrifugation, washed twice, and resuspended in culture medium (RPMI-1640 Dutch 
modification, ICN Biomedicals, Aurora, OH) (14). To generate pseudohyphae, C. albicans 
blastoconidia were grown at 370C in culture medium, adjusted to pH 6.4 by using 
hydrochloric acid. Pseudohyphae were killed for 1 h at 100oC and resuspended in culture 
medium to a hyphal inoculom size that originated from 106 per ml blastoconidia (referred to 
as 106 per ml pseudohyphae) (14). 
In vitro cytokine production 
Separation and stimulation of peripheral blood mononuclear cells (PBMC) was performed as 
described elsewhere (2). Briefly, venous blood was drawn from six healthy volunteers into 
10ml EDTA tubes (Terumo, Leuven, Belgium) and the PBMC fraction was obtained by density 
centrifugation of diluted blood (1 part blood to 1 part pyrogen-free saline) over Ficoll-Paque 
(Pharmacia Biotech, Uppsala, Sweden). PBMC were washed twice in saline and suspended in 
culture medium supplemented with gentamicin 1%, L-glutamine 1%, and pyruvate 1%. The 
cells were counted in a Bürker counting chamber, their number was adjusted to 5xl0e6 
cells/ml, and cells were incubated with C. albicans blastoconidia or pseudohyphae at 
Ixl0e6 microorganisms/ml in the absence or presence of a TLR9 specific antagonist; 
ODN TTAGGG: 50-ttt agg gtt agg gtt agg gtt agg g-30 (InvivoGen, San Diego, USA), for 24 h at 
37 1C. 
Recognition of C. albicans by macrophages of TLR9-/- mice 
Resident peritoneal macrophages were harvested from groups of five TLR9-/- and their 
control littermates by injecting 4ml of sterile PBS containing 0.38% sodium citrate (15). After 
washing, the cells were resuspended in culture medium in 96-well microliter plates (Greiner, 
Alphen, The Netherlands) at 10e5cells/well, in a final volume of 200ml. The cells were 
stimulated with either control medium or heat killed (Ih, 100oC) C. albicans at Ixl0e7 
microorganisms/ml. After 24h of incubation at 37°C, the plates were centrifuged (500g, 
10min), and the supernatant and cell lysate (three freeze-thaw cycles) were collected and 
stored at 801C until cytokine assays were performed. 
Cytokine assays 
TNFa was determined by specific radioimmunoassay (detection limit 20 pg/ml), as 
previously described (16). IL-6 and IL-10 concentrations were measured by a commercial 
ELISA (Biosource, Camarillo, CA; detection limit 16pg/ml), according to the instructions of 
the manufacturer. 
C. albicans infection model 
TLR9-/- mice and their control littermates were injected intravenously with C albicans 
blastoconidia (5xl0e5 CFU/mouse) in a 100 ml volume of sterile pyrogen-free phosphate-
buffered saline (PBS). Survival was assessed daily for 2 weeks. Subgroups of 5 animals were 
killed on days 3, 7, or 14 of infection. To assess the tissue outgrowth of the microorganisms, 
the liver and the kidneys of the sacrificed animals were removed aseptically, weighed, and 
homogenized in sterile saline in a tissue grinder. The number of viable Candida cells in the 
tissues was determined by plating serial dilutions on Sabouraud dextrose agar plates as 
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previously described (17). The CPU were counted after 24h of incubation at 370C, and 
expressed as log CFU/g tissue. 
Phagocytosis and killing of C. albicans by macrophages 
Phagocytosis and killing of C. albicans blastoconidia were assessed according to a method 
described elsewhere(17,18). Exudate peritoneal phagocytes from groups of 5 TLR9-/- mice 
and their control littermates were elicited by an i.p. injection of 10% proteose peptone. After 
72 h, cells were collected in separate sterile tubes by washing the peritoneal cavity with 4ml 
of ice-cold PBS that contained 50U/ml heparin. Phagocytes were centrifuged (for 10 min at 
2250g), counted in a Bürker counting chamber, and resuspended in culture medium. The 
processes of phagocytosis and intracellular killing were studied in an adherent monolayer of 
phagocytes, as described (18). Briefly, 5xl0e5 cells were dispensed into the wells of a 96-
well flatbottom plate (Costar), allowed to adhere for 2h, and washed to remove 
nonadherent cells. Subsequently, the cells were incubated with Ixl0e4 CPU C. albicans, 
which were opsonized for 45 min at 240C in modified Eagle's medium (MEM; Gibco Life 
Technologies) containing 2.5% fresh mouse serum (effectontarget ratio, 40:1). After 15 min, 
supernatants were aspirated, and monolayers were gently washed with MEM to remove 
noningested microorganisms. The supernatant and well washings that contained the 
noningested Candida blastoconidia were plated in serial dilutions on Sabouraud agar plates. 
The percentage of phagocytized microorganisms was defined as [l-(number of uningested 
CFU/CFU at the start of incubation)] χ 100. Killing of C. albicans by phagocytes was assessed 
in the same monolayers. After removal of the nonphagocytized Cond/doblastoconidia, 200 
ml of culture medium, consisting of Sabouraud in MEM (50% vol/vol), was added to the 
monolayers. After 3h of incubation at 37°C in air and 5% C02, the wells were scraped gently 
with a plastic paddle and washed with 200 ml distilled H20 to achieve lysis of phagocytes in 
3 cycles, and 10-fold dilutions of each sample were spread on Sabouraud agar plates and 
incubated at 37°C for 24 h. The percentage of yeast killed by the phagocytes was determined 
as follows: [1-(CFU after incubation/ number of phagocytized CFU)] χ 100. Phagocyte-free 
incubations of blastoconidia were included as a control for yeast viability. In earlier 
experiments we have shown that 90-97% of attached/internalized C. albicans are intra­
cellular (19). 
Statistical analysis 
The differences between groups were analyzed by the Mann-Whitney U test, and where 
appropriate by the Wilcoxon rank test. The level of significance between groups was set at 
p<0.05. All experiments were performed at least twice, and the data are presented as 
cumulative results of all experiments performed. 
Results 
In vitro cytokine production 
Blocking TLR9 on human PBMC reduced the TNFa production induced by heat-killed C. 
albicans blastoconidia, and reduced IL-10 production (Fig. 1). IL-6 was marginally increased. 
Likewise, a similar trend towards decreased TNFa and IL-10 production was observed when 
cells were stimulated with heat-killed C. albicans pseudohyphae, although the difference 
was not statistically significant. Stimulation with live C. albicans resulted in overall lower 
cytokine production. Blocking TLR9 in experiments with live yeast increased TNFa and IL-6 
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production, whereas IL-10 production was reduced (Fig. 1). 
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Figure 1. In vitro cytokine production. Human PBMC were stimulated with heat-killed C. albicans blastoconidia 
( Ix l0e6 microorganisms/ml), heat-killed C. albicans pseudohyphae (obtained from Ixl0e6 blastoconidia) or 
live C. albicans in the presence or absence of a TLR9 antagonist (TLR9a). Production of TNFa, IL-6 and IL-10 in 
the supernatants was measured after 24 h of stimulation at 370C. Data is pooled from 2 separate experiments 
with a total of 6 healthy volunteers (median ± IQR, ·ρ<0.05, Wilcoxon rank test). 
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Recognition of C. albicans by TLR9-/- macrophages 
To investigate the role of TLR9 for the recognition of C. albicans, resident peritoneal 
macrophages of TLR9-/- and TLR9+/+ control mice were stimulated with heat-killed C. 
albicans blastoconidia and pseudohyphae in vitro. Cytokine production by unstimulated 
macrophages of all mouse strains was below the detection limit for all cytokines studied (not 
shown). After stimulation with Candida blastoconidia, the production of TNFa, IL-6, and IL­
IO did not differ between TLR9-/- and control mice (Fig. 2). However, after stimulation with 
Candida pseudohyphae, the release of IL-6 and IL-10 release was significantly reduced as 
compared to the TLR9+/+ control mice (Fig. 2). 
Disseminated C. albicans infection in TLR9-/- mice 
To determine the role of TLR9 in the host defense against invasive C. albicans infection, 
TLR9-/- and TLR9+/+ control mice were infected with Candida blastospores and compared 
for their susceptibility to infection. No significant difference was observed in the survival 
(80% in both groups) during disseminated candidiasis. The fungal burden in the kidneys, the 
target organ of disseminated candidiasis in mice, was similar in TLR9-/- and TLR9+/+ control 
mice on day 3, 7, and 14 of infection (Fig. 3). The fungal burden in the livers was 10-100-fold 
lower than that in the kidneys, and did not differ between TLR9+/+ and TLR9-/- mice (data 
not shown). 
Phagocytosis and killing of C. albicans by macrophages 
Phagocytosis of C. albicans by TLR9-/- macrophages was similar to that by macrophages of 
their control littermates (21% vs 19% phagocytized in 15min; p>0.05). TLR9-/- macrophages 
killed 70% of phagocytized Candida blastoconidia in 3 h, which was not different from the 
killing activity of TLR9+/+ control macrophages (73%, p>0.05. Fig. 3). 
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Figure 2. Recognition of C. albicans by macrophages of TLR9-/- mice. Resident peritoneal macrophages from 
TLR9-/- mice and TLR9+/+ mice were stimulated with either IxlOe? microorganisms/ml Candida blastoconidia 
or pseudohyphae. Production of TNFa, IL-6 and IL-10 in the supernatants was measured after 24 h of 
stimulation at 370C. The results are pooled data from two separate experiments with a total of 8 TLR9-/- mice 
and 7 TLR9+/+ mice (median ± IQR, **p<0.01, Mann-Whitney U test). 
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Figure 3. C. albicans infection in TLR9-/- mice. (Upper panel) TLR9-/- mice and TLR9+/+ mice (wt) were infected 
i.V. with C. albicans blastoconidia (5xl0e5 CFU/mouse). Subgroups of animals were killed on days 3, 7 or 14 of 
infection, and fungal outgrowth was assessed in the kidneys. The results are pooled data from two separate 
experiments with at least 5 mice per group (median ± IQR). (Lower panel) Phagocytosis and killing of C. albicans 
by TLR9-/- mice and TLR9+/+ macrophages. Percentage of Candida blastoconidia of the initial inoculum that 
was ingested by macrophages of TLR9-/- and TLR9+/+ after 15 min of phagocytosis and percentage of 
phagocytized Candida blastoconidia that was killed after incubation at 370C for 3h is shown. The results are 
pooled data with a total of 3 TLR9-/- mice and 6 TLR9+/+ mice (median ± IQR). 
Discussion 
In the present study, the role of TLR9 in the recognition of C. albicans and the anti-Candida 
host defense was investigated by using a murine model of disseminated candidiasis and ex-
vivo stimulation of human PBMC. A moderate decrease in cytokine production was observed 
when TLR9 was blocked in human PBMC, and when TLR9-/- peritoneal mouse macrophages 
were stimulated with C. albicans. However, this was not accompanied by an increased 
susceptibility to disseminated candidiasis, arguing for a redundant role for TLR9 in anti-
Candida host defense. 
TLR9 is known to be involved in cytokine stimulation in response to bacterial DNA (20) and 
has been implicated in the recognition of viral DNA (21). In line with these data, we observed 
that stimulation with C. albicans led to a reduction in cytokine production, most obviously 
for IL-10 production, in human PBMC and mouse macrophages when the TLR9-pathway was 
blocked. This is supported by other studies, which have shown that recognition of bacterial 
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DNA by TLR9 is involved in the stimulation of cytokine production when human PBMC are 
stimulated with whole bacteria, e.g. Streptococcus pneumoniae or Neisseria meningitidis 
(22). Similarly Brucella abortus engages TLR9 in murine dendritic cells, resulting in a Thl 
cytokine response (23), DNA from Trypanosoma cruzi stimulates cytokine production in a 
TLR9-dependent manner (24), infected TLR9-/- mice display defective Mycobacteria 
tuberculosis-'mduced cytokine responses in vivo (25), and TLR9 is required for the induction 
of ΙΡΝγ by Propionibacterium acnes (26). 
Despite a decrease in cytokine production, we did not observe increased susceptibility of 
TLR9-/-mice to infection with C. albicans. Several explanations could account for this. Firstly, 
the decrease in cytokines observed was moderate, and alternative routes are likely to 
compensate for the loss of TLR9 signaling. Several other pathways are involved in the 
recognition of C. albicans, leading to cytokine induction: TLR4 stimulates CXC chemokine 
production and neutrophil recruitment (5), the mannose receptor pathway induces IL-lß, IL-
6, and granulocyte-macrophage colony-stimulating factor (27), and TLR2/dectin-l signaling 
induces TNFa and IL-12 production (28). Secondly, no significant difference in phagocytosis 
and killing was observed. This was not unexpected as TLR9 is located intracellularly (30) and 
probably has no role in phagocytosis. Our findings are also supported by Bellocchio et al. (4). 
In their model using Candida blastoconidia, these authors found very small differences in 
fungal burden in the kidneys, and there was no significant difference in survival between 
TLR9-/- mice and TLR9+/+ control mice infected with Candida blastoconidia (4). An 
important additional aspect of our study, compared to the previous data in the literature 
from experiments performed only in experimental animals, was the assessment of the role 
of human TLR9 for recognition of C. albicans. The data in human cells mostly overlap that in 
mice. To increase the biological relevance of the data, stimulations were performed with 
both heat-killed and live Candida. Interestingly, TLR9 was mainly involved in the induction of 
IL-10. The lack of IL-10 when TLR9 was blocked lead to increased IL-6 production, and in the 
case of stimulation with live Candida also increased TNFa release. TNFa production by heat-
killed or live Candida was differentially modulated by blocking TLR9. This is most likely due to 
the differences in the PAMP/PRR interaction in live and heat-killed Candida as previously 
shown by our group and others (2,31). 
However, the fact that we found no significant difference in survival and fungal load in 
organs between TLR9-/- mice and TLR9+/+ control mice does not necessarily indicate that 
TLR9 is not important in ar\t\-Candida host defense. The importance of parallel signaling 
routes has been exemplified during a M. tuberculosis mouse model (25). Whereas TLR2-/-
and TLR9-/- single knock-out mice had almost similar susceptibility to M. tuberculosis com-
pared to wild-type mice, TLR2-/- TLR9-/- double knock-out mice displayed a significant 
increased susceptibility (25). This increased susceptibility of TLR2-/- TLR9-/- mice compared 
to TLR2-/- and TLR9-/- mice has also been observed for infection with T. cruzi (24). This may 
also very well be the case for C. albicans infection, in which deficiency of TLR9 alone leads to 
no significant difference in survival, while TLR9 deficiency in combination with other factors 
may lead to a significantly increased susceptibility to Candida infection. The viability of this 
hypothesis and the potential role of TLR9 in human disease is currently tested in our 
laboratory by assessing the role of TLR9 polymorphisms in patients with candidemia. 
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In conclusion, TLR9 is involved in the production of cytokines in response to C. albicans. 
Although alternative TLR and non-TLR pathways can compensate for an isolated TLR9 
deficiency, in the case of a "multiple-hit" condition, TLR9 deficiency could prove significant. 
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Chapter 4 
Summary 
Toll-like receptor-1 (TLRl) and TLR6 are receptors of the TLR family that form heterodimers 
with TLR2. The role of TLRl and TLR6 for the recognition of the fungal pathogen Candida 
albicans was investigated. TLRl is not involved in the recognition of C. albicans, and TLRl 
knock-out (TLRl-/-) mice showed a normal susceptibility to disseminated candidiasis. In 
contrast, recognition of C. albicans by TLR6 modulated the balance between Thl and Th2 
cytokines, and TLR6 knockout mice displayed a defective production of IL-10 and an 
increased IFN-γ release. Production of the monocyte-derived cytokines tumor necrosis 
factor, IL-1, and IL-6 was normal in TLR6-/- mice, and this was accompanied by a normal 
susceptibility to disseminated candidiasis. In conclusion, TLR6 is involved in the recognition 
of C albicans and modulates the Thl/Th2 cytokine balance, but this results in a mild 
phenotype with a normal susceptibility of TLR6-/-mice to Candida infection. 
Introduction 
Invasive fungal infections, especially those caused by Candida albicans, are a serious clinical 
threat in immunocompromised patients and those who undergo major surgical procedures, 
with mortality reaching 30-40% despite the availability of new classes of antifungal drugs 
(1,2). New therapies for the treatment of disseminated fungal infections are therefore 
needed, and adjunctive immunotherapy is one promising, yet unfulfilled, strategy. 
Understanding the mechanisms through which the host immune system recognizes and 
eliminates fungal pathogens is an important step towards achieving this goal. 
Much has been done to elucidate the host defense mechanisms against systemic candidiasis. 
The innate host defense mechanisms leading to elimination of Candida during infection have 
been characterized, and comprise the release of proinflammatory cytokines, leading to 
activation of phagocytosis and killing of the fungus by neutrophils and macrophages (3-5). 
Recently, it has been shown that recognition of microbial structures called pathogen-
associated molecular patterns (PAMPs) by pattern-recognition receptors (PRRs) is essential 
for the effective activation of host defense mechanisms in general, and for cytokine 
production in particular. Earlier studies by the authors' group and others have described the 
role of several PRRs for the recognition of components of the C albicans cell wall, including 
recognition of mannans and mannoproteins by mannose receptor and Toll-like receptor-4 
(TLR4) (6-11), of phospholipomannan (PLM) by TLR2 (12), and of ß-mannosides by galectin-3 
(13). In addition, several studies have demonstrated the important role of these receptors 
for the host defense in experimental models of disseminated candidiasis. The TLR-adapter 
molecule MyD88 has been demonstrated to be essential for the resistance to disseminated 
candidiasis (9,14,15), and individual receptors such as TLR4 (7,9), TLR2 (10,14,15) and dectin-
1 (16) have been reported to be involved in the defense against C. albicans infection. 
TLRl and TLR6 are two receptors of the TLR family that have been shown to form 
heterodimers with TLR2 (17). Through heterodimerization, receptor complexes are formed 
that recognize specific microbial structures: TLR2/TLR1 heterodimers recognize bacterial 
triacyl lipopeptides (18) while TLR2/TLR6 heterodimers recognize bacterial diacyl 
lipopeptides and lipoteichoic acid (19,20). The specificity in recognition of various microbial 
components by TLR heterodimers permits an adjusted response to different classes of 
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microorganisms. Although the role of TLR2 for the recognition of C. albicans is well 
established, nothing is known about the potential involvement of TLRl and/or TLR6 in the 
recognition of Candida and anti-Cond/'do host defense. The possibility that heterodimers 
between TLR2 and other TLRs may be involved in Candida recognition has been suggested by 
an earlier report showing that TLR2/TLR6 heterodimers recognize zymosan from 
Saccharomyces cerevisiae (21). In the present study we investigate the role of TLRl and TLR6 
for the recognition of C. albicans and the antifungal host defense. 
Materials and methods 
Animals 
TLRl-/- and TLR6-/- mice were kindly provided by Dr. Shizuo Akira (Osaka University, 
Japan). In all experiments, knock-out mice and their control littermates (20-25g, 6-8-weeks 
old) were used. The mice were fed sterilized laboratory chow (Hope Farms, Woerden, The 
Netherlands) and water ad libitum. The experiments were approved by the Ethics 
Committee on Animal Experiments of Radboud University, Nijmegen. 
Recognition of C. albicans and in vitro cytokine production 
Groups of five TLRl-/- and TLR6-/-mice and their control littermates were sacrificed, and 
resident peritoneal macrophages were harvested by injecting 4mL of sterile phosphate-
buffered saline (PBS) containing 0.38% sodium citrate (22). After washing, the cells were 
resuspended in RPMI 1640 containing ImM pyruvate, 2 mM L-glutamine, 100 μg/mL 
gentamicin and 2% fresh mouse plasma (culture medium). Cells were cultured in 96-well 
microliter plates (Greiner, Alphen, The Netherlands) at lOeS cells per well, in a final volume 
of 200 μΐ. The cells were stimulated with either control medium or heat-killed (Ih, 100oC) C. 
albicans at Ixl0e7 CFU/mL (ATCC MYA-3573). After 24h of incubation at 37°C, the plates 
were centrifuged (500g, 10 min), and the supernatant and cell lysate (three freeze-thaw 
cycles) were collected and stored at -80 1C until cytokine assays were performed. 
To assess ΙΡΝγ and IL-10 production, primed spleen cells from mice on day 3 of infection with 
IxlOeS CFU of C. albicans per mouse were stimulated in vitro with heat-killed Candida 
(Ixl0e7 CFU/mL), zymosan (1 μg/mL), Pam3Cys (10 μg/mL) or MALP (10 μ§/Γηί). Spleen 
cells were obtained by gently squeezing spleens in a sterile 200 mm filter chamber. 
Microscopic examination of Giemsa-stained cytospin preparations showed that these cells 
consisted of 95% lymphocytes, 2% monocytes and 3% granulocytes. The cells were washed 
and resuspended in RPMI1640, counted in a Biirker counting chamber and the number was 
adjusted to 5xl0e6/mL. One milliliter of the cell suspension was stimulated with Ixl0e7 
heat-killed C. albicans yeasts (E : Τ ratio 2 :1). Measurement of IFN and IL-10 concentrations 
was performed in supernatants collected after 48h of incubation at 370C in 5% C02 in 24-
well plates. 
Cytokine assays 
IL-la, IL-ip and TNFa were determined by specific radio-immunoassays (detection limit 
20pg/mL), as described previously (23). IL-6, IFNy and IL-10 concentrations were measured 
by a commercial enzyme- linked immunosorbent assay (ELISA) (Biosource, Camarillo, CA; 
detection limit 16 pg/mL), according to the instructions of the manufacturer. 
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Candida albicans infection model 
Candida albicans ATCC MYA-3573 (UC820), a strain well- described earlier (24), has been 
used in all experiments. TLRl-/-and TLR6-/- mice and their control littermates were injected 
intravenously with C. albicans (5xl0e5 CPU per mouse) in a 100 mL volume of sterile 
pyrogen-free PBS. Survival was assessed daily for 2 weeks. Subgroups of five animals were 
sacrificed on days 3, 7 or 14 of infection. To assess the tissue outgrowth of the 
microorganisms on these days, the liver and the kidneys of the sacrificed animals were 
removed aseptically, weighed and homogenized in sterile saline in a tissue grinder. The 
number of viable Candida cells in the tissues was determined by plating serial dilutions on 
Sabouraud dextrose agar plates as described previously (25). The CPU were counted after 
24h of incubation at 370C, and expressed as log CFU/g tissue. 
Statistical analysis 
The differences between groups were analyzed by the Mann-Whitney U-test and, where 
appropriate, by Kruskal-Wallis ANOVA. The level of significance between groups was set at 
P<0.05. All experiments were performed at least twice, and the data are presented as 
cumulative results of all experiments performed. 
Results 
Recognition ofC. albicans by macrophages ofTLRl-/- and TLR6-/- mice 
To investigate the role of TLR1 and TLR6 for the recognition of C. albicans, peritoneal macro-
phages of TLR1-/-, TLR6-/- and control mice were stimulated with heat-killed Candida 
blastospores in vitro. Cytokine production by unstimulated macrophages of all mouse strains 
was below the detection limit for all cytokines studied (not shown). Cond/cto-stimulated 
production of TNFa, IL-lß and IL-6, as measured by ELISA in the supernatants of the 
stimulate cells, did not differ between TLR1-/-, TLR6-/- and control mice (Fig. 1). Similarly, 
the concentrations of intracellular IL-la measured in the cell lysates did not differ between 
the knock-out and control mice (Fig. 1). 
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Figure 1. Recognition of Candida albicans by macrophages of TLR1-/- and TLR6-/- mice. 
Peritoneal macrophages of TLR1+/+ and TLR1-/- mice (a) as well as TLR6+/+ and TLR6-/- mice (b) were 
stimulated with Ix l0e6 yeast cells/mL of heat-killed C. albicans. Production of TNF, IL-lß and IL-6 in the 
supernatants and of IL-la in cell lysates was measured by specific ELISA after 24 h of stimulation at 370C. The 
results are pooled data from two separate experiments with a total of 10 mice per group (means ± SD). 
Role of TLR1 and TLRSfor the Thl/Th2 cytokine balance 
The balance between Thl-derived proinflammatory cytokines such as IFNy and Th2-derived 
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anti-inflammatory cytokines such as IL-10 plays an important role in the host defense against 
disseminated candidiasis (26). When primed splenocytes of TLRl-/- mice were stimulated 
with C. albicans blastospores, they released similar amounts of IFNy and IL-10 as splenocytes 
isolated from control animals did (Fig. 2a). In contrast, primed splenocytes of TLR6-/- mice 
released greater amounts of IFNy compared with control mice, while IL-10 production was 
significantly lower compared with controls (Fig. 2b). Similar results were obtained when IL­
IO and IFN production was stimulated with zymosan (not shown). In contrast, none of the 
two lipopeptides (PamBCys and MALP) stimulated IFNy production either in control or in the 
knockout mice (concentrations below the 16 pg/mL detection limit of the assay), 
demonstrating that complex interaction or several types of receptors with fungal PAMPs of 
the cell wall of fungi are responsible for IFNy induction, rather than TLR2/TLR1 or TLR2/TLR6 
complexes alone. As expected, PamBCys did not induce IL-10 in TLRl-/- mice, and MALP did 
not stimulate IL-10 production in TLR6-/- mice. PamBCys induced normal amounts of IL-10 in 
TLR6-/- mice (322 ± 57 vs. 299 ± 29 pg/mL in control mice, P>0.05), and MALP induced 
similar amounts of IL-10 in TLRl-/- mice (145 ± 39 vs. 188 ± 51 pg/mL in control mice, Ρ > 
0.05). 
Disseminated C. albicans infection in TLRl-/-and TLR6-/- mice 
To determine the role of TLRl and TLR6 in the host defense against C. albicans, TLRl-/- , 
TLR6-/- and control mice were infected with Candida blastospores and their susceptibility to 
infection was compared. No difference was observed in either the survival (90% in both 
groups) or the fungal burden in the kidneys, the target organ of disseminated candidiasis in 
mice, between TLRl-/- and control mice (Fig. 3a). The fungal burden in the livers was 10-
100-fold lower than that in the kidneys, and did not differ between TLR1+/+ and TLR1-/-
mice (not shown). The survival of TLR6 +/+ mice at 2 weeks after infection with C. albicans 
was 80%, and that in TLR6-/- mice was 90% (P = NS). The growth of C. albicans in the kidneys 
(Fig. 3b) and liver (not shown) of the TLR6-/- mice was also similar to that in TLR6+/+ mice. 
Although fewer Candida microorganisms tended to be recovered from the kidneys of TLR6-/-
mice than from of control animals on Day 14 of infection, the difference did not reach 
statistical significance (Fig. 3b). 
Figure 2. Role of TLRl and TLR6 In the Thl/Th2 cytokine balance. 
Mice (TLRl-/,a; TLR6-/-, b) were infected intravenously with C. albicans (IxlOeS CFU/mouse), and after 3 days 
splenocytes were harvested and stimulated in vitro with Ix l0e7 heat-killed C. albicans blastospores (E : Τ ratio 
2 :1). Measurement of IFNy and IL-10 concentrations was performed in supernatants collected after 48 h of 
incubation at 370C. The results are pooled data from two separate experiments with a total of 10 mice per 
group (means ± SD, P<0.05). 
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Figure 3. Disseminated Candida albicans infection in TLRl-/- and TLR6-/- mice. 
TLR1+/+ and TLRl-/- (a) and TLR6+/+ and TLR6-/- mice (b) were infected intravenously with C albicans (SxlOeS 
CFU per mouse). Subgroups of animals were sacrificed on Days 3, 7 or 14 of infection, and fungal outgrowth 
was assessed in the kidneys. The results, expressed as log CFU/g tissue, are pooled data from two separate 
experiments with a total of 10 mice per group (means ± SD). 
Discussion 
This study investigated the role of TLRl and TLR6 for the recognition of C. albicans and the 
host defense during disseminated candidiasis. TLRl is not involved in the recognition of 
Candida by the innate immune system, and did not affect susceptibility to disseminated 
candidiasis. In contrast, recognition of C. albicans by TLR6 modulated the balance between 
Thl and Th2 cytokines, with TLR6 knockout mice displaying a more proinflammatory 
cytokine profile, characterized by increased ΙΡΝγ production and reduced IL-10. However, 
this Th2-biased pattern was not accompanied by a significant modulation of the 
susceptibility to disseminated candidiasis. 
The involvement of TLR6 in the recognition of C. albicans is indirectly supported by the 
established role of TLR2 in the recognition of C. albicans, as TLR2 is known to form 
heterodimers with TLR6 and TLRl (17). Recognition of S. cerew's/oe-derived zymosan by 
TLR2/TLR6 heterodimers has been described (21). In the present study, in vitro stimulation 
of cells isolated from TLR6-/- mice with C. albicans blastospores has demonstrated a role for 
TLR6 in the recognition of Candida and subsequent stimulation of cytokines. However, these 
effects seem to be cell type-specific, with little effect of TLR6 on the Cond/do-induced 
production of cytokines by resident murine peritoneal macrophages, while the production of 
cytokines by splenocytes was strongly influenced by the absence of TLR6. 
The defective production of IL-10 by splenocytes of TLR6-/- mice in response to C. albicans 
or zymosan, which was accompanied by an increase in ΙΡΝγ, supports the hypothesis that 
TLR6, most likely in the form of a heterodimer with TLR2, is mainly involved in mediating the 
release of Th2-cytokines (27). In this respect, the phenotype of TLR6-/- mice resembles that 
of TLR2-/- mice (9,10), supporting the concept of a functional unity between these 
receptors. However, it should be acknowledged that the phenotype of TLR6-/- mice is milder 
than that of TLR2-/- mice, consistent with the notion that TLR2 is the main signaling 
receptor, while TLR6 has an adjunctive function. No defects in the release of 
monocyte/macrophage-derived cytokines were observed in the TLR6-/- mice, in contrast to 
the severely affected cytokine production by TLR2-/- cells, as described earlier (14,15). The 
milder phenotype of TLR6-/- mice at the level of cytokine production most likely explains the 
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normal susceptibility to Candida infection. 
The structural cell wall component of C. albicans that is recognized by TLR6 remains to be 
elucidated. The original identification of zymosan as a ligand for TLR2/TLR6 heterodimers 
suggests that a polysaccharide component, either ß-glucan or a mannan, is the ligand for 
TLR6. In case of C. albicans, the most likely candidate is phospholipomannan, as it has been 
recently proposed that stimulation of cytokines by phospholipomannan is mediated by both 
TLR2 and TLR6 (12). As phospholipomannan and other ß-mannoside structures are also 
recognized by galectin-3 on the surface of macrophages (13), it may be speculated whether 
a TLR2/TLR6/galectin- 3 receptor complex may be involved in the recognition of 
phospholipomannan. Similar receptor complexes between TLR and non-TLR receptors have 
been described for the recognition of LPS (TLR4/MD2/CD14/CDllc/18) (28), lipoteichoic acid 
and diacyl lipoproteins (TLR2/TLR6/CD14/ CD36) (Triantafilou et al., 2006) and ß(l,3)-glucan 
(TLR2/dectin-l) (29,30). ß(l,3)-glucan may be considered as an additional candidate ligand, 
as the ß-glucan receptor dectin-1 forms a complex with TLR2, and a recent study has 
suggested the recognition of ß-glucans of Tinospora cordifolia by TLR6 (31). 
In contrast to TLR6, no role of TLRl in the recognition of C. albicans or the anti-Candida host 
defense has been observed. The absence of the involvement of TLRl in the recognition of C. 
albicans is not completely unexpected, as no function of TLRl has been reported in the 
recognition of zymosan (21). Of note, the antifungal agent amphotericin B, itself a product 
obtained from the fungus Streptomyces nodosus, activates production of cytokines through 
complexes of TLR2/TLR1 (32). This does not seem to be the case for C. albicans. 
In conclusion, in this first study on the role of TLRl and TLR6 in the recognition of C. albicans, 
the absence of a major function of TLRl in the host defense against disseminated candidiasis 
is reported. In contrast, TLR6 is involved in the stimulation of the anti-inflammatory Th2-type 
cytokine IL-10, resulting in a skewed proinflammatory profile in TLR6 knockout mice. 
However, this phenotype was not associated with a significant difference in susceptibility to 
disseminated candidiasis. The absence of a role of TLRl and the moderate effects of TLR6 
deficiency on disseminated candidiasis in the mouse model do not preclude a role of either 
receptor in innate immunity to Candida infections in humans, as differences between 
murine and human TLRs are known to be present (33). Interestingly, a recent study 
suggested an association between TLR6 and TLRl polymorphisms and susceptibility to 
invasive aspergillosis (34), and a potential role of these TLRs in a large cohort of patients 
with disseminated candidiasis is currently being investigated. 
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Summary 
Background: lnterleukin-ΐβ is one of the most important pro-inflammatory cytokines. In 
contrast to other cytokines, activation of IL-lß requires processing from an inactive 
precursor by the cysteine protease caspase-1. Caspase-1 forms a protein platform called the 
inflammasome, together with proteins of the nucleotide-binding oligomerization domain-
like receptor (NLR) family. Objective/methods: A review of literature investigating the 
stimulation of IL-lß production by microbial pathogens and their components. 
Results/conclusions: To produce IL-lß, macrophages need a double stimulation with Toll like 
receptor (TLR) ligands that induce gene transcription, and NLR agonists (such as ATP or 
muramyl dipeptide (MDP)) that activate the inflammasome. Monocytes can release active 
IL-lß upon stimulation with TLR ligands alone. This probably represents an adaptation of 
each cell type to its environment. 
Interleukin-l (IL-1) in the pathogenesis of human diseases 
IL-la and IL-lß are proinflammatory cytokines exerting similar biological activities after 
interaction with a receptor complex formed by IL-1 type I receptor (IL-1RI) and the IL-1R 
accessory protein [1]. Mice deficient in IL-1 have an increased susceptibility to infections, 
and administration of recombinant human IL-la or IL-lß have indicated a protective role for 
IL-1 in infections [2,3]. However, in addition to its beneficial roles in infections, IL-1 also 
exerts important deleterious effects during the inflammation of autoimmune diseases such 
as rheumatoid arthritis, Crohn's disease or type 1 diabetes [4]. 
In addition to its role in infections and autoimmune diseases, an increased interest in the 
biology of IL-lß has been generated after the discovery that an entire group of 
autoinflammatory disorders that specifically respond to blockade of IL-1 receptor with the 
IL-1 receptor antagonist (IL-IRa), or neutralization of IL-lß by monoclonal anti-IL-lß 
antibodies. These syndromes include familial Mediteranean fever [5], familial cold auto-
inflammatory syndrome [6], Muckle-Wells syndrome [7], neonatal onset multisystem 
inflammatory disease [8], hyperimmunoglobulin D syndrome [9], and adult-onset Still's 
disease [10]. Blood monocytes from patients with some of these disorders, especially 
cryopyrinopathies, readily release more IL-lß than monocytes from unaffected controls, 
revealing a loss of the tight control regulating processing and release of active IL-lß. 
Processing of IL-lb: caspase-1 activation by the NLR inflammasomes 
Because IL-lß is one of the most active pro-inflammatory cytokines, which can also exert 
deleterious effects when overproduced in the circulation, several control mechanisms have 
evolved to modulate its production and activity (Figure 1): transcription of IL-lß mRNA, 
translation, processing of the 31-kDa inactive IL-lß precursor form into the bioactive 17-kDa 
IL-lß [11], and the release from secretory lysosomes through K+-dependent mechanisms 
[12,13]. In contrast to IL-lß that requires processing before being secreted from the cell, IL-
l a is not processed and it mainly remains cell-associated [1]. However, it has been reported 
that ILla does partially need caspase-1 and calpain for processing and secretion [14]. In 
addition to the regulatory mechanisms at the level of processing, the control of IL-1 activity 
is also exerted by IL-IRa or the type II decoy receptors [15] that block the interaction of 
57 
NLRs, TLRs and the inflammasome 
bioactive IL-1 with the signaling type I IL-lreceptor. 
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IL-1 Ril 
Figure 1. Regulatory steps of IL-lß biological activity. Several control mechanisms have evolved to modulate 
the production and activity of IL-lß: (1) transcription of IL-lß mRNA; (2) translation; (3) processing of the 31-
kDa inactive IL-lß precursor form (ProlL-lß) into the bioactive 17-kDa IL-lß; (4) release through K+-dependent 
mechanisms; (5) control of IL-lß activity by the IL-1 receptor antagonist (IL-lRa); (6) the type II decoy receptors 
(IL-1 Rll); (7) blockade of the interaction of bioactive IL-lß with the signaling type I IL-lR-l/interleukin 1 
receptor accessory protein (IL-lRAcP) complex. Card: Caspase recruitment domain; LPS: Lipopolysaccharide; 
mal: Myelin and lymphocyte protein; MyD88: Myeloid differentiation primary response gene 88; P2X7: 
Purinergic receptor P2X; ligand-gated ion channel 7; TLR Toll-like receptor. 
One of the most important steps in the regulation of IL-lß production is the processing of 
the inactive pro-IL-lß into the bioactive IL-lß. Cleavage of the 31-kDa precursor is mainly 
exerted by a cysteine protease initially called IL-1 converting enzyme, and later termed 
caspase-1. In its turn, caspase-1 Is also initially produced as inactive pro-caspase-1. Its 
autocatalytic activation depends on changes in the three-dimensional conformation of a 
protein complex termed the inflammasome [16]. Several protein platforms/inflammasomes 
have been described for the activation of caspase-1, and each of them include members of 
the nucleotide-binding oligomerization domain-like receptor (NLR) family of proteins [17]. 
The most intensely studied have been the inflammasomes formed by the NLR family 
members NACHT leucine rich repeat and PYD (pyrin domain)-containing (NALP)3 and NALP1, 
that, in addition to caspase-1 and NLR proteins, also includes the adapter protein apoptosis-
associated speck-like protein containing a caspase recruitment domain (ASC) (Figure 2). In 
addition to the NALPs, another NLR member, ILl-ß converting enzyme-protease activating 
factor (IPAF), forms an inflammasome that activates caspase-1 in response to intracellular 
flagellin but also in response to flagellin-deficient Pseudomonas and non-flagellated Shigella 
[18,19]. While several studies have suggested that the IPAF inflammasome activate caspase-
1 in an ASC-independent manner [20,21], other studies suggested a role for ASC in the 
function of the IPAF inflammasome [18]. Mutations in NALP3 exits in familial cold-induced 
autoinflammatory syndrome (FCAS) [6], Muckle-Wells Syndrome (MWS) [7], and neonatal 
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onset multisystem inflammatory disease (NOMID) [8], whereas specific 
polymorphisms have been associated with vitiligo and autoimmune diseases [22]. 
NALP1 
LRR 
Inflammasome 
NALP-3 d l - i 1 - Ο - Γ J 
cardinal >—•>. 
ATP, MDP 
Inactive pro-caspase-1 
φ Precursor piece 
Active pro-caspase-1 
Figure 2. The NALP3 inflammasome. The inactive form of caspase-1 forms a complex with the NLR proteins 
NALP3, apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC) and cardinal. 
Upon interaction of ATP or muramyl dipeptide (MDP) with the leucine rich repeat (LRR) domain of NALP3, 
conformational changes in the inflammasome de-repress caspase-1 which is released from the complex in its 
active form. It should be noted that cardinal is not present in the mouse. NALP3: NLR family apoptosis 
inhibitory protein, class II transactivator, heterockaryon incompatibility E and transition protein 1 (NACHT)-
domain leucine rich repeat and PYD (pyrin domain)-containing 3. 
In addition to caspase-1, a cysteine protease mainly present in monocytes and macrophages, 
a secondary mechanisms for the processing of IL-lß is represented by a group of serine 
proteases mainly released by the neutrophils: protease-3, cathepsin G and elastase, that 
have been reported to cleave prolL-lß into a 21-kDa fragment with biological activity [23]. 
Among these proteases, protease-3 has been recently shown to be the dominant enzyme 
processing IL-lß in the neutrophil [24]. However, the biological relevance of this secondary 
pathway of IL-lß processing is less well established. 
TLR engagement and the stimulation of IL-lß production 
On the basis of results obtained using transfected cell lines and/or NALP3-knockout mice, a 
broad panel of stimuli have been proposed to activate the NALP3 inflammasome, including 
bacterial products such as peptidoglycans and muramyl dipeptide (MDP) [25], bacterial 
toxins [26], silica [27], alum [28], asbestos [27] but also endogenous products such as uric 
acid [29], ATP [26] or amyloid-ß [30]. In addition to NALP3, the peptidoglycan component 
MDP also induces association of the NLR proteins NOD2 and NALP1, and this complex 
mediates caspase-1-dependent secretion of IL-lß [31]. A similar process mediates activation 
of IL-lß by Bacillus anthracis infection [31]. 
Based on responses in the THP-1 cell line, a concept has arisen that IL-lß production induced 
by the Gram-negative bacteria cell-wall component lipopolysaccharide (LPS) is due to 
contamination with non-LPS ligands such as peptidoglycans [25], while LPS by itself is 
ineffective as a stimulator of IL-lß release. According to this model, LPS induces activation of 
IL-lß gene transcription and during the 15 (up to 30) minute interval when cells are exposed 
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to ATP is used as a parameter of IL-lß production. In contrast, 'classical' IL-lß Stimulation is 
performed in primary human monocytes, in which the release of the processed cytokine 
takes place over 24 - 48 h stimulation of the cells. 
These methodological differences can explain the apparent discrepancies between these 
various studies on the one hand but also hint at important biological phenomena. Firstly, 
there is a very strong body of evidence demonstrating that two signals are needed for the 
stimulation of IL-lß production in THP-1 cells and primary macrophages. When stimulated 
with TLR ligands such LPS (TLR4) or tripalmitoyl-S-glyceryl cysteine (Pam3Cys) (TLR2) alone, 
macrophages or THP-1 cells do not release IL-lß. The lack of IL-lß release was observed not 
only for cell lines or in vitro-differentiated monocyte-derived macrophages but also for 
alveolar macrophages isolated from healthy volunteers [42,43]. Only after a TLR ligand is 
combined with ATP, an inflammasome activator, can the macrophages release active IL-lß. 
Secondly, these studies suggest that monocytes are functionally different from macrophages 
in terms of IL-lß release, and they can produce active IL-lß in response to TLR stimulation 
alone. The precise molecular mechanisms leading to TLR-induction of IL-lß production in 
monocytes remain however to be elucidated. 
The capability of monocytes to release IL-lß secretion after stimulation with TLR ligands 
alone explains much experimental data. On the one hand, this explains the many clinical 
studies showing stimulation of IL-lß by TLR ligands in whole-blood assays, or after infusion 
of clinical-grade LPS in human volunteers [44]. Similarly, mice defective for the 
inflammasome components ASC [45] or NALP3 [46] show resistance to lethal endotoxemia, 
an observation that can be explained only if a circulating cell population (e.g., monocytes) 
releases active IL-lß after the infusion of LPS. One possible explanation that could unify the 
findings of the 'classical' long-exposure assays, and the short-stimulation assays used for 
inflammasome activation, is that during the 24h needed for stimulation of IL-lß by TLR 
ligands, danger signals (e.g., ATP, uric acid) are released from the cells and collaborate with 
TLR ligands in the release of active IL-lß. 
On the other hand, these data explain the profile of IL-lß release from monocytes of 
patients with autoinflammatory diseases. Although they are highly responsive to TLR 
stimulation and they release IL-lß, blood monocytes also respond to ATP challenge, leading 
to a greater release of IL-lß [12]. This is highly relevant to the role of NALP3 in monocytes 
isolated from patients with autoinflammatory diseases. Monocytes from patients with 
Muckle-Wells syndrome and NALP3 mutations do not respond to additional ATP stimulation 
for the release of IL-lß [47]. Thus, the NALP3 mutations result in an inflammasome, which is 
already maximally stimulated without the need for a second signal from ATP [47]. Having a 
maximally activated inflammasome that efficiently processes IL-lß even after minimal 
stimulation may explain the inflammatory attacks in these syndromes, which are induced by 
most trivial of stimuli [6,48]. 
Conclusions 
This review of published studies investigating the stimulation of IL-lß production by 
microbial pathogens and their components reveals an important dichotomy in the capacity 
of myeloid cells to release active IL-lß. While macrophages need a double stimulation with 
TLR ligands that induce gene transcription, and NLR agonists that activate the inflammasome 
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for caspase-1 activation and processing of prolL-lß, monocytes can release active IL-lß upon 
stimulation with TLR ligands alone (Figure 3). The relevance of this difference is apparent 
when one considers the role of IL-ΙβΘ in the host response to exogenous challenges. The 
single (TLR only) stimulation of IL-lß in monocytes compared with the double (TLR/ATP) 
stimulation in macrophages probably represents an adaptation of each cell type to their 
respective environments. Circulating monocytes are responsible for the surveillance of an 
essentially pathogen-free environment, so they must respond promptly to any danger signal 
(especially of microbial origin). In contrast, macrophages are confined to an environment 
(e.g., alveolar space, mucosal surfaces) in which they are constantly exposed to microbial 
stimuli. A sensitive response in macrophages to such stimuli for the release of IL-lß at each 
encounter with such exogenous stimuli would result in recurring and deleterious 
inflammatory reactions. Thus, repeated bouts of inflammation are probably reduced by the 
requirement for a second stimulus for the activation of the inflammasome and release of 
active IL-lß. 
Signal 1 
I LPS 
CrjJii 
TLR4 
Macrophage 
Signal 2 .
 A T p 
MyD88 
à 
IL-lß 
NALP3ASC 
Pro-caspase-1 caspase-1 
NF-KB • ProlL-lß - • IL-lß 
Sigial i 
I LPS 
«-»Mal 
Monocyte 
IL-1ß 
'Mal 
MyDSB 
NF-κβ 
NALP3 ASC 
Pro-caspase-1 
— • ProlL-lß 
»caspase-1 
1. 
-» IL-1ß 
Figure 3. Diagram representing the IL-lß activation pathways in macrophages and monocytes. Macrophages 
need a double stimulation for IL-lß production: one stimulus (TLR-ligands) induces transcription, and a second 
stimulus (ATP) induces IL-lß secretion. In contrast, monocytes release mature IL-lß after single stimulation 
with TLR ligands alone. 
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Summary 
Background: Interleukin (IL)-lß has an important role in antifungal defense mechanisms. The 
inflammasome is thought to be required for caspase-1 activation and processing of the 
inactive precursor pro-IL-lß. The aim of the present study was to investigate the pathways 
of IL-lß production induced by Candida albicans in human monocytes. 
Methods: Human mononuclear cells were stimulated with C. albicans or mutant strains 
defective in mannosylation or chitin. Receptors were blocked with specific antagonists, and 
the IL-lß concentration was measured. 
Results: Human primary monocytes produce bioactive IL-lß when stimulated with C 
albicans. The transcription of IL-lß was induced through mannose receptor (MR), Toll-like 
receptor (TLR) 2, and dectin-1 but not through TLR4 and TLR9. W-mannan-linked residues, 
chitin, and ß-glucan from C albicans are important for IL-lß stimulation. Surprisingly, 
processing and secretion of IL-lß in monocytes did not require pathogen-mediated 
inflammasome activation, because of the constitutive activation of caspase-1 and the 
capability of monocytes to release endogenous adenosine-5'-triphosphate. 
Conclusions: This study is the first dissection of the molecular mechanisms of IL-lß 
production by a fungal pathogen. Transcription through mannan/chitin/MR and ß-
glucan/dectin-l/TLR2 induces production of IL-lß by C. albicans in human monocytes, 
whereas processing of IL-lß is mediated by constitutively active caspase-1. 
Introduction 
Candida species are among the most common nosocomial bloodstream pathogens in the 
United States and Europe (1,2), and candidemia is associated with a high crude mortality 
rate of 40% (3,4). The main host defense mechanisms in systemic candidiasis are 
phagocytosis and the killing of Candida albicans by neutrophilic granulocytes, monocytes, 
and macrophages (5,6). The proinflammatory cytokines tumor necrosis factor-α (TNF-a) and 
interleukin (IL)-lß are essential for anti-Candida host defense through neutrophil 
recruitment and phagocytosis (7), and interferon-γ (IFN-γ) has been shown to be important 
for nitric oxide (NO) production by macrophages (8). IL-1-α and IL-lß-deficient mice have 
increased mortality rates, with endogenous IL-la and IL-lß required for the induction of 
protective inflammatory responses in disseminated candidiasis (9). 
In contrast to other proinflammatory cytokines, IL-lß and IL-18 lack a signal peptide (10). 
After transcription and translation, pro-IL-lß is processed by the caspase-1 protease; 
secretion that is dependent on the interaction of adenosine-5'-triphosphate (ATP) with the 
P2X7 receptor then follows (11). It has been recently shown that activation of caspase-1 in 
human monocytic leukemia (THP-1) cells and mouse macrophages requires a protein 
complex known as the "inflammasome" (12,13). Detection of specific pathogen-associated 
molecular patterns (PAMPs) or danger signals by the inflammasome is achieved by proteins 
of the nucleotide-binding oligomerization domain-like receptor (NLR) family, such as 
cryopirin (NALP3) or IL-1-converting enzyme (ICE) protease-activating factor (Ipaf), leading to 
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a conformational change in caspase-1 and caspase-1 activation (14). Caspase-1 activity is 
essential for host defense against infection with Francisella tularensis (15), Legionella 
pneumophila (16), Shigella species (17), and Pseudomonas aeruginosa (18). In addition to IL-
lß and IL-18, ΙΡΝγ is also indirectly dependent on caspase-1 activity, because of its induction 
by IL-18 (19). 
No component of C. albicans has yet been reported to be able to interact with the NLR 
receptors that form the protein platform of the inflammasome. Therefore, the formal 
possibility exists that C. albicans differs significantly from other pathogens in the way that IL-
lß is induced. In the present study, we investigated how IL-lß is induced, processed, 
secreted, and regulated by C. albicans in human monocytes, as well as the extent to which 
caspase-1 plays a role in this pathway. We concluded that the conventional pathway of 
caspase-1 activation by the inflammasome complex is bypassed during host-Cand/da 
interaction. 
Methods 
Volunteers 
Blood samples were collected from 14 healthy, nonsmoking volunteers who were free of 
obvious diseases. After written informed consent was obtained, venipuncture was 
performed to collect blood into 10-mL ethylenediaminetetraacetic acid (EDTA) syringes 
(Monoject). 
Mice 
Ipaf-deficient, NALP3-deficient, and caspase-1-deficient mice on a C57BL/6 background were 
previously described elsewhere (20-22). Age-matched C57BL/6 mice were used as control 
mice. Animal experiments were approved by the Institutional Animal Care and Use 
Committee at St. Jude Children's Research Hospital (Memphis, Tennessee). 
Reagents 
The irreversible caspase-1 inhibitor Ac-Tyr-Val- Ala-Asp-2,6 dimethylbenzoyl-
oxymethylketone (YVAD) was purchased from Alexis Biochemicals, reconstituted in 10 
mmol/L dimethyl sulfoxide (DMSO), and subsequently diluted to the desired concentration 
in medium (RPMI1640). The proteinase 3 inhibitor and lipopolysaccharide (LPS) (Escherichia 
coli serotype 055:B5) were purchased from Sigma. LPS was repurified as described 
elsewhere (23). Mouse anti-human monoclonal anti-Toll-like receptor (TLR) 4 HTA125 
antibody (aTLR4) was provided by Kensuke Miyake (Saga Medical School, Saga, Japan). 
Mouse anti-human monoclonal anti-TLR2 antibody (aTLR2) was provided by Douglas 
Golenbock (University of Massachusetts, Boston). Mouse anti-human monoclonal anti-
CD14 WT14 antibody (aCD14) was a gift of Wil Tax (Radboud University Nijmegen Medical 
Centre, Nijmegen, The Netherlands). Anti-dectin-1 antibody (aDectin-1) was a gift of Gordon 
Brown (University of Capetown, Capetown, South Africa). Mouse control antibody was 
purchased from Sigma. Chitin was prepared according to protocols described elsewhere 
(24). C. albicans mannan (mannan) was provided by David L. Williams (East Tennessee State 
University, Johnson City, Tennessee). TLR9 was inhibited with oligodeoxynucleotide 
TTAGGG: 5'- TTTAGGGTTAGGGTTAGGGTTAGGG-S' (aTLR9) (InvivoGen). Syk inhibitor (Syk-i) 
was purchased from Calbiochem. P2X7 receptor was inhibited with oxATP (Sigma). In 
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experiments using pharmacological inhibitors, control cells were treated with an equivalent 
concentration of vehicle (0.01%-0.1% DMSO). 
C. albicans strains and mutants 
C. albicans ATCC ΜΥΑ- 3573 (UC 820) (25) was used, unless otherwise indicated. Candida 
organisms were grown overnight in Sabouraud broth at 37°C, and cells were then harvested 
by centrifugation, washed twice, and resuspended in culture medium (RPMI 1640; ICN 
Biomedicals) (26). To generate pseudohyphae, C. albicans bias- toconidia were grown at 
370C in culture medium, which was adjusted to a pH of 6.4 by use of hydrochloric acid. 
Pseudohyphae were killed for 1 h at 100°C and were resuspended in culture medium to a 
hyphal inoculum size that originated from Ixl0e6 microorganisms/mL blastoconidia 
(referred to as "Ixl0e6 microorganisms/mL pseudohyphae") (26). The C. albicans CAI4 strain 
(i.e., the wild-type strain), ochl null mutant (defective in outer, branched /V-linked glycans) 
(27), mntl/mnt2 double null mutant (lacking the 4 terminal O-linked 1,2-mannosyl residues) 
(28), mnn4 null mutant (lacking phosphomannan) (29), CAF2 wild-type strain, and chsl null 
mutant (defective in chitin) were used and have been well described elsewhere (30). 
Isolation of peripheral blood mononuclear cells (PBMCs) and in-vitro stimulations 
Separation and stimulation of PBMCs were performed as described elsewhere (31). Cells 
were adjusted to 5xl0e6 cells/mL They then were incubated at 37°C in round-bottom 96-
well plates (5xl0e5 cells in total volume 200 L/well) with either heat-killed C. albicans (10e6 
microorganisms/mL) or culture medium, with or without caspase-1 inhibitor at different 
concentrations. In some experiments, PBMCs were preincubated for Ih with antibodies 
(anti-TLR4, 20 μg/mL; anti-TLR2, 20 μg/mL; anti-CD14, 20 μg/mL; and anti-Dectin-1, 10 
μ£/Γπί) or inhibitors (Syk-i, 50 nmol/L; chitin, 20 μg/mL; and mannan, 200 μg/mL) before 
stimulation with C. albicans. After 24h, supernatants were collected and stored at 20°C until 
assayed. To investigate the role of endogenous ATP in the secretion of IL-lß, stimulations 
with RPMI and C. albicans were performed with or without oxATP for 24 h. For ATP 
measurements, PBMCs and macrophages were stimulated with RPMI or C. albicans. After 
24h, the supernatants were collected and directly measured. 
Production of cytokines by mouse macrophages 
Resident peritoneal mouse macrophages were obtained aseptically with ice-cold PBS. Cells 
were resuspended in RPMI in a round-bottom 96-well plate (10e5 cells/well). For cytokine 
production, mouse macrophages were stimulated with culture medium as a negative control 
or with heat-killed blastoconidia (ATCC ΜΥΑ- 3573; 107 microorganisms/mL). 
Cytokine assays 
IL-lß concentrations were measured using a commercial ELISA kit (DY201; R&D Systems; 
Pelikine-Compact (Sanguin)), according to the manufacturers instructions. The presence of 
TNFa was determined by specific radioimmunoassay (detection limit, 20 pg/mL), as 
described elsewhere (32). Murine IL-la, IL-lß, and IL-6 concentrations were determined 
using specific radioimmunoassay, as described elsewhere (32). ATP concentrations in the 
supernatants were assessed using a firefly luciferase assay (ATP determination kit; 
Invitrogen). 
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Western blot assay 
PBMCs (10e7 cells/well in a total volume of 1 mL) were incubated for 2h (to evaluate 
caspase-1 activation) and 24h (to assess pro-IL-lß processing) with either heat-killed C. 
albicans (10e6 microorganisms/mL) or culture medium. THP-1 cells were cultured in RPMI 
medium and 10% fetal calf serum and were used for Western blot analysis of caspase-1. 
Cells were lysed in 100 μ ι of lysis buffer and were centrifuged (at 10,000 g for 5 min), and 
the protein content was determined by use of a bicinchonic acid protein assay (Pierce). 
Equal amounts of protein were loaded on 12% SDS-PAGE and transferred onto nitrocellulose 
membranes. For supernatants, 30 μΐ aliquots were loaded. Membranes were blocked in 
Tris-buffered saline-Tween (TBS-T) containing 3% w/v skim milk. For measurement of (pro-
)IL-lß, membranes were incubated with anti-(pro-)IL-lß polyclonal antibody (1/1000 
dilution) (Cell Signaling). For caspase-1 quantitation, membranes were incubated with 
specific caspase-1 plO polyclonal antiserum (1/500 dilution) (Santa Cruz), ß-actin was 
quantified as an internal control by use of specific anti-ß-actin polyclonal antiserum (1 / 1000 
dilution) (Santa Cruz). Blots were washed and incubated with peroxidase-conjugated goat 
anti-rabbit IgG (1/1000 dilution). After the blots were washed 3 times with TBS-T, they were 
developed with Hyper ECL(GE Healthcare), according to the manufacturer's instructions. 
Quantitative polymerase chain reaction (qPCR) 
PBMCs were stimulated as described above. After 4h, the supernatant was removed, and 
the cells were resuspended in 200μί of RNAzolB RNA isolation solvent (Campro Scientific) 
and stored at 80°C. mRNA was isolated according to the manufacturer's protocol. cDNA was 
synthesized from 1 μg of total RNA by use of SuperScript reverse transcriptase (Invitrogen). 
Relative mRNA levels were determined using the Bio-Rad i-Cycler and the SYBR Green 
method (Invitrogen). The following primers were used: IL-lß forward primer 5'-
TGGCCCAGGCAGTCAGA-S' and reverse primer 51- GGTTTGCTACAACATGGGCTACA-S' and 
ß2M forward primer 5'-ATGAGTATGCCTGCCGTGTG-3' and reverse primer 5'-
CCAAATGCGGCATCTTCAAAC-3' (Biolegio). Values are expressed as fold increases in mRNA 
levels, relative to those in unstimulated cells. 
Statistical analyses 
Differences were analyzed by the Wilcoxon rank test or the Mann-Whitney U test. P<0.05 
was considered to denote significance. All experiments were performed at least twice, and 
the data presented are the cumulative result of all experiments performed. Data are 
expressed as the median ± interquartile range (IQR). 
Results 
Induction of IL-lß production in PBMCs by Candida albicans 
Heat-killed C. albicans yeast cells, heat-killed C. albicans pseudohyphae, and live C. albicans 
are all capable of inducing secretion of IL-lß in the supernatant of PBMCs (Figure 1A). 
Mature IL-lß, but not pro-IL-lß, was found to be present in the supernatant by use of 
Western blot analysis (Figure IB). TaqMan reverse-transcriptase PCR analysis showed that 
heat- killed C. albicans yeast cells or pseudohyphae induced expression of IL-lß mRNA in 
human PBMCs 4h after stimulation. In line with the findings for IL-lß secretion, stimulation 
with heat-killed pseudohyphae was lower than stimulation with heat-killed yeast cells 
(Figure 1C). 
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Figure 1. Candida o/b/cons-induced production of interleukin (IL)-lß in peripheral blood mononuclear cells 
(PBMCs). 
A, Human PBMCs were stimulated with heat-killed C. albicans yeast cells, heat-killed C. albicans pseudohyphae, 
or live C. albicans yeast cells (expressed as the no. of microorganisms per milliliter). ELISA was used to measure 
the production of IL-lß in the supernatants of PBMCs incubated at 37°C for 24h. B, Western blot analysis for IL-
lß in the supernatants of PBMCs stimulated with either control RPMI 1640 medium or heat-killed C. albicans 
yeast cells (10e6 microorganisms/mL). C, Reverse-transcriptase quantitative polymerase chain reaction analysis 
of mRNA for IL-lß production in PBMCs stimulated for 4h with heat-killed C. albicans yeast cells or 
pseudohyphae {10e6 microorganisms/mL) or with RPMI 1640 medium. In panel A, the data are pooled from 3 
separate experiments involving a total of 8 healthy volunteers (median ± interquartile range; ·Ρ<0.05, by 
Wilcoxon rank test). Panel Β presents findings from 2 separate experiments (n=4), and panel C presents the 
average value of data from 2 separate experiments (n=4). 
Caspase-1-dependent IL-lß production induced by C. albicans 
IL-lß, but not TNFa, production induced by C. albicans was reduced in the presence of the 
caspase-1 inhibitor (YVAD), in a dose-dependent manner (Figure 2A). LPS-induced IL-lß 
production was also inhibited by YVAD, with a reduction of 50%-60% observed (Figure 2A). 
Interestingly, the proteinase 3 inhibitor alone did not result in a reduction in amounts of IL-
lß production; however, when used in combination with caspase-1 inhibitor, there was a 
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slight yet statistically significant inhibitory effect on IL-lß production (Figure 2A). Neither the 
PR3 inhibitor nor the caspase-1 inhibitor alone induced IL-lß production (data not shown). 
Western blot analysis confirmed that the lower IL-lß level denoted a reduction in mature IL-
lß (Figure 2B). Endogenous IL-lß can induce its own transcription (33). Indeed, transcription 
of IL-lß mRNA was reduced by the caspase-1 inhibitor (Figure 2C). 
Figure 2. Caspase-l-dependent Candida albicans-induced interleukin (IL)-lß production. 
A, Human peripheral blood mononuclear cells (PBMCs) were stimulated for 24h with heat-killed C. albicans 
yeast cells or pseudohyphae (106 microorganisms/mL) or with lipopolysaccharide (LPS; 1 ng/mL), with or 
without various concentrations of the caspase-1 inhibitor (casp-1 inh.; WAD) and with or without a PR3 
inhibitor (PR3 inh.) or a combination of PR3 inh. and YVAD. Production of IL-lß and tumor necrosis factor 
(TNF)a in the supernatants was measured by ELISA after incubation at 37°C for 24 h. B, Western blot analysis 
was performed for the detection of IL-lß in supernatants from PBMCs stimulated for 24h with heat-killed C. 
albicans yeast cells (10e6 microorganisms/mL) with or without a casp-1 inhibitor (20 μπιοΙΑ). C, Reverse-
transcriptase quantitative polymerase chain reaction analysis of mRNA for IL-lß in PBMCs stimulated for 4h 
with C albicans yeast cells (IxlOeS microorganisms/mL) with or without a caspase-1 inhibitor. In panel A, data 
are pooled from 3 separate experiments involving a total of 7 healthy volunteers (median ± interquartile range; 
*P<0.05, by Wilcoxon rank test). The data in panels Β and C are the average values from 2 separate 
experiments (n=4). 
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Constitutively active caspase-1 in human monocytes and endogenous ATP- dependent 
secretion of IL-Iß 
The possibility that C albicans stimulation activates caspase-1 was investigated by Western 
blot analysis Surprisingly, unstimulated PBMCs were found to have activated/processed 
caspase-1 (p35), and this was not upregulated by heat-killed C albicans yeast cells (Figure 
3A) To rule out the possibility that activation of caspase-1 occurred during the period of 
preparation of PBMCs, control experiments were performed using freshly isolated 
unstimulated PBMCs that were immediately lysed Once again, caspase-1 was found to be 
present in its processed/active form (Figure 3B) The THP-1 cells commonly used for studies 
of mflammasome activation showed no constitutively active caspase-1 (data not shown) 
We investigated the role of ATP in IL-lß secretion by stimulating monocytes with heat-killed 
C albicans in the presence or absence of a P2X7 receptor inhibitor (oxATP) oxATP strongly 
reduced IL-lß stimulation by C albicans, whereas the intracellular concentration was 
elevated (Figure 3C) This finding suggested that endogenous ATP was present m the 
supernatants, indeed, endogenous ATP was released in the supernatants by monocytes but 
not by macrophages (data not shown) To assess whether induction of IL-lß by C albicans 
was dependent on the mflammasome, peritoneal macrophages from mice deficient in 
NALP3, Ipaf, or caspase-1 were stimulated with heat-killed C albicans The production of IL-
lß was dependent on caspase-1 (Figure 3D) However, the absence of NALP3 or Ipaf did not 
alter IL-lß production (Figure 3D) In contrast to IL-lß, the production of IL-lß and IL-6 was 
not reduced in macrophages from mice deficient m either caspase-1 or NALP3/lpaf (data not 
shown) 
Mediation of IL-lß production through TLRl/dectm-l, mannose receptor (MR), and chitm 
receptor pathways 
The C albicans ochl null mutant is defective m outer, branched /V-lmked glycan formations, 
the mntl/mntl double null mutant lacks the 4 terminal O-lmked 1,2-mannosyl residues but 
has normal W-mannan, the mnn4 null mutant lacks phosphomannan, and the chsl null 
mutant has a 70% reduction in the chitm content of the wall PBMCs stimulated with the 
ochl null mutant or the chsl null mutant released significantly lower amounts of IL-lß than 
did the wild-type strains (Figure 4A) In contrast, were no differences in IL-lß production 
between the mntl/mntl double null mutant and mnn4 null mutants The ochl and chsl null 
mutants expressed lower levels of mRNA for IL-lß than did their wild-type strains (Figure 
4B), whereas transcription of the IL-lß gene was not affected when PBMCs were stimulated 
with the mntl/mntl and mnn4 mutants (data not shown). 
To investigate which receptors were involved in IL-lß production, PBMCs were stimulated 
with heat-killed C albicans yeast cells in the presence of anti-TLR4 antibodies (aTLR4), 
aCD14, aTLR9, aTLR2, aDectm-l, and mannan Chitin was used to block chitin-bindmg sites 
Inhibition of the mannan and chitm-signalmg pathway resulted in reduced IL-lß production, 
whereas TLR4, CD14, and TLR9 inhibition did not modify IL-lß production (Figure 4C) A 
second mechanism of IL-lß stimulation was represented by the TLR2/dectin-l pathway, 
because blocking of TLR2 or dectm-l inhibited the production of IL-lß In addition, 
pharmacologic Syk inhibition also resulted in reduced IL-lß production (Figure 4C) C 
albicans hyphae shield their ß-glucans from recognition (34) PBMCs stimulated with heat-
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killed Candida pseudohyphae showed no reduction in IL-lß production when the dectin-1 
receptor was blocked {Figure 4D). 
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Figure 3. Constitutively active caspase-1 in human monocytes and adenosine-5'-triphosphate (ATP)-
dependent interleukin (iL)-lß secretion in human peripheral blood mononuclear cells (PBMCs). 
A, Western blot analysis for the detection of caspase-1 and ß-actin in cellular lysates from PBMCs incubated 
with RPMI 1640 or Candida albicans at 37°C for 2h. B, Western blot analysis for the detection of caspase-1 and 
ß-actin in cellular lysates from unstimulated PBMCs directly lysed after isolation. C, Human PBMCs were 
stimulated with heat-killed C. albicans yeast cells (10e6 microorganisms/mL) in the presence or absence of the 
P2X7 receptor inhibitor oxATP. Production of IL-lß in the supernatants was measured by ELISA after 
stimulation at 37°C for 24h. Data are pooled from 2 separate experiments involving a total of 5 healthy 
volunteers (median ± interquartile range (IQR); *P<0.05, by Wilcoxon ranktest). D, In vitro IL-lß production by 
resident peritoneal macrophages (10e5 microorganisms/mL) stimulated with heat-killed C. albicans (10e7 
microorganisms/mL). The data in panel D are pooled from 2 separate experiments involving a total of 8 mice 
(median ± IQR; *P<0.05, by Mann-Whitney U test). Ipaf, IL-1 converting enzyme protease-activating factor; 
NALP3, cryopirin; NS, nonsignificant; WT BL6, wild-type C57BL/6. 
7A 
Chapter 6 
Figure 4. Dependence of interleukin (iL)-lß production on Toll-like receptor (TLR) 2, dectin-1, mannose 
receptor, and chitin pathways. 
A, Human peripheral blood mononuclear cells (PBMCs) were stimulated with heat-killed wild-type Candida 
albicans CAI4 or CAF2 and null mutants affected in cell wall glycosylation at a concentration of 10e6 
microorganisms/mL for 24h. IL-lß concentrations were measured by ELISA. Β, Reverse-transcriptase 
quantitative polymerase chain reaction analysis of mRNA for IL-lß in PBMCs stimulated with C. albicans chsl 
and ochl null mutants and their wild types. Human PBMCs were stimulated with heat-killed C. albicans yeast 
cells (C) or heat-killed pseudohyphae (10e6 microorganisms/mL) (D) in the presence or absence of specific 
receptor inhibitors (anti-TLR4 antibody (aTLR4), 20 μg/mL; anti-TLR2 antibody (aTLR2), 20 μg/mL; anti-CD14 
WT14 antibody (aCD14), 20 μg/mL; and antibody to the dectin-1 receptor (aDectin-1), 10 μg/mL), mannan (200 
μg/mL), or chitin (20 μg/mL) or Syk inhibitor (50 nmol/L). Production of IL-lp in the supernatants was 
measured by ELISA after stimulation at 37°C for 24h. Data are pooled from at least 2 separate experiments 
involving a total of at least 5 healthy volunteers (median ± interquartile range; *P<0.05, by Wilcoxon rank test). 
DMSO, dimethylsulfoxide; Syk-i, Syk inhibitor. 
Discussion 
In the present study, we demonstrated that C. oAb/cons-induced production of IL-lß in 
human PBMCs is dependent on the recognition of /V-mannan-linked residues, chitin, and ß-
glucan components of the C. albicans cell wall. This recognition is mediated through the MR 
and dectin-l/TLR2. Caspase-1 is the main enzyme responsible for IL-lß processing, whereas 
the serine protease PR3 plays a secondary role. However, although IL-lß production is 
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caspase-1 dependent, the regulation of its production mainly takes place at the level of 
transcription. This is because of the constitutive activation of caspase-1 in human PBMCs, as 
well as the capability of PBMCs to release endogenous ATP, leading to the secretion of the 
processed IL-lß. The implication of these findings is that Cond/do-induced activation of the 
inflammasome complex is not required for the induction of IL-lß by this fungal pathogen. 
The importance of understanding the mechanisms responsible for the production of IL-lß by 
C. albicans is underlined by the important role that IL-lß plays in ant\-Candida host defense 
(6). It is known that IL-lß is produced during infection with C. albicans (35). Accordingly, we 
show that, after contact with C. albicans, human PBMCs up-regulate mRNA for IL-lß and 
secrete mature IL-lß. To determine which receptors of human PBMCs and components of C. 
albicans are responsible for these developments, receptor inhibitors and C. albicans cell wall 
mutants were used. The outer layer of the C. albicans cell wall is enriched with 
mannoproteins, whereas the inner layer is composed of chitin and ßl,3- and ßl,6-glucan. 
Recently, we and other investigators have shown that mannoproteins, phospholipomannan, 
and ß-glucans are involved in cytokine stimulation induced by C. albicans (36-39). 
Recognition of mannosyl residues is mediated by MR binding to W-linked mannosyl residues 
and by TLR4 binding to O-linked mannosyl residues (40). 
A second pathway of cytokine production is mediated by the recognition of ß-glucan through 
the dectin-l/TLR2 receptor complex. This has been demonstrated for TNFa and IL-6, in 
which transcriptional regulation of cytokine production is very important. We demonstrated 
that stimulation of monocytes with C. albicans lacking W-linked mannosyl residues or 
blockade of the MR leads to a reduction in IL-lß production. In addition, chitin has also been 
reported to be recognized by MR (41). When chitin-binding sites were blocked, IL-lß 
production by C. albicans was significantly impaired. 
The lectin receptor dectin-1 recognizes ß-glucan and interacts with TLR2 (42, 43). TLR2 and 
dectin-1 are also involved in IL-lß production after activation by C. albicans yeast cells in 
human monocytes. Interestingly, TLR2, but not dectin-1, is involved in the induction of IL-lß 
by pseudohyphae, which is in line with the observation that C. albicans is able to completely 
mask its ß-glucans after transition from the yeast to the hyphal form (34). It is tempting to 
speculate that the loss of the additional effect of dectin-1 on TLR2 explains the lower 
amount of pseudohyphae-induced IL-lß production. Syk tyrosine kinase, which can be 
phosphorylated by the immunoreceptor tyrosine-based activation motif of dectin-1 (44), is 
also involved in the induction of IL-lß. 
In contrast, TLR4 is not involved in IL-lß production induced by C. albicans, because neither 
blocking of TLR4 or CD14 nor stimulation with the mntl/mr^double null mutant lacking the 
terminal 4 O-linked 1,2-mannosyl residues that bind to TLR4 (29) altered IL-lß production. 
This observation is surprising, considering that (1) C. albicans possesses known TLR4 ligands, 
such as O-linked mannosyl residues, that induce production of such proinflammatory 
cytokines as TNFa, and (2) LPS leads to potent IL-1 production after contact with human 
monocytes, suggesting that TLR4 is involved in induction of IL-lß (45). These findings show 
that redundant mechanisms are responsible for IL-lß stimulation by C albicans, and they 
un- derline the principle that specific receptors can induce transcription of different subsets 
of genes in response to the same ligand. This results in the ability of immune cells to induce 
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many different cytokine responses from a limited repertoire of receptors, according to the 
specific PAMPs that are present, and it helps to explain how the immune system induces 
tailored responses to specific pathogens. Similarly, phosphomannan is not involved. 
One has to acknowledge differences in the stimulation of cytokines - in this case IL-lß- by 
live or dead Candida organisms. Both of these forms of Candida organisms stimulated IL-lß. 
However, exposure of ß-glucans at the cell wall surface is more prominent when yeasts are 
heat killed (34). It is likely that the role of dectin-1 in IL-lß induction is more prominent 
when heat-killed Candida organisms are used instead of live yeasts. 
It has been suggested that processing of IL-lß is mediated by caspase-1 activation by the 
"inflammasome," a protein complex formed mainly by receptors of the NLR family (12). 
Several inflammasomes activate IL-lß during bacterial infections, including NALP3 (20) and 
Ipaf inflammasomes (46). Of note, no component of C. albicans has yet been reported to be 
able to interact with NLR receptors. We demonstrated that caspase-1 is the main enzyme 
that processes IL-lß produced by human monocytes stimulated with C. albicans. However, 
the inflammasome components NALP3 and Ipaf were not needed for Cond/do-induced 
production of IL-lß. The fact that we observed a reduction in mRNA transcription for IL-lß in 
PBMCs treated with a caspase-1 inhibitor can be explained by the known feedback loop of 
IL-lß transcriptional induction and confirms that the endogenous IL-lß production is 
bioactive (33). Furthermore, we observed that caspase-1 was already present in its active 
form in freshly isolated human PBMCs, and p35 was not up-regulated by C. albicans. This 
observation suggests that inflammasome activation in human monocytes is not an important 
regulatory step in IL-lß synthesis and release after stimulation with C. albicans, and it shows 
that, similar to IL-6 and TNFa production, IL-lß production by monocytes encountering C. 
albicans is mainly regulated at the level of transcription. In addition to caspase-1, the serine 
protease PR3 has also been proposed to be able to process pro-IL-lß (47). Our data show 
that PR3 has an additional effect, albeit a relatively limited one, in the processing of IL-lß. 
Other serine proteases, such as cathepsin G and elastase, can play similar additional roles. 
This likely explains the residual IL-lß production observed after maximal caspase-1 
inhibition. 
Although secretion of IL-lß is incompletely understood, evidence points to the P2X7 
receptor, a membrane receptor for extracellular ATP, as a key player in this process (48). In 
line with this evidence, we found that blocking the P2X7 receptor leads to a reduction in IL-
lß secretion by stimulated monocytes. In addition, it has been reported that monocytes can 
release endogenous ATP (49). We also observed that monocytes could release endogenous 
ATP and thus were able to provide their own signal for IL-lß secretion. 
In conclusion, we dissected the molecular mechanisms responsible for production of IL-lß 
by a fungal pathogen. Several important pathways are involved in these processes: C. 
albicans activates IL-lß through /V-mannan and chitin recognition by MR, and ß-glucan 
recognition by dectin-l/TLR2. It has also been suggested by Reese et al. (50) that chitin plays 
an important role as a PAMP in the innate immune system; however, whether receptors 
other than MR can recognize chitin remains to be elucidated. The tyrosine kinase Syk plays a 
role in the intracellular pathway inducing IL-lß gene activation (see the diagram presented 
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in Figure 5). We demonstrated that caspase-1 activation is constitutive and does not need 
recognition of C. albicans by the inflammasome in human primary mononuclear cells. These 
data question the role of the inflammasome in the induction of IL-lß by fungal pathogens. A 
deeper knowledge of the mechanisms of cell activation by Candida organisms may represent 
the basis for the future design of immunotherapeutic strategies in fungal infections. 
Figure 5. Pathway of activation of interleukin (IL)-lß by Candida albicans in human monocytes. 
Schematic representation of the induction and signaling pathway of IL-lß Induced by the fungal pathogen C. 
albicans in the human primary monocyte. Induction Involves a dectin-1/Toll-like receptor (TLR) 2 complex that 
recognizes ß-glucan, as well as mannose receptor (MR) recognizing W-linked mannan and chitin, leading to 
transcription of mRNA for IL-lß. There is a possibility that chitin induces cytokines through other receptors, but 
this has not yet been confirmed. The dectln-1 signaling pathway Is dependent on Syk and also induces 
transcription of mRNA for pro-IL-lß. Pro-IL-lß, in its turn, is cleaved by active caspase-1, which is constitutively 
activated in human monocytes, resulting in IL-lß processing and secretion. The end result of this cascade Is 
production of bioactive endogenous IL-lß. AP-1, activator protein-1; JNK, Jun N-terminal kinase; TNF, tumor 
necrosis factor. 
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Summary 
Introduction IL-lß is crucial for antifungal host defense and its processing is mediated by 
caspase-1, a protease that is activated by the Nlrp3 inflammasome Several studies have 
suggested that the inflammasome component Nlrp3 is involved in caspase-1 activation by 
Candida components In the present study we investigated the role of Nlrp3 in an m-vivo 
model model of murine disseminated candidiasis 
Materials and Method Bone marrow derived dendritic cells (BMDCs) from wild type (WT) 
and Nlrp3-/- mice were cultured for four hours in the presence or absence of live Candida 
albicans and western blots for capase-1 were performed on cell lysates WT and Nlrp3-/-
mice were intravenously infected with live Candida albicans and survival, fungal loads in the 
kidney, splenocyte restimulation with C albicans, and histology of the kidneys was assessed 
Results Western blots demonstrated that Nlrp3 was essential for caspase-1 activation by C 
albicans in BMDCs in vitro However, no differences were observed on survival or fungal 
outgrowth m the kidneys between wild type mice and Nlrp3/- mice IL-lß production by 
Nlrp3-/- splenocytes that were restimulated at day 3 and day 7 of infection with C albicans 
was not different from WT splenocytes In addition, concentrations of bioactive IL-1 in 
kidney homogenates was not different between Nlrp3-/- mice and WT mice Histological 
images of the kidneys from Nlrp3-/- mice were indistinguishable from the kidneys isolated 
from WT mice 
Conclusions The m-vitro induction of caspase-1 activation by C albicans involves 
engagement of Nlrp3 However, Nlrp3 is redundant for ll-lß processing in vivo and for the 
host defense against disseminated candidiasis in mice 
Introduction 
IL-lß plays an important role in anti-Candida host defense Mice deficient in IL-lß are more 
susceptible to disseminated Candida infection, and generation of reactive oxygen species is 
diminished in IL-lß-/- granulocytes (3) Furthermore, IL-lß-/- mice show decreased 
recruitment of granulocytes in response to intraperitoneal C albicans infection (3) In 
contrast to other promflammatorv cytokines, IL-lß lacks a signal peptide After transcription 
and translation, the inactive pro-IL-lß precursor is processed by caspase-1 into the active 
cytokine The activation of caspase-1 in macrophages and the subsequent processing of IL-
lß is dependent on the inflammasome, a multimene protein complex composed of ASC 
(apoptosis-associated speck-like protein containing a caspase recruitment domain), caspase-
1 and one or more nucleotide-bmding domain leucme-nch repeat receptors (NLRs) (4) The 
NLRs link pattern recognition to caspase-1 activation and subsequently IL-lß production (5). 
Recent studies suggest that the inflammasome component Nlrp3 transduces Candida 
recognition into caspase-1 activation, and that this process is important for antifungal host 
defense (6, 7) However, a previous m-vitro investigation in human primary cells suggested 
IL-lß induction by C albicans in a Nlrp3-independent pathway (8) To address the role of the 
Nlrp3 inflammasome in invasive Candida infection, we studied the susceptibility to 
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disseminated candidiasis of mice deficient in Nlrp3. We report that NlrpS has a redundant 
role for host defense in disseminated Candida infection. 
Results 
In vitro caspase-1 activation is dependent on Nlrp3 
Upon recognition of pathogens the intracellular microbial sensors (such as Nlrp3) will be 
activated. Nlrp3 will then interact and recruit the adaptor molecule ASC. Subsequently, ASC 
will bind and recruit caspase-1 to the inflarnmasome (4). The key function of this process is 
to convert inactive pro-caspase-1 (p45) into its active form caspase-1 (plO). We examined 
whether Nlrp3 was essential for the C. o/fa/cons-induced caspase-1 activation. When BMDCs 
were stimulated with Candida, caspase-1 activation was dependent on Nlrp3 (Figure 1). 
These data are in line with previous studies reporting that Nlrp3 is crucial for caspase-1 
activation in-vitro. 
NlrpS'''' mice are equally susceptible to disseminated candidiasis 
Twenty two days after intravenous injection of 2xl05 colony forming units (CFU) of C. 
albicans, 83% of the WT mice survived the infection (Figure 2A). In contrast to the recently 
reported data, Nlrp3 -/- mice did not show an increased susceptibility (Figure 2A). In 
addition, no differences were observed in the fungal loads in the kidneys of Nlrp3-/- mice on 
day 3 and day 7 of infection compared to the WT mice (Figure 2B). We repeated this 
experiment on day 7 of infection and again found no significant difference: control mice 4.2 
± 0.6 (mean ± SD) versus Nlrp3-/- mice 3.4 ± 2.3 (mean ± SD) Log/CFU per gram kidney 
(P=0.52). 
Cytokine production in Nlrp3 knockout mice 
Because it has been suggested that Nlrp3 controls IL-lß production in response to C. 
albicans (6, 7, 9, 10), we tested the importance of Nlrp3 in the production of IL-lß by 
splenocytes. Splenocytes from WT mice and Nlrp3 deficient mice were isolated on day 3 and 
day 7 of infection and re-stimulated with heat killed C. albicans. The ability of C. albicans to 
transform into hyphae is crucial for providing the second signal for Nlrp3 inflarnmasome 
activation and subsequently IL-lß production (9), therefore we stimulated with C. albicans 
yeast cells and hyphae. We observed no difference in the amount of IL-lß produced by 
either wild-type splenocytes or Nlrp3-/- splenocytes (Figure 3A,B). Furthermore, IFNy and 
the inflarnmasome independent cytokine TNFa were also not impaired in the Nlrp3-/- and 
mice (Figure 3A,B). 
Equal inflammatory response in the kidneys ofNlrp3-/- mice compared to WTmice 
Although NlrpS deficiency did not result in increased susceptibility or a different cytokine 
profile, it did play a crucial role in the induction of caspase-1 in-vitro. Therefore the kidneys 
were examined by histology for abnormalities. Nlrp3 deficient mice did not display any 
difference in inflammatory characteristics on day 3 or day 7 when compared to WT mice 
(Figure 4A). When cytokines were measured in the kidney homogenates, there was no 
difference in the amount of bioactive IL-1 or ΙΡΝγ between control and Nlrp3-/- mice (Figure 
4B). 
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Figure 1. In vitro caspase-1 activation is dependent on Nlrp3. 
Lysates from bone marrow-derived dendritic cells (BMDCs) from WT and Nlrp3-/- mice were collected 4 hours 
after exposure to 1x10 CFU live C albicans/m\, and immunoblotted with anti-caspase-1 antibody. p45 
indicates procaspase-1 and p20 processed caspase-1. 
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Figure 2. Nlrp3 mice are equally susceptible to disseminated candidiasis. 
(A) Kaplan-Meier survival plots of WT and Nlrp37-mice after intravenous infection with 2xl0 5 CFU C. 
albicons/mouse. n=10 mice per group. (B) Fungal burden of kidneys of WT and Nlrp37- mice after intravenous 
infection with 2x10 CFU C albicans/mouse. n=5 mice per group. 
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Figure 3. Cytokine production in Nlrp3 knockout mice. 
(A) Splenocytes from WT and Nlrp3 / mice were restimulated with IxlO 6 C albicans yeast cells/ml (black bars) 
or 1x10 C. albicans hyphae/ml (grey bars) at day 3 (A) and day 7 (B) after Intravenous infection with C. 
albicans. Cytokines were measured 48 hours after stimulation with ELISA. *p<0.05. n=5 mice per group. 
Figure 4. Equal inflammatory response in the kidneys of Nlrp3-/- mice compared to WT mice. 
(A) Histopathologic assessment of the kidneys of WT and Nlrp37- mice after intravenous injection with 2xl0 5 
CFU C albicans. No differences were seen In the Inflammatory reaction on day 3 and 7 after infection between 
Nlrp3-/- mice and WT mice. (A) Neutrophilic infiltrates In the kidneys of WT and Nlrp3-/- mice with 
disseminated candidiasis at day 3 of Infection; Images represent the observed equal inflammation in WT and 
Nlrp3-/- mice at day 3 and day 7 of infection. (Β) ΙΡΝγ and bioactive IL-lß measured In the kidney homogenates 
from WT and Nlrp37- mice, 7 days after intravenous infection with C albicans. n=5 mice per group. 
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Discussion 
Despite the fact that several studies have attempted to investigate the activation of the 
inflammasome by C. albicans, the role of the inflammasome in vivo remains controversial 
(11). On the one hand, IL-lß is important for mounting an efficient anti-Candida host 
defense and its tight regulation is of critical importance during infection (3). Recently, it has 
been proposed that the production of IL-lß in response to C. albicans was dependent on the 
Nlrp3 inflammasome (6, 7, 9). Nlrp3 links pattern recognition of Candida to caspase-1 
activation and subsequently IL-lß production. On the other hand, these novel studies are in 
contradiction with the study of Mencacci et al., who suggested that caspase-1 is not 
essential during primary disseminated infection with C albicans in a murine model (12), and 
the report that IL-lß induction in human primary cells circumvents activation of the 
inflammasome (8). Another controversial observation was made by Gross et al. who 
reported that all Nlrp3 deficient mice with disseminated candidiasis died within 7 days and 
fungal loads were 10.000 times higher in the kidneys (6), while previous reports have shown 
that IL-lß deficient mice during disseminated candidiasis have a moderate mortality and 
much less increase in fungal loads (3). 
Because of all these inconsistencies in the literature concerning this potentially important 
anti-candidal host defense mechanism, we aimed to assess the role of Nlrp3 during 
disseminated candidiasis. Although we were able to demonstrate that the in-vitro induction 
of caspase-1 by live Candida was Nlrp3-dependent, Nlrp3 deficient mice were not more 
susceptible to disseminated candidiasis. It is of course possible that the use of Nlrp3 
deficient mice generated in different institutes, and infection with different Candida strains 
could explain the contradictory observations found in our study and that of Gross et al. It 
must however be mentioned that the differences found are remarkably striking. Even when 
we used a double dose of intravenously administered live Candida compared to that used by 
Gross et al., we observed that 100% of the Nlrp3 deficient mice survived 22 days after the 
initiation of infection and they had no significant differences in fungal loads, while in the 
study of Gross et al. there was 100% mortality after 7 days and a 10.000 higher fungal 
burden in the kidneys (6). While we can confirm the in-vitro role of Nlrp3 for caspase-1 
activation, as reported by Joly et al., their in-vivo experiments involved only four mice, 
precluding any strong conclusions (9). In contrast, the study of Mise et al. investigated a 
model of oral candidiasis (7) that is known to have a different pathophysiology. Additional 
studies are needed to address these contradictory findings. 
Notably, our observation that Nlrp3 is not essential for bioactive IL-1 at the site of infection 
underscores the argument that IL-lß processing during disseminated Candida infection does 
not require pathogen-mediated Nlrp3 activation (8). This observation suggests that during 
the early stages of infection prolL-lß can be processed without the need of inflammasome 
induction and subsequently caspase-1 activation, most likely through the activity of 
neutrophil-derived serine proteases (13,14). In line with this, histology of the kidneys at day 
3 and day 7 of infection predominantly shows neutrophil infiltrates in both WT and Nlrp3 
deficient mice, and neutrophils are the main source of proteinase-3 that is also able to 
process pro-IL-lß into mature bioactive IL-lß. 
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In conclusion, in the present study we have dissected the role of Nlrp3 for IL-lß production 
and antifungal host defense in vitro and in vivo. These experiments clearly demonstrate a 
crucial role for Nlrp3 in the activation of caspase-1 by live Candida in-vitro. However, in in-
vivo disseminated candidiasis, Nlrp3-mediated antifungal host defense was redundant. The 
Nlrp3-induced activation of the inflammasome by Candida most likely represents one of the 
mechanisms by which the host can regulate IL-lß in vivo, but in the absence of Nlrp3 other 
mechanisms such as neutrophil derived proteinase-3 can compensate for Nlrp3 deficiency 
during infectious states. 
Materials and Methods 
Mice and bone marrow derived dendritic cells (BMDCs) 
Nlrp3-/- mice backcrossed to C57BL/6 background for at least 10 generations have been 
described before (15,16). Bone marrow was prepared from the leg bones of 8-20-week-old 
mice. The legs were dissected, and the bone marrow flushed out. DCs were differentiated 
from bone marrow cells cultured with RPMI-1640 supplemented with 20ng/ml GM-CSF 
along with 10% heat inactivated fetal bovine serum (Invitrogen), 100 U/ml penicillin and 100 
mg/ml streptomycin at 37 °C in 5% C02 for 7 days. Mice were housed in a pathogen-free 
facility. 
C. albicans growth conditions 
C. albicans ATCC MYA-3573 (UC 820), a strain well described elsewhere (17), was used in all 
experiments. Candida was grown overnight in Sabouraud broth at 37°C, cells were 
harvested by centrifugation, washed twice, and resuspended in culture medium in culture 
medium (RPMI-1640 Dutch modification, ICN Biomedicals, Aurora, OH) (18). For in-vitro 
experiments, C. albicans was heat-killed for Ih at 100oC. To generate pseudohyphae, C. 
albicans blastoconidia were grown at 37°C in culture medium, adjusted to pH 6.4 by using 
hydrochloric acid. Pseudohyphae were killed for Ih at 100oC and resuspended in culture 
medium to a hyphal inoculom size that originated from 106/ml blastoconidia (referred to as 
106/ml pseudohyphae) (18). 
C. albicans infection model 
Knock-out mice and WT mice were injected intravenously with C. albicans blastoconidia (2 χ 
105 CFU/mouse) in a 100 μΙ volume of sterile pyrogen-free phosphate-buffered saline (PBS). 
Survival was assessed daily for 22 days. Subgroups of 5 animals were killed on days 3 or 7 of 
infection. To assess the tissue outgrowth of the microorganisms, the kidneys of the 
sacrificed animals were removed aseptically, weighed, and homogenized in sterile saline in a 
tissue grinder. The number of viable Candida cells in the tissues was determined by plating 
serial dilutions on Sabouraud dextrose agar plates as previously described (19). The CFU 
were counted after 24h of incubation at 370C, and expressed as log CFU/g tissue. For 
histologic analysis, kidneys of subgroups of mice (5 mice/group) were fixed in buffered 
formaldehyde (4%). Paraffin-embedded sections were stained with hematoxylin-eosin. 
In vitro cytokine production by primed splenocytes 
To assess cytokine production, primed spleen cells from mice on day 3 and day 7 of infection 
with 2xl05 CFU of C. albicans per mouse were stimulated in vitro with heat-killed Candida 
conidia or hyphae (IxlO6 microorganisms/ml). Spleen cells were obtained by gently 
90 
Chapter 7 
squeezing spleens in a sterile 200 mm filter chamber. The cells were washed and 
resuspended in RPMI1640, counted in a Bürker counting chamber and the number was 
adjusted to 5xl06/ml. 500 μί of the cell suspension was stimulated with IxlO6 heat killed C. 
albicans/mi. Measurement of IL-lß, IFNy and TNFct concentrations was performed in 
supernatants collected after 48 h of incubation at 37 1C in 5% C02 in 48-well plate. 
Cytokine quantification 
A Bioplex mouse X-plex assay (BioRad) was used according to the manufacturer's 
instructions in order to evaluate the quantity of the following cytokines: TNFct, IL-lß and 
IFN-y. Bioactive IL-1 secretion was determined in a bioassay using the murine thymoma cell 
line EL4/NOB 1 as an IL-1-specific cell-producing IL-2 response. IL-2 was subsequently 
determined by ELISA (R&D). 
Immunoblottingfor caspase-1 
BMDCs were first stimulated for 4 hours with live C. albicans in a concentration of IxlO4 
CFU/ml and subsequenlty washed twice with phosphate-buffered saline and scraped in lysis 
buffer solution (150 mm NaCI, 10 mm Tris, pH 7.4, 5 mm EDTA, 1 mm EGTA, 0.1% Nonidet P-
40) supplemented with a protease inhibitor mixture tablet (Roche Applied Science). Samples 
were clarified, denatured with SDS buffer, and boiled for 5 min. Proteins were separated by 
SDS-PAGE and transferred to nitrocellulose membranes. The membranes were 
immunoblotted with primary antibodies and proteins detected with appropriate secondary 
anti-rabbit antibody conjugated to horseradish peroxidase followed by enhanced 
chemiluminescence. Rabbit anti-mouse caspase-1 was a generous gift from Dr. P. 
Vandenabeele (Gent University, Belgium). 
Statistical analysis 
Data were analyzed using GraphPad software. The differences between groups were 
analyzed by the Mann-Whitney U test or Student's t-test where appropriate. Comparison of 
two survival curves was done using the Logrank test. The level of significance between 
groups was set at p<0.05. Reproducibility of data was tested in two separate experiments. 
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Chapters 
Summary 
The Nlrp3 inflammasome has been proposed to play an important role in antifungal host 
defense. However, the in-vivo role of the inflammasome component ASC in disseminated 
candidiasis has not been studied, and previous studies examining the role of caspase-1 in 
anti-Cand/do host defense are contradictory. Furthermore, the main mechanisms controlled 
by the inflammasome that are responsible for antifungal host defense have not yet been 
elucidated. In the present study we demonstrate an essential role for caspase-1 and ASC in 
disseminated candidiasis through regulating antifungal Thl and Thl7 responses. These 
observations identify a critical role for the inflammasome in controlling protective adaptive 
immune responses during invasive fungal infection. 
Introduction 
The available treatment options have not reduced the mortality and morbidity associated 
with invasive Candida infections over the recent years, and a better understanding of the 
host defense against Candida is crucial to develop new strategies that will improve clinical 
outcome in patients with disseminated candidiasis. IL-lß and IL-18 play an important role in 
anti-Candida host defense and these cytokines are specifically controlled by the 
inflammasome, a multimeric protein complex composed of ASC (apoptosis-associated speck-
like protein containing a caspase recruitment domain), caspase-1 and one or more 
nucleotide-binding domain leucine-rich repeat receptors (NLRs) (1). The NLRs serve as 
danger sensors which connect upstream signals to caspase-1 activation (2). 
Recently, it has been reported that Nlrp3 is the crucial NLR family member that connects 
Candida recognition to caspase-1 activation. Mice deficient in Nlrp3 were highly susceptible 
to disseminated candidiasis (3) and mucosal candidiasis (4). It has therefore been suggested 
that the inflammasome is crucial for antifungal host defense. However, the in-vivo role of 
the inflammasome component ASC has not been studied in disseminated candidiasis, and 
previous studies examining the role of caspase-1 in ant\-Candida host defense are 
contradictory (5). In the present study we have addressed the role of the inflammasome in 
invasive candidiasis by studying the susceptibility of caspase-1, ASC, or P2X7 deficient mice 
to disseminated candidiasis, and observed that caspase-1 and ASC, but not P2X7, have 
strong protective antifungal capacities by controlling Thl and Thl7 responses during 
disseminated candidiasis. 
Results and discussion 
Caspase-l^' and ASC^, but not P2X7~/~ mice, are more susceptible to disseminated 
candidiasis 
Recent studies suggest that the production of IL-lß in response to C. albicans is critically 
dependent on the Nlrp3 inflammasome (3). However, the essential role of Nlrp3 and 
caspase-1 in anti-Candida host defense is controversial (5, 6). Because of all these 
inconsistencies in the literature concerning this potentially important anti-Candida host 
defense mechanism, we aimed to assess the role of the inflammasome during disseminated 
candidiasis using knock-out animals deficient in the crucial components of the 
inflammasome; caspase-1 and ASC. Twenty two days after intravenous injection of 2xl05 
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colony forming units (CFU) of C. albicans, 83% of the WT mice survived the infection (Figure 
1A). When caspase-l"'" mice were infected, they showed a higher susceptibility to 
disseminated candidiasis, with 50% overall survival after 22 days of infection (Figure 1A). 
ASC"'" mice also showed a higher mortality than WT mice with 54% survival of ASC"'" mice 22 
days after infection (Figure IB). 
Mice with hematogenously disseminated candidiasis die because of progressive sepsis (7). 
Notably, kidney fungal burden is correlated with severity of renal failure and systemic 
acidosis, which are hallmarks of severe sepsis (7). We therefore investigated the fungal loads 
in the kidneys of the WT mice and knockout mice. In line with the higher susceptibility to 
disseminated candidiasis demonstrated by the survival experiments, caspase-1 mice had a 
62-fold increase, and ASC-/- mice had a 13-fold increase in fungal load on day 7 compared to 
wild-type mice (Figure IC). Histology showed that large amounts of C. albicans had 
accumulated on day 7 of infection in the collecting ducts of caspase-l"'" mice that directly 
invaded the tissue (Figure ID), which was not observed in the WT mice. These findings are 
different from a previous study which reported that caspase-1 deficiency had no critical 
effect on primary disseminated candidiasis (5). In the latter study however, infection with a 
virulent C. albicans strain resulted in 100% mortality in both the control group and caspase-1 
deficient mice, while infection with an avirulent C. albicans strain resulted in almost 100% 
survival in both groups. This makes it difficult to draw conclusions about the susceptibility of 
the caspase-1 deficient mice during these infections, as no intermediary (LD50) mortality 
rates were performed in any of the experiments. Overall our data clearly demonstrate an 
important role for the inflammasome components ASC and caspase-1 in antifungal host 
defense against disseminated candidiasis. 
Processing of IL-lß and IL-18 by the inflammasome in macrophages and DCs requires two 
signals. One signal such as LPS is needed to provide the substrate, pro-IL-lß or pro-IL-18, and 
a second signal is required to activate the caspase-1. A second signal that is able to induce 
caspase-1 activation is ATP, and this effect is dependent on the ATP membrane receptor 
P2X7. Although P2X7 could therefore be crucial in the induction of the inflammasome in vivo 
it did not play a major role in disseminated candidiasis, since there was no significant 
difference in survival or fungal outgrowth compared to WT mice (Figure IE). Furthermore, 
C albicans was able to induce ASC-dependent caspase-1 activation in BMDC without the 
need of ATP (Figure IF). Therefore, the P2X7 receptor is redundant for Cond/do-induced 
activation of the inflammasome in vitro and in vivo. 
Caspase-1 and ASC deficiency results in impaired Thl and Tbl7 responses 
Caspase-1, the essential enzyme of the inflammasome, is able to cleave the precursors pro-
IL-lß an pro-IL-18 into their mature active forms (8, 9). IL-lß plays an important role in the 
induction of the Thl7 response, which is characterized by the production of IL-17, a cytokine 
that is important for recruiting neutrophils and maintaining optimal neutrophil responses at 
the site of infection (10). Thl7 responses are crucial for protective anti-Candida host 
defense, since mice that are deficient in the IL-17 signaling pathway are highly susceptible to 
disseminated candidiasis (11), and patients that are deficient in Thl7 responses are highly 
susceptible to mucosal candidiasis (12). 
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We therefore tested the hypothesis that the inflammasome could play an important role in 
the induction of a protective antifungal Thl7 response. We observed that splenocytes from 
mice deficient in caspase-1 or ASC that were infected with Candida, had an impaired IL-lß 
response and were unable to mount normal production of IL-17 after restimulation with 
Candida (Figure 2A). Histology supported these findings since we observed remarkable little 
influx of neutrophils in the caspase-1 deficient mice (Figure ID). IL-17 concentrations and 
levels of bioactive IL-1 were also significantly lower in vivo at the site of infection (Figure 2B). 
Our data are in contrast with a recent report suggesting that the Nlrp3 inflammasome has no 
effect on Thl7 responses. However, this study only investigated the impact of Nlrp3 
deficiency on Thl7 responses, but not the impact of caspase-1, ASC, or P2X7 deficiency. 
IL-18 production is controlled by the inflammasome and is necessary for an optimal Thl 
response. Thl responses are characterized by IFNy production, and IFNy plays an important 
role in disseminated candidiasis (13,14). In line with these reports, we observed an impaired 
Thl response in response to C. albicans on day 7 of infection by splenocytes isolated from 
caspase-1-/- and ASC-/- mice (Figure 2A). IFNy levels in the kidney homogenstes were also 
significantly lower in the caspase-1-/- mice (Figure 2B). Although IL-lß, IFNy and IL-17 were 
reduced in the caspase-1 and ASC deficient mice, the production of the inflammasome-
independent cytokine TNFa was not reduced in the caspase-1 deficient mice and was even 
significantly elevated in the ASC-/- mice (Figure 2A). It is unknown why the TNF responses 
differ between ASC-/- and caspase-1-/- splenocytes and this is currently under investigation. 
Interestingly, we and others have observed that during early infection (day 3), the caspase-1 
deficient splenocytes did not have an impaired IL-lß or IFNy production when re-stimulated 
with C. albicans (data not shown, (5)). These observations suggest that during the early 
stages of infection prolL-lß and pro-IL-18 can be processed without the need of 
inflammasome induction and subsequently caspase-1 activation. Most likely the activity of 
neutrophil-derived serine proteases, which can also cleave pro-IL-lß and pro-IL-18, is 
responsible for these effects (15,16). 
We observed that the inflammasome specifically controls optimal IL-lß and IL-18 
concentrations during the later stages of infection, a time point where Thl and Thl7 
responses are critical for protective immunity. This would indicate that the inflammasome is 
a critical link between the innate and adaptive immune response during disseminated 
candidiasis. 
A recent study defined the protective mechanisms of immunity during Candida albicans 
bloodstream infections in mice immunized with the recombinant N-terminus of Als3p 
(rAls3p-N) vaccine plus aluminum hydroxide (alum) (17). Interestingly, vaccination resulted 
in protective Thl and Thl7 responses that enhanced phagocytic killing of C albicans, 
increased neutrophil influx, and decreased fungal burden in tissues. Since alum activates 
caspase-1 (18), it is tempting to speculate that adjuvant alum modulated the immune 
response towards protective Thl and Thl7 responses by activating the inflammasome, 
which would be in line with our findings. 
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Figure 1. Caspase-l and ASC , but not P2X7 mice, are more susceptible to disseminated candidiasis. 
(A) Kaplan-Meier survival plots of WT (n=10), caspase-l-/- (n=6) (B) Kaplan-Meier survival plots of WT, ASC-/-, 
n=10 mice per group. (C) Fungal burden of kidneys of WT, Caspase-l-/-, and ASC-/- mice at day 3 and 7 after 
infection. n> 5 mice per group. (D) Histopathologic assessment of the kidneys of WT and caspase-l -/- mice 7 
days after intravenous injection with 2xl05 CFU C. albicans. Kidneys from caspase-l-/- mice show C. albicans 
hyphae invading the tissue in the presence of little inflammation. Arrowheads mark neutrophil infiltrates and 
full arrows mark Candida hyphae. (E) Kaplan-Meier survival plots of WT and P2X7-/- mice, n=10 mice per 
group. (F) Fungal burden of kidneys of WT and P2X7-/- mice at day 3 and 7 after infection. n=5 mice per group. 
(G) Lysates from bone marrow-derived dendritic cells (BMDCs) from WT and ASC-/- mice were collected 4 
hours after exposure to 1x10 CFU C. albicans/m\, and immunoblotted with anti-caspase-1 antibody. p45 
indicates procaspase-1 and p20 processed caspase-l. 
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Figure 2. Cytokines in ASC, caspase-1 or P2X7 deficient mice. 
(A) Splenocytes from WT, ASC-/-, caspase-1-/-, and P2X7-/- mice were re-stimulated with RPMI (grey bars) or 
heat-killed Ix lO 6 C. albicans hyphae cells/ml (black bars) 7 days after intravenous infection with C. albicans. 
Cytokines were measured 48 hours after stimulation with ELISA. *p<0.05. n=5 mice per group. (Β) ΙΡΝγ, IL-17 
and bioactive IL-lß were measured in the kidney homogenates from WT and caspase-1-/- mice 7 days after 
intravenous infection with C. albicans. n=5 mice per group. 
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Conclusions 
An increasing interest has been elicited in the role of the inflammasome for the host defense 
against Candida infections. In the present study we have dissected the contribution of the 
inflammasome components caspase-1, ASC and P2X7 to the host defense against 
disseminated candidiasis. The data reported demonstrate that caspase-1 and ASC are crucial 
for anti-Candida host defense during disseminated candidiasis by promoting optimal 
antifungal protective Thl/Thl7 responses. 
Materials and Methods 
Mice and bone marrow derived dendritic cells (BMDCs) 
ASC-/-, caspase-1-/-, and P2X7-/- mice backcrossed to C57BL/6 background for at least 10 
generations have been described before (19, 20). Bone marrow was prepared from the leg 
bones of 8-20-week-old mice. The legs were dissected, and the bone marrow flushed out. 
DCs were differentiated from bone marrow cells cultured with RPMI-1640 supplemented 
with 20ng/ml GM-CSF along with 10% heat inactivated fetal bovine serum (Invitrogen), 100 
U/ml penicillin and 100 mg/ml streptomycin at 37 °C in 5% C02 for 7 days. Mice were 
housed in a pathogen-free facility. 
C. albicans growth conditions 
C. albicans ATCC MYA-3573 (UC 820), a strain well described elsewhere (21), was used in all 
experiments. Candida was grown overnight in Sabouraud broth at 37°C, cells were harvested 
by centrifugation, washed twice, and resuspended in culture medium in culture medium 
(RPMI-1640 Dutch modification, ICN Biomedicals, Aurora, OH) (22). For in-vitro experiments, 
C. albicans was heat-killed for Ih at 100oC. To generate pseudohyphae, C. albicans 
blastoconidia were grown at 37°C in culture medium, adjusted to pH 6.4 by using 
hydrochloric acid. Pseudohyphae were killed for Ih at 100oC and resuspended in culture 
medium to a hyphal inoculom size that originated from 106/ml blastoconidia (referred to as 
106/ml pseudohyphae) (22). 
C. albicans infection model 
Knock-out mice and WT mice were injected intravenously with C. albicans blastoconidia (2 χ 
105 CFU/mouse) in a 100 μΙ volume of sterile pyrogen-free phosphate-buffered saline (PBS). 
Survival was assessed daily for 22 days. Subgroups of 5 animals were killed on days 3 or 7 of 
infection. To assess the tissue outgrowth of the microorganisms, the kidneys of the sacrificed 
animals were removed aseptically, weighed, and homogenized in sterile saline in a tissue 
grinder. The number of viable Candida cells in the tissues was determined by plating serial 
dilutions on Sabouraud dextrose agar plates as previously described (23). The CFU were 
counted after 24h of incubation at 370C, and expressed as log CFU/g tissue. For histologic 
analysis, kidneys of subgroups of mice (5 mice/group) were fixed in buffered formaldehyde 
(4%). Paraffin-embedded sections were stained with hematoxylin-eosin. 
In vitro cytokine production by primed splenocytes 
To assess cytokine production, primed spleen cells from mice on day 7 of infection with 
2xl05 CFU of C. albicans per mouse were stimulated in vitro with heat-killed Candida conidia 
or pseudohyphae (IxlO6 microorganisms/ml). Spleen cells were obtained by gently 
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squeezing spleens in a sterile 200 mm filter chamber. The cells were washed and 
resuspended in RPMI1640, counted in a Bürker counting chamber and the number was 
adjusted to 5xl06/ml. 500 μ ι of the cell suspension was stimulated with IxlO6 heat killed C. 
albicans/m\. Measurement of IFNy, IL-lß, IL-17, and TNFa concentrations was performed in 
supernatants collected after 48 h of incubation at 37 1C in 5% C02 in 48-well plate. 
Cytokine quantification 
A Bioplex mouse X-plex assay (BioRad) was used according to the manufacturer's 
instructions in order to evaluate the quantity of the following cytokines: IL-lß, IFN-y, and IL-
17. Bioactive IL-1 secretion was determined in a bioassay using the murine thymoma cell line 
EL4/NOB1 as an IL-1-specific cell-producing IL-2 response. IL-2 was subsequently determined 
by ELISA (R&D). 
Immunoblotting for caspase-1 
BMDCs were first stimulated for 4 hours with live C. albicans in a concentration of IxlO4 
CFU/ml, washed twice with phosphate-buffered saline and scraped in lysis buffer solution 
(150 mm NaCI, 10 mm Tris, pH 7.4, 5 mm EDTA, 1 mm EGTA, 0.1% Nonidet P-40) 
supplemented with a protease inhibitor mixture tablet (Roche Applied Science). Samples 
were clarified, denatured with SDS buffer, and boiled for 5 min. Proteins were separated by 
SDS-PAGE and transferred to nitrocellulose membranes. The membranes were 
immunoblotted with primary antibodies and proteins detected with appropriate secondary 
anti-rabbit antibody conjugated to horseradish peroxidase followed by enhanced 
chemiluminescence. Rabbit anti-mouse caspase-1 was a generous gift from Dr. P. 
Vandenabeele (Gent University, Belgium). 
Statistical analysis 
Data were analyzed using GraphPad software. The differences between groups were 
analyzed by the Mann-Whitney U test or Student's t-test where appropriate. Comparison of 
two survival curves was done using the Logrank test. The level of significance between 
groups was set at p<0.05. 
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Summary 
Τ helper (Th) 17 cells have recently been described as a third subset of Τ helper cells, and 
have provided new insights into the mechanisms that are important m the development of 
autoimmune diseases and the immune responses that are essential for effective 
antimicrobial host defense Both protective and harmful effects of Thl7 responses during 
infection have been described In general, Thl7 responses are critical for mucosal and 
epithelial host defense against extracellular bacteria and fungi However, recent studies have 
reported that Thl7 responses can also contribute to viral persistence and chronic 
inflammation associated with parasitic infection It has become evident that the type of 
microorganisms and the setting in which they triggers the Thl7 response determines the 
outcome of the delicate balance that exists between Thl7 induced protection and 
immunopathogenesis 
Introduction 
Mosmann and Coffman have introduced the concept of different sets of Τ helper (Th) cells, 
namely Thl cells and Th2 cells (1) Thl cells are characterized by the production of 
mterferon-y, which is essential for the defense against intracellular pathogens Th2 cells are 
characterized by the production of mterleukm (IL)-4 and are important in the host defense 
against parasitic infections Recently, a new subset of Τ helper cells called Thl7 cells has 
been described and these cells are characterized by the production of IL-17 (2), which is 
important for neutrophil recruitment and host defense against extracellular bacteria and 
fungi Thl7 cells produce a distinct cytokine profile, namely IL-17A (IL-17), IL-17F, IL 21 and 
IL-22 Like Thl and Th2 cells, the development of Thl7 cells from naive Τ cells is dependent 
on antigen presentation by professional antigen presenting cells, co-stimulatory stimulation, 
and a specific cytokine milieu In summary, the cytokines IL-lß, IL-6, TGFß have been 
reported to induce the development of Thl7 cells and IL-23 has been reported to be 
important for the maintenance of Thl7 cells, whereas IL-12 is important for Thl 
differentiation and IL-4 drives activated naive Τ cells towards Th2 cells (3) (Figure 1) It is 
important to mention that the cytokine IL-12 is composed of the subumts IL-12p40 and IL-
12-p35, and the cytokine IL-23 is composed of IL-12-p40 and IL-23pl9 Therefore IL-23pl9 
deficient mice are generally used as a model to study the role of IL-23, and IL-12p35 
deficient mice are used to investigate IL-12 dependent mechanisms of disease The functions 
of Thl7 cells, called Thl7 responses, m infectious diseases and autoimmune diseases have 
only recently started to be elucidated It has become apparent that Thl7 responses are 
associated with chronic inflammation and autoimmune diseases such as multiple sclerosis 
and rheumatoid arthritis (4) Furthermore, Thl7 responses have been shown to be 
important for the host defense against many microorganisms, although they can also 
contribute to immunopathology during infection In this review we will provide an overview 
of the rapidly extending literature that has investigated the role of Thl7 responses in 
relation to viral, bacterial, fungal and parasitic infections 
Thl7 responses and infections in STAT3 deficient patients 
STAT3 deficiency m humans, demonstrated to be the cause hyperlgE syndrome, has 
provided crucial insights m the role of Thl7 responses in the setting of antimicrobial host 
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defense. STAT3 deficient patients suffer from S. aureus skin and pulmonary infections and 
mucocuteneous candidiasis (5). The cause of these complications has been linked to a 
defective Thl7 response against C. albicans and gram positive bacteria, such as S. aureus 
and S. pyogenes (6). Intriguingly, defective Thl7 responses were also seen with mitogenic 
stimulation of CD4 Τ helper cells from these patients, suggesting a severe defect in mounting 
an optimal Thl7 response against many stimuli. These observations provide strong evidence 
thatThU responses are needed to control fungal colonization at the mucosal level, and play 
an important role in host defense against extracellular bacteria, especially S. aureus, in the 
lung and skin. 
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Figure 1. Different types of Τ helper (Th) subsets. 
The cytokine profile which is responsible for the differentiation from activated naive Τ cells into the three 
distinct Th subsets is shown. The main effector cytokines of and functions for each Th subset is shown. 
Fungal infections 
Candida 
Involvement of Thl7 responses in protective antifungal host defense was first demonstrated 
in IL-17RA deficient mice that showed increased susceptibility to disseminated C. albicans 
infection (7). In addition, a model for oropharyngeal candidiasis in mice showed that IL-
23pl9 or IL-17 deficiency resulted in severe oropharyngeal candidiasis, while mice deficient 
for IL-12p35 did not show this (8). However, negative effects of Thl7 mediated inflammatory 
responses to intragastric C. albicans and intranasal Aspergillus fumingatus infection in mice 
have also been reported. IL-23pl9 deficiency was shown to reduce fungal burden and IL-17 
inhibited Thl responses to C albicans (9). Furthermore, mice with defects in Toll IL1R8 
(TIR8), a negative regulator of Thl7 responses, showed higher susceptibility to Candida and 
Aspergillus and more immunopathology (10). Differences in the animal model, Candida 
strains and mouse strains could account for these contradictory observations. However, 
patients with impaired Candida specific Thl7 responses such as patients with hyper IgE 
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syndrome or chronic mucocutaneous candidiasis (CMC), are highly susceptibility to mucosal 
C. albicans infections (5, 11). These observations strongly indicate that Thl7 responses are 
important for human anti-CancWa mucosal host defense. Thl7 induction in response to 
Candida infection is strongly dependent on C type lectin receptors (CLRs), since it has been 
shown that the CLRs: mannose receptor, dectin-1 and dectin-2 are important in the IL-17 
production in response to Candida (12-14). Furthermore, dectin-1 and dectin-2 signal 
through the Syk-CARD9 pathway, and CARD9 was shown to be involved in Cond/do-induced 
Thl7 responses (13). Recently, it has been reported that patients with genetic defects in 
dectin-1 or CARD9 suffer from chronic oychomycosis and mucosal fungal infection (15, 16). 
Both dectin-1 and CARD9 deficiency was shown to result in deficient fungal induced IL-17 
responses. These data further strengthen the crucial role of Thl7 cells in human antifungal 
mucosal defense. 
Otherfungi 
Patients with chronic granulomatous disease (CGD) lack NADPH oxidase activity and do not 
generate reactive oxygen species, which results in recurrent bacterial and fungal infections 
especially fungal infections with Aspergillus. It has been reported that in the setting of 
deficient reactive oxygen species generation in a mouse model of CGD, the tryptophan 
metabolism in mice is deficient, which eventually resulted in increased IL-17 responses (17). 
These increased IL-17 responses were suggested to be detrimental to the host when CGD 
mice were infected with Aspergillus. It has been suggested that the IL-17 pathway also plays 
a role in Pneumocystis carinii infections. Stimulation of alveolar macrophages with 
Pneumocystis carinii induces IL-23 mRNA. Furthermore, neutralization of IL-23 or IL-17 
increased disease severity during P.carinii infection in WT mice (18). Another important 
fungal pathogen is Cryptococcus neoformans, which is associated with HIV infection and 
causes lethal fungal meningoencephalitis in patients suffering from AIDS. Mice deficient of 
IL-12p40 show much higher mortality and had impaired IL-17 expression when compared to 
IL-12p35 deficient mice (19). This indicates a role for IL-23 and thus Thl7 responses in 
protection against C. neoformans infection. Another study that investigated the role of the 
Thl7 response in antifungal host defense reported that in a mice model of Paracoccidioides 
braziliensis infection, TLR2 deficiency resulted in increased Thl7 responses which were 
associated with protection (20). Overall, these data indicate that Thl7 responses can be 
induced by fungi and that the IL-17 pathway plays an important role in protective antifungal 
host defense. 
Thl7 responses in bacterial infections 
ßorre//'a 
One of the first studies that reported pathogen specific induced IL-17 production showed 
that Borrelia burgdorferi and Mycobacterium bovis BCG lipopetides were able to induce IL-17 
in addition to IFNy in CD4 positive Τ helper cells (21). Furthermore, it was shown that these 
responses were dependent on antigen presentation (21). Another study reported that 
B.burgdorferi triggers bone marrow derived DCs to produce IL-23, causing stimulation of IL-
17 producing T-cells (22). Codolo et al. presented that B.burgdorferi neutrophil-activating 
protein A (NapA) is capable of generating increased IL-6, IL-lß, IL-23, and TGF-ß expression 
by cells of the innate immune system, thereby inducing Thl7 responses in human synovial 
fluid (23). Notably, in an animal model of öorre//'o-induced destructive arthritis, anti-IL-17 
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and anti-IL-17R treatment resulted in prevention of severe destructive arthritis (24) In 
addition, it was shown that IL-23, which is a survival factor for Thl7 cells, was associated 
with Lyme arthritis, and depletion of IL-23pl9 or blockade of IL-23 resulted in the absence of 
Borrelia induced arthritis m mice (25) These studies provide evidence that while Thl7 
effector functions are likely to be involved m the host defense against Borrelia spp, they also 
play an important role in mediating the strong immunopathology associated with chronic 
Borrelia infection 
Helicobacter pylori 
IL-17 has been shown to be increased m H pylon-infected gastric mucosa and stimulated the 
synthesis of IL-8 which is a strong chemoattractant for neutrophils (26) Another study 
provided evidence that STAT3 activation in lamina propria mononuclear cells could lead to 
sustained IL-17 production, resulting in persistent inflammation (27) In an experimental 
mouse model, IL-17 neutralization resulted in an increased Thl response with elevated IL-
12, TNF-a and IFN-y mRNAs levels, while replenishing IL-17 showed reduction of the Thl 
response (28) This underscores that counter-regulation between Thl and Thl7 responses is 
present during infection As with many other infections, it remains to be determined which 
response is protective for host defense against H pylori and which response will lead to 
persistent infection that could be detrimental to the host Notably, it has been shown in a 
recent publication that IL-17RA signaling regulates gastric Β cell recruitment (29) This 
indicates that IL-17 has an important role m the orchestration of immune cells such as 
neutrophils and Β cells at the site of infection during Η pylori infection 
Klebsiella pneumonia 
IL-17 deficient mice suffer from lethal Κ pneumoniae infection in contrast to control mice 
(30) In addition, overexpression of IL-17 leads to increased IL-lß, TNF-α and MIP-2 and G-
CSF, which results in higher leukocyte numbers and increased clearance of infection (30) 
Experimental Κ pneumoniae infection in mice was reported to induce IL-23pl9 and 
subsequently IL-17 production (31) Furthermore, the importance of the Thl7 cytokines for 
protection against Κ pneumonia infection was shown m mice deficient in IL-12p40, IL-23pl9 
or IL-17R, which suffer from higher susceptibility and mortality (32) Furthermore, IL-17 
administration was able to restore the normal host defense against Κ pneumoniae in IL-23 
deficient mice (32) Both IL-17 and IL-22 were shown to be crucial for protective local host 
defense against Κ pneumonia However, only IL-22 was crucial for defense against 
transepithelial damage, since in contrast to IL-17, IL-22 was able to enhance repair of 
transepithelial resistance Interestingly, it was shown that blocking IL-22 in mice infected 
with Κ pneumonia resulted in 100% mortality within one day, which was significantly earlier 
than control mice or IL-17 deficient mice Furthermore, IL-22 blockade resulted in increased 
dissemination of bacteria in both control mice and IL-17 deficient mice These data argue 
that IL-22 plays a more important role than IL-17 m mucosal host defense against Κ 
pneumonia A recent study has reported that lipocalin-2 is important for mucosal host 
defense against Κ pneumonia Although IL-17 can induce Lcn2 in vitro, it was not necessary 
for in vivo induction (33, 34) IL-22 is also able to induce Lcn2 in vitro (33) However, to what 
extend IL-22 plays a role in the induction of Lcn2 in vivo remains to be determined In 
conclusion, Thl7 responses provide protective host defense against Κ pneumonia 
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Citrobacter rodentium 
Infection of IL-23pl9 deficient mice with Citrobacter rodentium showed reduced survival 
rates due to increased bacterial dissemination as a result of impaired Thl7 responses (35). 
Also, a role for IL-17A and IL-17F induced ß-defensin expression in the defense against C. 
rodentium has been described (36). In addition, by using the C. rodentium as a mouse model 
for human intestinal infection, Zheng et al. hypothesized that the influence of the Thl7 
cytokine IL-22 also plays an important role in human intestinal infection (37). Interestingly, it 
has recently been shown that Thl7 differentiation in the small intestine is dependent on 
specific commensal flora (38). A single microbe, namely a segmented filamentous bacterium, 
was responsible for inducing Thl7 responses in the lamina propria of the small intestine (39). 
Colonization with this specific commensal resulted in increased Thl7 responses, which were 
protective during experimental infection with C. rodentium (39). 
Salmonella spp. 
Salmonella enterica serotype Typhimurium can induce Thl7 responses in the intestinal 
mucosa in mice (40). Another study showed that Salmonella enterica serotype Typhimurium 
infection resulted in increased levels of IL-17, IL-22 and IL-23, and induction of MIP-2 and 
Lcn2 genes in the intestine (41). These responses were mainly driven by IL-23(41). In the 
setting of IL-12 deficiency, IL-23 dependent IL-22 was shown to be crucial in protection 
against disseminated infection with Salmonella enterica serotype Enteritidis, while IL-17 was 
redundant in this model (42). However, it has also been shown that IL-17 deficient mice had 
slightly higher bacterial load in liver and spleen when compared to control mice in this model 
of disseminated Salmonella infection (42). During Salmonella enterica serotype Typhimurium 
infection, IL-17 deficiency in mice resulted in impaired neutrophil recruitment to the 
intestinal mucosa (43). It has been reported that HIV-infected patients are more susceptible 
to non-typhoid Salmonella bacteremia (44). IL-17 deficiency caused by Simian 
immunodeficiency virus (SIV) in macaques, which is the primate variant of HIV, resulted in 
increased translocation of Salmonella enterica serotype Typhimurium (43). Interestingly, 5. 
typhimurium infection in SIV positive macaques caused significant less IL-17 and IL-22, 
whereas IFNy production was normal. These data indicate that Thl7 responses play an 
important role in controlling mucosal host defense against non-thyphoid Salmonella and 
protection against disseminated salmonellosis. In addition, S. enterica serotype Typhi can 
inhibit Thl7 responses, which probably contributes to the higher virulence associated with 
this Salmonella spp. (40). 
Mycobacteria 
M. bovis was one of the first microorganisms that was able to induce IL-17 production in CD4 
positive Τ cells (21). In addition, dendritic cells that are stimulated with M. tuberculosis 
produce IL-12 and IL-23 (45). IL-23 was shown to be crucial for the induction of Thl7 
responses against M. tuberculosis and M. Bovis (46). IL-23 has also been shown to be 
important for M. tuberculosis-'\nduced Thl responses (45). Interestingly, it has been reported 
that when the IL-17A receptor is absent in mice, no difference in clearance of M. tuberculosis 
infection was observed compared to control mice (47). Thl cells seem to be more important 
in the protection against primary M. tuberculosis infection, while the absence of Thl7 cells 
does not alter protection against primary infection (48). These data are supported by the 
absence of mycobacterial infections in patients with hyperlgE syndrome. Although IL-17 
does not appear to play a role in primary TB infection, it may play a role in the maintenance 
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of the inflammatory response. In line with this, granuloma formation in the lungs of IL-17 
deficient mice infected with BCG was reported to be impaired and IL-17 was shown to play a 
role in the trafficing of Thl cells to the site of infection (49). These data suggest that Thl7 
responses play an important role in providing long lasting immunity against M. tuberculosis, 
and could therefore be crucial for vaccine development against M. tuberculosis. 
Bordetella spp. 
Although earlier studies have reported that ß. pertussis infection promotes the Thl response 
(50), more recent studies have shown that B. pertussis is also able to skew the host response 
towards a Thl7 profile (51). Blocking of IL-17 during fl. pertussis infection in mice resulted in 
reduced neutrophil recruitment and modestly increased bacterial burden (51). In addition, 
B. pertussis toxin is able to induce IL-17 responses (52). B.bronchiseptica is also able to skew 
the immune response towards a Thl7 response (53). Interestingly, lung tissue from mice 
infected with B.bronchiseptica expressed a strong Thl7 response. It remains however to be 
established if Thl7 responses contribute to host defense against Bordetella spp. 
Other bacteria 
Porphyromonas givinalis is an anaerobic bacterium which causes periodontal disease (PD). 
This is associated with periodontal bone destruction. It has been reported that patients with 
severe PD have elevated IL-17 responses (54). Despite this observation and the observations 
that Thl7 responses have been associated with bone destruction and the induction of Lyme 
arthritis, it has been reported that the Thl7 response induced by P. gingivalis infection 
prevented bone destruction in mice (55). In case of Mycoplasma pneumonia it has been 
reported that this pathogen triggered alveolar macrophages to produce IL-23, which 
subsequently contributed to an increase of IL-17 production (56). Depletion of IL-23 resulted 
in less IL-17 production and reduced lung neutrophil recruitment (56). 
However, Thl7 responses during bacterial infection are not always beneficial for the host. 
Patients with cystic fibrosis (CF), which have defects in a chlorine channel which contributes 
to thick mucus production in the lungs (57), are more susceptible to Pseudomonas 
aeruginosa infection. CF patients with P. aeruginosa infection had higher levels of the Thl7 
cytokines IL-23 and IL-17 (58). An important observation made by others was that mice 
deficient in IL-23 showed decreased inflammation compared to wild type mice, although 
they had the same amount of P. aeruginosa dissemination (59). These data suggest that the 
Thl7 response against P. aeruginosa does not play a crucial role in the host defense against 
this pathogen, but that it contributes to the pathology of the airways which leads to 
bronchiectasis seen in CF patients. It must however also be mentioned that IL-17 was 
recently shown to be a critical factor in a vaccine that induced protection to P.aeruginosa 
(60). Another study has shown that mice injected intraperitoneal with fl. fragilis formed 
abscesses in an IL-17 dependant way, and that co-localization of IL-17 producing CD4 
positive cells within the abscess wall was shown (61). Furthermore, when these mice were 
treated with an IL-17 neutralizing antibody, the formation of these abcesses was blocked. 
These studies suggest that Thl7 responses during certain types of bacterial infections can 
result in deleterious host effects. 
Patients with hyperlgE syndrome are especially susceptible to 5. aureus (6, 62-64). It has 
recently been reported that human keratinocytes and bronchial epithelial cells were 
114 
Chapter 9 
especially dependent on Thl7 cytokines for their anti-staphylococcal host defense, such as 
secretion of chemokines that recruit neutrophils and the production of antimicrobial 
peptides (64). In addition, an association between the severity of the defective Thl7 
response against S. aureus and the susceptibility to S. aureus pneumonia has been reported 
(van de Veerdonk et al. in press). Three patients with a STAT3 mutation and hyperlgE 
syndrome that had a partial S. aureus-induced IL-17 deficiency, never developed S. aureus 
pneumonia in contrast to patients with a complete deficiency in S. aureus induced IL-17. 
Finally, studies that investigated the role of IL-17 in antibacterial host defense have also 
provided insights in the role of IL-17 production by innate immune cells such as y5 T-cells. yö 
T-cells rather than CD4 Τ helper cells were found to be the main source of IL-17 during 
mycobacteria infection in mice (65). This was further supported by the observation that 
patients with TB had higher proportions of y6 T-cells that were able to produce IL-17 in their 
peripheral blood compared to healthy controls (66). In addition, it has been shown that IL-17 
mediates protection against Listeria monocytogenis in the liver (67, 68) and this IL-17 
production was mainly derived from y5 T-cells (67, 68). Similar findings were reported for 
Escherichia coli in a mouse model of intraperitoneal infection (69), where neutrophils were 
shown to infiltrate in an IL-17 dependant manner and interestingly and y6 T-cells were the 
major source for IL-17 (69). These observations suggest that innate immune cells are also an 
important source of IL-17 during bacterial infections and supports the hypothesis that IL-17 
producing y5 T-cells are able to provide an efficient first line of defense against bacterial 
invasion (70). 
Thl7 responses in viral infections 
Vaccinia virus and Theilers murine encephalomyelitis virus 
It is generally accepted that antiviral host defense is mainly mediated through the 
production of type 1 IFN and IFNy. Thl responses have clearly been associated with 
protective host defense against viruses. Since there were no suggestions that STAT3 
deficient patients were more susceptible to viral infections, it may be hypothesized that 
Thl7 responses played a minor role in antiviral host defense and that Thl and type I 
interferon responses are the main protective adaptive immune response against viral 
infection. However, recent evidence suggests that viruses can also induce Thl7 cells, 
although their role in antiviral host defense still remains to be elucidated. 
Smallpox, which represents a serious threat as a possible agent for bioterrorism, has been 
eradicated by the smallpox vaccine that consists of live vaccinia virus (W). One of the first 
reports that studied the role of IL-17 in viral infection was from Patera et al. They inserted 
murine IL-17 into vaccinia virus (W-IL-17) and showed that VV-IL-17 was much more virulent 
than wild type W (71). Mice infected with W-IL-17 had higher viral burdens and had 
impaired NK cell cytotoxicity. In contrast, another study reported that W-IL-17 was less 
virulent than W-WT in mice, and IL-17-deficient mice were more sensitive to W-WT than 
control mice (72). In addition, W expressing IL-23 were shown to be less virulent than wild 
type W (72). This controversy still has to be addressed in additional studies. 
In patients with atopic dermatitis, W vaccination can result in eczema vaccinatum, which is 
a disseminated form of vaccinia infection and can be lethal. Recently, two reports showed an 
immunopathological role for IL-17 in eczema vaccinatum (73, 74). IL-17 was shown to reduce 
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NK activity in mice with atopic dermatitis, resulting in higher susceptibility to eczema 
vaccinatum (73). Similar results were obtained by eliciting Th2 responses using ovalbumin, 
thereby simulating allergic skin inflammation (74). After W inoculation, mice with sensitized 
skin showed localized IL-17 expression, increased IL-23, IL-6 levels and neutrophil influx, 
which resulted in increased viral loads in the skin and organs when compared with mice that 
had unsensitized skin (74). Moreover, IL-17 neutralization using anti-IL-17 showed decrease 
of lesions and viral load while IL-17 administration promoted viral replication. In conclusion, 
these data suggest that IL-17 contributes to viral replication in a model of disseminated 
vaccinia infection rather than providing host defense against viral infection, and suggests 
that IL-17 is a potential target during disseminated vaccinia virus infection. 
Theilers murine encephalomyelitis virus (TMEV) infects microglial cells, oligodendrocytes, 
astrocytes and macrophages in the central nervous system of mice, thereby inducing 
demyelating disease. In response to TMEV, macrophages are able to produce IL-23pl9 and 
IL-12p40 (75). Recently, it has been shown that Thl7 cells promote chronic viral infection in 
an experimental TMEV infection model, and play an important role in demyelinating disease. 
IL-17 was responsible for the induction of anti-apoptotic mechanisms that resulted in the 
survival of cells infected with TMEV (76). Blocking IL-17 resulted in more efficient clearance 
of TMEV and cytotoxic Τ cell responses and could prevent disease development. It has been 
proposed that IL-17 could be a potential therapeutic target in chronic diseases associated 
with viral infections. 
Herpes Simplex Virus 
An important complication of Herpes simplex virus infection (HSV) is damage to the cornea, 
also called herpetic stromal keratitis. It has been shown that patients with corneal HSV 
infection have increased levels of local IL-17, which can bind to IL-17R on corneal fibroblasts 
(77). This triggers expression of the neutrophil attracting chemokines IL-8 (CXCI-8) and MMP-
1, which can subsequently result in neutrophil influx and inflammation that causes damage 
to the cornea and eventually blindness. In addition, mice lacking the IL-17R have decreased 
neutrophilic migration in the cornea and corneal pathology, although this effect was 
transient and control of viral growth in the cornea was not affected in IL-17R-/- mice (78). 
However, it has also been proposed that the immunopathology in herpetic stromal keratitis 
is mainly driven by Thl responses and not Thl7 responses (79). 
Human Immunodeficiency Virus 
Interestingly, early HIV infection is associated with an increase of IL-17 production by CD4 
positive and CD4 negative cells in peripheral blood (80). Misse et al. have proposed that IL-
22 contributed to antiviral defense by activating acute-phase proteins and induction of IL-22 
might be a protective mechanism during HIV infection (81). Although Thl7 responses could 
have a protective role against HIV infection, HIV infection has mainly provided supporting 
evidence of the role of CD4 positive Τ cells during specific infections. This is due to the fact 
that HIV specifically infects CD4 positive Τ helper cells, which results in a depletion of CD4 
positive IL-17 producing cells in humans in vivo. The observation that HIV patients are 
especially susceptible to oropharyngeal C. albicans infection supports the important role for 
CD4 positive cells that secrete IL-17 in ant\-Candida host defense. Furthermore, the 
increased susceptibility to non-typhiod salmonella infections underscores the important role 
forThl7 cells in the protection against non-typhoid Salmonella spp. 
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Hepatitis viruses 
It has been shown that during hepatitis C infection virus specific Thl7 cells are induced (82). 
However, hepatitis C also induces immunosuppressive cytokines IL-10 and TGF-ß, which are 
able to inhibit Thl7 and Thl. Neutralization of TGF-ß has been shown to increase IL-17 
production in response to hepatitis C nonstructural protein 4 (82). In patients with chronic 
hepatitis B, Thl cells were decreased and Thl7 cells were increased (83). The Thl7 cytokine 
IL-22 was shown to be protective, however a protective function for IL-17 was not observed 
(84). The balance between Thl and Thl7 seems to play an important role in viral hepatitis, 
although it remains to be elucidated if Thl7 responses favor protective host defense. 
Other viruses 
Several other studies have shown that IL-17 is elevated during viral infection: when mice 
that are deficient in Thl responses are infected with lymphocytic choriomeningitis viral 
infection, they display elevated IL-17 producing CD8 Τ cells and develop progressive 
inflammation (85). Human T-cell leukemia virus (HTLV) was shown to up-regulate IL-17 
expression in CD4 T-cells (86). In studies where epithelial cells were exposed to human 
rhinovirus, increased induction of IL-17 was shown, together with specific infiltration of 
neutrophils in the lungs (87). It was however not clear in these studies if IL-17 provides a 
protective antiviral role or that it contributes to inflammation that is detrimental for the 
host. Notably, Thl7 responses were shown to be protective in IL-10 deficient mice infected 
with Influenza virus (88). 
Thl7 responses in parasite infections 
Protozoa 
Evidence regarding the role of Thl7 responses in the host defense against protozoa is 
relatively limited. IL-4 which is the prototypical effector cytokine of Th2 cells can negative 
regulate Thl7 responses (2), and therefore it may be hypothesized that Thl7 responses 
would not be strongly involved in host defense against parasites. However, new studies have 
suggested a more subtle view. Oral Toxoplasma gondii infection in IL-17 deficient mice leads 
to higher mortality than in control mice (89). These mice were shown to have less parasite 
burden and normal neutrophil infiltration during T.gondii infection (89). Despite the 
beneficial effect of IL-17 mediated inflammation which effectively cleared T.gondii infection, 
increased liver and intestinal pathology was observed. Stumhofer et al, have shown that IL-
27 deficient mice show a profound Thl7 response and severe neuroinflammation (90). These 
data indicate that Thl7 responses can contribute to persistent inflammation in the organs 
affected by Toxoplasma. Furthermore, IL-27 which suppresses Thl7 responses was found to 
be beneficial in infections with the protozoan Trypanosoma cruzi (91). In an experimental 
model of Leishmania infection, IL-17 and IL-22 were shown to be important in the protection 
against Ldonovani (92), but in Lmajor infection IL-27 was shown to inhibit Thl7 responses 
and this prevented immunopathology (93). These data suggest that the inhibiting effect of 
IL-27 during infection with protozoa is of utmost importance to control the Thl7 responses 
that contribute to persistent inflammation. Mice deficient in bradykinin receptor 2 were 
shown to have higher Thl responses at the cost of lower Thl7 responses, and were better 
protected against intraperitoneal Γ. cruzi infection than control mice, which provides further 
evidence that Thl7 responses can be detrimental for the host during protozoal infection 
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(94). However, it must be mentioned that a study on Leishmania braziliensis showed 
protection that was mediated by IFN-y and IL-17 producing T-cells (95). 
Helminths 
Infection with Schistosoma monsoni in mice causes development of hepatic granuloma 
around the S.mansoni eggs (96). Antigens from these parasite eggs have been shown to 
cause CD4 positive T-cell mediated immunopathology. IL-12p40 deficient mice not able to 
make IL-12 and 11.-23 were completely resistant to immunopathology (96), while mice with 
IL-12p35 deficiency that are not capable of making IL-12 still showed severe 
immunopathology. In addition, IL-17 neutralization significantly reduced immunopathology 
observed in S. monsoni infection (96, 97). Despite this immunopathological role for Thl7 
responses in 5. monsoni infection, it has also been shown that TGF-ß can up-regulated Thl7 
responses which result in increased resistance against lung-stage schistosomula (98). 
Evidence for a negative role for Thl7 was also described during infection with Trichuris 
muris, which is the murine variant of Trichuris trichuria. Down-regulation of the Th2 
promoting cytokine IL-25 caused severe inflammation associated with high levels of IFN-y 
and IL-17, although it still remains to be elucidated which cytokine contributed most 
substantial (99). In general, these observations suggest that Thl7 responses in the setting of 
parasitic infections can contribute to host defense, but they have to be controlled, for 
example by cytokines such as IL-27, in order to prevent immunopathology. 
Thl7 responses in infection: the balance between protection and immunopathogenesis 
Both pathological and protective roles have been described with respect to the Thl7 lineage 
in infectious diseases (Table 1). In infections caused by bacteria and fungi, the pathogen 
induced Thl7 response has been reported as an important mediator of protective mucosal 
host defense. Thl7 cells improve mucosal barrier function during infection by secretion of 
antimicrobial peptides and additional chemokine signaling for neutrophil reinforcements. 
The importance of the Thl7 subset in mucosal host defense is underscored by the 
observation that patients with hyperlgE syndrome and chronic mucocutaneous candidiasis 
suffer from a severe form of mucosal candidiasis and they display specific defects in their 
Thl7 response against C. albicans. 
However, in viral infections and parasitic infections the role of Thl7 responses is less clear 
and IL-17 has even been reported to be detrimental for the host. Interestingly, Thl7 
responses inhibit apoptosis of virus infected cells and contribute to persistence of the virus. 
In parasitic infections IL-17 was shown to contribute to persistent inflammation. Since Thl7 
cells are associated with autoimmune diseases and hence chronic inflammation, it seems 
logical that persistent en chronic induction of Thl7 responses, triggered by pathogens that 
are not sufficiently cleared, can results in immunopathology that is detrimental for the host. 
Thl7 responses can effectively recruit and orchestrate neutrophils, and therefore are 
probably very efficient in inducing the killing of extracellular invading pathogens, while the 
killing and clearance of intracellular pathogens such as viruses may be more efficient in the 
setting of a strong Thl response and host defense against parasitic infection requires an 
optimal Th2 response. Since skewing towards Thl7 responses can result in downregulation 
of Thl and possibly Th2 responses, Thl7 cells might in this way contribute to a suboptimal 
host defense against viruses and parasites (Figure 2). Although Thl7 cells have only recently 
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been discovered, they have already provided crucial insights into the host defense against 
microorganisms. Understanding the Thl7 responses and their interactions with the immune 
repertoire will likely provide crucial insights in the host defense and immune responses, and 
this will provide new tools for the development of effective immunomodulatory treatment 
strategies in the setting of infectious diseases. 
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Figure 2. Thl7 responses in infection: the balance between protection and immunopathogenesis. 
Thl7 responses are important for the host defense against extracellular bacteria and fungi by orchestrating 
neutrophil recruitment and stimulating antimicrobial peptides (AMPs). However, Thl7 responses can also 
contribute to chronic inflammation and can be favorable for the pathogen, as has been shown for parasites and 
viruses. 
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Table 1. Overview regarding the role of Thl7 responses In relation to viral, bacterial, fungal and parasitic 
infections. 
m 
c 
IL· 
to 
S 
Candida albicans 
Aspergillus fumungatus 
Pneumocystis carimi 
Cryptococcus 
neoformans 
Paracoccidioides 
brazihensis 
Borrelia burgdorferi 
Helicobacter pylori 
Klebsiella pneumoniae 
Salmonella enterica 
Typhimunum 
Salmonella enterica 
Enteritidis 
Salmonella enterica 
Typhi 
Mycobacterium bovis 
BCG 
Mycobacterium 
tuberculosis 
Bordetella pertussis 
Bacteroidesfragilis 
Porphyromonas givmalis 
Pseudomonas aeruginosa 
SH^^^BHffî^^PI^^^H^BI^^S^^^H^IHH^^^^S 
Systemic 
Mucosal 
Intra gastric 
Intranasal 
Pulmonary 
Pulmonary 
Brain 
Pulmonary 
Synovium 
Gastric 
Pulmonary 
Intestinal 
mucosa 
Intestinal 
mucosa 
Intestinal 
mucosa 
Pulmonary 
Pulmonary 
Pulmonary 
Abdominal 
Periodontal 
Pulmonary 
Increased susceptibility in IL-17RA deficient mice (7) 
Deficient Thl7 response in humans and mice leads to increased 
susceptibility to candidiasis (6,11, 63, 64) 
IL-17 deficiency increases susceptibility to oropharyngal 
candidiasis in mice (8) 
Thl7 responses are detrimental to the host (10) 
IL-23 deficiency reduces fungal burden, IL-17 inhibits 
protectiveThl responses (9) 
Deficient ROS results in increased Thl7 responses detrimental for 
the host (17) 
IL-17 neutralization increases disease severity (18) 
IL-23 deficiency leads to impaired IL-17 expression and higher 
mortality in mice (19) 
Mice deficient for TLR2 show increased protective Thl7 responses 
(20) 
Neutralization of Thl7 responses prevents Borrelia induced 
arthritis (25) 
STAT3 induction resulting in sustained IL-17 expression and 
persistent inflammation (27) 
Thl7 deficiency leads to lethal infection in mice, IL-17 
administration restores normal host defence (30, 32) 
Induction of AMPs by Thl7 cytokines IL-17 and IL-22 (33, 34) 
IL-17 deficiency results in impaired neutrophil recruitment (43) 
IL-22 crucial in protection against dissemination of infection (42) 
IL-17 deficiency causes higher bacterial load in liver and spleen 
(42) 
viaB capsule encoding locus inhibits IL-17 expression (40) 
Induction of IL-17 expression in CD4 Τ cells (21) 
IL-23 crucial for Thl7 response (46) 
IL-17RA deficiency gives no difference in bacterial clearance (47) 
Host response is skewed towards Thl7 response and 
neutralization of IL-17 before challenge showed reduced vaccine 
protection(51) 
Pertussis toxin induces IL-17 responses (52) 
IL-17 is associated with abscess formation (61) 
Elevated IL-17 in patients with severe PD (54) 
Thl7 responses prevent bone destruction in mice (55) 
High levels of IL-23 and IL-17 associated with severe inflammation 
during infection in CF patients (58) 
IL-23 deficiency causes decreased inflammation but unchanged 
bacterial dissemination in CF mice (59) 
IL-17 critical in vaccine induced protectivity (60) 
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Mycoplasma 
pneumoniae 
Citrobacter rodentium 
Listeria monocytogems 
Escherichia coli 
Staphylococcus aureus 
Haemophilus influenzae 
Vaccinia Virus 
Theilers murine 
encephalomyelitis virus 
Herpes Simplex Virus 
Human 
Immunodeficiency Virus 
Hepatitis Β Virus 
Rhinovirus 
Influenza virus 
Toxoplasma gondii 
Trypanosoma cruzi 
Cryptosporidum parvum 
Leishmania brazihensis 
Leishmania donovani 
Leishmania major 
Schistosoma monsoni 
Trichuris muris 
Pulmonary 
Intestinal 
mucosa 
Liver 
Intra 
peritoneal 
Epithelium 
(lung, skin) 
Pulmonary 
Skin 
Brain 
Eye 
Systemic 
Liver 
Pulmonary 
Intestinal 
Brain 
Systemic 
Intestinal 
Systemic 
Systemic 
Systemic 
Liver 
Lung 
Intestine 
IL-23 depletion results in reduced neutrophil recruitment in mice 
(56) 
Reduced survival rates in IL-23 deficient mice (35) 
Induction of AMPs by Thl7 responses in mice (36, 37) 
IL-17 contributes to protection, mainly derived from y6 T-cells (67, 
68) 
IL-17 contributes to protection, mainly derived from y6 T-cells (69) 
Deficient Thl7 response in humans and mice leads to increased 
susceptibility infection (6, 62-64) 
Induction of AMPs by Thl7 responses in mice (36) 
Deficient Thl7 response in humans and mice leads to increased 
susceptibility infection (62) 
localized Thl7 responses are associated with increased viral loads 
(74) 
IL-17 contributed to viral persistence (76) 
IL-17R deficient mice have less corneal pathology but unaffected 
viral growth (78) 
Increased IL-17 production in early HIV infection (80) 
Induction of acute-phase proteins by IL-22 (81) 
Chronic hepatitis show increased Thl7 and decreased Thl 
responses (83) 
IL-22 is protective in conA induced hepatitis (84) 
Increased induction of Thl7 and pulmonary neutrophil infiltration 
(87) 
Protective Thl7 responses in IL-10 deficient mice (88) 
IL-17 contributes to host defense, but also inflammatory damage 
(89) 
IL-27 deficiency results in higher Thl7 responses and 
neuroinflammation (90) 
IL-27 mediated suppression of Thl7 responses is beneficial (91) 
IL-23 and IFN-y reduced parasite shedding (100) 
Protection by IFN-y and Thl7 producing T-cells (95) 
IL-22 and IL-17 shown to be protective (92) 
Less pathology when Thl7 response is inhibited by IL-27 (93) 
Less Thl7 responses resulted in absence of pathology (96, 97) 
TGF-ß mediated upregulation of Thl7 responses resulted in 
protection (98) 
Downregulation of Th2 responses resulted in immunopathology 
through Thl and Thl7 responses (99) 
127 
Infections and Thl7 
128 
Chapter 10 
The macrophage mannose receptor induces IL-17 in response to 
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Summary 
IL-17 controls neutrophil-mediated responses in inflammation. Little is known about the 
pattern recognition receptors that induce Thl7 responses during infection models, in the 
absence of artificial mitogenic induction of IL-17 with anti-CD3/anti-CD28 antibodies. The 
fungal pathogen Candida albicans induced significantly more IL-17 compared to Gram-
negative bacteria, and the mannose receptor (MR) played a central role in this process. 
Candida mannan, but not zymosan, Toll-like receptor (TLR) agonists or the NOD2 ligand 
MDP, induced IL-17 production in the absence of anti-CD3/anti-CD28 antibodies. The 
TLR2/dectin-l pathway, but not TLR4 or NOD2, is involved in the amplification of MR-
induced IL-17 production. This is the first pathway described that can trigger the Thl7 
response mediated by a specific pathogen in the absence of anti-CD3/anti-CD28 stimulation. 
Introduction 
The recently described Τ helper 17 cells (Thl7 cells) produce interleukin-17A (IL-17), a 
cytokine that is important in the host defense against various pathogens (1), including Gram 
negative bacteria such as Kleibsiella pneumonia (2) and Citrobacter rodentium (3), the 
spirochetal infection Borrelia burgdorferi (4), and the fungal pathogen C. albicans (5). 
Cond/do-specific Thl7 responses have also been observed in peripheral blood in humans (6). 
IL-17 induces infiltration of polymorphonuclear leucocytes (PMN) at the site of infection, 
activation of tissue neutrophils and macrophages, and the synthesis of antimicrobial 
peptides (1). These data suggest an important role for the Thl7 response in the host defense 
against pathogens. However, overproduction of IL-17 can also lead to autoimmune 
processes (7-9), underscoring the delicate balance in regulation of the Thl7 response. 
Recently, much has been learned about the cytokine profiles that are needed to differentiate 
naive Τ cells into Thl7 cells, and how to enable central memory Τ cells to secrete IL-17. 
Whereas IL-lß alone is capable of inducing IL-17 secretion in human central memory Τ cells 
(10), IL-21 and TGFß seem to be needed for driving differentiation of naive T- cells into Thl7 
cells (11). More controversial are the receptor pathways that direct the immune response 
towards a Thl7 profile, with each of the TLRs (12), dectin-1 (13) and NOD2 (14) pathways 
individually being implicated in the induction Thl7 cells by different researchers. However, 
these studies have used simultaneous stimulation of these receptors with proliferation 
cocktails such as anti-CD3/anti-CD28, a model with limited relevance for the in-vivo 
situation. Little is known about the interplay between the various receptor pathways of the 
innate immune system that will eventually lead to a Thl7 response during infection with 
human pathogens. In the present study, we have focused on the induction of IL-17 by human 
microbial pathogens, and tried to clarify which innate immune receptors and pathogen-
associated molecular patterns (PAMPs) are involved in triggering a Thl7 response during the 
pathogen-specific host defense. Surprisingly, we have identified the prototypic fungal 
pathogen C. albicans as a much more potent inducer of IL-17 production compared to Gram-
negative bacteria. The most important pathway of IL-17 induction was represented by the 
engagement of the macrophage mannose receptor (MR), with the TLR2/dectin-l pathway 
having a secondary amplification effect on MR-induced IL-17 production. 
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Results 
Receptor-vs proliferation-dependent induction of IL-17 production 
Several receptor-dependent pathways have been described to induce IL-17 induction, such 
as dectin-1 (6), NOD2 (14) or TLRs (12). However, all of these studies have used 
combinations of receptor ligands and proliferation stimuli such as anti-CD3/anti-CD28 
antibodies (aCD3/aCD28). We wanted to differentiate the relative importance of the 
receptor-specific and proliferation-dependent induction of IL-17 by stimulating cells with a 
known IL-17 inducer, zymosan, in the presence or absence of aCD3/aCD28. Zymosan alone 
was able to induce only very limited amounts of IL-17 in the presence of human serum, and 
anti-CD3 as a co-stimulatory signal was needed in order to potentiate the zymosan induced 
IL-17 production (Fig. la). The non-specific stimuli aCD3/aCD28, in the presence of serum, 
induced the highest amount of IL-17 secretion (Fig. la). To investigate whether TLR and NLR 
ligands alone were able to induce IL-17 production, PBMCs were stimulated with a TLR2 
ligand (Pam3Cys 10 Mg/ml), TLR4 ligand (LPS 10 ng/ml), TLR3 ligand (PolyhC 10 μg/ml), TLR5 
ligand (flagellin 10 μg/ml), TLR9 ligand (ODN 10 μg/ml) and the NOD2 ligand MDP (10 μg/ml) 
in the presence of human serum, without additional co-stimulatory factors. No single ligand 
was able to induce IL-17 production, although all ligands were able to induce IL-6 production 
(Fig. lb). Several combinations of these ligands (TLR2 with TLR4, TLR2 with NOD2 and TLR4 
with NOD2) were also not able to induce IL-17 production in human PBMCs (data not 
shown). Thus, stimulation of TLRs and NOD2 pathways alone cannot induce production of IL-
17. 
Pathogen induced production of IL-17 
IL-17 is important in the host defense against extracellular bacterial and fungal infections (2, 
15). We investigated the capacity of whole microorganisms to induce IL-17 production. Both 
Gram-negative and fungal pathogens induced IL-17 secretion. However, C. albicans was by 
far the most potent inducer of IL-17 production, in concentrations comparable to those 
induced by anti-CD3/anti-CD28 antibodies. In contrast, comparable amounts of monocyte 
derived IL-lß, a cytokine known to be important for the induction of IL-17, were induced by 
Gram-negative bacteria and C. albicans (Fig. 2a). Because bacteria and fungi differ in size, 
and therefore in surface area and antigen load, we compared high dosages of Gram-negative 
bacteria with low dosages of fungi. Even a 1000 fold higher concentration of Gram-negative 
bacteria was still less potent in the induction of IL-17 production (data not shown). RT-PCR 
showed that the induced IL-17 mRNA was accompanied by upregulation of RORyt (Fig. 2b). 
The conidial form of C. albicans was the most potent for the induction of IL-17 (Fig. 2a), and 
both heat-killed and live C. albicans induced significant amounts of IL-17 (Fig. 2c). Cytokine 
kinetics during these stimulations showed that IL-17 increased steadily during the 7 day 
period, while IL-23 production was maximal in the first 24 hours and decreased thereafter 
(Fig. 2d). IL-10 was present in the first 48 hours and decreased to undetectable limits at day 
3 and stayed undetectable (Fig. 2d). IFNy was present at 48 hours and reached its maximum 
at 4-5 days, while IL-lß reached its maximum level at 24 hours after which a plateau was 
attained (Fig. 2d). At day 5 of stimulation, flow cytometry of PBMCs stimulated with C. 
albicans yeast cells showed a subset of CD4 positive cells that was capable of producing IL-17 
alone or in combination with IFNy (Fig. 2e,f). 
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Figure 1. Receptor vs proliferation-dependent Induction of IL-17 production. 
(a) Human PBMCs were stimulated for 5 days with RPMI, zymosan 100 μΒ/ηιΙ, beads coated with anti-CD3, anti-
CD28 or various combinations, in the presence or absence of human serum. Production of IL-17 in the 
supernatants was measured by ELISA, (b) Human PBMCs were stimulated for 5 days in the presence of human 
serum with either TLR ligands (LPS 10 ng/ml, Pam3Cys 10 pg/ml, PolyhC 10 μg/ml, Flagellin 10 μg/ml and ODN 
M362 10 μg/ml) or the NOD2 ligand MDP (10 μg/ml), or anti-CD3/anti-CD28 (cell:bead ratio of 2:1). IL-6 and IL-
17 were measured by ELISA. All experiments were performed at least twice with a total of 5 healthy volunteers. 
Data are pooled and expressed as mean ± SEM. 
The mannose receptor is crucial for the induction of IL-17 production by C. albicans 
The structure of the C. albicans cell wall is very different from that of bacteria, being 
composed of polysaccharides such as mannans, ß-glucans and chitin (16). Single fungal 
components were tested for the induction of IL-17. C. albicans mannan, but not S. cerevisiae 
mannan, was able to induce IL-17 production (Fig. 3a). Surprisingly, the other fungal 
components, ß-glucan and chitin, did not induce IL-17 production. Although zymosan was 
able to induce IL-lß, it did not lead to a significant production of IL-17 (Fig. 3a). C. albicans 
mannan showed a dose-dependent induction of IL-17 production (Fig. 3a). C. albicans 
mannan did not stimulate IL-17 production in the absence of serum (data not shown). 
Subsequently, we assessed the receptors leading to IL-17 production in human PBMCs, by 
blocking them with specific antibodies. Blocking of the mannose receptor resulted in the 
strongest inhibition of IL-17 production and quantitative RT-PCR showed that mRNA for IL-
17A and RORytwere downregulated in the presence of the mannose receptor inhibitor (Fig. 
3b,c). Blocking of the dectin-l/TLR2 pathway also lead to partial inhibition of IL-17 
production (fig. 3c). Blocking TLR4 did not alter mannan-induced IL-17 secretion (Fig 3c), 
while blocking of TLR4 decreased LPS induced IL-lß on day 5 was still effective (data not 
shown). Furthermore, C. albicans was able to induce pro- and anti-inflammatory cytokines 
(Fig. 3d). Interestingly, in the presence of the antl-MR there was no effect on IL-12, IL-23, IL-
2, IL-lß, TNF« and IFNy production, but there was a significant reduction in IL-10 (Fig. 3d). 
Next, we determined if the observed lower IL-17 production was in line with a lower 
133 
Macrophage Mannose Receptor and Thl7 
induction of IL-17 producing ceils. We observed that blocking the mannose receptor 
inhibited the percentage of CD4+ IL-17 producing cells (Fig. 3e,f). Since S. cerevisiae mannan 
itself cannot induce IL-17 production, but is able to interact with the MR, we preincubated 
PBMCs with an excess of S. cerevisiae mannan (Fig. 4a). This inhibited the IL-17 production 
induced by C. albicans mannan and C. albicans. To further establish that C. albicans mannan 
induces a Th-17 response specifically through the MR, we investigated the effect of siRNA 
depletion of the MR from monocytes. The IL-17 production induced by C. albicans mannan 
was reduced by roughly 50 % in PBMCs treated with MR siRNA (Fig. 4b). 
Figure 2. Pathogen Induced production of IL-17. 
(a) Human PBMCs were stimulated for 5 days with RPMI or several pathogens. IL-lß and IL-17 were measured 
by ELISA, (b) RT-PCR of the expression of RORyt and IL-17A In PBMCs stimulated with RPMI or C. albicans for 3 
days. Data is given as relative mRNA expression (2 Δ<ΓΓ χ 1000). (c) PBMCs stimulated for 5 days with either live 
C. albicans (105/ml) or heat-killed (HK) C. albicans (105/ml). (d) Time course of IL-17 production in human 
PBMCs stimulated with heat-killed C. albicans yeasts or pseudohyphae. Cyokines were measured by ELISA, (e) 
Intracellular cytokine staining of IL-17 and IFNy in human PBMCs (n=5) stimulated for 5 days with RPMI or C. 
albicans, and than stimulated for 4 h with PMA and ionomycin. Cells were gated for CD4 and dat is given as % 
of total gated CD4 positive cells, (f) Representative intracellular cytokine staining of IL-17 and IFNy for data 
given in (e). (a,c) n=10; data are pooled and expressed as mean ± SEM. (d,f) Data from one healthy volunteer, 
that represents the pattern observed in two separate experiments with a total of n=5. (b) Data is expressed as 
median from two separate experiments n=3. 
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Figure 3. The mannose receptor is the main receptor pathway for the induction of IL-17 production by C. 
albicans. 
(a) Human PBMCs were stimulated for 5 days with RPMI or several fungal components (10 μg/ml), zymosan 
100 μg/ml. Mannan was given in different concentrations ^g/ml) . IL-lß and IL-17 were measured by ELISA, (b) 
Human PBMCs were stimulated for 5 days with heat-killed C. albicans yeast cells in the presence or absence of 
specific receptor inhibitors and isotype controls, (c) Human PBMCs were stimulated for 48 h with RPMI as a 
control or heat-killed C. albicans yeast cells in the presence or absence of blocking antibodies and and isotype 
controls, (d) RT-PCR of the expression of RORyt and IL-17A in PBMCs stimulated with RPMI or C. albicans at 3 
days in the presence or absence of the blocking antibody for MR (aMR). Data is given as relative mRNA 
expression (2"'CT χ 1000). (e) Intracellular cytokine staining of IL-17 and IFNy in human PBMCs (n=5) stimulated 
for 5 days with C. albicans in the presence or absence of the aMR, and than stimulated for 4 h with PMA and 
ionomycin. Cells were gated for CD4 and data is given as % of total gated CD4 positive cells, (f) Representative 
intracellular cytokine staining of IL-17 and IFNy for data given in (d). (a,b,c,) Data are pooled from at least 2 
separate experiments with a total of 6 healthy volunteers (mean ± SEM), (d) Data is expressed as median; two 
separate experiments n=3. (f) Data from one healthy volunteer, that represents the pattern observed in (e). 
Figure 4. Blocking the MR with 5. cerevisiae mannan and Inhibiting MR expression using siRNA transfectlon. 
(a) Human PBMCs were preincubated for 1 h with 100 μg/ml of S. cerevisiae mannan and stimulated for 5 days 
with RPMI, C. albicans mannan (10 pg/ml), or heat killed C albicans, (b) RT-PCR for the expression of MR in 
cells transfected with control siRNA and MR siRNA. (c) Flow cytometry: expression of the MR on the cell surface 
of cells stimulated for 5 days with 10 pg/ml of C. albicans mannan that were treated with control siRNA (red) or 
MR SiRNA (green), (d) IL-17 production in cells transfected with control siRNA or MR siRNA and stimulated with 
RPMI or C. albicans mannan. (a,b,d) A total of 5 healthy volunteers. Data are pooled and expressed as mean ± 
SEM. (c) Data are shown from one volunteer which is representative for all volunteers. 
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IL-17 production induced by C. albicans and mannan is monocyte dependent 
It is known that fungal mannans contain immunodominant Τ cell epitopes (17) and that 
Candida can directly interact with lymphocytes (18). We therefore investigated whether C. 
albicans or purified C albicans mannan alone were able to directly activate Τ cells and would 
lead to the production of IL-17. Neither naive nor memory CD4+ Τ cells were able to produce 
IL-17 when stimulated in the absence of antigen-presenting cells (APC) (Fig. 5a). We 
therefore explored the role of APCs for the induction of IL-17. Monocytes were isolated and 
stimulated with C. albicans or C. albicans mannan, in the presence or absence of naive or 
memory Τ cells. We demonstrate that monocytes alone were not able to produce IL-17, but 
the co-culture of monocytes with memory CD4+ Τ cells induced a strong Th-17 response (Fig 
5b). 
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Figure 5. IL-17 production induced by C. albicans and mannan is monocyte dependent. 
(a) CD4+ naïve (CD25-CD45RA+) and CD4+ memory (CD25-CD45RA-) Τ cells (2.5 χ IO4) were cultured with or 
without autologous monocytes (1.0 χ 105) and stimulated for 8 days with culture medium, C. albicans mannan 
or heat killed C. albicans. IL-17 was measured in supernatants by ELISA, (b) Density plots show intracellular IL-
17 staining of the same experiment as shown in (a). Τ cells were gated on CD3, CD14+ monocytes were CD3 
negative. Data are representative for 2 identical separate experiments. 
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Dectin-1 deficient PBMCs have a relatively lower Th 17 réponse to C. albicans yeasts 
The in-vitro stimulations described above suggest that although ß-glucan by itself cannot 
stimulate IL-17 production, the dectin-l/TLR2 pathway can still contribute to the IL-17 
induction by C. albicans, possibly by potentiating other routes of stimulation. To assess 
whether this is the case in patients, we investigated IL-17 production in 3 patients with a 
complete defect in dectin-1 expression due to an early stop codon mutation (Tyr238Stop) 
(Netea et al., personal communication). FACS analysis confirmed that the cells of the three 
patients used in these experiments expressed no dectin-1 on their surface (Fig. 6a). Dectin-1 
deficient PBMCs showed a lower IL-17 production compared to healthy controls when 
stimulated with C. albicans yeasts (Fig. 6b), but not in pseudohyphae that do not express ß-
glucans on their surface (19). The normal pattern of a higher IL-17 production induced by C. 
albicans yeast cells compared to pseudohyphae was lost in PBMCs that were dectin-1 
deficient. IL-lß and IL-6 induction by C. albicans was also defective in these patients (data 
not shown). 
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Figure 6. Dectin-1 deficient PBMCs have a relatively lower Thl7 réponse to C. albicans yeasts. 
(a) Flow cytometry of the expression of dectin-1 on the surface of PBMCs isolated from healthy volunteers (CI 
and C2) and from three individuals homozygous for the Tyr238 stop mutation (P1-P3). (b) PBMCs described in 
(a) were stimulated for 5 days with heat-killed C. albicans yeasts or pseudohyphae. IL-17 was measured by 
ELISA. 
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TLR2 is synergistic with the mannose receptor for IL-17 production 
Dectin-1 is known to associate with TLR2, and can induce synergistic effects on TLR2 
responses {20, 21). In order to assess whether stimulation of both receptors could induce IL-
17, we tested the combination of ß-glucan with a TLR2 ligand (Pam3Cys). Although ß-glucans 
synergized with Pam3Cys for the production of IL-lß, IL-10, IFNy and TNFa, no IL-17 
production was induced by this combination of stimuli (Fig. 7a). Preparations of ß-glucans (ß-
glucan or curdlan) were not able to stimulate IL-17 production either alone or in 
combination with C albicans mannan (data not shown). This is most likely due to the 
requirement of spadai presentation of the ß-glucans in the fungal cell wall, stimulating 
dectin-1 more efficiently compared to the purified ß-glucan preparations. Surprisingly, 
although Pam3Cys alone was not capable of inducing IL-17, combining Pam3Cys to C. 
albicans mannan resulted in strong synergism for IL-17 production (Fig. 7a). RT-PCR 
demonstrated that upreguiation of mRNA for IL-17 was also synergistic (Fig. 7b). 
Interestingly, the mannan-induced IFNy and IL-lß was significantly inhibited by stimulating 
the TLR2 pathway, while the production of IL-10 and TNFa by Candida mannan was 
unaffected by Pam3Cys (Fig. 7c). 
Figure 7. TLR2 is synergistic with the mannose receptor for IL-17 production. 
(a) Human PBMCs were stimulated for 5 days with RPMI, fungal components or/and the TLR2 ligand Pam3Cys. 
IL-17 was measured by ELISA, (b) RT-PCR of the expression of IL-17A in PBMCs stimulated with RPMI, Pam3Cys 
and mannan or combinations for 3 days. Data is given as relative mRNA expression (2"Δ<ΓΓ χ 1000). (c) Human 
PBMCs were stimulated for 48 h with the same set of stimuli used In (b) and IL-lß, IL-10, IFNy and TNFa were 
measured by ELISA. (a,c) Data are pooled from at least 2 separate experiments with a total of 6 healthy 
volunteers (mean ± SEM), (b) Data Is expressed as median; two separate experiments n=3. 
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Discussion 
IL-17 has emerged as one of the most important pro-inflammatory cytokines, due to its 
modulation of neutrophil mediated responses, with important roles for both host defense 
(2, 5, 15) and autoimmunity (7-9). While most studies to date have focused on the 
conditions (cytokine profiles) necessary for generating Thl7 cells in vitro (10, 11), or the 
generation of Th-17 cells in mice (22, 23), very little is known about the pathways regulating 
IL-17 upon the encounter of pathogenic microorganisms by human cells. In addition, in order 
to stimulate IL-17 production, these studies have used anti-CD3/anti-CD28 antibodies for 
inducing T-cell proliferation, artificial conditions obviously not encountered during in-vivo 
infections or inflammation. In the present study, we have investigated the pathways of IL-17 
stimulation by human primary cells stimulated with whole microorganisms, conditions that 
mimic real life infections. In addition, we deciphered the receptor-ligand pathways 
responsible for IL-17 induction by the fungal pathogen C. albicans. We demonstrate that C. 
albicans is the most potent pathogen in eliciting a pathogen-mediated Thl7 response in 
human PBMCs in the absence of anti-CD3 and/or anti-CD28 antibodies. The mannose 
receptor (MR) is the main pathway through which C. albicans induces the Thl7 response. 
While no single TLR or NOD2 ligand was able to induce IL-17 in the absence of anti-CD3/anti-
CD28 antibodies, mannan from C. albicans was the only component capable of inducing IL-
17 secretion. Interestingly, the dectin-l/TLR2 pathway was able to synergize with the MR-
induced IL-17 secretion, revealing a novel interaction between a C-type lectin receptor and 
TLRs. These data imply that direct recognition through the mannose receptor is sufficient for 
inducing a Thl7 response, and that this ability is unique to the mannose receptor within the 
family of pattern recognition receptors. 
Using anti-CD3 or a combination of anti-CD3 and anti-CD28 antibodies in order to investigate 
the pathways leading to the generation of Thl7 cells, several studies suggested that either 
dectin-1 (13), NOD2 (14) or TLR (12) receptors specifically induce Thl7 generation. However, 
these results are potentially biased by the use of anti-CD3 and anti-CD28 antibodies that can 
by themselves induce IL-17, as clearly demonstrated by our results. In this study we did not 
use anti-CD3/anti-CD28 antibodies to investigate the IL-17 responses to specific pathogens 
or ligands, but instead optimized the conditions necessary for the induction of IL-17 in 
human cells by pathogens alone. Human serum alone did not induce IL-17 secretion in 
human PBMCs, but was able to optimize the conditions needed for the induction of a Thl7 
response. Recently, it has been speculated that serum contains small amounts of TGF-ß that 
may be responsible for the observed differences between IL-17 production of cells cultured 
in the absence or presence of human serum (24). Furthermore, we have addressed the role 
of serum antibodies in our experiments, by using serum from patients with X-linked 
agammaglobulinemia (XLA). These patients cannot produce antibodies because they lack 
functional B-cells. No differences were observed between pooled serum and XLA serum 
devoid of antibodies, concluding that IL-17 production was not antibody dependent (data 
not shown). Notably, in the absence of anti-CD3/anti-CD28, we show that no single TLR or 
NOD2 ligand was able to induce IL-17 production in human PBMCs. 
IL-17 is important for the host defense against human pathogens (2, 5). Although both Gram-
negative bacteria and the fungus S. cerevisiae were able to induce IL-17 production in human 
PBMCs, C. albicans was by far the most potent inducer of IL-17 secretion. The IL-17 
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production corresponded with the appearance of a subset of CD4+ cells that contained cells 
capable of producing IL-17, or both IFNy and IL-17. Since C. albicans was the most potent 
inducer of IL-17 production, we wanted to further dissect the pathways responsible for 
inducing the Thl7 response by this fungal pathogen. When purified fungal components were 
tested, we observed a strong IL-17 production in PBMCs upon stimulation with C. albicans 
mannan. This is in line with the fact that live Candida was even more potent in the induction 
of IL-17 production compared to heat-killed yeasts, since mainly mannoproteins are exposed 
when live Candida is used as a stimulus. Interestingly, S. cerevisiae mannan was not able to 
induce IL-17, and this is in line with the absent Thl7 response to zymosan, as zymosan is 
derived from S. cerevisiae cell wall. The differential recognition of mannans from C. albicans 
and Saccharomyces is most likely due to the different branching of these structures: while 
Candida-denved mannan has a highly branched structure, Saccharomyces mannan mainly 
contains short linear chains of mannose polymers (25). These data argue that the MR is able 
to coordinate the different responses to fungal pathogens, particularly regarding the Thl7 
response. To investigate further the receptor pathways responsible for IL-17 induction by 
Candida, the main receptors involved in fungal recognition were blocked with specific 
antibodies, before stimulation of IL-17 was triggered. In line with the effects of Candida 
mannan, blocking of the MR resulted in the strongest inhibition of IL-17 production, 
confirming its important role in the Thl7 response to C. albicans. Blockade of MR did not 
only result in a lower amount of IL-17, but also lead to a lower percentage of CD4+ cells that 
were able to produce IL-17 alone, or the combination of IFNy and IL-17. Furthermore, 
blocking the MR with an excess of S. cerevisiae mannan or decreasing the MR expression 
with siRNA also inhibited IL-17 production. 
It has been demonstrated in the literature that mannanoproteins contain immunodominant 
Τ cell epitopes (17). The mannoprotein 65 kDa (MP65) stimulates both Τ cell proliferation 
through its protein part, with the mannan component being responsible for the cytokine 
induction (26). Indeed, recombinant MP65 devoid of its mannan structure was unable to 
stimulate cytokine production (17). We have measured the amount of protein in our highly 
purified C. albicans mannan preparation. Despite the extensive purification procedures, we 
have measured a quantity of 0.77 μg/ml protein in the C. albicans mannan preparation with 
a concentration of 100 μg/ml. Although this amount is far lower than protein content in the 
MP65 used in the literature, which has a protein-to-polysaccharide ratio of 1.8:1 (27), we 
cannot exclude that these protein components induced TCR -dependent cell proliferation. 
These effects due to Cond/do-specific epitopes may in fact explain why the memory Τ cells 
were by far more effective for the release of IL-17, in comparison with the naive Τ cells. 
Therefore we envisage a model in which TCR dependent effects are responsible for Τ cell 
activation/proliferation, while the mannan/MR interaction induces the skewing of this 
population towards a Th-17 phenotype. Saccharomyces mannan also contained these low 
amounts of protein. However, it did not stimulate IL-17 release, most likely due to the 
important differences in the branching of the mannan structures that does not allow proper 
stimulation of MR by Saccharomyces mannan (25). 
Blockade of the TLR2/dectin-l pathway partially inhibited IL-17 production, while TLR4 
blockade had no effect. Stimulation of cells with both TLR2 and dectin-1 ligand alone or in 
combination did not result in IL-17 production, although synergism for the production of 
other cytokines has been previously reported (21) and confirmed in our study. Interestingly, 
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TLR2 showed a specific synergistic effect on the IL-17 production induced by the MR, while 
no such effect was apparent on IL-lß production. The role of dectin-1 was further 
investigated by stimulating PBMCs isolated from individuals homozygous for an early stop 
codon mutation in the dectin-1 gene, that leads to a total loss of dectin-1 activity (data not 
shown). When compared to cells isolated from healthy volunteers, the dectin-1-deficient 
PBMCs released less IL-17 after stimulation with C. albicans. The role of dectin-1 for the 
amplification of IL-17 production is supported by an additional line of evidence. C. albicans 
pseudohyphae do not express ß-glucan on their surface (19), and this is likely why we 
observed a stronger Thl7 response induced by C. albicans yeast cells, that stimulate both 
MR and dectin-1 trigger a stronger IL-17 response when compared to C. albicans 
pseudohyphae. This pattern was lost in PBMCs lacking dectin-1 expression on their 
membrane, again suggesting an amplification of β-glucan/dectin-l on IL-17 production 
induced by other C. albicans components (e.g. mannan). It has been recently shown that the 
pathway of IL-17 induction by dectin-1 involves Syk and CARD9 (13). In contrast, when cells 
were stimulated with a combination of TLR ligands, or TLR ligands with the NOD2 ligand 
MDP, no IL-17 production was observed in human PBMCs. These data imply that the MR is 
the only receptor that can directly lead to IL-17 production in human PBMCs, and this 
pathway is amplified by dectin-l/TLR2 signaling. 
In the present study we report a new methodology to investigate the pathogen-specific 
stimulation of Thl7 cells, in conditions mimicking the in-vivo situation. We demonstrate the 
strong capacity of C. albicans to induce IL-17 production, and we have deciphered the 
receptor pathways involved. However, the data presented here also bring new questions 
into light and open new avenues for future research. Firstly, one of the most interesting 
observations regards the capacity of TLR2 ligation to amplify MR-induced IL-17 on the one 
hand, but to inhibit IFNy production on the other hand. We and others have previously 
shown that TLR2 engagement is not able to induce Thl cytokines (28-30). The data 
presented here demonstrate that the TLR2 pathway shifts the immune response towards a 
Thl7 type, with important consequences for understanding pathophysiology of disease. In 
addition, previous studies have shown the capacity of TLR2 to induce Treg proliferation (31). 
It has been recently shown that FOXP3+ cells control the secondary induction of RORyt, and 
TREG cells can be directed to induce differentiation of Thl7 cells in the presence of IL-6 (32), 
or even differentiate themselves into Thl7 cells (33). Our data suggest that TLR2 may play an 
important role in this process, but future studies are needed to assesss this hypothesis in 
more detail. Secondly, an important aspect to be investigated regards the pathways through 
which MR induces IL-17. Indeed, a very recent study has demonstrated that MR is recruited 
to the phagosome and has a crucial role for cytokine induction by C. albicans (34). However, 
the intracellular signaling induced by MR is yet unknown, and the cytokine profile induced by 
MR that is responsible for IL-17 induction is the first aim of future studies in our laboratory. 
All cytokines known to be required for the induction of IL-17, e.g. IL-23, IL-lß and IL-6 are 
stimulated by MR engagement by C. albicans or mannan, fulfilling a first set of conditions 
necessary for IL-17 production. However, none of these cytokines has been specifically 
induced only by or especially by MR, implying that an additional factor important for IL-17 
production is induced by MR recognition. Thirdly, one has to acknowledge that although C. 
albicans was by far the most potent inducer of IL-17 production, the Gram-negative bacteria 
F. coli, Κ. pneumonia and 5. enteritidis also stimulated small amounts of IL-17. TLR and NOD2 
ligands alone or in combination did not stimulate IL-17 release, and therefore the precise 
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pathways through which Gram-negative bacteria stimulate IL-17 production remain to be 
elucidated. 
In conclusion, we have analyzed for the first time the innate receptors and PAMPs 
responsible for inducing a Thl7 response during a specific pathogen-host interaction. In anti-
C. albicans host defense, the mannose receptor takes centre stage in the induction of the 
Thl7 response, and this pathway can be augmented by TLR2/dectin-l. These data reveal a 
novel pathway leading to the induction of the Thl7 response in human PBMCs. The essential 
position played by the mannose receptor warrants further investigation for its role in the 
Thl7 response during infection or autoimmune diseases, and might lead to the design of 
novel immunotherapeutic strategies. 
Experimental procedures 
Volunteers 
Blood was collected from 10 healthy, nonsmoking volunteers who were free of infectious or 
inflammatory disease, and from three patients that were defective in dectin-1 expression 
(Netea et al., personal communication), after informed consent. This was due to a SNP at 
position 238, leading to a premature STOP codon, and a defective transport of the truncated 
dectin-1 protein to the cell surface. Blood was collected by venipuncture into 10 ml EDTA 
syringes (Monoject). Serum was obtained from a patient with XLA after informed consent. 
Reagents and ligands 
Bartonella LPS was used as a potent TLR4 inhibitor (anti-TLR4) (35). TLR2-blocking antibody 
(anti-TLR2) and its control IgAl (Catalog # maba-htlr2 and mabal -etri) were purchased from 
InvivoGen (San Diego, CA). Anti-dectin-1 antibody GE2 (anti-Dectin-1) was a kind gift of Dr. 
Gordon Brown (University of Capetown, South Africa) (36). Mannose macrophage antibody 
(anti-MR) (catalog # 555953, clone 19.2) was purchased from BD biosciences (Dendermonde, 
Belgium). Matching mlgGl isotype control (anti-IgG) was purchased from R&D systems 
(Minneapolis, MN). E. coli LPS (serotype 055:B5) was purchased from Sigma (St. Louis, MO) 
and re-purified as previously described and was used as an ultra pure TLR4 ligand (29). TLR 
ligands Pam3Cys, PolyhC, Flagellin and ODN M362 were from InvivoGen (San Diego, CA). 
Synthetic MDP was purchased from Sigma (St. Louis, MO). Chitin was kindly provided by 
Prof. Neil AR Gow (School of Medical Scienses, Aberdeen, UK) and prepared according to 
previous protocols (37). Candida mannan and particulated ß-glucan were prepared as 
previously described (38, 39). Briefly, for Candida mannan: 100 g wet wt of yeast biomass 
was suspended in 400 ml 2% (wt/vol) KOH and heated for 1 hour at 100°C. Insoluble residues 
were separated by centrifugation, and mannan was precipitated from supernatant with 
Fehling's reagent. The sedimented mannan-copper complex was dissolved in a minimum 
volume of 3 M HCl and added dropwise to methanol/acetic acid at a ratio of 8:1 (vol/vol). 
The procedure of dissolution and precipitation was repeated twice. Finally, the sediment was 
separated, dissolved in distilled water, and dialysed for 24 hours. The purified mannan was 
considered to be maximally deproteinized. Protein analysis by BCA kit (Pierce) measured 
0.77 |ig/ml of protein in the preparation of 100 μg/ml. Curdlan (WAKO) is a dectin-1 ligand 
consisting of linear ß-l,3-glucan polymers derived from Alcaligenes faecalis (40). Zymosan 
and mannan (Lot 16H3842 from Saccharomyces cerevisiae) were from Sigma (St. Louis, MO). 
All stimulations with fungal ligands were in a concentration of 10 μ§/ΓηΙ, unless indicated 
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otherwise. Beads were coated with anti-CD3a alone or in combination with anti-CD28 and 
were prepared according to the manufacturer's instructions (Miltenyi Biotech, Utrecht, the 
Netherlands). 
Microorganisms 
C. albicans ATCC MYA-3573 (UC 820), a strain well described elsewhere (41) was used. C. 
albicans was grown overnight in Sabouraud broth at 37°C, cells were harvested by 
centrifugation, washed twice, and resuspended in culture medium (RPMI-1640 Dutch 
modification, ICN Biomedicals, Aurora, OH) (42). To generate pseudohyphae, C. albicans 
blastoconidia were grown at 37°C in culture medium, adjusted to pH 6.4 by using 
hydrochloric acid. Pseudohyphae were killed for Ih at 100oC and resuspended in culture 
medium to a hyphal inoculom size that originated from 106/ml blastoconidia (referred to as 
106/ml pseudohyphae). All stimulations with C. albicans were with a concentration of 106/ml 
unless indicated otherwise. Clinical isolates of Salmonella enteritidis, Kleibsiella pneumonia 
and Escherichia coli were heat-killed and used in a dosage of 107/ml. A heat-killed clinical 
isolate of S. cerevisiae was kindly provided by Prof. Neil A.R. Gow and used in a dosage of 
106/ml (School of Medical Sciences, Aberdeen, UK). 
In vitro cytokine production 
Separation and stimulation of PBMCs was performed as described previously (43). Briefly, 
the PBMCs fraction was obtained by density centrifugation of diluted blood (1 part blood to 
1 part pyrogen-free saline) over Ficoll-Paque (Pharmacia Biotech, Uppsala, Sweden). PBMCs 
were washed twice in saline and suspended in culture medium supplemented with 
gentamicin 1%, L-glutamine 1%, and pyruvate 1%. The cells were counted in a Bürker 
counting chamber, and their number was adjusted to 5 χ IO6 cells/ml. 5 χ IO5 PBMCs in a 
volume of 100 μΙ per well were incubated at 37°C in round-bottom 96-wells plates (Greiner, 
Nuremberg, Germany), in the presence of 10% human pooled serum (unless indicated 
otherwise), with stimuli or culture medium alone. In blocking experiments, PBMCs were 
preincubated for 1 h with various inhibitors (anti-TLR4 100 ng/ml, anti-TLR2 10 μg/ml, anti-
Dectin-110 μg/ml, anti-MR 5 μg/ml, anti-lgGl 10 μg/ml) before stimulation with C. albicans. 
After 48 h or 5 days of incubation, supernatants were collected and stored at -20°C until 
assayed. 
Cytokine assays 
ILlß, IL-17, and TNFct concentrations were measured by commercial ELISA kits (R&D 
systems); IL-6, IFNy, IL-10 (Pelikine Compact, Sanquin, Amsterdam, The Netherlands); IL-23 
(eBioscience) according to the manufacturers instructions. IL-12p70 and IL-2 were measured 
using the Bioplex (Luminex) cytokine assays from Bio-Rad (Hercules, CA), following the 
manufacturer's instructions. 
Intracellular cytokine staining 
PBMCs cells were stimulated for 4-6 hours with PMA (50 ng/ml; Sigma) and ionomycine (1 
ug/ml; Sigma) in the presence of Golgiplug (BD biosciences) according to manufacturers 
protocol. Cells were first extracellularly stained using an anti-CD4 APC antibody (BD 
biosciences). Subsequently the cells were fixed and permeabilized with Cytofix/ Cytoperm 
solution (BD biosciences) and then intracellularly stained with anti-IFNy PE (eBiosciences) 
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and anti-IL-17 FITC (eBiosciences). Samples were measured on a FACS Calibur and data were 
analyzed using the CellQuest-Pro software (BD biosciences). 
Cell isolation, stimulation and flow cytometry 
Isolation of CD4+ cells was performed as described previously (33). Purified CD4 positive Τ 
cells were labeled with CD25-PEconjugated mAb-(MA251; BD Biosciences), and CD45RA-ECD 
conjugated mAb (2H4; Beckman-Coulter, Mijdrecht, The Netherlands); thereafter 
CD25negCD45RApos cells and CD25negCD45RAneg were isolated by high-purity flow 
cytometric cell sorting using an Altra cell sorter (Beckman-Coulter). A rerun was performed 
to analyze the cell purity of the sorted cells; sorted cells were always more than 98% pure. 
Monocytes were positively isolated from PBMCs with magnetic bead isolation using CD14 
microbeads (Miltenyi-Biotec, Utrecht, The Netherlands) according to the manufacturers' 
instruction. Cells were cultured in culture medium (RPMI-1640 with glutamax supplemented 
with pyruvate [0.02 mM[, 100 U/mL penicillin, 100 μg/mL streptomycin [all from Gibco, 
Paisley, United Kingdom], and 10% human pooled serum [HPS]) at 37°C, 95% humidity, and 
5% C02, in 96-well round-bottom plates (Greiner, Frickenhausen, Germany). Sorted naive 
(CD25-CD45RA+) and memory (CD25-CD45RA+) cells (2.5 χ IO4) populations were cultured 
with or without autologous monocytes (1.0 χ IO5) in 200 μ ι culture medium in the absence 
or presence of stimuli. All stimuli were added at the start of the cultures. Cells were 
phenotypically analyzed by flow cytometry. The following conjugated mAbs were used: CD3-
(UCHT1) ECD-labeled (Beekman Coulter). Intracellular analysis of cytokines was performed 
following stimulation for 4 hrs with PMA (12.5 ng/mL) plus ionomycin (500 ng/mL) in the 
presence of BrefeldinA (5 μg/mL; Sigma-Aldrich). Cells were fixed and permeabilized using 
Fix and Perm reagent (eBioscience) and subsequently stained with anti-IL-17-alexa fluor 647 
-(64DEC17,· eBioscience). Cell samples were measured on a FC500 flow cytometer (Beckman-
Coulter), and flow cytometry data were analyzed using CXP software (Beckman-Coulter). 
Quantitative PCR 
PBMCs were cultured for 3 days and RNA was extracted using TRI-reagent (Sigma). The 
isolated RNA was treated with DNase to remove genomic DNA and subsequently reverse 
transcribed with oligo(dT) primers in a reverse transcriptase procedure with a total volume 
of 20 μΙ. Quantitative real-time PCR was performed using the ABI/PRISM 7000 Sequence 
Detection System, with primer pairs and SYBR Green PCR Master Mix (Applied Biosystems). 
The sequences used, were as follows: IL-17A, forward 5'-TTGATTGGAAGAAACGATGA-3' 
reverse 5'-CTCAGCAGCAGTAGCAGTGACA-3'; RORyT, forward 5'TGAGAAGGACAGGGAGCCAA 
3' reverse S'-CCACAGATTTTGCAAGGGATCA -3'; MR, forward 5'-
CTCAAGACAATCCACCAGTTACTGA-3' reverse S'-CTTCTCTTTGCTGAAATAATACTGGTAGTC -3'. 
Quantification of the PCR signals was performed by comparing the cycle threshold value (Ct) 
of the gene of interest with the Ct values of the reference gene GAPDH. All primers were 
developed using Primer Express 2.0 (Applied Biosystems) and validated according to the 
protocol. Values are expressed as fold increases of mRNA relative to that in unstimulated 
cells. 
siRNA transfection 
PBMCs were transfected by electroporation with the Amaxa Human Monocyte Nucleofector 
kit (Amaxa Inc.) in accordance with the manufacturer's instructions. In brief, PBMCs (2 χ IO7) 
were harvested and resuspended in 100 μΙ of nucleofector solution. After addition of MR 
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siRNA (Dharmacon Inc., 011730) or control GFP siRNA (Amaxa Inc., VSC-1001) at final 
concentration of 125 nM, cells were electroporated with Amaxa program Y-001 and 
recovered for 24 h before further stimulation. 
Statistical analysis 
The differences between groups were analyzed by a two-tailed paired t-test. Differences 
were considered statistically significant when Ρ <0.05, and the actual Ρ value is given for 
each test. All experiments were performed at least twice, and the data presented as the 
cumulative result of all experiments performed, unless otherwise indicated. 
Acknowledgements 
This study was supported by a Vidi Grant of the Netherlands Foundation for Scientific 
Research to M.G.N. We thank Esther van Rijssen for the help with Τ cell isolation and flow 
cytometry. 
146 
Chapter 10 
References 
1. Ouyang, W., J. K. Kolls, and Y. Zheng. 2008. The biological functions of Τ helper 17 cell effector cytokines in 
inflammation. Immunity 28.454-467. 
2. Ye, P., F. H. Rodriguez, S. Kanaly, K. L Stocking, J. Schurr, P. Schwarzenberger, P. Oliver, W. Huang, Ρ Zhang, J. 
Zhang, J. E. Shellito, G. J. Bagby, S. Nelson, K. Charrier, J. J. Peschon, and J. K. Kolls. 2001. Requirement of mterleukm 
17 receptor signaling for lung CXC chemokme and granulocyte colony-stimulating factor expression, neutrophil 
recruitment, and host defense. The Journal of experimental medicine 194:519-527. 
3. Mangan, P. R., L. E. Harrington, D. B. O'Qumn, W. S. Helms, D. C. Bullard, C. Ο Elson, R. D Hatton, S. M. Wahl, T. R 
Schoeb, and C. T. Weaver. 2006. Transforming growth factor-beta induces development of the T(H)17 lineage. 
Nature 441:231-234. 
4. Infante-Duarte, C, H. F. Horton, M. C. Byrne, and T. Kamradt. 2000. Microbial lipopeptides induce the production of 
IL-17 in Th cells. J Immunol 165:6107-6115 
5. Huang, W., L. Na, P. L. Fidel, and P. Schwarzenberger. 2004. Requirement of interleukin-17A for systemic anti-
Candida albicans host defense in mice The Journal of infectious diseases 190:624-631. 
6 Acosta-Rodnguez, E. V., L Rivino, J. Gegmat, D. Jarrossay, M. Gattorno, A. Lanzavecchia, F. Sallusto, and G. 
Napolitani. 2007. Surface phenotype and antigenic specificity of human mterleukin 17-producing Τ helper memory 
cells. Nature immunology 8-639-646. 
7. Fujmo, S., A. Andoh, S. Bamba, A. Ogawa, Κ Hata, Y Araki, Τ Bamba, and Y. Fujiyama 2003. Increased expression of 
mterleukm 17 in inflammatory bowel disease. Gut 52:65-70. 
8. Cua, D. J., J. Sherlock, Y. Chen, C. A. Murphy, B. Joyce, B. Seymour, L. Lucian, W To, S Kwan, Τ Churakova, S. 
Zurawski, M. Wiekowski, S. A. Lira, D. Gorman, R A. Kastelein, and J D Sedgwick. 2003 lnterleukin-23 rather than 
interleukin-12 is the critical cytokine for autoimmune inflammation of the brain Nature 421-744-748. 
9. Murphy, C A, C. L Langnsh, Y. Chen, W. Blumenschem, T. McClanahan, R A. Kastelein, J D Sedgwick, and D J. Cua. 
2003. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. The Journal 
of experimental medicine 198:1951-1957. 
10. Acosta-Rodnguez, E V , G. Napolitani, A. Lanzavecchia, and F. Sallusto 2007 Interleukins Ibeta and 6 but not 
transforming growth factor-beta are essential for the differentiation of mterleukin 17-producing human Τ helper 
cells. Nature immunology 8-942-949. 
11. Yang, L, D. E. Anderson, C. Baecher-Allan, W. D. Hastings, E. Bettelli, M. Oukka, V. K. Kuchroo, and D. A Hafler 
2008. IL-21 and TGF-beta are required for differentiation of human T(H)17 cells. Nature. 
12. Evans, H G , T. Suddason, I. Jackson, L. S Taams, and G. M Lord 2007 Optimal induction of T helper 17 cells m 
humans requires T cell receptor ligation in the context of Toll-like receptor-activated monocytes Proceedings of the 
National Academy of Sciences of the United States of America 104:17034-17039. 
13. Leibundgut-Landmann, S., O. Gross, M. J. Robinson, F. Osorio, E. C. Slack, S. V. Tsom, E. Schweighoffer, V 
Tybulewicz, G. D. Brown, J. Ruland, and E. S. C. Reis. 2007. Syk- and CARD9-dependent coupling of innate immunity 
to the induction of Τ helper cells that produce interleukm 17. Nature immunology 8:630-638. 
14. van Beelen, A. J., Z. Zelmkova, E. W. Taanman-Kueter, F. J. Muller, D. W. Hommes, S. A. Zaat, M. L. Kapsenberg, and 
E. C. de Jong. 2007. Stimulation of the intracellular bacterial sensor NOD2 programs dendritic cells to promote 
interleukin-17 production in human memory Τ cells. Immunity 27:660-669. 
15. Happel, K. I., M. Zheng, E. Young, L. J. Quinton, E. Lockhart, A. J. Ramsay, J. E. Shellito, J. R. Schurr, G. J. Bagby, S. 
Nelson, and J. K. Kolls. 2003. Cutting edge: roles of Toll-like receptor 4 and IL-23 in IL-17 expression in response to 
Klebsiella pneumoniae infection. J Immunol 170:4432-4436. 
16. Bowman, S. M., and S. J. Free. 2006. The structure and synthesis of the fungal cell wall. Bioessays 28:799-808. 
17. Pietrella, D., P. Lupo, Α. Rachini, S. Sandini, A. Ciervo, S. Perito, F. Bistoni, and A. Vecchiarelli. 2008. A Candida 
albicans mannoprotein deprived of its mannan moiety is efficiently taken up and processed by human dendritic cells 
and induces T-cell activation without stimulating proinflammatory cytokine production. Infection and immunity 
76:4359-4367. 
147 
Macrophage Mannose Receptor and [hl7 
18. Forsyth, C. B., and H. L. Mathews 2002. Lymphocyte adhesion to Candida albicans. Infection and immunity 70:517-
527. 
19. Gantner, B. N., R. M. Simmons, and D. M. Underhill. 2005. Dectm-l mediates macrophage recognition of Candida 
albicans yeast but not filaments. The EMBO journal 241277-1286. 
20. Brown, G D, J. Herre, D. L Williams, J. A. Willment, A. S. Marshall, and S. Gordon 2003. Dectin-1 mediates the 
biological effects of beta-glucans. J Exp Med 197:1119-1124. 
21 Gantner, B. N., R. M. Simmons, S. J. Canavera, S. Akira, and D M. Underhill. 2003. Collaborative induction of 
inflammatory responses by dectm-l and Toll-like receptor 2. The Journal of experimental mediane 197 1107-1117. 
22. Bettelh, E., Y Carrier, W. Gao, T. Korn, Τ Β. Strom, M. Oukka, H L. Weiner, and V. Κ. Kuchroo. 2006. Reciprocal 
developmental pathways for the generation of pathogenic effector TH17 and regulatory Τ cells. Nature 441:235-
238 
23. Korn, Τ , E. Bettelh, W. Gao, A. Awasthi, A. Jager, Τ Β. Strom, M. Oukka, and V. Κ. Kuchroo 2007. IL-21 initiates an 
alternative pathway to induce proinflammatory T(H)17 cells. Nature 448:484-487. 
24 Manel, N., D. Unutmaz, and D. R. Littman. 2008 The differentiation of human T(H)-17 cells requires transforming 
growth factor-beta and induction of the nuclear receptor RORgammat. Nature immunology 9 641-649 
25. Cambi, A, M G Netea, H. M. Mora-Montes, N. A. Gow, S. V. Hato, D. W. Lowman, B J. Kullberg, R. Torensma, D L. 
Williams, and C. G. Figdor. 2008. Dendritic Cell Interaction with Candida albicans Critically Depends on N-Lmked 
Mannan. The Journal of biological chemistry 283:20590-20599. 
26. Pietrella, D, G. Bistom, C Corbucci, S. Pento, and A Vechiarelh. 2006. Candida albicans mannoprotein influences 
the biological function of dendritic cells. Cellular Microbiol. 8 602-612. 
27. Chaffin, W L, J L Lopez-Ribot, M. Casanova, D. Gozalbo, and J. P. Martinez. 1998. Cell wall and seceted proteins of 
Candida albicans: identification, function, and expression. Microbiol. Mol. Biol. Rev. 62 130-180. 
28. Re, F, and J. L. Strominger. 2001. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells. J 
Biol Chem 276-37692-37699. 
29. Hirschfeld, M., J. J. Weis, V Toshchakov, C. A. Salkowski, M. J. Cody, D. C. Ward, N. Qureshi, S. M Michalek, and S. 
N. Vogel. 2001. Signaling by Toll-like receptor 2 and 4 agonists results in differential gene expression m murine 
macrophages. Infect. Immun. 69.1477-1482. 
30. Netea, M. G., R. Sutmuller, C. Hermann, C. A. Van der Graaf, J. W. Van der Meer, J. H van Krieken, T. Härtung, G. 
Adema, and Β. J Kullberg. 2004 Toll-like receptor 2 suppresses immunity against Candida albicans through 
induction of IL-10 and regulatory Τ cells. J Immunol 172:3712-3718. 
3 1 . Sutmuller, R. P., M. H. den Brok, M. Kramer, E J. Bennink, L. W. Toonen, B. J. Kullberg, L. A. Joosten, S. Akira, M G. 
Netea, and G. J. Adema. 2006. Toll-like receptor 2 controls expansion and function of regulatory Τ cells. The Journal 
of clinical investigation 116.485-494. 
32. Xu, L., A. Kitani, I. Fuss, and W. Straber. 2007. Cutting edge- regulatory Τ cells induce CD4+CD25-Foxp3- Τ cells or are 
self-induced to become Thl7 cells in the absence of exogenous TGF-beta. J Immunol 178:6725-6729 
33. Koenen, Η. J., R. L. Smeets, P. M. Vmk, E. V. Rijssen, A. M. Boots, and I. Joosten. 2008. Human CD25highFoxp3pos 
regulatory T-cells differentiate into IL-17 producing cells. Blood 
34. Hemsbroek, S. E., P. R. Taylor, F. O. Martinez, L. Martinez-Pomares, G. D Brown, and S. Gordon. 2008. Stage-specific 
sampling by pattern recognition receptors during Candida albicans phagocytosis. PLoS pathogens 4el0O0218. 
35. Popa, C, S. Abdollahi-Roodsaz, L. A. Joosten, N. Takahashi, T. Sprong, G. Matera, M. C. Liberto, A. Foca, M. van 
Deuren, Β. J. Kullberg, W. Β. van den Berg, J. W. van der Meer, and M. G. Netea. 2007. Bartonella quintana 
lipopolysaccharide is a natural antagonist of Toll-like receptor 4. Infect Immun 75:4831-4837. 
148 
Chapter 10 
36. Willment, J. Α., A. S. Marshall, D. M. Reid, D. L. Williams, S. Y. Wong, S. Gordon, and G. D. Brown. 2005. The human 
beta-glucan receptor is widely expressed and functionally equivalent to murine Dectin-1 on primary cells European 
journal of immunology 35 1539-1547. 
37. Gow, Ν. Α., and G. W. Gooday. 1987. Cytological aspects of dimorphism in Candida albicans. Cnt Rev Microbiol 
15:73-78. 
38. Kogan, G., V. Pavliak, and L. Masler. 1988. Structural studies of mannans from the cell walls of the pathogenic yeasts 
Candida albicans serotypes A and Β and Candida parapsilosis. Carbohydr. Res. 172:243-253. 
39. Lowman, D. W , D. A. Ferguson, and D L. Williams. 2003. Structural characterization of (l~>3)-beta-D-glucans 
isolated from blastospore and hyphal forms of Candida albicans. Carbohydr. Res. 338:1491-1496. 
40 Yoshitomi, H., N. Sakaguchi, K. Kobayashi, G D. Brown, T. Tagami, T. Sakihama, Κ. Η ι rota, S. Tanaka, Τ Nomura, I. 
Miki, S Gordon, S Akira, T. Nakamura, and S. Sakaguchi. 2005. A role for fungal {beta}-glucans and their receptor 
Dectin-1 in the induction of autoimmune arthritis in genetically susceptible mice The Journal of experimental 
medicine 201:949-960 
4 1 . Lehrer, R. I., and M. J. Cline. 1969. Interaction of Candida albicans with human leukocytes and serum J Bacterial. 
98 996-1004. 
42. van der Graaf, C. A, M. G Netea, I. Verschueren, J. W. van der Meer, and Β. J Kullberg 2005 Differential cytokine 
production and Toll-like receptor signaling pathways by Candida albicans blastocomdia and hyphae. Infect Immun. 
73 7458-7464. 
43. Netea, M G , Ν. A Gow, C. A. Munro, S. Bates, C. Collins, G. Ferwerda, R. P. Hobson, G. Bertram, H. B. Hughes, T 
Jansen, L. Jacobs, E. T. Buurman, Κ. Gijzen, D. L. Williams, R. Torensma, A. McKmnon, D. M. MacCallum, F. C Odds, J 
W. Van der Meer, A. J. Brown, and B. J. Kullberg. 2006 Immune sensing of Candida albicans requires cooperative 
recognition of mannans and glucans by lectin and Toll-like receptors. J Clin Invest. 116 1642-1650 Epub 2006 May 
1618. 
149 
Macrophage Mannose Receptor and Thl7 
150 
Chapter 11 
The Candida Jhl7 response is dependent on mannan- and ß-glucan-
induced Prostaglandin E2 
International Immunology. 2010 Nov;22(ll):889-895 
Smeekens SP", van de Veerdonk FL', van der Meer JW, Kullberg BJ, Joosten LA, Netea MG. 
' Both authors contributed equally to this work. 

Chapter 11 
Summary 
Background: The fungus Candida albicans is a potent inducer of the Thl7 response. 
Prostaglandin E2 (PGE2) is a strong proinflammatory mediator, which has proven to be 
essential for the Thl7 response. In this study, we wanted to investigate the role of PGE2 in 
the Thl7 response induced by C. albicans in humans. 
Methods: Peripheral blood mononuclear cells (PBMCs) were stimulated with Candida 
albicans in the absence or presence of a non-steroidal anti-inflammatory drug (NSAID). In 
separate experiments, PGE2 or the agonists of prostlaglandin receptors butaprost or 
misoprostol were added to the cells. PBMCs were also stimulated with fungal components 
and siRNA for mannose receptor (MR) was performed. PGE2 and cytokines were measured 
by ELISA or luminex. 
Results: Blocking Cand/da-induced PGE2 production by an NSAID resulted in decreased IL-17 
and IL-22 production and inhibited the expression of RORyT mRNA. Furthermore when PGE2 
production was blocked, IL-6, IL-23 and IL-10 were decreased, while TNFa increased. 
Stimulation with PGE2 or EP2/EP4 agonists restored IL-17 production. C albicans mannan 
was the only fungal component that was able to directly induce PGE2 and silencing of the 
MR resulted in a reduction of Candida induced PGE2. ß-glucan engagement of dectin-1 
synergistically increased TLR2-induced PGE2 production. 
Discussion: These data provide evidence that the PGE2 pathway is important for the Thl7 
response induced by C. albicans, and that PGE2 is induced by the fungal components 
mannan and ß-glucan that are recognized by the MR and the dectin-l/TLR2 pathway, 
respectively. 
Introduction 
Prostaglandin E2 (PGE2 ) is the most widely produced prostanoid in the body in response to 
proinflammatory cytokines (1), and plays an important role in the regulation of inflammatory 
responses. It is primarily involved in the induction of the classical signs of inflammation, 
namely: erythema, increased vascular permeability, edema, pain and fever (2-4). 
Furthermore, PGE2 alters the capacity of antigen presenting cells (APCs) and Τ cells to 
produce certain cytokines, and may therefore influence the functional phenotype of Τ cells 
during priming (5). PGE2 favors a Th2 response, by inhibiting the production of the Thl 
cytokine IFN-y, and by up regulating the production of the Th2-associated cytokines IL-4 and 
IL-5 (6). 
The recently discovered Τ helper subset called Thl7 cells plays an important role in the 
protection against extracellular bacteria and fungi (7). Thl7 cells are characterized by the 
production of IL-17A (IL-17), IL-17F, IL-21 and IL-22 (7). IL-17 is capable of initiating and 
maintaining inflammation, and plays an important role in auto-immune diseases like 
rheumatoid arthritis, multiple sclerosis and psoriasis (8). The early differentiation of Thl7 
cells is initially regulated by IL-lß signaling (9), while IL-23 plays an important in role in the 
amplification and late stage of Thl7 development (10). Interestingly, PGE2 induces IL-23 
production (11-13), and together with IL-23 synergistically favors human Thl7 expansion (1, 
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14). PGE2 has also been reported to be necessary for the production of the Thl7 effector 
cytokine IL-17 (15). Furthermore, it has been shown that human memory Τ cells induce a 
robust Thl7 response in reaction to the fungus Candida albicans (16,17). 
In the present study, we investigated the mechanisms through which C. albicans induces 
PGE2 production, and whether this influences the Cand/cto-induced Thl7 response. It is 
shown that C. albicans is a potent inducer of PGE2, and that the Candida induced Thl7 
response is dependent on the induction of prostaglandins. C. albicans mannan was the only 
fungal component that was able to directly induce PGE2 production, while ß-glucan exerted 
synergistic effects on TLR2-induced prostaglandins. 
Material and Methods 
Volunteers 
Blood was collected from healthy volunteers who were free of infectious or inflammatory 
disease, after informed consent was given. Blood was collected by venipuncture into 10 ml 
EDTA syringes (Monoject, s-Hertogenbosch, The Netherlands). 
Reagents 
The following study materials were used: anti-CD3 and anti-CD28 coated (aCD3aCD28) 
beads prepared from a Τ cell activation/expansion kit (MACS milteny biotec, Bergisch 
Gladbach, Germany); Pam3Cys (EMC microcollections, Tuebingen, Germany). Chitin was 
kindly provided by Prof. Neil AR Gow (School of Medical Scienses, Aberdeen, UK) and 
prepared according to previous protocols (18). Candida mannan and particulated ß-glucan 
were are a kindly provided by Prof. David Wiliams and were prepared as previously 
described (19, 20). Curdlan was purchased from (WAKO, Richmond, USA) and diclofenac 
from Novartis Pharma (Arnhem, the Netherlands). PGE2, butaprost and misoprostol were 
commercially purchased (Sigma-Aldrich, Zwijndracht, the Netherlands). Culture medium 
used in the experiments was RPMI 1640 Dutch modifications (Sigma-Aldrich) supplemented 
with 1% gentamicin, 1% L-glutamine and 1% pyruvate (Life Technologies, Nieuwekerk, the 
Netherlands). 
Microorganism. C. albicans 
ATCC MYA-3573 (UC 820) (21) was grown overnight in Sabouraud broth at 370C, cells were 
harvested by centrifugation, washed twice, and resuspended in culture medium. C. albicans 
was heat-killed for one hour at 100°C. 
In vitro cytokine production 
Separation and stimulation of PBMCs was performed as described previously (22). Briefly, 
the PBMCs fraction was obtained by density centrifugation of diluted blood (1 part blood to 
1 part pyrogen-free saline) over Ficoll-Paque (Pharmacia Biotech, Uppsala, Sweden). PBMCs 
were washed twice in saline and suspended in culture. The cells were counted in a 
hemocytometer, and their number was adjusted to 5 χ IO6 cells/ml. 5 χ IO5 PBMCs in a 
volume of 100 μΙ per well were incubated at 37°C in round-bottom 96-wells plates (Greiner, 
Nürnberg, Germany), in the presence of 10% human pooled serum, with C. albicans or 
culture medium alone. After 1,2 or 7 days of incubation, supernatants were collected and 
stored at -20°C until assayed. 
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Cytokine assays 
The concentration of IL-lß, IL-17, IL-22, IL-23 and TNF-a (Sanquin, Amsterdam, the 
Netherlands) and IL-6, IL-10 and IFN-y (R&D Systems, Abingdon, UK) were measured in cell 
culture supernatants using enzyme-linked immuno sorbent assay (ELISA), according to the 
instructions of the manufacturer. IL-2, IL-4 and IL-12p70 were measured by using Luminex 
technology, according to instructions of the manufacturer (BioRad, Veenendaal, the 
Netherlands). 
RT-PCR 
Two million freshly isolated PBMC were incubated with the various stimuli. After 24 hours of 
incubation at 370C, total RNA was extracted in 800 μΙ of TRIzol reagent (Invitrogen, Breda, 
the Netherlands). Isolated RNA was being reverse transcribed into complementary DNA 
using oligo(dT) primers and MMLV reverse transcriptase. PCR was performed using a 7300 
realtime PCR system (Applied biosystems, Lennik, Belgium). Primer sequences for human 
RORyT: sense: 5'- TGA-GAA-GGA-CAG-GGA-GCC-AA-S' and antisense: 5'- CCA-CAG-ATT-TTG-
CAA-GGG-ATC-A-3'. B2M was used as a reference gene, for which the primers were: 5- ATG-
AGT-ATG-CCT-GCC-GTG-TG-3 (forward) and 5- CCA-AAT-GCG-GCA-TCT-TCA-AAC-3 (reverse). 
PCR conditions were as follows: 2 minutes at 50°C and 10 minutes at 95°C, followed by 40 
cycles of PCR reaction at 950C for 15, and 60°C for 1 minute. 
siRNA transfection 
PBMCs were transfected by electroporation with the Amaxa Human Monocyte Nucleofector 
kit (Lonza, Cologne, Germany) in accordance with the manufacturer's instructions. In brief, 
PBMCs (2 χ 107) were harvested and resuspended in 100 μΙ of nucleofector solution. After 
addition of MR siRNA (Dharmacon, Epson, UK, 011730) or control GFP siRNA (Lonza, VSC-
1001) at final concentration of 125 nM, cells were electroporated with Amaxa program Y-
001 and recovered for 24 hours before further stimulation. Both MR expression on the cell 
surface and mRNA expression for MR were decreased after MR siRNA transfection compared 
to GFP siRNA transfection (data not shown). 
Statistical analysis 
Experiments were performed in duplicate, and supernatants were pooled. The differences 
between groups were analyzed using the Wilcoxon signed rank test. The level of significance 
between groups was set on ρ < 0.05. Data are presented as mean ± SEM. 
Results 
Candida albicans-induced IL-17 and IL-22 is dependent on PGE2 
To determine whether C. albicans could induce PGE2 production, PBMCs from 8 healthy 
volunteers were stimulated for 48 hours with C. albicans blastoconidia. Stimulation of C. 
albicans resulted in PGE2 production by PBMCs (Figure la). In addition, when PBMCs were 
stimulated with C albicans in the presence of the prostaglandin inhibitor diclofenac, the 
PGE2 production was completely blocked (Figure la). To investigate if the Thl7 réponse 
induced by C.albicans is PGE2 dependent, PBMCs were stimulated for 7 days with C. albicans 
or beads coated with aCD3aCD28, in the absence or presence of diclofenac. Both IL-17 and 
IL-22 were produced upon stimulation with C albicans, and both cytokines were lower when 
PCMCs were cultured in the presence of diclofenac (Figure lb). Mitogenic Τ cell stimulation 
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with aCD3aCD28 beads resulted in IL-17 production, but not IL-22 production. The IL-17 
induced production by beads was not influenced by PGE2 inhibition (Figure lb). In addition, 
RORyT mRNA expression was decreased in the presence of addition of an NSAID to the 
system (Figure 1c). To assess whether the decrease in IL-17 production caused by the NSAIDs 
was due to the absence of PGE2, we added exogenous PGE2 to assess whether this could 
restore IL-17 production. Adding PGE2 to the cell culture partially restored IL-17 production 
(Figure Id). Also butaprost, which is a selective EP2 receptor agonist, and misoprostol, a non 
selective-agonist with the highest affinity for the EP4 and EP3 receptor, restored the NSAID-
inhibited IL-17 production (Figure Id). PBMCs in the presence of PGE2, butaprost or 
misoprostol alone did not produce IL-17 (data not shown). 
Figure 1. Candida albicans-induced IL-17 and IL-22 is dependent on PGE2. 
(a) Human PBMCs were stimulated for 48 hours, in the presence of human serum, with RPMI or C. albicans and 
in the absence or presence of NSAIDs ( n = l l ) . (b) Human PBMCs were cultured with human serum for 7 days 
with RPMI, C albicans or aCD3aCD28 beads, in the presence or absence of NSAIDs. Production of IL-17 (n=20) 
and IL-22 {n=7) in the supernatants was measured by ELISA, (c) qPCR of RORyt mRNA expression in human 
PBMCs that were stimulated for 24 hours, in the presence of human serum, with RPMI or C albicans and in the 
absence or presence of NSAIDs (n=5). (d) Human PBMCs were stimulated for 7 days, in the presence of human 
serum, with C. albicans in the absence or presence of NSAIDs and in the absence or presence of PGE2 (10 mM), 
butaprost (10 μΜ) or misoprostol (35 μΜ) (n=3). Cytokines and PGE2 were measured by ELISA, (a-c) Data are 
pooled and expressed as mean ± SEM. 
C. albicans mannan is the only fungal component that directly induces PGE2 production 
To elucidate which fungal components were responsible for the PGE2 production induced by 
C. albicans, PBMCs were cultured with RPMI, mannan, ß-glucan or curdlan, or chitin and 
PGE2 production was measured in cell culture supernatants. Interestingly, C. albicans 
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mannan was the only component able to induce PGE2 production (Figure 2a). In line with 
this, when the transcription of the MR was inhibited using sIRNA, PGE2 production 
decreased (Figure 2b). ß-glucan and curdlan alone were not able to Induce PGE2. Also, the 
TLR2 ligand Pam3Cys alone was not able to Induce PGE2 production. However, ß-glucan and 
curdlan were able to synerglze with the TLR2 ligand PamSCys and Induce PGE2 production 
(Figure 2c). 
Figure 2. C. albicans mannan Is the only fungal component that directly Induces PGE2 production. 
(a) Human PBMCs were stimulated for 48 hours in presence of human serum with RPMI, mannan, ß-glucan, 
chitin, curdlan. (n=4) (b) PGE2 production in cells from two healthy volunteers transfected with control siRNA 
(GFP) or MR siRNA and stimulated with RPMI or C. albicans, (c) Human PBMCs were stimulated for 48 hours in 
presence of human serum with RPMI, mannan, ß-glucan or curdlan, in the absence or presence of Pam3Cys 
(n=5). Production of PGE2 in the supernatants was measured using ELISA. Data are pooled and expressed as 
mean ±SEM. 
Prostaglandin E2 skewes the cytokine profile favoring a Thl7 response 
To determine the effects of prostaglandins on the cytokine profile induced by C. albicans, we 
stimulated human PBMCs with C. albicans in the presence or absence of the prostaglandin 
inhibitor diclofenac. Strikingly, IL-6 and IL-23 decreased when PBMCs were preincubated 
with diclofenac. In addition, IL-10 decreased when PGE2 was blocked, while TNF-a Increased 
(Figure 3). IL-lß was not affected by Inhibition of PGE2 production. 
Discussion 
In the present study we provide evidence for an Important role of PGE2 In the Candida 
Induced Thl7 response. PGE2 contributes to the Cond/cto-induced Thl7 response by inducing 
the Thl7 polarizing cytokines IL-6 and IL-23. Furthermore, the fungal components mannan 
and ß-glucan were shown to be responsible for the induction of PGE2 production. 
In line with previous studies, we show that C. albicans Is capable of Inducing a strong PGE2 
production In human PBMCs (23). A notable difference Is that most studies used viable C. 
albicans. It has been reported that live C albicans can produce PGE2 (24, 25), this Is why we 
used heat-killed C. albicans to Investigate the induction and functional role of PGE2 
produced by the host. Boniface et.al. found that PGE2 is necessary for the production of IL-
17 in the presence of antigen presenting cells (APCs), and that PGE2 directly promotes 
differentiation and proinflammatory functions of Thl7 cells, while differentially regulating 
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IFN-y production (15). In line with this, we found that blocking PGE2 production resulted in 
reduced RORyT mRNA expression, IL-17 and IL-22 production, and increased TNFa 
production. This indicates that PGE2 favours a Thl7 response. In line with these findings, the 
addition of PGE2 partially restored the IL-17 production. Furthermore, PGE2 signals through 
the EP2 and EP4 receptors and both receptors are important for mediating Thl7 responses 
(15, 26, 27). Our observations suggest that PGE2 induced by Candida also signals through the 
EP2 and EP4 receptor, since stimulation of these receptors in the absence of PGE2 partially, 
and sometimes completely, restored the Cond/da-induced Thl7 response. These data 
further support the concept that the Thl7 response induced by C. albicans is dependent on 
the PGE2 signaling pathway. 
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Figure 3. Prostaglandin E2 skewes the cytokine profile favoring Thl7 response. 
Human PBMCs were stimulated for 24 or 48 hours with RPMI or C. albicans, in the presence or absence of 
diclofenac. IL-lß, IL-6, IL-23, TNF-a, IL2, IL4 and IL-12p70 (24 hours stimulations), IL-10 and IFN-y (48 hours 
stimulations) were measured in the supernatants by ELISA or Luminex (n=6). Data are pooled and expressed as 
mean + SEIVI. 
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However, although in certain conditions the PGE2 release is completely blocked, the 
production of IL-17 and IL-22 is not completely inhibited. This indicates that other 
mechanisms contribute to the fungal-induced Thl7 responses. Importantly, blocking PGE2 
did not effect IL-lß, and there was still IL-6 and IL-23 production. Since IL-lß is essential for 
the early development of the Thl7 response, the IL-1 pathway is most likely responsible for 
the IL-17 production present in the absennce of PGE2. In addition, NSAIDs are not associated 
with mucosal candidiasis, while a defect in the Thl7 response has been linked to mucosal 
candidiasis (28, 29). The residual production of IL-17 is thus most likely to be sufficient to 
maintain adequate host defense against mucosal candidiasis when NSAIDs are used. 
In a subsequent set of experiments, we tried to elucidate which pathogen recognition 
receptors were involved and which components of C. albicans were responsible for the 
induction of PGE2. Mannans were the only fungal components that were able to directly 
induce PGE2 production. We have previously reported that mannan from C albicans was the 
only component capable of inducing IL-17 production (17). Furthermore, blocking of the MR 
with siRNA lead to inhibition of PGE2 production, suggesting that the MR receptor plays an 
important role in the induction of PGE2 production by PBMCs. This is supported by the 
previous observation that overexpression of the MR in HeLa cells which are challenged with 
mannan results in a significant induction of COX-2 expression (30). Another C-type lectin, the 
ß-glucan receptor dectin-1, also plays an important role in ant\-Candida host defense, and 
prostaglandin production can be enhanced by overexpressing dectin-1 in a mouse 
macrophage cell line (31). However, ß-glucans alone did not stimulate PGE2 production (31). 
In line with the known and previously reported synergism of dectin-1 and TLR2 (32, 33), ß-
glucans strongly increased the production of PGE2 induced by TLR2. Furthermore, dectin-1 
and TLR2 have also been linked to the induction of the Thl7 response (17). In contrast, we 
previously found that ß-glucans or curdlan did not augment the mannan induced IL-17 
response (17). Therefore, ß-glucans contribute through the dectin-l/TLR2 pathway to the 
Candida specific Thl7 response by inducing the production of PGE2 by the host. 
To understand how PGE2 polarizes the immune response towards a Thl7 profile, we 
investigated the changes in cytokine profiles when PGE2 production was inhibited. PGE2 is 
known to have a potent IL-6 inducing effect on monocytes (34). We observed that blocking 
of PGE2 by diclofenac reduced the production of IL-6 induced by Candida. IL-6 has been 
reported to be essential for the induction of Thl7 memory cells in humans (35). This 
suggests that skewing of PGE2 towards a Thl7 response is dependent on IL-6. When PGE2 
production was blocked, the induction of IL-23 by Candida was lower. The role of IL-23 in the 
Thl7 response has been well established and it is now generally accepted that it IL-23 is 
needed to maintain the Thl7 response (10, 36). Furthermore, it has been suggested in an 
experimental inflammatory bowel disease model that the proinflammatory effects of PGE2 
are due to the induction of dendritic cells derived IL-23 that subsequently supports the Thl7 
response (13). Interestingly, we found no effect on IL-lß when we blocked PGE2 production. 
Since IL-lß is one of the most important cytokines in the induction of an early Thl7 response 
(9), it is therefore notable that PGE2 does not induce the Thl7 response directly through IL-
lß. We found an increase of TNF-a when PGE2 was inhibited, which is in line with the 
literature which has reported that PGE2 inhibits TNF-a (37). However, the exact role of TNF-
α in the Thl7 response is not clear and still has to be elucidated (38). Finally, we found that 
IL-10 production was lower in the presence of a PGE2 inhibitor. Veldhoen et al. already 
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speculated that IL-10 production, that suppresses IL-12, might aid the development of IL-17 
producing Τ cells, and subsequently reported that anti-IL-10 caused a reduction in the 
proportion of T-cells that were able to produce IL-17 (39). Therefore, the loss of the 
suppressive effects of IL-10 could be a possible explanation for the observed lower IL-17 
production when PGE2 production was blocked. This would ultimately result in a stronger 
Thl response that is able to subvert the Thl7 response. In line with this hypothesis, we 
observed that IL-12p70 and IFNy were higher in the absence of PGE2, although this did not 
reach statistical significance. 
In conclusion, prostaglandins were shown to play an important role in the Candida albicans 
induced Thl7 response. Prostaglandin E2 (PGE2 ) production induced by C. albicans skewes 
the cytokine profile towards a Thl7 response, by decreasing IL-6, IL-23, IL-17 and IL-22. 
Interestingly, C. albicans mannan, which is the main inducer of the Thl7 response in C. 
albicans, was the only fungal component that was able to directly induce PGE2. 
Furthermore, dectin-1, the other major pathway important for the the induction of a Thl7 
response, was shown to act synergistically on the TLR2 induced PGE2 production. These data 
provide evidence that the Thl7 response induced by the MR and dectin-l/TLR2 is enhanced 
by prostaglandins, which in turn skew the cytokine profile favoring Thl7 polarization. 
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Chapter 12 
Summary 
The role of the IL-17 pathway in antifungal host defense is controversial. Several studies 
suggested that IL-17 is crucial for the protection against Candida infection, while other 
studies reported that IL-17 may contribute to inflammatory pathology and worsening of 
fungal disease. To address these discrepancies, we assessed the differential role of IL-17 
pathway in two models of fungal sepsis: intravenous infection with live C. albicans, in which 
fungal growth is the main cause of mortality, and zymosan-induced multiple organ failure in 
which the inflammatory pathology drives the mortality. Firstly, IL-17 receptor deficient (IL-
17RA-/-) mice showed increased mortality and higher fungal loads in the kidneys in the 
model of disseminated candidiasis, partly due to lower neutrophil recruitment in the IL-
17 RA-/- mice. Secondly, IL-17RA-/- mice were not protected against the multi-organ failure 
induced by zymosan. These data demonstrate that IL-17 does not have a major contribution 
to the inflammatory pathology leading to organ failure in fungal sepsis, and support the 
concept that the IL-17 pathway is protective in antifungal host defense. 
Introduction 
Τ helper 17 cells (Thl7 cells) which are characterized by the production of interleukin-17A 
(IL-17), IL-17F, IL-21 and IL-22 have been shown to be crucial in host defense against several 
pathogenic microorganisms (1-3). IL-17 induces infiltration of neutrophilic granulocytes at 
the site of infection, and is also able to stimulate activation of macrophages (2). In systemic 
candidiasis, the main host defense mechanism is phagocytosis and killing of C. albicans by 
neutrophilic granulocytes, monocytes, and macrophages (4, 5). 
IL-17 has been linked to neutrophil recruitment in several fungal infection models. 
Neutrophil influx was demonstrated to be decreased in the kidneys of IL-17RA-/- mice during 
disseminated candidiasis (6). Furthermore, mobilization of the neutrophils in the blood 
during systemic challenge with C. albicans was also impaired (6). Similarly, IL-17RA-/-
showed a reduced recruitment of neutrophils to the local site of inflammation in an oral 
model of candidiasis (7). Intratracheal challenge with Aspergillus fumigates in dectin-1-/-
mice resulted in insufficient neutrophil recruitment to the lung and uncontrolled fungal 
outgrowth (8). IL-17 was shown to be dependent on dectin-1 and neutralization of IL-17 
resulted in decreased fungal clearance in the lungs, linking IL-17 to neutrophil recruitment in 
pulmonary fungal infection. In addition, a recent study demonstrated that IL-17 plays an 
important role in neutrophil recruitment to the lungs in a pulmonary fungal infection model 
with Paracoccidioides brasiliensis (9). Taken together, these data point to a crucial protective 
role for IL-17 in the recruitment of neutrophils during fungal infection. However, others have 
proposed that the Thl7-induced activation of neutrophils may also result in an 
overwhelming inflammatory tissue response which impairs antifungal immune resistance 
and leads to defective pathogen clearance (10). The cause of the discrepancies between 
these studies is not known. 
In the present study, the role of the IL-17 pathway was investigated in two experimental 
models, using IL-17RA-/- and control mice. The role of the IL-17 pathway in anti-Candida 
host defense was assessed in a mouse model of disseminated candidiasis, while the 
contribution of IL-17 to an overwhelming inflammatory tissue response was investigated in a 
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septic multiple organ failure model based on the injection of the fungal component 
zymosan. The latter model is characterized by neutrophil influx and severe tissue 
inflammation that leads to organ failure and ultimately death (11). By using these two 
models we dissected the inflammatory mechanisms during fungal sepsis, in order to discern 
between the potential harmfull and protective effects of the IL-17 pathway that have been 
described in Candida infections. 
Materials and methods 
Animals 
Experiments were performed using IL-17 receptor knockout (IL-17RA-/-) mice (kindly 
provided by dr. J.J. Peshon, Amgen, Seattle) and wild-type mice, 7 to 9 weeks old, weighing 
20-25 g. The IL-17RA-/- mice were characterized elsewhere (1). The animals were fed 
standard chow (Hope Farms RMB-H, Woerden, The Netherlands) and acidified water ad 
libitum. The day/night cycle was 12 h/12 h. Before use, the animals were allowed to 
acclimatize for 5 days. The experiments were approved by the Animal Ethics Review 
Committee of the Radboud University Nijmegen Medical Centre. 
Candida albicans infection model 
C. albicans ATCC MYA-3573 (UC 820), a strain well described elsewhere (12), was used in all 
experiments. Candida was grown overnight in Sabouraud broth at 37°C) cells were harvested 
by centrifugation, washed twice, and resuspended in culture medium in culture medium 
(RPMI-1640 Dutch modification, ICN Biomedicals, Aurora, OH) (13). Candida yeasts were 
killed for Ih at 100oC and resuspended in culture medium. IL-17 RA-/- mice and their control 
littermates were injected intravenously with C albicans blastoconidia (2 χ IO5 CFU/mouse) in 
a 100 μΙ volume of sterile pyrogen-free phosphate-buffered saline (PBS). Survival was 
assessed daily for three weeks. Subgroups of 5 animals were killed on days 3 and 7. To assess 
the tissue outgrowth of the microorganisms, the kidneys of the sacrificed animals were 
removed aseptically, weighed, and homogenized in sterile saline in a tissue grinder. The 
number of viable Candida cells in the tissues was determined by plating serial dilutions on 
Sabouraud dextrose agar plates as previously described (5). The CFU were counted after 24h 
of incubation at 370C, and expressed as log CFU/g tissue. 
Zymosan-induced generalized inflammation 
The zymosan-induced generalized inflammation model for multi-organ failure has been 
described previously (14). To improve reproducibility and to limit mortality in the first phase, 
a small modification to the initial model was introduced, consisting of an aseptic 
intraperitoneal injection of 40 μg lipopolysaccharide (LPS;Fscfter/c/j/O coli, Sigma Chemical 
Co., St. Louis, MO) dissolved in 200 μ ι of phosphate-buffered saline 6 days before zymosan 
administration [13]. Zymosan A (Sigma) was sterilized by gamma radiation (5 kGray) and 
homogeneously suspended in sterile paraffin oil (25 mg/mL) by high frequency vibration for 
1 h. After sonification, the suspension was sterilized again in a waterbath at 100°C for 80 
min. All suspensions were freshly made before use. Zymosan was given intraperitoneally in a 
dose of 1 mg/g body weight. 
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Recruitment and in vitro cytokine production 
Groups of five IL-17RA-/- mice and their control littermates were sacrificed four hours and 
72 hours after intraperitoneal injection with heat-killed C. albicans 1 χ 
IO7 microorganisms/mL. Peritoneal cells were harvested by injecting 4 mL of sterile 
phosphate-buffered saline (PBS) containing 0.38% sodium citrate (15). After washing, the 
cells were resuspended in RPMI 1640 containing 1 mM pyruvate, 2 mM L-glutamine, 
100 μg mL"1 gentamicin and 2% fresh mouse plasma (culture medium). Cells were cultured in 
96-well microtiter plates (Greiner, Alphen, The Netherlands) at 105 cells per well, in a final 
volume of 200 μι. The cells were stimulated with either control medium or heat-killed (1 h, 
100 °C) C. albicans at 1 χ 107 microrgansisms/mL. After 24 h of incubation at 37 °C, the plates 
were centrifuged (500 g, 10 min), and the supernatant was collected and stored at -80 "C 
until cytokine assays were performed. 
To assess IFN-y, IL-17 and IL-10 production, primed spleen cells from mice on day 3 of 
infection with C. albicans 2 χ IO5 CFU/mouse were stimulated in vitro with heat-killed 
Candida yeast cells (1 χ IO7 microorgansims/mL). Spleen cells were obtained by gently 
squeezing spleens in a sterile 200 μπι filter chamber. The cells were washed and 
resuspended in RPMI1640, counted in a Bürker counting chamber and the number was 
adjusted to 5 χ IO6 mL"1. One milliliter of the cell suspension was stimulated with 1 χ IO7 
heat killed C. albicans yeasts. Measurement of IFN-y, IL-17 and IL-10 concentrations was 
performed in supernatants collected after 48 h of incubation at 37 °C in 5% CO2 in 24-well 
plates. 
Phagocytosis and killing of C. albicans 
Phagocytosis and killing of C. albicans yeast cells was assessed according to a method 
described elsewhere (16, 17). Exudate peritoneal phagocytes from groups of five IL-17RA-/-
mice and their control littermates were elicited by an intraperitoneal injection of 1 χ IO7 
heat killed C. albicans yeasts. After 4 hours, cells were collected in separate sterile tubes by 
washing the peritoneal cavity with 4mL of ice-cold PBS that contained 50 U/mL heparin. 
Peritoneal cells were centrifuged (for 10 min at 2250 g), counted in a Bürker counting 
chamber, and resuspended in culture medium. The processes of phagocytosis and 
intracellular killing were studied in an adherent monolayer of phagocytes, as described (16). 
Briefly, 5 χ IO5 cells were dispensed into the wells of a 96-well flatbottom plate (Costar), 
allowed to adhere for 2 h, and washed to remove nonadherent cells. Subsequently, the cells 
were incubated with 1 χ IO4 CFU C. albicans, which were opsonized for 45 min at 24°C in 
modified Eagle's medium (MEM; Gibco Life Technologies) containing 2.5% fresh mouse 
serum (effectortarget ratio, 40:1). After 15min, supernatants were aspirated, and 
monolayers were gently washed with MEM to remove noningested microorganisms. The 
supernatant and well washings that contained the noningested Candida blastoconidia were 
plated in serial dilutions on Sabouraud agar plates. The percentage of phagocytized 
microorganisms was defined as [1 - (number of uningested cfu/cfu at the start of 
incubation)] χ 100. Killing of C. albicans by phagocytes was assessed in the same monolayers. 
After removal of the nonphagocytized Candida blastoconidia, 200 mL of culture medium, 
consisting of Sabouraud in MEM (50% vol/vol), was added to the monolayers. After 3 h of 
incubation at 37°C in air and 5% C02, the wells were scraped gently with a plastic paddle and 
washed with 200mL distilled H2O to achieve lysis of phagocytes in 3 cycles, and 10-fold 
dilutions of each sample were spread on Sabouraud agar plates and incubated at 37°C for 24 
h. The percentage of yeast killed by the phagocytes was determined as follows: [1 - (cfu 
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after incubation/ number of phagocytized cfu)] χ 100. Phagocyte-free incubations of 
blastoconidia were included as a control for yeast viability. In earlier experiments we have 
shown that 90-97% of attached/internalized C. albicans are intracellular (18). 
Cytokine assays 
TNFa was determined by specific radioimmunoassay (detection limit 20 pg/ml), as previously 
described (19). IL-10, IFNy and IL-17 concentrations were measured by a commercial ELISA 
(Biosource, Camarillo, CA; detection limit 16 pg/ml), according to the instructions of the 
manufacturer. 
Statistical analysis 
Statistical significance of differences in mortality between experimental groups was 
determined using the Log-rank (Mantel-Cox) Test. Statistical significance of differences in 
cytokines, phagocytosis and killing experiments and fungal outgrowth were determined 
using a two-sided Mann-Whitney U test. Ρ values smaller than 0.05 were considered 
significant. 
Results 
The IL-17 pathway is protective in disseminated candidiasis 
The role of the IL-17 pathway in anti-Cand/cto host defense remains controversial. On the 
one hand IL-17RA-/- mice are reported to be more susceptible to Canidida infections (6, 7), 
while on the other hand IL-17 is said to be responsible for inflammatory pathology and 
defective clearance of Candida (10). To assess the role of the IL-17 pathway in anti-Cand/cto 
host defense, we tested the susceptibility of IL-17RA-/- mice to disseminated C. albicans 
infection. Mice were infected intravenously with Candida yeasts and monitored for survival 
and fungal growth. IL-17RA-/- mice were more susceptible to disseminated Candida 
infection, as judged by the decreased survival (Fig. la) and the increased fungal burden in 
the kidneys (Fig. lb) compared to the control mice. 
IL-1 IRA-/- mice are susceptible to zymosan-induced multiple organ failure 
IL-17 has been suggested to play a role in severe tissue inflammation that is detrimental for 
the host and impairs antifungal clearance. We investigated whether this is the case in an 
experimental model of zymosan-induced multi-organ failure. There was no significant 
statistical difference in survival between IL-17RA-/- and control mice (Fig. 1c). 
Neutrophil recruitment and phagocytosis and killing in IL-17RA-/- mice 
It has been reported in oral and disseminated candidiasis that a defect in IL-17 leads to lower 
neutrophil recruitment which causes disease susceptibility (6, 7). To investigate the 
dynamics of the influx of neutrophils and their function, we harvested cells from the 
peritoneal cavity at 4 hours and 72 hours after intraperitoneal injection with heat-killed 
Candida and addressed the number of monocytes, neutrophils and lymphocytes and the 
capacity of these cells to phagocytose and kill C. albicans. Although no difference in 
neutrophil recruitment between control mice and IL-17RA-/- mice was observed at 4 hours a 
significant decrease in neutrophil influx was apparent 72 hours after challenge with heat 
killed Candida (Fig. 2b). In addition, the capacity to phagocytose and kill Candida was not 
impaired in neutrophils from IL-17RA-/- mice (Fig. 2c). 
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A deficient IL-17 pathway is associated with lower production of tumor necrosis factor in 
response to C. albicans 
The cytokine profiles induced by C. albicans were assessed in cells isolated from control mice 
and IL-17RA-/- mice. Splenocytes isolated three days after the infection of control and IL-
17RA-/- mice with C. albicans showed no difference in the production of IL-10, IFNy and IL-17 
(Fig. 3a). Inflammatory peritoneal cells from IL-17RA-/- showed a significant lower 
production of TNFa in response to C. albicans, when compared to cells harvested from 
control mice (Fig. 3b). 
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Figure 1. IL-17 pathway In disseminated candidiasis and zymosan-induced multi-organ failure. 
(a) IL-17RA-/- and control mice were Intravenously infected with live C. albicans yeast (2 χ 10s CPU), (b) Control 
and IL-17RA-/- mice were sacrificed at 3 days and 7 days after infection. Candida albicans fungal outgrowth was 
determined in the kidneys, (c) Survival of IL-17RA-/- and control mice after administration of zymosan and LPS. 
(a,c) The disseminated candidiasis model was performed in a total of n=15 mice per group and the zymosan 
model with n=10 per group. Survival was assessed daily for three weeks and analyzed using the Log-rank 
(Mantel-Cox) Test, (b) The results are expressed as log CFU/g tissue (n=5 mice/group, means ± SD). * P<0.05. 
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Figure 2. Neutrophil recruitment and phagocytosis and killing in IL-17RA-/- mice. 
(a) Total cell recruitment and cell subpopulations harvested 4 hours after the intraperiteoneal injection with 
heat killed C. albicans, (b) Percentage of neutrophils in the peritoneal cavity at 4 hours versus 72 hours, (c) 
Phagocytosis and killing of C. albicans by neutrophils isolated from IL-17RA-/- and control mice at four hours. 
Percentage of Candida blastoconidia of the initial inoculum that was ingested after 15 min of phagocytosis and 
percentage of phagocytized Candida blastoconidia that was killed after incubation at 37 °C for 3 h is shown. All 
data are shown as median ± IQR. * P<0.05. 
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Figure 3. Cytokine production capacity in ceiis isolated from IL-17RA-/- mice. 
(a) Mice were infected intravenously with C. albicans (2 χ 10s CFU/mouse), and after 3 days splenocytes were 
harvested and stimulated In vitro with 1 χ IO7 heat-killed C. albicans (E : Τ ratio 2 :1). Measurements of IFN-y, 
IL-10 and IL-17 concentrations were performed in supernatants collected after 48 h of incubation at 37°C. (b) 
Peritoneal cells from IL-17RA-/- and control mice, harvested 4 hours after the intraperitoneal injection with 
heat-killed Candida albicans, were stimulated in vitro with additional heat-killed C. albicans yeasts. Production 
of TNF in the supernatants was measured by specific ELISA after 24 h of stimulation at 37°C. (a,b) The results 
are pooled data from two separate experiments with a total of 8 mice per group. Data are expressed as median 
± IQR. * P<0.05. 
Discussion 
In the present study, we addressed the controversy surrounding the role of the IL-17 
pathway in antifungal host defense and show that IL-17RA-/- mice have a decreased survival 
and display higher fungal loads in the kidneys in early stages of disseminated candidiasis 
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when compared to control mice. This demonstrates that the IL-17 pathway is non-redundant 
and protective in disseminated candidiasis. In line with previous studies, neutrophil 
recruitment to the peritoneal cavity was impaired in IL-17RA-/- mice challenged 
intraperitoneally with Candida. Interestingly, early neutrophil recruitment in the first 4 hours 
was not affected in these experiments. Furthermore, we found no defects in phagocytosis 
and killing of Canidida by the IL-17RA-/- neutrophils. Notably, we found a significantly lower 
TNF production in response to Candida in cells from IL-17RA-/- mice, which might contribute 
to susceptibility to disseminated candidiasis. IL-17 was not important for the severe tissue 
inflammation that leads to multiple organ failure in a sterile inflammatory fungal model 
using zymosan, which is in contrast with the suggestion that IL-17 is detrimental to the host 
by inducing severe tissue inflammation during infection. 
Recently, the cytokine IL-17 has received a lot of attention since Τ cells producing IL-17 were 
characterized as a different lineage of Τ helper cells with an important role in autoimmunity 
(2). Interestingly, human memory Τ helper cells were found to have the capability of 
inducing a robust IL-17 production in response to C. albicans (20). In addition, it has been 
found that patients with primary immunodeficiencies such as hyperlgE syndrome and 
chronic mucocutaneous candidiasis which suffer from chronic mucosal fungal infections, 
displayed a defect in their Candida specific Thl7 response (21, 22). Because these studies 
strongly indicate that the Thl7 memory response and the IL-17 pathway is essential in host 
defense against mucosal Candida, it was surprising to notice that IL-17 was reported to be 
detrimental for the host during murine mucosal Candida infection (10). This could be due to 
the different model that was used in this latter study, namely a gastric model of mucosal 
Candida infection. Furthermore, differences between mice and humans in the development 
of Thl7 responses have been described (23), and mice are not colonized by Candida in 
contrast to humans (24). However, Conti et al. have recently investigated the role of the IL-
17 response in a murine oropharyngeal Candida infection model, and clearly demonstrate 
that IL-17 was needed to provide an effective host defense against mucosal candidiasis (7). 
The controversial observation that IL-17 is counter-productive for protection in fungal 
infection has been explained by the fact that IL-17 induces neutrophil activation which 
causes excessive inflammation (10). To test this hypothesis, the role of IL-17 was addressed 
in a model that depends on neutrophil influx and leads to severe tissue inflammatory 
responses. The model is based on the injection of zymosan that will induce a strong 
inflammatory response eventually resulting in multi-organ failure (25). Notably, zymosan is a 
fungal component known to induce a predominant Thl7 response in mice (26, 27). It has 
been previously demonstrated that there is a strong influx of inflammatory cells in the 
various tissues during the development of organ damage in this animal model (14, 25). For 
instance, there is an influx of macrophages and neutrophils in the liver and there are 
accumulations of lymphocytes, plasma cells and neutrophils in the lungs. We speculated that 
if the IL-17 pathway plays a crucial role in severe tissue inflammation and regulation of 
neutrophil function, IL-17RA-/- mice should be protected from the severe inflammation and 
multiple organ failure which is induced by zymosan. However, we observed no difference in 
survival between control mice and IL-17RA-/- mice in this model. This argues against the 
suggestion that the IL-17 pathway is detrimental to the host by causing a diversion of 
neutrophil function that leads to uncontrolled inflammation during infection. 
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The observation that a deficient IL-17 pathway results in higher mortality and fungal burden 
in disseminated candidiasis is in line with several studies arguing that the Thl7 response is 
protective for the host during Candida infection. Huang et al. were the first to show that IL-
17 was non-redundant for the host defense against disseminated candidiasis (6). They 
observed significant increases of fungal outgrowth in the kidneys at day 4 of infection. In line 
with this, we observed a 10 fold increase in fungal burdens at day 3 in the kidneys of IL-
17RA-/- mice and a 6 fold higher burden on day 7. Notably, in the present study the IL-17RA-
/- and wild type mice had a similar survival curve until day 10, and only after this time point 
a higher mortality rate could be seen in the IL-17RA-/- mice. Although it is most likely that 
the increase in fungal burden leads to renal failure subsequently causing the higher mortality 
rate observed in the IL-17RA-/- mice (28), other mechanisms could account or contribute to 
the increased susceptibility. Interestingly, a significantly lower production of TNF was 
observed in response to stimulation with Candida albicans in cells recruited from IL-17RA-/-
mice. It has been reported that mice lacking the TNF receptor are highly susceptible to 
disseminated candidiasis (29), suggesting that the lower TNF response observed in IL-17RA-/-
mice may contribute to the increased susceptibility to disseminated Candida infection. An 
important observation presented here is that neutrophils from IL-17RA-/- mice do not 
display an intrinsic defect in phagocytosis and killing. In line with reports that suggest IL-17 
to be important for neutrophil recruitment, we found that at 72 hours after intraperitoneal 
injection with heat-killed Candida the neutrophils influx was lower in the IL-17RA-/- mice. 
This supports the previously reported finding that neutrophil recruitment is impaired in IL-
17RA-/- mice during fungal infection. However, the initial influx of neutrophils at four hours 
was not disturbed, which indicates that IL-17 is especially important for the neutrophil 
recruitment after the initial hours/days of infection. 
It has been reported that IL-23 driven inflammation promotes infection and impairs fungal 
resistance (10). Circulating IL-23 did not reach detectable concentrations in the disseminated 
candidiasis model or the multiple organ failure model, similar to other cytokines. Therefore, 
it is most likely that IL-23 exerts its effects locally in the inflamed tissue. As a consequence, 
IL-23 driven Thl7 responses could be context dependent, and promote either protective or 
pathogenic responses depending on additional local factors. 
In conclusion, host defense against systemic Candida infection critically depends on the IL-17 
pathway, while IL-17 does not appear to be involved in enhancing the inflammatory 
potential of neutrophils in a model of severe tissue inflammation induced by zymosan. Our 
observations support the idea that in ant\-Candida host defense the Thl7 response is 
essential for protective antifungal immunity. This knowledge is crucial with respect to the 
focus for the development of novel strategies to prevent and treat Candida infections. 
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Summary 
Both interferon-gamma-producing type 1 Τ helper (Thl)- and interleukin-17 (IL-17)-
producing type 17 Τ helper (Thl7) cells have been proposed to be involved in anti-fungal 
host defense. Although invasive aspergillosis is one of the most severe human fungal 
infections, little is known regarding the relative importance of the Thl versus Thl7 cellular 
immune pathways for the human anti-Aspergillus host defense. Using human peripheral 
blood mononuclear cells and a system consisting of monocyte-derived macrophages, we 
found that Aspergillus fumigatus is a weak inducer of human IL-17 but induces a strong Thl 
response. These data were validated by the very low IL-17 levels in bronchoalveolar lavage 
fluid and serum of patients with invasive aspergillosis. Surprisingly, live A. fumigatus reduced 
IL-17 production induced by mitogenic stimuli. This effect was mediated through the 
propensity of A. fumigatus to metabolize tryptophan and release kynurenine that modulates 
the inflammatory response through inhibition of the IL-17 production. In conclusion, A. 
fumigatus does not stimulate production of IL-17 and human host defense against 
aspergillosis may not rely on potent Thl7 responses. 
Introduction 
Aspergillus fumigatus, an opportunistic ubiquitous mold, causes invasive aspergillosis in 
immunocompromised hosts with high rates of mortality and morbidity [1, 2]. Until recently, 
the paradigm of the type 1Τ helper (Thl) and type 2 Τ helper (Th2) cells was traditionally the 
model upon which knowledge of host immune response to fungal infection was based [3, 4]. 
These CD4+ T-cell subtypes mediate distinct immune responses. Thl cells produce 
proinflammatory cytokines such as interferon-gamma (IFN-y) that induces protective 
antifungal defense mechanisms, whereas Th2 cells release IL-4 and IL-10 which evoke a 
humoral response and in turn down regulate Thl-dependent mechanisms [5]. It is the 
balance between Thl and Th2 responses that has been perceived as critical in determining 
outcome of invasive fungal diseases [6]. 
However, the recent discovery in both mice and man of a novel member of the CD4+ 
effector T-cell family (Thl7 cells) producing IL-17 has provided novel insights into the 
immune mechanisms that are responsible for both protection from infections and 
immunopathology in autoimmune diseases [7-9]. Differentiation of murine and human naive 
CD4+ Τ cells into either Thl, Th2 or Thl7 cells depends on the cytokine milieu present at the 
time of initial engagement of the T-cell receptor and co- stimulatory receptors [10]. 
Homology between human and murine IL-17 is high and the major function of IL-17 is to 
promote recruitment and activation of neutrophils [11]. As a result of these effects, IL-17 is 
generally perceived as having a protective role against fungal infection, as demonstrated by 
an increased susceptibility to disseminated candidiasis of mice lacking the IL-17 receptor [12]. 
However, human Thl7 cells have a different origin than those in mice [13], and the cytokines 
that direct Thl7 development exert their effect differently in the two hosts [14]. 
Few and conflicting data are available regarding the potential role of IL-17 for the host 
defense against A. fumigatus. On one hand, IL-17 was recently reported to hamper 
neutrophil-mediated killing of A. fumigatus and the in-vivo clearance of the organism in non-
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immunosuppressed mice [15]. In contrast, other data suggest a protective role for IL-17 in 
host defense against A. fumigatus. Neutralization of IL-17 early in host defense against A. 
fumigatus infection in non-immunosuppressed mice resulted in an increased pulmonary 
fungal burden [16]. Very little is known regarding the role of IL-17 for the host defense 
against Aspergillus infections in humans. 
On this background and with the understanding that regulation of Thl7 pathway may differ 
between murine and human cells, we studied the IL-17 host response to A. fumigatus in 
human leukocytes and in patients with invasive aspergillosis. 
Materials and methods 
/W/croorgon/sms 
The A. fumigatus strain V05-27 is a previously characterized clinical isolate [17]. Live conidia 
and heat-killed hyphae were obtained as previously described [18]. For the experiments 
involving Äsperg/7/i/s-conditioned medium, live V05-27 A. fumigatus (at concentrations as 
specified) were grown in RPMI 1640 DM (ICN Biomedicals, Costa Mesa, CA) supplemented 
with 10 μg/ml gentamicin, 10 mM L-glutamine, and 10 mM pyruvate at 370C. After 3 days, 
the culture suspension was centrifuged and the supernatant was passed through a 0.2 μηη 
filter (Whatman GmbH, Dassel, Germany). In addition, conidia arrested at the different 
growth phases were prepared from A. fumigatus B-5233, another well-characterized strain 
[19]. After incubation on Aspergillus minimal agar media for one week, both resting and 
germinating conidia (following incubation for 4 hours at 370C in liquid broth yeast nitrogen 
base, Difco, Franklin Lakes, NJ)) were harvested in 0.01% Tween-20/phosphate-buffered 
saline, washed with sterile distilled water and resuspended in Hanks' balanced saline 
solution without Ca2+ and Mg2+. Conidia were heat-inactivated by incubation at 650C [20]. 
The treatment was repeated until no viable conidia were detected on malt agar plate. All 
specimens were kept frozen at -20oC until use. 
Heat-killed Candida albicans blastoconidia, strain ATCC MYA-3573 (UC820) were used as a 
positive control [21, 22]. Experiments involving heat-killed C. albicans blastoconidia at a 
concentration of 106 microorganisms/ml were performed in a similar manner to that 
described above. 
Reagents 
Anti-CD3/anti-CD28-coated beads (to mimic action of antigen-presenting cells for T-cell 
activation) were purchased from Miltenyi-Biotech (Utrecht, the Netherlands) and used 
according to manufacturer's instructions. Recombinant human IL-lß (rIL-lß; 50ng/mL) from 
Biosource (Etten-Leur, the Netherlands), IL-6 (rlL-6; 50ng/mL) and IL-23 (rlL-23; 50ng/mL) 
from R&D Systems (Abingdon, UK) were used. Rabbit anti-human anti-interferon-gamma 
(anti-IFN-y) ( ^ g / m L ) was purchased from U-CyTech (Utrecht, the Netherlands) and 
corresponding isotype control, rabbit immunoglobulin G (IgG), from Jackson 
ImmunoResearch Laboratories (West Grove, PA). Kynurenine and tryptophan were 
purchased from Sigma-Aldrich (Zwijndrecht, the Netherlands). The Dectin-1 receptor 
antagonist, laminarin, was kindly provided by Dr David Williams (University of Tennessee, 
Knoxville, TN). Anti-human monoclonal antibody against mannose receptor CD206 (ct-MR) 
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and corresponding isotype control was purchased from BD Pharmingen (Breda, the 
Netherlands). 
In-vitro cytokine production 
Separation and stimulation of peripheral blood mononuclear cells (PBMC) was performed as 
described previously [23]. Briefly, venous blood was drawn into ethylenediaminetetraacetic 
acid tubes from healthy volunteers after informed consent. PBMC were isolated by density 
centrifugation on Ficoll-Hypaque (Pharmacia Biotech, Uppsala, Sweden). Cells were washed 
twice in saline, counted and the number adjusted to 5xl06 cells/mL. For experiments 
involving monocyte-derived macrophages (MDM) [24], PBMC were maintained in culture 
medium (RPMI 1640 DM supplemented with gentamicin, L-glutamine, and pyruvate) in the 
presence of 10% human pooled serum in humidified atmosphere (5% C02) at 370C for 6-7 
days to permit differentiation with the lymphocyte component in-situ. Culture medium was 
refreshed after 3 days. Stimulation assays were performed in 96-well plates (Greiner, Alphen 
a/d Rijn, the Netherlands) using 100 μΙ volume of PBMC or MDM with lymphocytes 
(abbreviated as MDM/lymphocytes), and the various stimuli to a total volume of 200 μΙ/well. 
For investigation of Thl7 responses, the cells were incubated with the pathogen at 370C for 
3 or 7 days [25]. After incubation, the supernatants were collected and stored at -20oC until 
assay. 
Flow cytometry 
MDM/lymphocytes were stimulated for 4-6 hours with 13-phorbol 12-myristate acetate 
(PMA) (50 ng/ml; Sigma) and ionomycine (1 μg/ml; Sigma) in the presence of Golgiplug (BD 
Biosciences, Breda, the Netherlands) according to manufacturer's protocol. Cells were first 
stained extracellularly using an allophycocyanin-conjugated anti-CD4 antibody (BD 
Biosciences). Subsequently the cells were fixed and permeabilized with Cytofix/ Cytoperm 
solution (BD Biosciences) and then intracellularly stained with fluorescein isothiocyanate-
conjugated anti-IL-17 (eBiosciences, Halle-Zoersel, Belgium). Samples were measured on a 
FACS Calibur and data were analyzed using the Flow Jo software (version 7.2.5.). 
Patients 
Serum from hematology patients diagnosed with proven or probable invasive aspergillosis 
(IA) [26] and bronchoalveolar lavage (BAL) fluid of IA patients as per European Organization 
for Research and Treatment of Cancer (EORTC) criteria [27] were obtained before the 
initiation of appropriate treatment and in line with the respective institutional guidelines. 
Matched controls consisted of similar patient cohorts with underlying hematological 
malignancies who did not have IA. 
Cytokine assay 
lnterleukin-6, IL-10 and IFN-y were measured by commercial ELISA kit (Pelikine Sanquin 
Compact, Amsterdam, the Netherlands), according to the instructions of the manufacturer. 
IL-17 was measured by the appropriate commercial ELISA kit (R&D Systems). Detection limits 
were 8 pg/ml (IL-6 and IL-10), 20pg/ml (IFN-γ), and 16 pg/ml (IL-17) respectively. 
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Tryptophan and kynurenine measurement 
Levels of tryptophan and kynurenine produced by A. fumlgatus in 4sperg/7/us-conditioned 
medium were quantified by UV detection with high performance liquid chromatography 
(HPLC). This was performed on a SpectraSYSTEM autosampler and pump (Thermo 
Separation Products, San Jose, CA). Chromatographic separation was performed using an 
Inertsil 5 ODS-2 column (100mm χ 3.0 I.D.) (Varian Inc., Middelburg, the Netherlands). 
Absorbance was monitored with a diode-array detector (UV6000LP, Thermo Separation 
Products, San Jose, CA) at wavelength of 280nm for tryptophan and 360nm for kynurenine 
[28]. The mobile phase for isocratic elution was made by dissolving 40mM sodium acetate. 
The pH of the eluent was adjusted to pH 4.5 with a solution of 40mM citric acid and 2% 
acetonitrile of the total volume buffer was added. The continuous flow rate was 0.3 ml/min 
[29]. For calibration, the standard was diluted in RPMI in the concentration range of 0-72 μΜ 
for tryptophan, and 0-42 μΜ for kynurenine. 50 μΐ of the standard or sample was injected 
into the column for measurement. 
Statistical analysis 
Experiments were performed in duplicates. For the in-vitro experiments, results from 3 sets 
of separate experiments (involving 5 or more distinct healthy volunteers) were pooled and 
analyzed using SPSS 16.0 statistical software. Data given as means + standard errors of the 
means (SEM) and the Wilcoxon signed rank test was used to compare differences between 
groups (unless otherwise stated). The level of significance was set at ρ < 0.05. 
Results 
Aspergillus fumlgatus is a poor inducer of human IL-17 by PBMC and MDM 
We investigated the capacity of A. fumlgatus to induce production of IL-17 by human PBMC. 
Incubation of live A. fumlgatus V05-27 conidia (at doses of IO4 - 106 microorganisms/ml) 
with PBMC over 7 days induced little IL-17, in contrast to C. albicans, a known inducer of IL-
17 (Fig. la) [25]. We also assessed the capacity of MDM/lymphocytes to mediate IL-17 
induction. However, IL-17 production upon incubation with live Aspergillus conidia was also 
nearly undetectable in this system (Fig. lb). Flow cytometric analysis further corroborated 
the low propensity of live Aspergillus to induce IL-17, in contrast to C. albicans, as illustrated 
by the absence of IL-17-producing CD4+ cells (Figs. Ic&d). 
To validate these findings and to demonstrate that the observed phenomenon was not 
strain-specific, we repeated the experiments using either heat-inactivated conidia of another 
well-characterized A. fumlgatus strain B-5233 that were arrested at the resting and 
germinating growth stage, or with heat-killed V05-27 A. fumigatus hyphae. All of the above 
Aspergillus preparations showed limited IL-17 responses across the concentration range of 
105 to 107 microorganisms/ml (Fig. le). In contrast, the Aspergillus components induced a 
distinct dose-dependent trend in IL-6 production, excluding significant cellular toxicity as the 
cause of the limited IL-17 production (Fig. If). In line with this, lactate dehydrogenase levels 
in supernatants of cells stimulated with live Aspergillus were not elevated as compared to 
vehicle-stimulated controls. Hence, both live and heat-inactivated A. fumigatus at different 
stadia were poor inducers of IL-17 in human cells. 
184 
Chapter 13 
(a) 
1000 
• 100 
io 
1 
PBMC χ 7 days 
I 
0 1 < X ) E * 0 4 
D 1 0 0 E . 0 5 
. 1 0 0 E - 0 6 
RPMI Uve Aspergillus Candida 
IO1 
0-01 
MP 
0 0 8 Asfjergiiios 
(b) 
10000-i 
f 1000 · 
κ 100 
- 10 
1 
MDM/tytnphocytes χ 7 days 
n 
α 1 ODE + 04 
D lOOE t 0 5 
• l O O E f 06 
RPMI Live Aspergillus Candida 
J 10° 10' Vf IO 1 
cu« ~ 
IO 1 
10 
lo­
in 
0 06 
Λ !
» ' 
0 6 4 
β R 5815 
J 10° 10' 10* 103 
CD4 ^ 
HK Aspeigtus components m PBMC HK Aspergillus components in PBMC 
160 
_ 140 
ι 120 
1 100 
;r »ο 
- 40 
20 
Τ DI-OOE-iOS 
• 1 0 0 E . 0 6 
100 000 
^ 10 000 
S ' 0 0 0 
2 too 
io M Ai D I O O E t O S α ϊ 0 0 E . 0 6 • 1 0 0 6 * 0 7 
Resting conidîa Germmaling 
conidia 
Hyphae Resting conidia Germinating 
condia 
Hyphae 
Figure 1. (a, b) lnterleukin-17 (IL-17) -inducing capacity of 10 -10 micro-organisms/ml Aspergillus fumigatus in 
peripheral blood mononuclear cells (PBMC) and monocyte-derived macrophages (MDM)/lymphocytes systems 
over 7 days with Candida albicans as positive control, (c, d) Flow cytometry of MDM/lymphocytes stimulated 
by A. fumigatus and C. albicans, respectively. The cells were labelled with anti-CD4-allophycocyanin and anti-IL-
17-fluorescein isothiocyanate. Density plots show surface staining of CD4 (x-axis) and intracellular staining of IL-
17 (y-axis). Numbers on the plots represent percentage of cells bearing positivity for the respective markers. 
Results from a representative experiment are shown, (e, f) IL-17 and IL-6 induced by 105-107 micro-
organisms/ml of heat-killed A. fumigatus components: resting conidia, germinating conidia and hyphae in 
PBMC. Stimulation studies are cumulative from three sets of experiments. *P < 005 compared with control 
(RPMI-1640). Aspergillus: live A. fumigatus conidia (unless otherwise stated), Candida: heat-killed C. albicans 
blastoconidia (as positive control), HK: heat-killed. 
Aspergillus fumigatus induces strong Thl responses 
It has been described that host immune response to A. fumigatus is primarily T-helper type 1 
(Thl)-mediated, accompanied by the production of IFN-y [30, 31]. We have also 
demonstrated the propensity of live A. fumigatus to induce a robust IFN-y response in 
contrast to absence of IL-17, or the limited IL-6 and IL-10 production in the 
MDM/lymphocyte system (Fig. 2). 
Live Aspergillus attenuates IL-17 production 
As other studies have used mitogenic stimulation with anti-CD3/anti-CD28 antibodies to 
induce Thl7 responses, live Aspergillus conidia were added to MDM/lymphocytes in the 
presence of anti-CD3/anti-CD28 beads. Surprisingly, IL-17 levels remained low in the 
presence oi A. fumigatus compared with the mitogenic stimulation alone and even showed a 
dose-dependent inverse relationship to the concentration of the pathogen. Adding 
185 
Aspergillus fumigatus Induces a limited Th l7 response 
recombinant IL-6, IL-lß and IL-23 to the anti-CD3/anti-CD28 T-cell activation failed to 
increase IL-17 induction by A. fumigatus (Figs. 3c&d). IFN-y production showed a trend 
towards inhibition by Aspergillus, but this was not as markedly attenuated as the IL-17 
response. 
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Figure 2. lnterleukin-6 (IL-6), IL-10, interferon-y (IFN-y) and IL-lß production by monocyte-derived 
macrophages ( M D M ) following stimulation by live Aspergillus fumigatus at incremental concentrations. IFN--y 
and IL-lß responses are robust compared with IL-6 and IL-10. ' P < 0 0 5 compared with RPMI-1640 control, η = 
8 subjects. 
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Figure 3. (a, b) Interferon-y (IFN-y) and interleukin-17 (IL-17) produced by monocyte-derived macrophages 
(MDM)/lymphocytes stimulated with anti-CD3/anti-CD28 beads alone and with incremental amounts of 
Aspergillus fumigatus or Candida albicans (positive control) over 3 days (c, d) In addition to anti-CD3/anti-CD28 
beads, recombinant IL-6 (rlL-6) + rIL-lß + rlL-23 were added to MDM/lymphocytes stimulated with A. fumigatus 
or C albicans (positive control) over 3 days. *P < 0 0 5 compared with stimulated MDM/lymphocytes but 
without pathogen, η = 6 subjects. Aspergillus: live A. fumigatus conidia, Candida: heat-killed C. albicans 
blastoconidia, aCD3CD28: anti-CD3/anti-CD28-coated beads. 
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Weak IL-17 response is not linked to the pro-Thl-propensity of A. fumigatus 
IFN-γ can suppress Thl7 responses and shift cellular responses towards a Thl bias. We 
attempted to silence the Thl response with anti-human IFN-y antibodies and investigate its 
effect on IL-17 induction by Aspergillus (Figs. 4a&b), although IFN-y production was 
effectively inhibited, there was no significant rescue of IL-17 production induced by anti-
CD3/anti-CD28 antibodies in the presence of A. fumigatus. Hence, the weak IL-17 response 
seen in A. fumigatus is not related to its pro-Thl-inducing propensity. 
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Figure 4. Interferon-v (IFN-v) and interleukin-17 (IL-17) from monocyte-derived macrophages 
(MDM)/lymphocytes stimulated with anti-CD3/anti-CD28 beads and incremental amounts of Aspergillus 
fumigatus or Candida albicans (positive control) in the presence of anti-IFN-y (a, b). *P < 0-05 compared with 
respective control (white bar) without anti-IFN-y, η = 6 subjects. Aspergillus: live A. fumigatus conidia, Candida: 
heat-killed C. albicans blastoconidia (as positive control). 
Secreted products from live Aspergillus attenuate IL-17 production 
The inhibitory effects of Aspergillus on the IL-17 response induced by mitogens may be 
exerted directly through cell-cell contact, or indirectly through products released by 
Aspergillus. To investigate this, ^sperg/V/us-conditioned medium was added to the activated 
cells. As observed in Fig. 5, IL-17 production was inhibited in a dose-dependent manner by 
the conditioned media on which live A. fumigatus conidia had grown. The IL-17-attenuating 
effects induced by Asperg/7/us-conditioned medium could not be assigned to shed ß-glucan 
or mannan-derivatives from the Aspergillus cell wall, as the addition of laminarin (inhibitor 
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of Dectin-1, the ß-glucan receptor) and anti-MR antibodies (which block the mannose 
receptor) did not reverse the effects of the conditioned medium (data not shown). 
The tryptophan metabolism pathway has recently been implicated for its role in regulating 
Thl7 response to fungal Infection [32]. Tryptophan and kynurenine concentrations were 
measured in the Asperg;7/us-conditioned media. Kynurenine concentrations in the 
Asperg;7/us-condltioned media were increased (as compared to control) across the 
concentration range of live A. fumigatus. This correlated with a drop in the concentration of 
the substrate, tryptophan, in the conditioned medium (Table 1). 
The effect of kynurenine was assessed on the IL-17 production induced by anti-CD3/antl-
CD28 antibodies. As depicted in Fig. 5c, kynurenine inhibited IL-17 production in a dose-
dependent manner as compared to control stimulation. 
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Figure 5. (a, b) lnterferon-v (IFN-v) and interleukin-17 (IL-17) produced by anti-CD3/anti-CD28-stimulated 
monocyte-derived macrophages (MDM)/lymphocytes over 3 days in the presence of conditioned medium in 
which the respective concentrations of live Aspergillus fumigatus had previously been grown over 72 hr. *P < 
005 compared with anti-CD3/anti-CD28-stimulated MDM/lymphocytes in the presence of conditioned medium 
in which no Aspergillus had been grown (control; first bar), η = 6 subjects, (c) IL-17 production by anti-CD3/anti-
CD28-stimulated MDM/lymphocytes over 3 days in the presence of increasing concentrations of kynurenine 
compared with control (without kynurenine). *P < 0-05 compared with control, η = 6 subjects. Aspergillus: live 
A. fumigatus conidia, aCD3CD28: anti-CD3/anti-CD28-coated beads. 
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Table 1. Tryptophan and kynurenine levels of conditioned media in which live A. fumigatus (of Incremental 
concentrations) had been grown over 3 days as compared to levels in conditioned medium incubated over 3 
days without Aspergillus (RPMI Control). Tryptophan and kynurenine levels were measured via high 
performance liquid chromatography (HPLC). The analysis was performed on 3 sets of assays and is presented as 
means+SD. 
Tryptophan (μΜ) 
Kynurenine (μΜ) 
CONDITIONED MEDIUM 
RPMI Control 
28.38 + 0.17 
0 
Live Aspergillus {microorganism/ml} 
104 
20.14 + 4.46 
0.12 + 0.01 
10s 
18.95 + 4.10 
0.18 + 0.05 
10e 
17.98 + 3.48 
0.26 + 0.04 
IL-17 concentrations are low in patients with invasive aspergillosis 
To assess the capacity of Aspergillus to stimulate Thl7 responses In vivo, we measured IL-17 
concentrations In clinical specimens of patients with Invasive aspergillosis. This consisted of 
BALs from 17 distinct patients diagnosed with proven/probable IA and another 20 BALs from 
corresponding control patients (I.e. patients with similar background underlying disease, but 
without Invasive aspergillosis). The same analysis was performed on the serum of 19 
patients with invasive aspergillosis (specimen obtained at the point of diagnosis of disease) 
and also 15 other control patients without IA. As seen In Fig. 6a, IL-17 levels are generally 
low In BALs of patients at risk of IA, and not higher than the concentrations found in patients 
without IA. Similarly, IL-17 concentrations were low In the circulation of patients with IA, and 
even decreased compared with controls (Fig. 6b). 
Figure 6. (a) lnterleukin-17 (IL-17) levels in bronchoalveolar lavage of patients diagnosed with proven/probable 
invasive aspergillosis (IA) compared with a corresponding patient cohort without IA (No ΙΑ): η = 17 in IA group 
(eight proven IA cases and nine probable IA cases), η = 20 in No IA group, (b) IL-17 levels in serum of IA patients 
(IA) and corresponding patient controls (No ΙΑ): η = 19 in IA group (eight proven IA cases and 11 probable IA 
cases), and π = 15 in No IA group. *P < 005 (unpaired t-test). 
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Discussion 
In the present study we investigated the activation of T-helper cellular responses activated 
by A. fumigatus. We demonstrate that A. fumigatus induces a very limited Thl7 response in 
humans, both in-vitro and in-vivo. In contrast, A. fumigatus induces robust stimulation of 
IFN-γ production, implying that Thl responses likely represent the cornerstone of Τ helper-
dependent immunity against Aspergillus species. 
Few studies have investigated the role of IL-17 in host defense against Aspergillus infection. 
The studies performed to date involved murine knock-out models, and reported 
contradicting results, with some studies suggesting a deleterious role of IL-17 [15, 33], while 
others have suggested that IL-17 is beneficial for anti-Aspergillus host defense [16]. In 
addition, induction of Thl7 cells in humans may differ from that of mice [34, 35]. No studies 
have assessed the induction of Thl7 responses in human cells. Moreover, patients with IA 
represent a unique susceptible cohort who have primarily hematological malignancies and 
are profoundly immunocompromised: being recipients of high-dose, long-term steroid 
therapy, chemotherapy, stem-cell transplantation and having prolonged agranulocytosis. 
Such mitigating conditions are difficult to simulate in the above-studied mice models. 
Therefore, studies in primary human cells are the only viable alternative for the study of 
Thl7 responses in humans. Because host immune responses to live and killed A. fumigatus 
are known to be different [20, 36], and in order to closely mimic the physiological conditions 
in which the host immune cells encounter the pathogen, the stimulation of 
MDM/lymphocytes and Uve A. fumigatus conidia was investigated. 
In the present study we report that A. fumigatus is a poor inducer of IL-17 in both PBMC and 
in a macrophage/T-cell system. Based on the current understanding of Th-17 activation 
pathway in other fungal infections such as C. albicans [25], this can be attributed to either 
the absence of specific memory T-cells against A. fumigatus or to a sub-optimal induction of 
the endogenous cytokines necessary for the induction of a Thl7 response (e.g. IL-23, IL-lß, 
IL-6). However, even mimicking T-cell activation by the use of anti-CD3/anti-CD28 beads, as 
well as adding a 'pro-Thl7 cytokine cocktail' consisting of IL-lß, IL-6 and IL-23 [34, 37, 38], 
failed to significantly augment IL-17 production in response to Aspergillus. 
In contrast to the failure to induce IL-17 production, A. fumigatus induced robust Thl IFN-γ 
responses [3, 30, 39]. It has been suggested by some studies that Thl and Thl7 
differentiation can be mutually exclusive [10, 15]. If this would be indeed the case, the 
strong induction of IFN-γ by Aspergillus, may inhibit the Thl7 responses and account for the 
lack of IL-17 induction in the presence of a predominant Thl response. However, when we 
neutralized IFN-y bioactivity with anti-human IFN-γ antibodies, this failed to stimulate IL-17, 
arguing for an intrinsic incapacity to stimulate Thl7 responses, rather than indirect effects 
through Thl induction. Similar to Aspergillus, the inhibition of IFN-γ during stimulation with 
C. albicans did not up-regulate IL-17 release, arguing against a major role of IFN-γ as a 
modulator of Thl7 responses in fungal infections. 
Interestingly, not only was A. fumigatus unable to induce much IL-17 production, it even 
actively inhibited the IL-17 release induced by mitogenic stimuli such as anti-CD3/anti-CD28 
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antibodies. The tryptophan metabolism pathway has recently been implicated for its role in 
regulating Thl7 response to fungal infection [32]. Tryptophan can be metabolized by the 
enzyme indoleamine 2,3-dioxygenase (IDO) into the catabolite kynurenine. IDO and 
kynurenine have been shown to inhibit Thl7 differentiation in mice [33]. IDO is also involved 
in modulation of Thl differentiation [40,41]. Interestingly, A.fumigatus also possess an IDO-
family enzyme [42], and we show that A. fumigatus can induce metabolization of tryptophan 
into kynurenine. We investigated whether kynurenine is able to modulate Thl7 also in 
human cells, and we have indeed observed inhibitory effects. Therefore, it seems rational to 
hypothesize that the observed inhibitory effect of A. fumigatus on the induction of IL-17 is at 
least in part mediated through its effects on tryptophan metabolites, via the generation of 
the inhibitory product kynurenine. However, besides kynurenine, we cannot exclude that 
additional factors may also mediate inhibition of Thl7 induction by Aspergillus. Nonetheless, 
in our hands, these additional IL-17-modulating effects were probably not linked to innate 
signaling via the macrophage receptor [43] or Dectin-1 ß-glucan receptor [16]. 
The importance of IL-17 in the pathogenesis of invasive aspergillosis remains to be proven. 
Recently it has been reported that IL-17 receptor-deficient mice, despite an initially elevated 
fungal burden, were eventually able to efficiently control aspergillosis [44]. This raises the 
question on the perceived non-redundancy of IL-17. From the clinical perspective, patients 
with hyper-lgE (HIE) syndrome are known to have deficiency of Thl7 cells due to mutations 
in signal transducer and activator of transcription 3 (STAT-3) [45, 46] and are susceptible to 
secondary Aspergillus infection of pneumatoceles, but not to primary invasive aspergillosis 
[47]. Whilst colonization of pneumatoceles with Aspergillus in hyper IgE syndrome patients 
would seemingly support the notion of a protective role of IL-17 against fungal infections, 
one will need to keep in mind that the pathogenic mechanism behind an Opportunistic 
colonization' of a lung cavity in a patient with hyper-lgE is perceivably distinct from that of 
invasive aspergillosis in a bone marrow transplant patient. Therefore, the clinical picture in 
Thl7-defective patients with hyper-lgE syndrome does not dispute the notion that Thl7 
responses may not be essential in the host defense against invasive aspergillosis. 
In conclusion, we demonstrate that A. fumigatus is a poor inducer of IL-17 response in 
humans, and this may be at least partly attributable to the pathogen's ability to metabolize 
tryptophan and secrete kynurenine which, in turn, down-regulates the Thl7 pathway. The 
importance of IL-17 in the pathogenesis of invasive aspergillosis remains therefore in 
question, as Thl response is likely the predominant Τ helper-dependent immunity mounted 
by the host against Aspergillus species. It is hence difficult to envisage a dominant role for IL-
17 in host defense against Aspergillus at this juncture. 
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Summary 
Humans with chronic granulomatous disease (CGD) due to mutations in p47-phox have 
defective NADPH activity and thus cannot generate NADPH-dependent reactive oxygen 
species (ROS). The role of ROS in inflammation is controversial; some in vitro studies suggest 
that ROS are crucial for secretion of IL-lß via inflammasome activation, whereas mice 
defective for ROS and patients with CGD have a proinflammatory phenotype. In this study, 
we evaluated activation of the IL-lß inflammasome in cells from CGD patients. In contrast to 
previous studies using the small molecule diphenylene iodonium (DPI) as a ROS inhibitor, we 
found no decrease in either caspase-1 activation or secretion of IL-lß and IL-18 in primary 
CGD monocytes. Moreover, activation of CGD monocytes by uric acid crystals induced a 4-
fold higher level of IL-lß secretion compared with that seen in monocytes from unaffected 
subjects, and this increase was not due to increased synthesis of the IL-lß precursor. In 
addition, Western blot analysis of CGD cells revealed that caspase-1 activation was not 
decreased, but rather was increased compared with control cells. Examination of the effects 
exerted by the inhibition of ROS activity by DPI revealed that the decrease in IL-lß secretion 
by DPI was actually due to inhibition of IL-lß gene expression. Thus, inconsistent with the 
proinflammatory role of ROS, the present findings support the concept that ROS likely 
dampen inflammasome activation. The absence of ROS in CGD monocytes may explain the 
presence of an inflammatory phenotype characterized by granulomas and inflammatory 
bowel disease occurring in CGD patients. 
Introduction 
There is much recent interest in the processing and release of bioactive IL-lß, especially 
since the discovery that blockade of IL-1 receptors with the IL-1 receptor antagonist (IL-IRa) 
is a very effective treatment for autoinflammatory disorders, such as familial Mediterranean 
fever (1), familial cold autoinflammatory syndrome (2), Muckle-Wells syndrome (3), 
neonatal-onset multisystem inflammatory disease (4), hyperimmunoglobulin D syndrome 
(HIDS) (5), and adult-onset Still's disease (6). Blood monocytes from patients with some of 
these disorders, especially cryopyrinopathies and HIDS, readily release more IL-lß than do 
monocytes from unaffected controls (7, 8). 
Activation of caspase-1 by the protein complex known as the inflammasome leads to the 
conversion of pro-IL-lß to IL-lß (9). Several protein platforms/inflammasomes have been 
described for the activation of caspase-1, each of which includes members of the NOD-like 
receptor (NLR) family of proteins (10). The most intensely studied of these are the 
inflammasomes formed by the NLR family members NLRP3 and NLRP1. Several conditions 
are thought to be required for the activation of the inflammasome, including the interaction 
of "danger-signaling" molecules with NLRP components, the induction of K+ efflux through 
the P2X7 receptor, and the generation of reactive oxygen species (ROS) (9,11). 
The role of ROS in inflammation is controversial, however. On the one hand, ROS have been 
suggested to induce NF-κΒ activation (12, 13), and several in vitro studies have proposed 
that activation of the inflammasome is strictly dependent on ROS generation (11,14). On the 
other hand, other studies have reported anti-inflammatory effects of the NADPH system and 
ROS (15), and a recent study in mice defective for the generation of ROS strongly suggested 
anti-inflammatory effects of oxygen species (16). In line with this, patients with chronic 
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granulomatous disease (CGD) with defects in the NADPH system and, consequently, 
defective ROS generation (17) display an inflammatory phenotype characterized by 
granulomas and Crohn-like colitis (18). To evaluate the role of ROS in inflammasome 
activation, we investigated the activation of caspase-1 and the production of IL-lß in the 
presence of NADPH inhibitors. We also assessed inflammasome activation in cells isolated 
from CGD patients. 
Results 
DPI inhibits transcription of proinflammatory cytokines 
We found that LPS induced production of IL-lß and TNF-a from primary human peripheral 
blood mononuclear cells (PBMCs), as reported previously (19). ROS inhibition by 
diphenylene iodonium (DPI) decreased production of both IL-lß and TNF-a induced by LPS 
(Fig. 1A). Because TNF-a release is independent of caspase-1 activation, this argues for 
effects of DPI independent of the inflammasome. Indeed, the effect of DPI was exerted at a 
transcriptional level, because mRNA for both IL-lß and TNF-a was decreased by DPI (Fig. IB), 
whereas active caspase-1 was still present (Fig. 1C). 
Toll-like receptor-induced production oflL-Ιβ is normal in CGD patients 
The Toll-like receptor (TLR) ligands Pam3Cys (TLR2 ligand) and LPS (TLR4 ligand) induced a 
strong IL-lß response in PBMCs of both healthy volunteers and CGD patients (Fig. 2A). 
Although ROS have been specifically implicated in the activation of the inflammasome (11), 
when PBMCs from CGD patients who lacked ROS were primed with LPS and subsequently 
stimulated with the inflammasome activator ATP for 15 min, no difference in the release of 
IL-lß was seen between cells of healthy individuals and those of CGD patients (Fig. 2B). As 
expected, intracellular pro-IL-lß intracellular concentrations did not differ between healthy 
volunteers and CGD patients (Fig. 2B). IL-18 also is an important proinflammatory cytokine of 
the IL-lß family that is processed by caspase-1. No differences in IL-18 production were 
observed between healthy volunteers and CGD patients (5.8 pg/mL vs 4.9 pg/mL), although 
the very low amounts of IL-18 released by primary monocytes must be noted. 
Inflammasome activation is increased in CGD patients 
Despite defective NADPH-dependent ROS generation, more prominent activation of 
caspase-1 was apparent in monocytes isolated from CGD patients compared with those from 
healthy volunteers (Fig. 3A). The NLRP3 inflammasome has been reported to be activated by 
uric acid crystals (11,20), and priming with a TLR stimulus such as LPS is required to 
accomplish this activation (21). However, PBMCs from CGD patients were able to produce IL-
lß when exposed to uric acid alone in the absence of LPS priming, a phenomenon not 
observed in normal volunteers (Fig. 3B), demonstrating increased activation of the 
inflammasome in cells from CGD patients. In addition, DPI decreased cytokine production in 
both cells from healthy controls and cells isolated from CGD patients (Fig. 4). 
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Figure 1. ROS inhibition decreases 
production and transcription of IL-lß 
and TNF-α. 
(A) Monocytes isolated from eight 
healthy controls were stimulated with 
LPS in the absence or presence of the 
ROS inhibitor DPI. In the presence of 
DPI, IL-lß production was completely 
inhibited (n = 8). (B) TNF-α production 
also was decreased when LPS-
stimulated PBMCs of healthy controls 
were cultured in the presence of DPI 
(n = 2). (C) PBMCs of healthy controls 
were stimulated for 4h with LPS in the 
absence or presence of DPI. mRNA 
was isolated from the cell lysates using 
TRIzol. DPI decreased mRNA 
expression of IL-lß (η = 6). (D) DPI also 
decreased mRNA expression of TNF-α 
(n = 2). (E) Active plO caspase-1 was 
still expressed in cells cultured in the 
presence of DPI. Data are 
representative for four healthy 
volunteers. 
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Figure 2. Inflammasome activation and IL-lß production in CGD patients. 
(A) Monocytes isolated from CGD patients and healthy controls produced IL-lß on stimulation with LPS, 
Pam3cys, and Candida. (B) IL-lß stimulation by LPS and ATP was similar in CGD and control individuals. Data 
are presentedas mean ±SEM of five healthy controls and of three CGD patients. 
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Figure 3. ROS inhibit inflammasome activation. 
(A) Active plO caspase-1 was expressed more strongly in unstimulated monocytes from CGD patients than in 
those from healthy controls. (B) NALP3 inflammasome stimulus uric acid crystals stimulated IL-lß release in 
monocytes isolated from CGD patients, but not in those from healthy controls. Data are presented as mean + 
SEM of five healthy controls and of three CGD patients. 
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Figure 4. ROS Inhibition decreased IL-lß production In both healthy controls and CGD patients. 
In both healthy controls and CGD patients, DPI decreased IL-lß production in LPS-stimulated cells. Data are 
presented as mean ± SEM. 
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Discussion 
Our findings indicate that ROS are not essential for inflammasome activation. This 
conclusion is based on several lines of evidence. First, treatment of human primary 
monocytes with the commonly used ROS inhibitor DPI did not inhibit generation of active 
caspase-1. Second, cells from CGD patients expressed more constitutively active caspase-1 
activation. Third, ROS-deficient cells from CGD patients produced more IL-lß after 
stimulation with urate crystals, a classical inflammasome stimulus. 
These findings differ from the results of other recently published studies suggesting that ROS 
induce inflammasome activation and IL-lß production (11,14). Those studies were based on 
the use of ROS inhibitors such as DPI in cell lines or mouse macrophages, however (11, 14, 
22). Thus, we investigated the effects of DPI on caspase-1 activation and IL-lß production in 
human PBMCs. We found that DPI can indeed inhibit IL-lß production in human PBMCs, as 
reported previously in THP-1 cells and mouse macrophages (11, 14). This inhibition was 
accompanied not only by lower IL-lß release, but also by decreased TNF-a production, 
suggesting that DPI can exert its effects independently of the inflammasome. These effects 
of DPI were exerted at the level of transcription, with repression of mRNA for both TNF-a 
and IL-lß, whereas the active caspase-1 p35 fragment was normally present. Our data 
demonstrating that the anti-inflammatory effects of DPI on IL-lß production are exerted at 
the transcriptional level are in line with the large body of literature reporting that ROS 
induce NF-κΒ activation (12, 23, 24). In addition, the clear inhibition of cytokine stimulation 
by DPI in cells of CGD patients, a system in which ROS production is defective, clearly 
demonstrates that the effects of DPI on cytokine production are largely independent of 
NADPH-oxydase generation of ROS. Possible additional mechanisms modulated by DPI 
include inhibition of nitric oxide synthetase and mitochondrial complex 1-dependent (25, 
26). Thus, results based on DPI as the sole method of inhibition of ROS production should be 
interpreted with caution. 
In addition to these arguments, it should be kept in mind that the concept that ROS induces 
inflammasome activation is at odds with the known proinflammatory phenotype of patients 
with CGD, characterized by the occurrence of sterile granulomas, colitis, and inflammatory 
skin and urogenital reactions, in which IL-lß is thought to play an important pathogenic role 
(15). In contrast, our findings of the inhibitory effects of ROS on caspase-1 activation agree 
with a proinflammatory state in CGD, because we found that the release of mature IL-lß was 
normal and after certain stimuli even increased in cells of CGD patients. Our data do not 
stand alone; they are in line with several previous studies that have demonstrated 
consistent up-regulation of various proinflammatory cytokines in cells isolated from CGD 
patients (27-30). 
Unexpectedly, whereas we found that primary monocytes from healthy volunteers did not 
produce IL-lß in response to uric acid alone, monocytes from CGD patients secreted 
substantial amounts of IL-lß. In addition, we observed more constitutively activated 
caspase-1 in monocytes from CGD patients compared with healthy volunteers. In line with 
our data, there is additional evidence that increased ROS production inhibits caspase-1 
activation. Superoxide dismutase 1 (SOD-1) degrades ROS, and thus SOD-1 deficiency results 
in increased endogenous ROS production. It was recently reported that the increased super-
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oxide production in SOD-1-deficient macrophages specifically inhibits caspase-1 activation 
by oxidation and glutathionylation (31). SOD-1-deficient mice produced less IL-lß in vivo 
and were less susceptible to LPS-induced shock (31). Another recent study demonstrated 
that silencing SOD-1 in human monocytes results in a reduction of IL-lß secretion on 
stimulation with zymosan (32). Taken together, these data are in agreement with our 
findings and strongly suggest that ROS inhibit inflammasome activation and, subsequently, 
IL-lß production. 
In conclusion, our findings of the present study settle the controversy regarding the role of 
ROS in inflammasome activation in human cells by providing evidence that oxygen radicals 
have an inhibitory effect on caspase-1 activation and IL-lß release. These data explain the 
proinflammatory clinical phenotype seen in patients with CGD. 
Methods 
Patients and Controls 
Eight healthy volunteers with no known infectious or inflammatory disorders donated blood 
as a control group for the assessment of cytokine production capacity. In addition, PBMCs 
were isolated from three patients with CGD harboring homozygous mutations in the NCF1 
gene (p47-phox), in which defective ROS production has been demonstrated. After informed 
consent was obtained, blood was collected by venipuncture from both patients and 
volunteers into 10-mL EDTA tubes [BD, Plymouth, UK (art. no. 367525)]. 
In Vitro Cytokine Production 
Separation and stimulation of PBMCs was performed as described previously (33). In brief, 
the PBMC fraction was obtained by density centrifugation of diluted blood (1 part blood to 1 
part pyrogen-free saline) over Ficoll-Paque (Pharmacia Biotech). PBMCs were washed twice 
in saline and suspended in culture medium supplemented with gentamicin 1%, L-glutamine 
1%, and pyruvate 1%. The cells were counted in a Bürker counting chamber, and their 
number was adjusted to 5xl0e6 cells/mL. Then 5xl0e5 PBMCs in a volume of 100 μ ι per 
well were incubated at 37 0C in round- bottomed 96-well plates (Greiner). After 24h of 
incubation with the various stimuli as described below, supernatants were collected and 
stored at -80 °C until being assayed for IL-lß and TNF-a production. DPI in a concentration 
of 10 μΜ was used as a ROS inhibitor (34). Two methodologies were used to assess 
inflammasome stimulation. One assay used stimulation for 3h with LPS, followed by ATP-
induced IL-lß release for 15 min (35), and a second assay used specific stimulation with LPS-
free monosodium urate, also known as uric acid crystals, a putative NLRP3 ligand (20). 
Cytokine Assays 
IL-lß and TNF-a concentrations were measured with com- mereiai ELISA kits (R&D Systems). 
Pro-IL-lß concentrations in the cell lysates were measured by specific ELISA (R&D Systems). 
The concentration of IL-18 was measured with a BioPlex kit (Bio-Rad). 
RT-PCR 
Two million freshly isolated PBMCs were incubated with the various stimuli. After 4h of 
incubation at 37°C, total RNA was extracted in 800 μ ι of TRIzol reagent (Invitrogen). Isolated 
RNA was reverse-transcribed into cDNA using oligo(dT) primers and M-MLV reverse 
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transcriptase. PCR was performed using an Applied Biosystems 7300 real-time PCR system. 
The primer sequences for human IL-lß were as follows: sense, 5'- GCC-CTA-AAC-AGA-TGA-
AGT-GCT- C-3'; antisense, 5'- GAA-CCA-GCA-TCT-TCC-TCA-G-3'. ß2M was used as a reference 
gene, for which the primers were as follows: 5-ATG-AGT-ATG-CCT- GCC-GTG-TG-3 (forward) 
and 5-CCA-AAT-GCG-GCA-TCT-TCA-AAC-3 (reverse). PCR conditions were 2 min at 50°C and 
10 min at 95°C, followed by 40 cycles at 95 °C for 15 s and at 60oC for 1 min. 
Immunoblotting for Caspase-1 
For immunoblotting, 10xl0e6 cells were lysed in 100 mL of lysis buffer [50 mM Tris (pH 7.4), 
150 mM NaCI, 2 mM EDTA, 2 mM EGTA, 10% glycerol, 1% Triton X-100, 40 mM a-
glycerophosphate, 50 mM sodium fluoride, 200 mM sodium vanadate, 10 mg/mL leupeptin, 
10 mg/mL aprotinin, 1 mM pepstatin A, and 1 mM phenylmethylsulfonyl fluoride]. The 
homogenate was frozen, then thawed and centrifuged at 4°C for 10 min at "15,000 χ g", and 
the supernatant was taken for Western blot analysis. Equal amounts of protein were 
subjected to SDS/PAGE using 10% and 15% Polyacrylamide gels at a constant voltage of 100 
V. After SDS/PAGE, proteins were transferred to nitrocellulose membrane (0.2 mm). The 
membrane was blocked with 5% (wt/vol) milk powder in PBS for Ih at room temperature, 
followed by incubation overnight at 4°C with a caspase-1 plO antibody (SC-515; Santa Cruz 
Biotechnology) in 5% BSA/TBS/Tween 20. After overnight incubation, the blots were washed 
three times with TBS/Tween 20 and then incubated with HRP-conjugated goat anti-rabbit 
antibody at a dilution of 1:10 000 in 5% (wt/vol) milk powder in PBS for Ih at room 
temperature. After being washed three times with TBS/Tween 20, the blots where 
developed with ECL (GE Healthcare) according to the manufacturer's instructions. 
Statistical Analyses 
Differences between groups were analyzed using the Mann-Whitney U test for unpaired 
data and the Wilcoxon signed-rank test for paired data. Differences were considered 
statistically significant at Ρ £ 0.05. Data represent the cumulative results of all experiments 
performed and are presented as mean ± SEM. 
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Summary 
Β cell depleting therapy with rituximab is unexpectedly succesful in rheumatoid arthritis (RA) 
and multiple sclerosis (MS). The findings that Β cells in MS and RA play an important role, 
raises the question of the mechanism of action of rituximab. In the present study, we 
demonstrate that rituximab specifically inhibits the Thl7 response which correlates with an 
improved clinical outcome in rheumatoid arthritis. In agammaglobulinemia patients, that do 
not have functional Β cells, the inhibitory effect of rituximab on the Thl7 response was not 
observed. Thus supporting a direct effect of rituximab on Β cells. Taken together, these data 
demonstrate an unexpected role of Β cells for the development of Thl7 responses, possibly 
leading to Β cell-based strategies in patients with Thl7-related immune diseases. 
Introduction 
Rituximab is a monoclonal antibody directed towards the CD20 antigen on Β lymphocytes, 
which is nowadays a first line treatment in antibody-mediated autoimmune disorders such 
as autoimmune thrombocytopenia and autoimmune hemolytic anemia. More surprising and 
less easy to explain, is the ability of rituximab to reduce disease severity in patients with 
rheumatoid arthritis (RA) (1), as this effect cannot be attributed to a reduction in circulating 
autoantibodies (2). Also, it has been shown that rituximab remarkably reduces brain lesions 
in patients with multiple sclerosis (MS), a disease with a proven T-lymphocyte-mediated 
pathology (3). The effect of rituximab on disease activity in MS is rapid and since rituximab 
does not deplete mature plasma cells, it is unlikely that a reduction of pathogenic antibodies 
is responsible for these effects (4). Thus, mechanisms other than depleting (auto)antibodies 
should be sought for. 
Recently, MS, RA, Crohn's disease and psoriasis have been linked to a subgroup of Τ helper 
(Th) lymphocytes, called Thl7 cells (5). These lymphocytes are preferential producers of a 
series of cytokines (IL-17A, IL-21 and IL-22) (6) which are thought to contribute to the tissue 
damage in RA (7) and MS (8). The role of Thl7 cells in the pathogenesis of these 
autoimmune diseases led us to hypothesize that rituximab leads to inhibition of Thl7 cells. 
In the present study we assessed this hypothesis in synovial biopsies in RA patients treated 
with rituximab, and in in-vitro experiments. 
Material and Methods 
Ethics Statement 
The clinical study was approved by the ethics committee of the Université Catholique de 
Louvain and informed consent was obtained from all patients. 
Volunteer 
Blood was collected from 21 healthy, non-smoking volunteers who were free of infectious or 
inflammatory disease, and from four patients with genetically proven X-linked 
agammaglobulinemia, after informed consent. Blood samples were collected in 10 ml EDTA 
tubes (BD Vacutainer·, United Kingdom). 
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RA Patients and synovial biopsies 
12 patients with RA (9 women and 3 men, average age ± SEM: 54.6 ± 4.6 years) were 
included in the study. All patients met the American College of Rheumatology classification 
criteria for RA. All patients had active disease at the time of baseline tissue sampling and 
were resistant to TNF blockade. They all had erosive changes imaged on conventional x-rays 
of the hands and/or feet. All of them had a swollen knee at inclusion. Mean baseline C-
reactive protein ± SEM was 33.08 ± 6.76 mg/l and mean baseline Disease Activity (DAS28)-
CRP score (4 variables) ± SEM was 5.80 ± 0.38. Rituximab therapy was administered at a dose 
of 1,000 mg IV at baseline (TO) and week 2, together with 125 mg IV Methylprednisolone. 
Disease activity at baseline (TO) and 12 weeks after initiation of therapy (T12) was evaluated 
using DAS(28)-CRP (4-variables) scores (DAS-28 score). Synovial biopsies were obtained by 
needle-arthroscopy of the affected knee of all patients at TO and T12. For each procedure, 4 
to 8 synovial samples were kept overnight at 4°C in a RNA stabilizing solution and then 
stored at -80oC for later RNA extraction. The same amount of tissue was snap-frozen in 
liquid nitrogen and kept at -80°C for immunostaining experiments on frozen sections. The 
remaining material was fixed in 10% formaldehyde and paraffin embedded for conventional 
optical evaluation and immunostaining of selected markers. All the experiments (RNA 
extraction, histology, immunohistochemistry) were performed on at least 4 biopsies 
harvested during every procedure in order to correct for variations related to the potential 
heterogeneous distribution of synovial inflammation. 
Microorganism 
C. albicans ATCC MYA-3573 (UC 820)(9) was grown overnight in Sabouraud broth at 37°C, 
cells were harvested by centrifugation, washed twice, and resuspended in culture medium 
(RPMI-1640 Dutch modification, ICN Biomedicals, Aurora, OH) (10). C. albicans was heat-
killed (Ih at 100oC). 
In vitro cytokine production 
Separation and stimulation of PBMCs was performed as described previously (11). Briefly, 
the PBMCs fraction was obtained by density centrifugation of diluted blood (1 part blood to 
1 part pyrogen-free saline) over Ficoll-Paque (Pharmacia Biotech, Uppsala, Sweden). PBMCs 
were washed twice in saline and suspended in culture medium supplemented with 
gentamicin 1%, L-glutamine 1%, and pyruvate 1%. The cells were counted in a 
hemocytometer, and their number was adjusted to 5 χ IO6 cells/ml. 5 χ IO5 PBMCs in a 
volume of 200 μΙ per well were incubated at 37°C in round-bottom 96-wells plates (Greiner, 
Nürnberg, Germany), in the presence of 10% human pooled serum, with C. albicans or 
culture medium alone. In blocking experiments, PBMCs were preincubated for 2 h with 
Rituximab 10 ug/ml. After 5 days of incubation, supernatants were collected and stored at -
20oC until assayed. 
Cytokine assays 
IL-17A, IL-22, IFNy, and TNFa concentrations were measured by commercial ELISA kits (R&D 
systems) following the manufacturer's instructions. 
Intracellular cytokine staining 
PBMCs were stimulated for 4-6 hours with PMA (50 ng/ml; Sigma) and ionomycine (1 ug/ml; 
Sigma) in the presence of Golgiplug (BD biosciences) according to manufacturer's protocol. 
212 
Chapter 15 
Cells were first extracellularly stained using an anti-CD4 APC antibody (BD biosciences). 
Subsequently the cells were fixed and permeabilized with Cytofix/ Cytoperm solution (BD 
biosciences) and then intracellularly stained with anti-IFNy PE (eBiosciences) and anti-IL-17A 
FITC (eBiosciences). Samples were measured on a FACS Calibur and data were analyzed using 
the CellQuest-Pro software (BD biosciences). 
Quantitative PCR 
PBMCs were cultured for 3 days and RNA was extracted using TRI-reagent (Sigma). The 
isolated RNA was treated with DNase to remove genomic DNA and subsequently reverse 
transcribed with oligo(dT) primers in a reverse transcriptase procedure with a total volume 
of 20 μΙ. Quantitative real-time PCR was performed using the ABI/PRISM 7000 Sequence 
Detection System, with primer pairs and SYBR Green PCR Master Mix (Applied Biosystems). 
The sequences used, were as follows: IL-22, forward 5'-TGCAGGL 11 GACAAGTCCAA-3' 
reverse 5'-CTAGCCTCCTTAGCCAGCATGA-3'; RORyT, forward 5'TGAGAAGGACAGGGAGCCAA 
3' reverse S'-CCACAGATTTTGCAAGGGATCA -3'; TNF, forward 5'-TCTTCTCGAACCCCGAGTGA-
3'reverse 5'-CaCTGATGGCCCCACCAG-3';/F/Vi/, forward 5'-GGAACTU I I ICI lAGGCATTTTGA-
3'reverse 5'-GATGGTCTCCACACTC 111IGGA-3'. Quantification of the PCR signals was 
performed by comparing the cycle threshold value (Ct) of the gene of interest with the Ct 
values of the reference gene GAPDH. All primers were developed using Primer Express 2.0 
(Applied Biosystems) and validated according to the protocol. Values are expressed as fold 
increases of mRNA relative to that in unstimulated cells. 
Microarray hybridization 
Total RNA was extracted from the synovial biopsies using the Nucleospin" RNA II extraction 
kit (Macherey-Nagel), including DNase treatment of the samples. At least 1 ug total RNA 
could be extracted from 12 paired samples at TO and T12 for further processing. RNA quality 
was assessed using an Agilent 2100 Bioanalyzer and RNA nanochips (Agilent Technologies 
Ine). All samples had a 28s/18s ratio > 1.8. Labeling of RNA (cRNA synthesis) was performed 
according to a standard Affymetrix· procedure (One-Cycle Target Labeling kit, Affymetrix UK 
Ltd., High Wycombe, UK); briefly total RNA was first reverse transcribed into single-stranded 
cDNA using a T7-Oligo(dT) Promoter Primer and Superscript II reverse transcriptase. Next, 
RNase H was added together with E. Coli DNA polymerase I and E. Coli DNA ligase, followed 
by a short incubation with T4 DNA polymerase in order to achieve synthesis of the second-
strand cDNA. The purified double-stranded cDNA served as the template for the in vitro 
transcription reaction, which was carried out overnight in the presence of T7 RNA 
polymerase and a biotinylated nucleotide analog/ribonucleotide mix. At the end of this 
procedure, the biotinylated complementary RNA (cRNA) was cleaned, and fragmented by a 
35-minute incubation at 95°c. GeneChip· Human genome U133 Plus 2.0 Arrays (spotted with 
1,300,000 oligonucleotides informative for 47,000 transcripts originated from 39,000 genes, 
Affymetrix UK Ltd, High Wycombe, UK) were hybridized overnight at 45°c in monoplicates 
with 10 ug cRNA. The slides were then washed and stained using the EukGE-WS2v5 Fluidics 
protocol on the Genechip· Fluidics Station (Affymetrix) before being scanned on a 
Genechip" Scanner 3000. For the initial normalization and analysis steps, data were 
retrieved on Affymetrix GCOS software. The frequency of positive genes (genes with a flag 
present) was between 40 and 50% on each slide. After scaling of all probe sets to a value of 
100, the range of the reported amplification scales was between 0.7 and 6.7. The signals 
yielded by the poly-A RNA, hybridization and housekeeping controls (GAPDH 375' ratio < 2.3 
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in all the slides) were indicative of the good quality of the amplification and hybridization 
procedures. Since values were labeled as "absent" we used these data only to support our 
observations. In the text and figures we use the microarray data, but mention that the data 
was only suggestive. 
Immunolabeling experiments on paraffin-embedded sections 
Fresh synovial biopsy tissue samples (n=12 at TO and T12) were fixed overnight in 10 % 
formalin buffer at pH 7.0 and embedded in paraffin for immunohistochemical analyses. 
Immunolabeling experiments were performed using a standard protocol. After removal of 
paraffin and inactivation of endogenous peroxidases with 0.3% H2O2 for 30 minutes at room 
temperature, sections were incubated in 10 m M sodium citrate buffer, pH 5.8, and heated in 
a bain-marie at 98°C for 75 minutes to retrieve the antigenic sites. Non-specific binding was 
blocked by a 30-minutes incubation with 50 mM Tris-HCI, pH 7.4, containing 10% 
(volume/volume) normal goat serum and 1% (weight/volume) bovine serum albumin. 
Sections were then incubated overnight at A°C with the primary antibody. The following 
antibodies were used: CD3 (Neomarkers, Westinghouse, CA), CD20 (Biocare medica, Walnut 
Creek, CA), CD68 (DakoCytomation, Glastrup, Denmark), CD138 (DakoCytomation), IL17 
(eBioscience, San Diego, CA) and LRRC32 (Enzo Life Sciences, Farmingdale, NY, USA). After 3 
washes in 50 mM Tris-HCI, pH 7.4, specifically bound antibodies were labeled for 1 hour at 
room temperature with Envision™ (DakoCytomation), and the activity of peroxidases was 
revealed by a 10-minutes incubation with 0.5 mg/ml diaminobenzidine in Tris-HCI buffer. As 
a final step, sections were washed in tap water and lightly counterstained with hematoxylin. 
Semiquantitative analyses were performed using a semiquantitative score on a scale of 0-3. 
Quantitative analysis of the CD20 and IL-17A antibody immunostained sections was 
performed using ImageJ software, according to the Digital Image Analysis process. Six 
digitalized pictures (400X magnification) were obtained for each slide by an operator who 
was blinded to the identity of the specimens. Each picture included lining and sublining 
regions when possible. When the distribution of the staining was heterogeneous, the 
pictures were taken in order to be representative of the globality of the slide. The surface 
staining (S) and the surface of the nuclei (N) were determined for each image, and the area 
of staining was then normalized by calculating the ratio of surface staining to nuclei staining. 
Statistical analysis 
The differences between groups were analyzed by the Wilcoxon rank test. Differences were 
considered statistically significant when Ρ <0.05. All experiments were performed at least 
twice, and the data is presented as the cumulative result of all experiments performed, 
unless otherwise indicated. 
Results 
Rituximab inhibits the Thl 7 response in patients with RA 
To assess the influence of rituximab on inflammation and more specific, Thl7 responses in 
vivo, 12 patients with refractory RA treated with rituximab were investigated. At day 0 and 
12 weeks after rituximab treatment, disease activity scores (DAS-28) were calculated and 
synovial tissue biopsies were taken from the knee joints. This group of RA patients treated 
with rituximab showed a significant improvement of their DAS-28 score (Fig. la). 
Immunohistochemistry showed that rituximab had efficiently depleted the CD20+ Β cells in 
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the synovium of inflamed knee joints at 12 weeks (Fig. lb,c). The next step was to evaluate 
the effect of rituximab on Thl7 responses in the joints of these patients before and after 
treatment of rituximab. Using immunostaining, we investigated the affected synovial tissue 
for IL-17A, before and after treatment with rituximab and found that rituximab therapy 
induced a significant decrease in synovial IL-17A (Fig ld,e). In addition, the mRNA signals for 
the relevant Thl7 cytokines IL-17A, IL-21 and IL-22 were measured in the inflamed joints, 
using microarray analysis. The mRNA for these three cytokines was lower in the affected 
joints of patients with RA at 12 weeks after treatment with rituximab (Supplemental data. 
Fig. SI). RT-qPCR confirmed the results of the microarray analysis, with mRNA for RORC and 
IL-22 being markedly reduced after treatment (Fig. If). 
Figure 1. Rituximab Inhibits the Thl7 response In patients with RA. 
(a) DAS-28 score of RA patients (n=12) treated with rituximab. (b) Histologic scores of CD3, CD20, CD68 and 
CD131 In synovial tissue obtained by biopsy of affected joints of patients with rheumatoid arthritis (n=12) 
before and after treatment, (c) Staining of CD20 in synovium before and after treatment with rituximab in two 
patients with a good clinical response (magnification 400x). Bars represent staining of CD20 in synovium before 
and after treatment with rituximab (n=12 patients), (d) IL-17A immunostaining in synovial biopsies of RA 
patients before and after rituximab therapy, characteristic images from three different patients at TO and T12 
(original magnification 400x). (e) IL-17A immunostaining in synovial biopsies from patients with RA before and 
after rituximab therapy In (n=12 patients) (f) qPCR of the expression of RORyt, IL-22 in Inflamed synovial tissue 
from patients with RA before and after treatment with rituximab (n=4). 
Rituximab specifically inhibits the Thl7 response 
Since the balance between Τ regulatory cells (Treg) and Thl7 cells has been advocated to 
play an important role in autoimmune diseases (12,13), it was investigated if the réponse to 
rituximab was Treg dependent. It has recently been shown that activated Tregs express 
mRNA for a transmembrane protein called glycoprotein A repetitions predominant (GARP, or 
LRRC32), and that expression of GARP on activated Tregs correlates with their 
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immunosupressive capacity (14). When GARP was stained in the knee joints of these 
patients, no significant difference was seen (Fig. 2a). Furthermore, to address if the response 
to rituximab was due to an overall effect on Τ cell responses CD3 positive cells were stained 
in the synovial tissue and the effects of rituximab on the Thl response were studied. In line 
with previous studies (1, 3), there was no reduction seen in the amount of Τ cells after 
treatment with rituximab (Fig. lb). In addition to the Thl7 response, the proinflammatory 
Thl response plays a critical role in autoimmunity. However, IFNy was not affected by the 
treatment with rituximab in vivo (Fig. 2b). Inhibition of TNFa is known to be effective in RA 
(15). We therefore wanted to investigate if the effects seen in patients with RA that were 
treated with Β cell depleting therapy was dependent on TNFa. Interestingly, the mRNA 
expression for TNFa was not influenced by treatment with Rituximab in the affected knee 
joints of patients with RA (supplemental data Fig SI, Fig 2b). These results demonstrate that 
rituximab exerts its effects in vivo specifically through the Inhibition of the Th 17 response 
and not through Τ regulatory, Thl or TNFa responses. 
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Figure 2. Rituximab inhibits the Thl? response. 
(a) GARP immunostaining in synovial biopsies from RTX-treated RA patients at TO and T12 (n=12). (b) qPCR of 
the expression of TNF and IFNy. in inflamed synovial tissue from patients with RA before and after treatment 
with rituximab (n=4). (a) Results are the mean (+/- SEM) surface/Nuclei ratio and digital quantification was 
performed using ImageJ, with 6 digitalized pictures (400x magnification) analyzed for each sample at TO and 
T12. (b) Data is given as relative mRNA expression (2-.CT χ 1000). *P<0.05 using Wilcoxon matched-pairs 
signed-rank tests. 
The effect of rituximab on Thl7 responses is mediated through depletion of Β cells 
To further investigate the effects of rituximab on the Thl7 response, we used an in-vitro 
system in which peripheral blood mononuclear cells (PBMCs) from healthy volunteers were 
stimulated with the potent Thl7-lnducing stimulus C. albicans (16) in the absence or 
presence of rituximab. Notably, antigen presenting cells (APCs) are needed together with 
memory Τ cells in order for C. albicans to induce a Thl7 response in human PBMCs (17). 
When PBMCs were treated with rituximab, all CD20 positive cells were depleted (Fig. 3a). 
PBMCs exposed to C. albicans showed a clear Thl7 response reflected by a significant 
production of IL-17A and IL-22 (Fig. 3b). Baseline production of cytokines was undetectable 
In all experiments performed (data not shown). In the presence of rituximab, the IL-17A 
production induced by C. albicans was reduced by 50% and IL-22 production by 20-30% (Fig. 
3b), while the addition of 10 μg of human IgG as a control had no inhibitory effect (data not 
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shown). Flow cytometry showed that the reduction in IL-17A production by rituximab was 
associated with a decrease in the percentage of IL-17A producing T-cells (Fig. 3c). No IL-17A 
positive cells were observed in the CD4 negative fraction (Supplemental data. Fig S2). In line 
with the results obtained in vivo, the exposure to rituximab did not have any effect on the 
Thl or TNFa response (Fig. 3b). To determine whether the effect of rituximab on the C. 
o/b/cons-induced Thl7 response was mediated by Β cell depletion, the Thl7 responses of 
PBMCs from four patients with X-linked agammaglobulinemia (XLA) were investigated. 
Patients with XLA do not have circulating functional Β lymphocytes and are deficient in 
immunoglobulins. PBMCs from these patients that completely lack mature Β cells exhibited a 
Thl7 response upon stimulation with C. albicans (Fig 3d). When these PBMCs were 
stimulated with C. albicans in the absence or presence of rituximab, no difference was 
observed in the Thl7 cytokine profile (Fig. 3d), and Thl7 cells were not reduced in the 
presence of rituximab in contrast to healthy volunteers (Supplemental data. Fig. S2). These 
results suggest that rituximab exerts its effects through the depletion of Β cells. 
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Figure 3. The effect of ritximab on Thl7 responses is mediated through depletion of Β cells. 
(a) Flow cytometry analysis of CD4 and CD20 on human PBMCs cultured for 5 days with C. albicans in the 
presence or absence of rituximab, and then exposed for 4 h to PMA and ionomycin. (b) Human PBMCs were 
incubated for 5 days in the presence of human serum with either medium or C. albicans and in the presence or 
absence of rituximab 10 ug/ml. Cytokines in the supernatants were measured by ELISA, (c) Intracellular 
cytokine staining of IL-17A and IFNy in human PBMCs (n=5) stimulated for 5 days with C. albicans, with or 
without rituximab. Cells were gated for CD4 and data is given as % of total gated CD4 positive cells, (d) PBMCs 
from four patients with X-linked agammaglobulinemia (XLA) and 4 healthy controls were treated as in (b). 
Values after exposure to C albicans were set at 100% and data are shown for incubation with C. albicans in the 
presence of rituximab and is given as percentages compared to incubation with C. albicans alone. (a,c) Data 
from one healthy volunteer, that represents the pattern observed in two separate experiments with a total of 
n=5. Data are pooled and expressed as mean ± SEM. · ρ < 0.05 using Wilcoxon matched-pairs signed-ranks 
tests. RTX=rituximab. 
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Discussion 
In the present study we demonstrate that rituximab inhibits the Thl7 response in humans. 
Rituximab reduces the local Thl7 response in patients with RA and this is associated with a 
decrease in inflammation and a better clinical outcome. Interestingly, the effect of rituximab 
is Thl7 specific, since rituximab had no effects on Treg, Thl or TNF responses. Inhibition of 
the Thl7 response by rituximab is lost in the absence of Β lymphocytes. These data strongly 
argue that Β cells are able to modulate the Thl7 response, and rituximab inhibits the Thl7 
function through Β cell depletion. 
Our data linking Β lymphocytes to an IL-17A response shed light on the enigmatic 
observation that B-cell-targeted therapy with rituximab is beneficial in patients with 
autoimmune diseases such as RA and MS(2, 3). These findings would fit with the 
accumulating evidence that Thl7 cells play an important role in the pathogenesis of RA(18), 
and MS (19). In this respect, our findings point to a so far undiscovered role for Β cells in the 
pathology of human autoimmune diseases. The studies in patients with XLA (which lack 
functional Β lymphocytes) showing that Cond/do-induced IL-17A production was not 
inhibited by rituximab, provide a strong argument for a key role of functional Β cells in the IL-
17A response. Nevertheless, we also entertained the possibility that cells other than Β cells 
are directly affected by rituximab. It has been reported that a subset of Τ cells are CD20 
positive (20), and these could be the target for rituximab. We found that only CD4 positive 
cells expressed IL-17A after stimulation with C. albicans, and CD4 positive cells did not show 
CD20 expression (data not shown), making it unlikely that rituximab acted directly on Thl7 
cells. 
The studies performed in patients with RA who received treatment with rituximab support a 
relationship between Β cell depletion, inhibition of the IL-17A response and clinical benefit. 
The depletion of CD20+ cells in the affected joints after 12 weeks of treatment with 
rituximab was associated with clear reduction of the Thl7 cells as well as by a decrease of IL-
17A, IL-21 and IL-22, and this in turn was accompanied by an improvement in clinical status, 
as measured by DAS. Most interestingly, these data suggest that Β cell depleting therapies in 
RA work by virtue of a reduction of the Thl7 response. An important question that had to be 
addressed was whether rituximab specifically inhibited the Thl7 response or that it had 
additional effects which could explain the improvement in clinical outcome. It has been 
suggested that drugs for RA may work, in part, by promoting the function or increasing the 
numbers of Tregs (21). We found however no effects of Β cell depletion on local Tregs in 
vivo. The proinflammatory Thl response has been shown to contribute to the pathogenesis 
of RA (22), yet no effects on the Thl effector cytokine IFNy were observed when Β cells were 
depleted by rituximab in vitro and in vivo. Importantly, targeting TN Fa as a therapy has 
revolutionized the treatment of RA, demonstrating an important role for TN Fa in RA. We 
therefore investigated the possibility that rituximab additionally inhibited TNFa production. 
We found no effects on TNFa in vitro and in vivo. Notably, this provides a rationale for 
investigating the combination of rituximab with anti-TNF therapy in patients with active RA. 
Altogether, these data advocate the concept that the Thl7 response is specifically inhibited 
by Β cell depletion. 
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In conclusion, the present study demonstrates an important role for Β cells in the Thl7 
response during inflammation and underscore the concept that Β cells are key players in 
regulating immune processes (23-25). It is tempting to speculate that the effect of Β cell-
depleting treatment in other Thl7 related diseases, such as MS, Crohn's disease and 
psoriasis, is also based on the mechanism proposed in this paper. We feel that this insight 
may lead to novel therapeutic strategies for the large group of patients with Thl7 related 
immune diseases. 
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Supplemental data 
IL-17 
IL-21 TNFa 
Figure SI. Microarray analysis of the synovial tissue before and after treatment with rituximab. 
Microarray analysis of the expression of IL-17AA, IL-21, IL-22, TNFa in the affected synovial tissue from 12 
patients with RA before (black bars) and after (grey bars) treatment with rituximab. 
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Figure S2. Rituximab reduces IL-17A producing cells in healthy controls but not in patients with 
agammaglobulinemia (XLA). 
Intracellular cytokine staining of CD4 and IL-17A in PBMCs from a healthy volunteer and a patient with XLA 
cultured for 5 days with C. albicans, with or without rituximab. 
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Summary 
Mutations in the signal transducer and activator of transcription 3 (STAT3) were reported to 
cause hyperimmunoglobulin E syndrome (HIES). The present study investigates J»17 
responses triggered by the relevant stimuli S. aureus and C. albicans in five "classical" HIES 
patients and a family with three patients that all had a milder HIES phenotype. We 
demonstrate that patients with various forms of HIES have different defects in their Thl7 
response to S. aureus and C. albicans, and this is in line with the clinical features of the 
disease. Interestingly, a partial deficiency of IL-17 production, even associated with STAT3 
mutations, leads to a milder clinical phenotype. We also observed defective TH17 responses 
in patients with the "classical" presentation of the disease but without STAT3 mutations. 
These data demonstrate that the defective IL-17 production in response to specific 
pathogens can differ between patients with HIES and that the extend of the defective TH17 
response determines their clinical phenotype. 
Introduction 
Hyperimmunoglobulin E syndrome (HIES) is a primary immunodeficiency disorder 
characterized by recurrent staphylococcal skin abscesses, pulmonary infections, 
mucocutaneous candidiasis, skeletal and dental abnormalities, and elevated serum 
imunoglobulin E concentrations (1, 2). Although most cases of HIES are sporadic, familial 
cases are encountered, mostly with an autosomal dominant mode of inheritance (3). 
Recently, mutations in the evolutionary conserved SH2 and DNA-binding domains of the 
signal transducer and activator of transcription 3 (STAT 3) were found to be present in 
approximately 60% of the patients with HIES (4, 5). STAT3 is an important component of 
receptor signalling pathways for several cytokines, including interleukin-6 (IL-6) and IL-10, 
and patients with HIES have shown defective responses to these cytokines (4). The role of 
STAT3 for the normal signaling of IL-6 receptor has important consequences for the normal 
host defense. The IL-6/STAT3 pathway is crucial, together with other cytokines such as IL-lß 
and IL-23, for the normal development of CD4+- TH17 cells (6, 7). Because IL-17 has an 
important role for the activation of the neutrophil-dependent immunity (8), defective TH17 
generation as a result of STAT3 mutation may play an important role in the pathogenesis of 
HIES. 
In a recent paper, Milner et al have demonstrated that Τ lymphocytes from patients with 
HIES are unable to differentiate into TH17 after mitogenic stimulation (9). These data were 
supported by two reports that also showed defective generation of TH17 when anti-
CD3/anti-CD28/IL-2 or cytokine cocktails were used (10, 11). These studies reported the 
defective generation of TH17 using mitogenic cocktails in patients with established mutations 
in the SH2 and DNA-binding domains of STAT3. In contrast, patients with atopic dermatitis 
and high IgE, but without skin and respiratory infections and without STAT3 mutations, had 
normal TH17 responses (9,12). 
In the present paper, we aimed to extend these initial findings by investigating the 
generation of TH17 cells and IL-17 production by relevant microbial stimuli for HIES. In 
addition, we assessed TH17 profiles in three distinct groups of patients: "classical" HIES 
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patients with STAT3 mutations in the SH2/DNA-binding domains, "classical" HIES without 
STAT3 mutations, and a family with "variant" HIES that we described as having a milder 
clinical phenotype (13), and with a deletion of a triplet in the linker domain. The differences 
in the degree of IL-17 production defects after stimulations with Staphylococcus aureus or 
Candida albicans determined the severity of the clinical phenotype. 
Materials and methods 
Patients and controls 
Eight patients with the clinical diagnosis of HIES at the outpatient clinic for infectious 
diseases and immunodeficiencies of the Department of General Internal Medicine of 
Radboud University Nijmegen Medical Centre were enrolled in the study. Three of these 
patients were family members. After informed consent, blood was collected from eight 
healthy, nonsmoking volunteers who were free of infectious or inflammatory disease and 
the enrolled HIES patients by venipuncture into 10 ml EDTA syringes (Monoject). STAT3 
mutation analysis was kindly performed in the Laboratory of Human Molecular Biology and 
Genetics, Catholic University of the Sacred Heart, Milan, Italy, head Prof. Roberto Colombo. 
Microorganisms 
C. albicans ATCC MYA-3573 (UC820), a strain well described elsewhere (14) was used. C. 
albicans was grown overnight in Sabouraud broth at 37°C, cells were harvested by 
centrifugation, washed twice, and resuspended in culture medium (RPMI-1640 Dutch 
modification, ICN Biomedicals, Aurora, OH) (15). C. albicans was heat killed for 1 hour at 
100oC and all experiments were performed with heat-killed C. albicans. The clinical isolate of 
5. aureus was heat-killed and used in a dosage of 107/ml. 
In-vitro cytokine production 
Separation and stimulation of PBMCs was performed as described previously (16). Briefly, 
the PBMCs fraction was obtained by density centrifugation of diluted blood (1 part blood to 
1 part pyrogen-free saline) over Ficoll-Paque (Pharmacia Biotech, Uppsala, Sweden). PBMCs 
were washed twice in saline and suspended in culture medium supplemented with 
gentamicin 1%, L-glutamine 1%, and pyruvate 1%. The cells were counted in a Bürker 
counting chamber, and their number was adjusted to 5 χ IO6 cells/ml. 5 χ IO5 PBMCs in a 
volume of 100 μΙ per well were incubated at 37°C in round-bottom 96-wells plates (Greiner, 
Nuremberg, Germany), in the presence of 10% human pooled serum with stimuli or culture 
medium alone, and where indicated with the cytokines IL-6 and IL-10 (100 ng/ml). After 5 
days of incubation, supernatants were collected and stored at -20°C until assayed. 
Cytokine assays 
ILlß and IL-17 concentrations were measured by commercial ELISA kits (R&D systems); IFNy 
and IL-10 (Pelikine Compact, Sanquin, Amsterdam, The Netherlands); according to the 
manufacturer's instructions. 
Intracellular cytokine staining 
PBMC cells were stimulated as described above and restimulated for 4-6 hours with PMA (50 
ng/ml; Sigma) and ionomycine (1 ug/ml; Sigma) in the presence of Golgiplug (BD biosciences) 
according to manufacturers protocol. Cells were first extracellularly stained using an anti-
226 
Chapter 16 
CD4 APC antibody (BD biosciences). Subsequently the cells were fixed and permeabilized 
with Cytofix/ Cytoperm solution (BD biosciences) and then intracellularly stained with anti-
IFNy PE (eBiosciences) and anti-IL-17 FITC (eBiosciences). Samples were measured on a FACS 
Calibur and data were analyzed using the CellQuest-Pro software (BD biosciences). 
Statistical analyses 
The differences between groups were analyzed by the Mann-Whitney U test, and considered 
statistically significant when ρ <0.05. Data is presented as the cumulative result of all 
experiments performed, unless otherwise indicated. Data are given as median or mean ± 
SEM unless otherwise indicated. 
Results 
Patients 
In table 1, the clinical description of the patients with HIES are summarized. All patients 
were of Dutch ancestry. In Fig.l the pedigrees of the HIES family is presented. Of note, the 
clinical data of the HIES family have been published elsewhere (13,17). Blood sampling and 
TH17 profile were assessed in cells isolated from the three HIES patients in the third 
generation of the family, and the five patients with "classical" HIES. In the large HIES family 
with a milder HIES (variant HIES) the STAT3 gene had a deletion of a triplet, leading to the 
deletion of serine in position 560 of the linker domain. Three of the five "classical" HIES 
patients had known STAT3 mutations (R382W twice and V463del)(5) (Table 1). Two of the 
patients with "classical" HIES had no STAT3 mutation. 
Defective IL-17 and IFNy production in HIES patients in response to S. aureus and C. albicans 
To investigate the immunological functional properties with respect to the TH17 responses 
in HIES patients with different mutations, PBMC from healthy volunteers, "classical" HIES 
patients and three members from a HIES family with a milder form of disease (variant HIES), 
were assessed for the capacity to mount IL-17 responses. We have developed a new 
methodology of TH17 generation using human PBMC stimulated with whole microbial stimuli 
relevant for HIES: S. aureus and C. albicans (18). HIES patients had a defective response to C 
albicans, although IL-17 was measurable in all patients (Fig. 2a). Interestingly, there was a 
completely absent IL-17 production in PBMC stimulated with S. aureus in all "classical" HIES 
patients (Fig. 2b). In contrast, PBMC isolated from the variant HIES patients, bearing the 
STAT3 mutations in the linker domain, were able to produce IL-17 in response to S. aureus, 
albeit at lower concentrations when compared to healthy volunteers (Fig. 2b,c). IFNy 
production was distorted in HIES patients when compared to healthy controls, while IL-10 
was found to be elevated in HIES patients when stimulated with both 5. aureus and C. 
albicans. 
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su 
1 2 3 
Figure 1. The pedigree of a family with HIES of Dutch ancestry. 
Clinical symptoms characteristic for HIES were recorded in a large kindred, with patients affected (closed black 
symbols are family members affected STAT3 mutation) from several generations. Closed grey symbols 
represent suspected for the STAT3 mutation but not proven. Line through symbol represents deceased family 
member. 
Table 1. Clinical characteristics of the patients with hyperlmmunoglobuline E syndrome. 
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Figure 2. Defective IL-17 and IFNy production in HIES patients in response to S.aureus and C. albicans. 
Human PBMCs from healthy controls (n=8), "classical" HIES (n=S) and three members of the HIES family 
bearing the STAT3 linker domain mutation, were stimulated for 5 days with C. albicans (a) or S. aureus (b). 
Cytokines were measured by ELISA, (c) IL-17 production by PBMC stimulated as in (a) and (b) from "classical" 
HIES patients and familial HIES patients. 
Normal induction of Τ
Μ
17 cells in familial variant HIES patients 
The in-vitro stimulations described above suggest that HIES patients have a significant defect 
in the generation of TH17 cells. This was indeed the case for the patients with "classical" 
HIES, either bearing STAT3 mutations or not (Fig. 3). Surprisingly, when the familial variant 
HIES patients were challenged with disease related microorganisms, they showed a clear 
induction of single IL-17 positive and IL-U/INFy positive CD4+ cells, comparable to normal 
controls (Fig 3). 
HIES patients have a defect in IL-6, but not in IL-10, signaling 
IL-6 augmented the IL-17 production induced by C. albicans and S. aureus in cells isolated 
from healthy controls (Fig. 4a). No effect was apparent in the HIES patients, independently 
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of the type of STA3 mutation. In contrast to IL-6, IL-10 reduced the amount of IL-17, and this 
effect was observed both in healthy controls and the HIES patients (Fig. 4b). 
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Figure 3. TH17 cell generation in HIES patients. 
Human PBMCs from healthy controls (n=8), "classical" HIES (n=5) and three members of the HIES family 
bearing the STAT3 linker domain mutation, were stimulated for 5 days with C. albicans or S. aureus. The IL-17-
or IFNß- producing TH17 cells were assessed by intracellular staining (see description in the Methods). 
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Figure 4. Defective IL-6, but not IL-10, pathway in HIES patients. 
Human PBMCs from healthy controls (n=8), "classical" HIES (n=5) and three members of the HIES family 
bearing the STAT3 linker domain mutation, were stimulated for 5 days with C. albicans or S. aureus. The effect 
of either IL-6 or IL-10 on the induction of IL-17 was assessed by ELISA. *p<0.05 
Discussion 
Mutations in the SH2 and DNA-bindings domain of STAT3 have been reported to be the 
cause of disease in a large proportion of HIES patients (4). These mutations function as 
dominant-negative mutations (4) and result in a defective TH17 response in these patients 
(9, 10), explaining many of the clinical features of HIES. In the present study we confirm on 
the one hand the relationship between HIES and defective TH17 responses, but on the other 
hand we also refine this notion to include the relationships between the type of STAT3 
mutation, the immunological response to relevant microbial stimulation, and the clinical 
phenotype of the patients. 
All studies to date have used an artificial methodology to generate TH17 cells and induce IL-
17 production in cells from HIES patients, that used either mitogenic antibodies such as anti-
CD3 and anti-CD28 (9, 10) or recombinant cytokine cocktails (11). We have recently 
developed a novel method to induce IL-17 production and generate TH17 cells using 
exclusively microbial stimulation (18), method that mimics much closer the in-vivo 
conditions during infection. Although we can confirm the defective TH17 generation and IL-
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17 production by cells isolated from patients with HIES (9-11), several important aspects are 
now apparent when using this improved methodology. Firstly, the defective IL-17 induction 
differs between stimulation with S. aureus or C. albicans. When TH17 responses were 
assessed, both these two microorganisms that are the most important in HIES patients were 
equally defective in generating CD4+ IL-17+ cells. Surprisingly however, C albicans was still 
capable to stimulate approximately 20 to 30% of the normal IL-17 production, while S. 
aureus was completely defective as an IL-17 stimulus in HIES patients (Fig.lc). This finding is 
important as it may explain why it is mostly mucosal and nail bed infection which is the most 
common Candida complication in HIES patients (83% of them in one large study), while 
systemic candidiasis is relatively rare (3). Notably, patients with chronic mucocutaneous 
candidiasis, which have the same clinical spectrum of Candida infection [19], have also been 
reported to have a specific defect in Candida induced IL-17 production [20]. This supports 
the conclusion that IL-17 is important in mucosal anti-Cond/do host defense and that the 
lower IL-17 found in our patients is indeed clinically relevant. 
Secondly, an important observation of our study is represented by the indistinguishable 
immunological responses in patients with the "classical" clinical form of HIES, independent 
on the presence or absence of STAT3 mutations. All these patients that had a strong 
phenotype of the disease displayed similar defects in IL-17 production and TH17 generation. 
Our data are supported by the report of one HIES patient without STAT3 mutation and 
defective TH17 responses (21), and strongly suggests that in patients with the "classical" 
presentation of HIES but in which no STAT3 mutation is found, defects in the same 
immunological pathways are most likely the cause of the disease. This may also imply that 
the defective TH17 responses are a more sensitive diagnostic tool for HIES. 
Thirdly, one of the most interesting finding of our study is the description of a clear 
association of a milder phenotype of the disease in a Dutch family with a less severe defect 
in IL-17 production, likely due to the linker domain triplet that did not lead to a frameshift 
(13). Patients from this family suffer from skin infections with S. aureus, candidiasis of the 
nail beds (but not of the mucosae), dermatitis, hyper IgE and eosinophilia, but they lack any 
respiratory infections (either with S. aureus or other pathogens). With regard to the non-
infectious manifestations, persistent primary dentition, a rather common sign in HIES, was 
seen in one patient of this family, one patient displayed scoliosis, cheilognathopalatoschisis 
and pathological fractures, and one patient suffered from an aortic aneurysm. The defects in 
IL-17 responses to S. aureus in cells isolated from this family were milder compared to the 
"classical" HIES patients, as they were still able to release approximately 30% of the normal 
IL-17 production. In line with the presence of candidiasis as a clinical symptom in the family, 
the IL-17 production after C. albicans stimulation was equally defective compared to the 
other patients. 
In addition to IL-17, other defects in the cytokine response of HIES patients have also been 
reported, such as a defective IFNy production (17, 22), and increased GM-CSF (23). In line 
with these previous studies, IFNy production was decreased in HIES patients in our study, 
while IL-10 release was significantly higher compared to controls. The production of IFNy 
was defective in response to both C albicans and S. aureus. IFNy is the prototype of THI 
cytokines and plays a crucial role in the activation of the innate and adaptive host response 
against these pathogens [24]. Therefore the defective IFNy response could be at least as 
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relevant as the defect found in IL-17. Furthermore, it should be kept in mind that IFNy 
therapy is a relatively safe therapeutic option [25] and it has been reported that 
recombinant IFNy can enhance neutrophil chemotactic responses in patients with HIES [26]. 
Alltogether, these data strongly argue for a dysbalance of TH subsets in patients with HIES, 
with defective responses of the proinflammatory subsets T H I and TH17, and increased 
function of the antiinflammatory TH2 subset. 
In contrast to the TH-derived cytokines, the release of IL-lßwas normal in HIES patients. As 
IL-lß is important for the generation of TH17 cells (27), this result suggests that it is not a 
defective IL-lß/IL-lRI axis that is responsible for the defects of IL-17 production in HIES 
patients. This hypothesis is sustained by the normal generation of TH17 responses in 
individuals with MyD88 or IRAK4 mutations, that are defective in the IL-1RI signalling (as well 
as TLR and IL-18R pathways) (11). 
The defective generation of TH17 responses in HIES must therefore be located at the level of 
another immunological pathway, and the most obvious is the IL-6/STAT3 axis (6). To test this 
hypothesis, we investigated the effect of IL-17 costimulation with microbial stimuli in 
combination with IL-6. While IL-6 potentiated the production of IL-17 induced by C. albicans 
or S. aureus in healthy individuals, no such effect was observed in either the "classical" HIES 
or the family with the variant HIES. The striking observation that the members of the HIES 
family were able to generate TH17 cells upon contact with pathogens suggests that the linker 
domain of the STAT3 gene is involved in another unknown function of the STAT3 molecule, 
and highlights the observation that a mutation at a different location in the STAT3 gene 
leads to a different functional and clinical outcome. In contrast to the defective responses to 
IL-6, the inhibitory effects of IL-10 on IL-17 production were similar in the healthy volunteers 
or the HIES patients, suggesting that STAT3 is redundant for IL-10 signaling leading to 
reduced IL-17 production. 
In conclusion, the present study demonstrates that patients with HIES have differential 
defects of the IL-17 responses to the two main pathogens associated with the disease, S. 
aureus and C. albicans, and this is comparable with the clinical features of this syndrome. In 
addition, the extent of the TH17 defect is due to the location of the STAT3 mutation, and is 
associated with the clinical phenotype in the patients. Furthermore, the defective TH17 
responses are a more sensitive marker of the disease in HIES patients than STAT3 mutations. 
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Summary 
Background: Chronic mucocutaneous candidiasis (CMC) is a primary immunodeficiency 
characterised by selective susceptibility to fungal infections of skin, nails and mucous 
membranes caused by Candida species. While patients with recessive CMC and 
autoimmunity have mutations in the AIRE gene (autoimmune regulator), the cause of 
autosomal dominant CMC is unknown. 
Method: Twelve patients from five families with autosomal dominant CMC from the 
Netherlands and the United Kingdom were investigated. The immune pathways in these 
patients were investigated after incubation of peripheral blood mononuclear cells with 
different combinations of cytokines or microbial stimuli. Using the information obtained 
from these functional studies, we selected 100 genes most likely to contain the genetic 
defect responsible for autosomal dominant CMC. An array-based sequence capture assay, 
followed by next generation sequencing to simultaneously analyze these 100 genes, was 
used to find and identify relevant mutations. 
Findings: Pronounced defects in the production of the T-helper 1 cytokine interferon-γ (IFNy) 
and the T-helper 17 cytokines interleukin (IL)-17 and IL-22 were identified in CMC patients. 
The functional studies led to the conclusion that the defect would most likely be within the 
IL-12R and IL-23R signalling pathway. Using the array-based sequence capture assay, we 
found that all patients harboured heterozygous missense mutations in the CC domain of the 
STATI gene: patients from two families were heterozygous for the Arg274Trp mutation, 
while patients from three families were heterozygous for Ala267Val mutation. While the IL-
12R and IL-23R pathways were defective, leading to absent Thl and Thl7 responses, the 
IFNyR pathway was intact in the CMC patients, thus explaining the absence of mycobacterial 
or viral infections. 
Interpretation: Mutations in the CC domain of STATI underlie autosomal dominant CMC. 
These STATI mutations lead to defective Thl and Thl7 responses, and thereby to increased 
susceptibility to mucosal and skin fungal infections. 
Funding. The Netherlands Organization for Scientific Research; The Primary 
Immunodeficiency Association UK; EU-funded TECHGENE project and the AnEUploidy 
project. 
Introduction 
Chronic mucocutaneous candidiasis (CMC) is a primary immunodeficiency characterised by 
selective susceptibility to fungal infections of skin, nails and mucous membranes caused by 
Candida species and dermatophytes (1). There are several CMC subtypes: autosomal 
recessive CMC associated with autoimmune involvement of endocrine glands (autoimmune 
polyendocrinopathy candidiasis ectodermal dystrophy - APECED, OMIM 240300), autosomal 
dominant CMC with or without associated thyroid disease (OMIM 114580), and autosomal 
recessive, isolated CMC (OMIM 212050). 
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The genetic defect in APECED resides in the AIRE gene (autoimmune regulator), which has a 
key role in the induction of immunotolerance (2). Susceptibility to Candida infections in 
APECED is believed to be due to auto-antibodies to interleukin-17 (IL-17) and IL-22 (3), as the 
Thl7 cytokines are crucial for mucosal antifungal immunity (4). In contrast, very little is 
known about the genetic defects underlying increased susceptibility to Candida in non-
APECED patients with CMC. Previously we have demonstrated defective Thl/interferon-
gamma (IFNy) responses in CMC patients (5), and a recent study in two CMC patients 
suggested also defective Thl7 responses in these patients (6). Defects in the recognition of 
ß-glucans from Candida due to mutations in the dectin-l/CARD9 pathway have been shown 
to be responsible for an increased susceptibility to mucosal fungal infections (7, 8), but the 
clinical presentation in these patients is less severe than in the classic CMC. 
In the present study, we assessed the immunological defects responsible for the increased 
susceptibility to skin and mucosal fungal infections in a Dutch family with autosomal 
dominant CMC without AIRE mutations. Based on the defective Thl and Thl7 responses in 
these patients, we selected a panel of 100 genes encoding for proteins involved in the 
induction and modulation of these responses. We identified mutations in the CC domain of 
the gene encoding Signal Transducer and Activator of Transcription 1 (STATI) as the cause of 
the immunological defects. Genetic and functional studies in three unrelated CMC families 
from United Kingdom, as well as one patient from an unrelated Dutch family with CMC, 
confirmed this finding. 
Methods 
Patients and controls 
Family #1: We investigated a Dutch Caucasian family in which the father (index patient), his 
daughter and son suffer from severe CMC since early youth. There is no known 
consanguinity. The clinical characteristics are summarized in Table 1, the pedigree is 
depicted in Fig 1A. The patients have severe chronic Candida infections of the oropharynx, as 
well as severe dermatophytosis and candidiasis of the feet (Fig IB). The index patient was 
diagnosed with autoimmune hepatitis, while his daughter is known with autoimmune 
haemolytic anemia and pernicious anemia; she has anti-phospholipid antibodies, suffered 
from pulmonary embolism, and recently had Pneumocystis jirovecii pneumonia and 
symptomatic cytomegalovirus infection. The son had a very severe dermatophytosis 
(Trichophyton rubrum) of the feet, but no autoimmune phenomena. No AIRE mutations 
were present in the family (Van der Graaf, personal communication). Immunological analysis 
was performed on peripheral blood mononuclear cells (PBMCs) isolated from the three 
affected family members, the unaffected mother and two healthy controls. The index 
patient has eight siblings, all unaffected by CMC (Fig 1A). Genetic analysis was performed in 
all affected and unaffected family members. 
Family #2, #3, and #4: To confirm our findings in family #1, eight patients classified as 
autosomal dominant CMC and thyroid disease, from three unrelated Caucasian families from 
the UK, were immunologically and genetically analysed. The characteristics of these patients 
are reported elsewhere (9) and summarised in Table 1 (supplementary text). These patients 
have manifest thyroid disease. All patients were screened for AIRE mutations to exclude 
APECED syndrome (10). 
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Family #5: Genetic analysis was also performed in one patient from a Dutch family with CMC. 
The mother of the patient and the patient himself suffered from oesophageal cancer (Table 
1). 
Ethical approval 
The study protocol was approved by the Ethics Committee of Radboud University Nijmegen 
Medical Centre, and the Newcastle and North Tyneslde Local Research Ethics Committee. 
Informed consent was obtained from all family members and healthy controls studied. 
Immunological studies 
PBMCs were obtained by density centrifugation and resuspended in RPMI medium 
supplemented with gentamicin 1%, L-glutamine 1%, and pyruvate 1%, as previously 
described (11). PBMCs (5 χ IO5 cells) were incubated at 37°C in 96-wells plates (Grelner, 
Nuremberg, Germany), with RPMI or with heat-killed Candida albicans IxlO6 
microorganisms/ml (strain UC820), E. coli lipopolysaccharide (LPS, Slgma-Aldrlch, 1 ng/ml) 
and/or IL-lß (10 ng/ml), IL-12 (10 ng/ml), IL-18 (50 ng/ml), IL-23 (10 ng/ml) (R&D systems, 
Minneapolis, ΜΑ), ΙΡΝγ (1 μg/ml Boehrlnger Ingelheim, Alkmaar, The Netherlands). After 24 
hours, 48 hours (without serum) or 5 days of incubation (in the presence of 10% serum), 
supernatants were stored at -20°C. Cytokine concentrations were measured by commercial 
ELISA kits according to the manufacturer's instructions: ILlß, TNFa, IL-17, IL-22 (R&D 
Systems, Minneapolis, ΜΑ); ΙΡΝγ, IL-6 (Pelikine Compact, Sanquin, Amsterdam, The 
Netherlands). Supernatants from unstimulated PBMCs had no detectable cytokine 
concentrations (data not shown). 
Figure 1. The pedigree of a family with autosomal dominant CMC of Dutch ancestry. 
(A) Clinical symptoms characteristic for CMC were recorded in a Dutch family # 1 , with three patients affected 
(closed black symbols are family members affected) from two generations. (B) Pictures of clinical signs from 
affected family members with CMC. 
241 
Chapter 17 
Table 1. Clinical characteristics of 12 patients with autosomal dominant CMC from 5 families. 
Gender 
&age 
Country 
of origin 
Fungal 
infection 
Hypo-
thyroidism 
Thyroid 
antibodies 
other AID1 
Family #1 
Patient 1 
Patient 2 
Patient 3 
Male 
67 y 
Female 
38 y 
Male 
37 y 
NL 
NL 
NL 
Oral 
Nails 
Skin 
Oral 
Nails 
Skin 
Oral 
Nails 
Skin 
no 
no 
no 
no 
no 
no 
Al hepatitis 
Al haemolytic anemia 
Pernicious anemia 
Anti -phospholipid antibodies 
no 
Family #2 
Patient 1 
Patient 2 
Patient 3 
Patient 4 
Patient 5 
Female 
59 y 
Male 
36 y 
Male 29 y 
Female 
27 y 
Female 
6y 
UK 
UK 
UK 
UK 
UK 
Oral 
Nails 
Skin 
Oral 
Nails 
Skin 
Oral 
Nails 
Skin 
Oral 
Nails 
Skin 
Oral 
Skin 
yes 
no 
no 
no 
no 
yes 
no 
yes 
no 
no 
no 
no 
no 
no 
no 
Family M3 
Patient 1 
Patient 2 
Female 
37 y 
Male 
32 y 
UK 
UK 
Oral 
Nails 
Skin 
Vaginal 
Oral 
Nails 
Skin 
yes 
no 
no 
no 
no 
no 
Family «4 
Patient 1 Female 
40 y 
UK Oral 
Nails 
Skin 
Vaginal 
yes yes no 
Family »5 
Patient 1 Female 
48 y 
NL Oral 
Nails 
Skin 
no no no 
AID = autoimmune disease 
Custom 12-plex sequence capture followed by Roche 454 sequencing 
We applied array-based sequence capture followed by Roche 454 next generation 
sequencing to simultaneously analyze 100 genes (Table SI) from known immunologic 
pathways. We designed a custom-made 12-plex sequence capture array (Roche NimbleGen, 
Madison, Wl, USA) including all known exons and untranslated regions (UTRs). In total, 1134 
exons (of which 1059 were coding exons) from 100 RefSeq genes were selected, targeting 
485,768 bases. After stringent probe selection by NimbleGen (Roche NimbleGen, Madison, 
Wl, USA) (uniqueness tested by Sequence Search and Alignment by Hashing Algorithm-
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SSAHA), a total of 443,488 bases were represented on an HD2 array, with 12-times 135000 
oligonucleotide probes targeting the regions of interest. Sequence capture was performed in 
accordance with the manufacturer's instructions with a 'Titanium-optimized protocol' 
(Roche NimbleGen). 3ng of genomic DNA were used for sequence-capture hybridization. 
This included Titanium-optimized sequence primers with MID tags for barcoding (Table S2). 
After independent pre-hybridization ligation-mediated (LM-) PCR per DNA, a final amount of 
1.125 μg DNA was hybridized for 72h to the customized array each one DNA to a individual 
sub-array, together with 37,5 μg Coti DNA and 0,24 μΙ of each 1 mM barcode 
complementary blocking oligos (Table S2). Subsequently, all DNAs were eluted together and 
amplified by ligation-mediated PCR. This pooled DNA library was used for massive parallel 
sequencing, with the use of a Roche 454 GS FLX sequencer with Titanium series reagents. All 
target and tiled regions of the array are available upon request. 
Coverage statistics 
The pooled sample was sequenced by using one full Roche-sequencing run, yielding on 
average 15.9 Mb of map-able sequence data per individual. Approximately 85.3% of the 
sequence data mapped back to unique regions of the human genome (hglS, NCBI Build 
36.1), with the use of the Roche Newbler software (version 2.3). Of all mapped reads, 98.2% 
was located on or near the targeted regions (i.e. within 500 bp target proximity). This was 
sufficient to reach an average target coverage of 23.1-fold per individual (Table S3). For all 
regions of interest, only 5 regions sequences were not covered at all in any individual, all 
were GC-rich or repeat rich regions, therefore representing most likely an enrichment bias 
(Table S4). We observed a range of 5-29 regions without coverage per individual (on average 
12 regions per individual). The Roche software detected on average 723 nucleotide 
variations per individual compared to the reference genome (Table S5). We used a custom-
made data analysis pipeline to annotate detected variants with various kinds of information, 
including known single-nucleotide polymorphisms (SNPs), aminoacid consequences, 
genomic location, and evolutionary conservation. 
Sequencing validation of STATI mutations 
To validate the presence of STATI mutations in the patients, conventional PCR assays and 
subsequently Sanger sequencing of the amplified DNA fragments were performed. All coding 
exons of the CC domain of STATI, including exon 10, were amplified and analyzed. Primer 
sequences and PCR conditions are available upon request. 
Results 
Immunological defects in the Dutch family with CMC 
The monocyte-derived cytokines IL-lß, IL-6 and TNFa in response to Candida were normal 
(Fig 2A, Fig SIA), as were the TLR4, TLR2 and dectin-1 receptor signalling pathways (Fig 2B) 
(12). In contrast, the production of the Th cytokines IFNy, IL-17, and IL-22 in response to 
Candida was strongly reduced in the patients with CMC (Fig 2C). 
We subsequently assessed the pathways leading to production of IFNy, IL-17, and IL-22 by T-
cells. The induction of ΙΡΝγ by the combination of IL-12 and IL-18 was partially impaired (Fig 
2D). Stimulation with IL-12 alone resulted in undetectable IFNy in the patients, in contrast to 
healthy controls (Fig 2D). Moreover, we detected no IL-17 and IL-22 production in the 
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patients (Fig 2E, Fig SIB). In contrast, mitogenic stimulation induced normal IFNy production 
by cells of CMC patients (not shown). The IL-lRI-dependent pathway was intact, as shown by 
normal production of IL-6 in response to IL-lß (Fig 2E). We concluded that one of the 
molecules involved in both the IL-12 and IL-23 pathway is deficient in the Dutch family with 
CMC (Fig 2F). 
Figure 2. Immunological defects in the Dutch family with CMC. 
Human PBMCs from healthy controls (n=2), the mother and three affected members of the Dutch family #1 
with CMC (PI, P2, P3) were stimulated with (A) heat-killed Candida albicans ( Ixl0e6 microorganisms/ml) for 24 
hours, (B) LPS (1 ng/ml), PamBCys ( ^ g / m l ) , ß-glucan (K^g/ml) , or a combination of ß-glucan for 24 hours, (C) 
heat-killed C. albicans ( Ix l0e6 microorganisms/ml) for 5 days (IL-17) and 48 hours (ΙΡΝγ), (D) IL-12 (10 
ng/ml)/IL-18 (50 ng/ml) for 48 hours, (E) IL-lß (10 ng/ml)/IL-23 (10 ng/ml) for 5 days and IL-6 (10 ng/ml) for 24 
hours. Cytokines were measured by ELISA. (G) Scheme of molecules shared by the IL-12 and IL-23 pathway. 
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Missense mutation in the CC domain of STATI in the Dutch family with CMC 
The STAT3 genetic defect of hyper IgE syndrome (HIES) was not present in our three CMC 
patients. Neither did we find mutations in the gene for STAT4, another important molecule 
involved in both IL-23 and IL-12 pathways. Based on the cytokine defects found, we selected 
a panel of 100 genes encoding proteins known to induce or modulate Thl/Thl7 responses 
(Table SI). Using array-based sequence capture followed by Roche 454 next generation 
sequencing, on average 723 variants were identified, of which 651 variants were found to 
correspond to known SNPs or to overlap with a known polymorphic region (dbSNP130). 
After we excluded variants from an in-house database, on average 38 novel variants 
remained (Table S5). Of these variants, only 4 were non-synonymous coding variants per 
individual, of which only between 0-3 variants were called in at least 20% of all reads, and 
therefore are considered as true heterozygous candidate variants. Of the total of 11 
candidate variants, only 7 were observed in diseased individuals, of which 3 identical 
variants co-segregated in the three affected individuals from the family (Table S6). They all 
shared a heterozygous variant in exon 10 of the STATI gene mapping to chromosome 2 
(g.l91,568,156G>A; C.820OT; p.Arg274Trp). 
The mutation leads to an aminoacid change (arginine to tryptophan) in the CC domain of 
STATI (Fig 3A). In all three affected individuals, STATI was the only gene with a novel, 
heterozygous, non-synonymous coding variant, making it the most likely candidate gene for 
CMC. Three control individuals tested did not show any mutation in STATI. When prioritising 
all novel, heterozygous, non-synonymous coding variants for base-pair conservation (phyloP 
values), the variants showing the highest conservation over all 44 species were the STATI 
variants. 
Confirmation of STATI mutations in additional CMC patients and controls 
Next we investigated two families from the UK with affected family members with 
autosomal dominant CMC (Fig 4A, Table 1, and supplemental data). Using the same 
sequencing technique, an independent STATI variant was found in a patient from one of the 
families (g.l91,568,176G>A; c.800C>T; p.Ala267Val) also affecting exon 10. A second patient 
from another independent UK family showed very poor coverage for exon 10 of STATI, 
however manual read inspection showed the same variant (g.l91,568,176G>A; c.SOOOT; 
p.Ala267Val) in 2 out of 5 reads. These mutations were confirmed by standard PCR 
amplification and sequencing of the CC domain (Fig 4B). STATI sequencing in additional 
patients revealed Ala274Trp mutation in a member of a third independent UK family and an 
Ala267\/al mutation in a patient from a second Dutch family with autosomal dominant CMC 
and oesophageal cancer (Fig 4A,B). Sequencing of STATI did not identify any of these 
mutations in 162 unrelated healthy Caucasians. 
Functional studies 
Cytokine analysis in the CMC patients in the confirmation study revealed similar defects as 
those observed in family #1: defective IFNy production in response to IL-12, and no IL-22 
production in response to IL-lß and IL-23 (Fig 5A). In addition, we tested ΙΡΝγ signalling in 
the CMC patients from family #1. We observed that the addition of ΙΡΝγ to LPS resulted in an 
increased TNFa production by cells isolated from patients with autosomal dominant CMC 
and healthy controls, demonstrating that the ΙΡΝγ signalling is intact in the CMC patients (Fig 
5B). 
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Figure 3. Next generation sequencing coverage and mutation detection for STATI in patient PI - family 01. 
(A) Sequence read histogram uploaded to UCSC genome browser, displaying the sequencing depth of all exons 
of STATI. Tracks displayed: Scale, chromosomal position, read depth histogram per bp (between 0 and 70-fold 
coverage), target regions, tiled regions (oligos represented on sequence capture array), refseq gene track. (B) 
Next generation sequencing read coverage of STATI exons 9 and 10. Tracks displayed: Scale, chromosomal 
position, individual 454 sequencing reads, target regions, tiled regions refseq gene track. (C) Mutation 
visualization in the IGV browser. Individual reads overlapping with the mutation are displayed, showing the 
heterozygous G>A mutation at genomic position chr2:191,568,156 (the reads are mapped and displayed on the 
+ strand). The inserted caption displays the Sanger sequencing validation of the mutation (sequencing of the -
strand shows heterozygous C>T mutation). 
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Figure 4 (A). Confirmation of STATI mutations in patients with CMC. 
Pedigrees of the additional four families with autosomal dominant CMC of which 9 patients were tested for 
STATI mutations; three families from the United Kingdom with CMC and thyroid disease (family #2, #3, #4), 
and one Dutch family with CMC and oesophageal carcinoma (family #5). i g j Summary of all STATI mutations 
identified. 
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Figure 5. The IL-12 and IL-23 pathway is defect in patients with a mutation in the CC domain of STATI, but 
the IFNy pathway is intact. 
(A) Human PBMCs from healthy controls (n=4), and CMC patients (n=6) were stimulated with IL-12 (10 ng/ml) 
for 48 hours or IL-lß (10 ng/ml)/IL-23 (10 ng/ml) for 5 days. (B) Human PBMCs from healthy controls (n=3), and 
CMC patients (n=3) were stimulated with LPS (1 ng/ml) with or without ΙΡΝγ (1 μg/ml) for 24 hours. Cytokines 
were measured by ELISA. 
Discussion 
In the present study, we demonstrate that mutations in the CC domain of STATI are a major 
genetic defect in autosomal dominant CMC. These mutations lead to defective Thl and Thl7 
responses characterized by low production of IFNy, IL-17 and IL-22, crucial cytokines in the 
antifungal host defence of skin and mucosae. 
We initiated the study by showing normal monocyte-dependent cytokine responses, but 
severely impaired Thl and Thl7 responses. These findings were in line with previous reports 
showing defective ΙΡΝγ (5), IL-17, and IL-22 production in CMC (6) and hyper IgE syndrome 
(HIES) (13), as well as with the increased susceptibility to oral candidiasis described in IL-17-
defective mice (4). Since the clinical presentation somewhat resembles HIES with STAT3 
mutations (14,15), we sequenced of the STAT3 gene. No STAT3 mutations were identified in 
the family. The autosomal dominant mode of inheritance in the index family was not 
compatible with the recessive APECED syndrome; no mutations were found in the AIRE 
gene. 
In subsequent functional studies, we obtained evidence that the defect was located in one of 
the molecules shared by the IL-12R and IL-23R pathway. Based on this knowledge, we 
selected a panel of 100 genes encoding proteins involved in the induction of Thl and Thl7 
responses (Fig 2P, Table SI). The array-based sequence capture, followed by next generation 
sequencing to simultaneously analyze a large number of genes, yielded a mutation in the CC 
domain of STATI (R274W) present in all three affected members of the family, but in none 
of the unaffected individuals from the family or the healthy controls. As the index patient 
has nine unaffected siblings, none bearing a mutated STATlgene, it is most likely that this is 
a de novo mutation in the index patient. When assessing basepair conservation (phyloP 
values), STATI variants at this position showed a very high level of conservation over all 44 
species. The variant co-segregation in the family showed very high Grantham scores, 
indicating a strong effect on the protein. 
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To strengthen the proof of the role of STATI mutations as a cause of CMC, we performed a 
confirmation study in 9 CMC patients from 4 unrelated families from the UK and the 
Netherlands. All patients of family #2 and #3 from the United Kingdom were heterozygous 
for another mutation in the CC domain of SM Π (Ala267Val), as was the Dutch patient from 
family #5. The patient from family #4 from the UK had the same mutation as the Dutch 
patients from family #1. In 162 healthy controls no STATI mutations were found, further 
supporting the notion that STATI mutations in the CC domain are a major genetic cause of 
non-AIRECMC. 
It is of interest that STATI mutations have been described before in patients with increased 
susceptibility to viral and/or mycobacterial infections (16-19). These mutations are located in 
the SH2 or DNA binding domains of STATI and result in defective signalling of IFNy and/or 
type I IFN receptor pathways (16-19). On the other hand, a mutation in the CC domain of 
STATI (F172S) resulted in decreased STATI expression (20), while other mutations in the CC 
domain block dimerization of non-phosphorylated molecules (21). Our data show that 
mutations in the CC domain found in CMC patients are mainly involved in the regulation of 
Thl and Thl7 responses, possibly through the known interactions of STATI with STAT3 and 
STAT4 (22). In contrast, STATI/STATI homodimers mediate signalling transmitted by the 
IFNy receptor, that induce resistance to intracellular microorganisms (22). The biological 
function of STATI for mediating IFNy-receptor signalling pathways was preserved in CMC 
patients, which may explain their apparently normal susceptibility to mycobacteria and 
viruses. It should be noted, however, that infections other than those caused by Candida and 
dermatophytes occurred in the Dutch and UK patients, ranging from bacterial chest 
infections to opportunistic infections caused by Pneumocystis jiroveci and cytomegalovirus. 
Another important aspect is the co-morbidity found in some of the CMC patients. Two of the 
patients from family #1 displayed autoimmune phenomena (autoimmune hepatitis, 
autoimmune haemolytic anaemia, pernicious anaemia, and anti-phospholipid antibodies), 
despite a normal AIRE gene. STATI has been reported to be involved in the pathogenesis of 
autoimmune diseases (23). Since IL-17 is an inducer of autoimmunity, the defective Thl7 
responses cannot explain the observed autoimmune phenomena. Noteworthy, the daughter 
of patient 1 from family #4 also had autoimmune hepatitis, and shared the R274W mutation 
with family #1. 
A substantial number of CMC patients have hypothyroidism (OMIM 114580). It has been 
shown before that thyroid stimulating hormone (TSH) induces Suppressor of Cytokine 
Signalling 1 (SOCS-1), which in turn can alter STATI phosphorylation (24). In this way, TSH 
might act as a negative regulator of cytokine action in thyroid tissue, which could be relevant 
to the pathogenesis of thyroid disease. Thus, mutated STATI may hamper the rescue of 
thyroid cells by TSH and hence lead to thyroid disease. An additional mechanism through 
which STATI mutations can induce hypothyroidism is decreased iodine accumulation which 
occurs in SMTl-deficient mice (25). Finally, one of the Dutch CMC patients (and her 
deceased mother) and two members of the UK families suffered from oesophageal/oral 
carcinoma (9), and within this context it is relevant that the loss of function of STATI has 
been linked to oesophageal carcinoma (26, 27). It is striking that these families share the 
A267V mutation. 
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In conclusion, mutations in the CC domain of the SM Π gene are an important genetic cause 
of autosomal dominant CMC. The defective STATI affects mucosal host defence responses 
against Candida spp. through abnormal Thl and Thl7 responses. These findings will facilitate 
the diagnosis in patients with chronic Candida infections and may help to anticipate serious 
complications (such as oesophageal cancer). In addition, this study opens new Insights into 
the pathogenesis of Candida Infections that could be helpful for developing new 
immunomodulatory strategies against mucocutaneous candidiasis. 
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Supplemental data 
UK Family #2 
Patient 1: 59 yr old female; oral and nail candidiasis since adolescence; hypothyroidism 
(since young adulthood) with thyroid (TPO) antibodies, eczema, skin infections, blepharitis, 
enamel dysplasia (loss of all teeth), alopetia, vitiligo, squamous cell carcinoma of the mouth 
(5yrs ago), iron deficiency anemia. Patient 2: 36 yr old male; oral and nail candidiasis since 
early childhood, no hypothyroidism nor thyroid (TPO) antibodies, severe eczema, skin boils 
and abscesses, blepharitis, enamel dysplasia (loss of all teeth). Patient 3: 29yr old male; oral 
and nail candidiasis since adolescence, incipient hypothyroidism and thyroid (TPO) 
antibodies, severe eczema, severe blepharitis, mild enamel dysplasia, oesophageal 
dysmotility, gastro-oesophageal reflux disease (GORD). Patient 4: 27 yr old female; oral and 
nail candidiasis since 5yrs old; no hypothyroidism nor thyroid (TPO) antibodies, eczema, skin 
infections, blepharitis, corneal vascularisation, mild enamel dysplasia, severe iron deficiency 
anemia, oesophageal dysmotilyty, gastro-oesophaeal reflux disease (GORD). Patient 5: 6 yr 
old female; oral candidiasis, no other symptoms. 
UK Family »3 
Patient 1: 32yr oldmale; oral and nail candidasis since childhood, hypothyroidism (since 
young adulthood) no thyroid (TPO) antibodies, eczema, skin infections, blepharitis. Patient 2: 
37yr female; oral, nail, vaginal candidiasis since early childhood, no hypothyroidism nor 
thyroid antibodies, iron deficiency anemia. Patient 3: 7 yr old male; oral candidiasis, no 
hypothyroidism, recurrent severe infections (sepsis, meningitis, pneumonia). Father of 
Patient 1: not included in this study, also had chronic candidiasis since childhood (oral and 
nail) and hypothyroidism; died of oesophageal squamous cell carcinoma. 
UK Family m 
Patient 1: 40 yr old woman; oral, nail, vaginal candidiasis since adolescence, hypothyroidism 
(since young adulthood) with thyroid (TPO) antibodies, skin infections, iron deficiency 
anemia; has 2 affected children not included in this study (son, 13 yr old, oral candidiasis and 
auotimmune hepatitis and daughter, 11 yr old, oral candidiasis and hypothyroidism) 
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Table SI. Genes targeted by sequence capture This table contains the common gene name, the genomic 
position (hgl8), the total number of exons, the total number of coding exons and the transcript ID of the 
largest isoform 
AHR 
AKTl 
FOS 
ATF2 
ATM 
BATF 
BcllO 
CARD9 
CARD11 
CD207 
TYROBP 
CLEC6A 
MAPK1 
FCRLB 
FOXP3 
GADD45b 
GADD45G 
IDOl 
IFNA2 
IFNAR1 
IFNAR2 
IFNGR2 
CHUK 
IKBKB 
IKBKE 
IL10RB 
IL12A 
IL12B 
IL12RB1 
IL12RB2 
IL17A 
IL17RA 
IL18 
IL18BP 
IL18RAP 
IL21 
IL22 
IL23A 
IL23R 
IFNW1 
IL21R 
IL6R 
IL22RA2 
IL22RA1 
IRF1 
IRF2 
IRF3 
IRF4 
IRF5 
chr7 17338276-17385775 
chrl4 104306732-104333125 
chrl4 74815284-74818665 
chr2 175647252-175741143 
chr l l 107598769-107745036 
Chrl4 75058537-75083086 
chrl 85504048-85516171 
Chr9 138377262-138387939 
chr7 2912295-3050105 
chr2 70910855-70916461 
chrl9 41087143-41091026 
chrl2 8499858-8522193 
chr22 20443947-20551970 
chrl 159959067-159964557 
chrX 48993841-49008232 
Chrl9 2427135-2429257 
chr9 91409748-91411289 
chr8 39890485-39905104 
ehrt 21374254-21375396 
Chr21 33619084-33653998 
Chr21 33524101-33558690 
Chr21 33697072-33731698 
chrlO 101938114-101979334 
chr8 42247986-42309122 
chrl 204710419-204736845 
chr21 33,562,103-33,591,390 
Chr3 161189323-161196500 
chrS 158674369-158690059 
chrl9 18031371-18058742 
chrl 67545635-67635171 
chr6 52159144-52163395 
chr22 15,945,849-15,971,389 
chr l l 111519186-111540050 
chr l l 71387606-71391498 
chr2 102401686-102435456 
chr4 123753233-123761661 
Chrl2 66928292-66933548 
Chrl2 55018930-55020461 
chrl 67404757-67498238 
ehrt 21130631-21132144 
Chrl6 27321924-27369616 
chrl 152644293-152706812 
chr6 137506650-137536478 
chrl 24318848-24342198 
ChrS 131846684-131854326 
Chr4 185545870-185632720 
chrl9 54854641-54860944 
chr6 336752-356443 
chr7 128365230-128377324 
12 
15 
4 
15 
63 
3 
4 
13 
25 
6 
5 
6 
9 
8 
12 
4 
4 
10 
1 
11 
9 
7 
21 
22 
22 
7 
7 
8 
17 
16 
3 
13 
6 
7 
12 
5 
5 
4 
11 
1 
9 
10 
7 
7 
10 
9 
8 
9 
9 
11 
13 
4 
12 
62 
3 
3 
12 
24 
6 
5 
6 
8 
6 
11 
4 
4 
10 
1 
11 
8 
7 
21 
21 
20 
7 
7 
6 
17 
15 
3 
13 
5 
5 
10 
5 
5 
4 
10 
1 
8 
10 
6 
7 
9 
8 
7 
8 
8 
NM 001621 
NM 001014432 
NM 005252 
NM 001880 
NM 000051 
NM 006399 
NM 003921 
NM_052813 
NM 032415 
NM_015717 
NM 003332 
NM 001007033 
NM 002745 
NM_001002901 
NM 014009 
NM 015675 
NM 006705 
NM_002164 
NM_000605 
NM 000629 
NM 207585 
NM 005534 
NM 001278 
NM 001556 
NM 014002 
NM 000628 
NM 000882 
NM 002187 
NM 005535 
NM 001559 
NM 002190 
NM 014339 
NM 001562 
NM 001039659 
NM 003853 
NM 021803 
NM 020525 
NM 016584 
NM 144701 
NM 002177 
NM 181078 
NM 000565 
NM 052962 
NM 021258 
NM 002198 
NM 002199 
NM 001571 
NM 002460 
NM 001098630 
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IRF6 
IRF7 
IRF8 
IRF9 
JAK1 
JAK2 
JAK3 
Malt i 
MRC1 
IL8 
NFATcl 
ST13 
PIK3CG 
PIASI 
PIAS3 
PRKD3 
PRKCE 
SPI1 
GNB2L1 
RASGRP3 
RELB 
RIPK1 
RORA 
RORC 
RUNX1 
Smad2 
Smad3 
Smad4 
SOCS1 
SOCS3 
SOCS5 
SplB 
STATI 
STAT2 
STAT5B 
STAT6 
SUMOl 
Syk 
MAP3K7IP2 
TANK 
TBK1 
TGFBR1 
TLR3 
TLR4 
TRAF3 
TRAF6 
TICAM2 
TICAM1 
TRIM21 
TxK 
ΤΎΚ2 
chrl:208027885-208046102 
chrll:602555-605999 
chrl6:B4490275-84513712 
chrl4:23699569-23705614 
chrl:65071494-65204775 
Chr9:4975245-5117995 
Chrl9:17796593-17819841 
chrl8:54489598-54568350 
Chrl0:17891368-17993184 
chr4.74825139-74828297 
chrl8:7S261314-75390311 
chr22:395S0547-39582633 
chr7:106293160-106334828 
chrlS.66133626-66267458 
chrll44287345-144297903 
Chr2 37331150-37397726 
chr2-45732547-46268633 
chrll:47332985-47356703 
chr5180596534-180603S12 
chr2:33514920-33643162 
chrl9:50196552-50233292 
chr6:3021997-3060420 
chrl5:58576755-58707024 
chrl:150O45171-150O70972 
chr21:35081968-35343465 
chrl8:43613464-43711510 
chrl5:65145249-65274587 
chrl8:46810581-46865409 
chrl6:11255775-11257540 
chrl7.73864457-73867753 
chr2:46779603-46843431 
chrl9:5S614028-55624060 
Chr2 191542007-191587221 
Chrl2:55021649-55040176 
Chrl7:37604721-37681950 
chrl2:55775460-55791428 
chr2:202779148-202811567 
chr9.92e03891-92698304 
chr6149680756-149774440 
Chr2 161701712-161800928 
chrl2:63132204-63182158 
chr9:l{)0907233-100956294 
Chr4:187227303-187243246 
Chr9:119506431-119519587 
Chrl4102313569-102442381 
chrll:36467299-36488398 
Chr5114942247-114989610 
Chrl9:4766992-4769451 
chrll:4362703-4371502 
Chr4:47763167-47831030 
chrl9:10322204-103S2248 
9 
11 
9 
9 
25 
25 
24 
17 
30 
4 
10 
12 
11 
14 
14 
18 
15 
5 
8 
19 
12 
10 
12 
11 
9 
11 
9 
13 
2 
2 
2 
6 
25 
24 
19 
22 
5 
14 
7 
8 
21 
9 
5 
4 
12 
8 
4 
1 
7 
15 
25 
7 
10 
8 
8 
24 
23 
23 
17 
30 
4 
10 
12 
10 
14 
14 
18 
15 
5 
8 
16 
12 
10 
12 
11 
8 
10 
9 
11 
1 
1 
1 
6 
23 
23 
18 
22 
5 
13 
6 
7 
20 
9 
4 
2 
10 
6 
1 
1 
6 
15 
23 
NM 006147 
NM 001572 
NM 002163 
NM 006084 
NM 002227 
NM 004972 
NM_0O0215 
NM 006785 
NM 002438 
NM 000584 
NM 006162 
NM 003932 
NM 002649 
NM 016166 
NM_006099 
NM 005813 
NM 005400 
NM 001080547 
NM_006098 
NM 170672 
NM 006509 
NM 003804 
NM_134260 
NM 005060 
NM_001754 
NM 001003652 
NM 005902 
NM 005359 
NM 003745 
NM 003955 
NM 144949 
NM 003121 
NM 007315 
NM 005419 
NM 012448 
NM 003153 
NM 003352 
NM 003177 
NM 015093 
NM 004180 
NM 013254 
NM 004612 
NM 003265 
NM 138554 
NM 145725 
NM 145803 
NM 021649 
NM 182919 
NM 003141 
NM 003328 
NM 003331 
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Table S2: Oligonucleotides used as bar-coded adaptors (Titanium optimized), and enhancing oligos for 12-plex 
sequence capture and subsequent 454 sequencing. 
Ti-MIDl-A 
•n-MID2-A 
TÌ-MID3-A 
TÌ-MID4-A 
TÌ-MID5-A 
TÌ-MID6-A 
TÌ-MID7-A 
Ti-MIDS-A 
Ti-MIDIO-A 
Ti-MIDll-A 
TÌ-MID13-A 
TÌ-MID14-A 
Ti-MIDl-Aprime 
Ti-MID2-Apnme 
Ti-MID3-Aprime 
Ti-MID4-Aprime 
Ti-MID5-Aprime 
Ti-MID6-Aprime 
Ti-MID7-Aprime 
Ti-MID8-Aprime 
Ti-MID10-Aprime 
Ti-MIDll-Aprime 
Ti-MID13-Aprime 
Ti-MID14-Aprime 
Ti-MID-B 
Ti-MID-Bprime 
Ti MID_1 Hyb enhancing oligo 
Ti MID_2 Hyb enhancing oligo 
Ti MID_3 Hyb enhancing oligo 
Ti MID_4 Hyb enhancing oligo 
Ti MID_5 Hyb enhancing oligo 
Ti MID_6 Hyb enhancing oligo 
Ti MID_7 Hyb enhancing oligo 
Ti MID_8 Hyb enhancing oligo 
Τι MID_10 Hyb enhancing oligo 
Ti MID_11 Hyb enhancing oligo 
Ti MID_13 Hyb enhancing oligo 
Ti MID_14 Hyb enhancing oligo 
Titanium Hyb enhancing Β 
C,C,A*T'CTCATCCaGCGTGTCTCCGACTCAGACGAGT*G*C*G*T 
C'C'A'T'CTCATCCCTGCGTGTCTCCGACTCAGACGCTC'G'A'C'A 
C'C'A'T'CTCATCCaGCGTGTaCCGAaCAGAGACGC'A'Cn'C 
C'C'A'T'CTCATCCaGCGTGTaCCGACTCAGAGCAa'Gn'A'G 
C'C'A'T'CTCATCCCTGCGTGTaCCGACTCAGATCAGA'C'A'C'G 
C'C'A'T'aCATCCCTGCGTGTCTCCGACTCAGATATCG'C'G'A'G 
C'C'A'T'CTCATCCCTGCGTGTaCCGACTCAGCGTGTC'T'C'T'A 
C'C'An^aCATCCCTGCGTGTCTCCGAaCAGCTCGCG'T'G'T'C 
C'C'An'CTCATCCCTGCGTGTCTCCGACTCAGTaaAn'G'C'G 
C*C*A*T*aCATCCCTGCGTGTCTCCGACTCAGTGATAC*G,T,C",T 
C'C'An'aCATCCCTGCGTGTCTCCGAaCAGCATAGT'A'G'T'G 
C^C'A'T'CTCATCCCTGCGTGTCTCCGACTCAGCGAGAG'A'T'A'C 
A»C,G,C',ACTCGTCTGAGTCG,G*A,G,A 
rG'T'C'GAGCGTCTGAGTCG'G'A'G'A 
α·Α*6·τ ·6οατσΓα6Αθτα6*α*Α*6*Α 
0·Τ*Α*α·Α6ΤΟ0ΤΓΓ6Α6Τ06*6*Α*6*Α 
C,GtTG*TClGAlCTGkGJCG*G*A*G*A 
C»T*C*G*CGATATaGAGTCG*G*A*G*A 
T'A'G'A'GACACGCTGAGTCG'G'A'G'A 
G*A*C*A*CGCGAGCJGAGJCG*GtA*G*A 
C*G*C*A*TAGAGACTGAGTCG*G'A*G*A 
A'G'A'C'GTATCACTGAGTCG'G'A'G'A 
C*A*T'A»GTAGTGCTGAGTCG*G*A*G*A 
C'G'A'G'AGATACCTGAGTCG'G'A'G'A 
/5ΒιοΤΕ6/0*ε*Τ·Α*Τ0α0αΤ6Τ6Τ60αΤ660Α6Τ0·Τ*α*Α*0 
C*T'G*A*GACT*G*C*C*A 
CCA TCT CAT CCC TGC GTG TCT CCG ACT CAG ACG AGT GCG T/3ddC/ 
CCA TCT CAT CCC TGC GTG TCT CCG ACT CAG ACG CTC GAC A/3ddC/ 
CCA TCT CAT CCC TGC GTG TCT CCG ACT CAG AGA CGC A a C/3ddC/ 
CCA TCT CAT CCC TGC GTG TCT CCG ACT CAG AGC ACT GTA G/3ddC/ 
CCA T a CAT CCC TGC GTG T a CCG A a CAG ATC AGA CAC G/3ddC/ 
CCA T a CAT CCC TGC GTG T a CCG A a CAG ATA TCG CGA G/3ddC/ 
CCA T a CAT CCC TGC GTG T a CCG ACT CAG CGT GTC T a A/3ddC/ 
CCA TCT CAT CCC TGC GTG T a CCG A a CAG CTC GCG TGT C/3ddC/ 
CCA T a CAT CCC TGC GTG T a CCG A a CAG TCT a A TGC G/3ddC/ 
CCA TCT CAT CCC TGC GTG T a CCG A a CAG TGA TAC GTC T/3ddC/ 
CCA T a CAT CCC TGC GTG T a CCG A a CAG CAT AGT AGT G/3ddC/ 
CCA T a CAT CCC TGC GTG T a CCG A a CAG CGA GAG ATA C/3ddC/ 
C a ATC CCC TGT GTG C a TGG CAG T a CAG /3ddc/ 
Each oligonucleotide should have phosphorothioate modifications in both the first four and the last four bases of the oligomers 
The adapter Β long oligonucleotide Ti-MID-B must be synthesized with a 5-prime biotm-TEG moiety 
All oligonucleotides must be purified using HPLC 
Oligos may be ordered lyophilized or in solution (TE, pH 8.0) at at fixed concentration (ΙΟΟμΜ) 
100 nmole scale (adapter A) and 1 micromole scale (adapter B) is for 40 libraries 
STATI mutations in CMC 
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Figure SI. Human PBMCs from healthy controls (n=2), the mother and three affected members of the Dutch 
family #1 with CMC (PI, P2, P3) were stimulated with (A) heat-killed Candida albicans ( Ix l0e6 
microorganisms/ml) for 24 hours, (B) IL-lß (10 ng/ml)/IL-23 (10 ng/ml) for 5 days. Cytokines were measured by 
ELISA. 
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Figure S2. (A) Sequence read histograms uploaded to UCSC genome browser, displaying the sequencing depth 
of all exons of STATI for all patients included in the next generation sequencing assay. Tracks displayed: Scale, 
chromosomal position, read depth histogram per bp (between 0 and 70-fold coverage), target regions, tiled 
regions (oligos represented on sequence capture array), refseq gene track. 
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Figure S2. (B) Next generation sequencing reads coverage of STATI exons 9 and 10. Tracks displayed: Scale, 
chromosomal position, individual 454 sequencing reads, target regions, tiled regions refseq gene track. (C) 
Mutation visualization in the IGV browser. Individual reads overlapping with the mutation are displayed, 
showing the heterozygous G>A mutation at genomic position chr2:191,568,156 (the reads are mapped and 
displayed on the + strand). The inserted caption displays the Sanger sequencing validation of the mutation 
(sequencing of the - strand shows heterozygous C>T mutation) for patients 1, 2, 3, and the unaffected mother 
from family #1. Likewise, individual reads overlapping with the mutation are displayed, showing the 
heterozygous G>A mutation at genomic position chr2:191,568,176 (the reads are mapped and displayed on the 
+ strand). The inserted caption displays the Sanger sequencing validation of the mutation (sequencing of the -
strand shows heterozygous C>T mutation) for patient 5 from family #2 and patient 1 from family #3. 
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Summary 
Infections caused by Candida species continue to be a substantial cause of disease burden, 
especially in immunocompromised patients. New approaches are needed to improve the 
outcome of patients suffering from Candida infections, since it seems unlikely that the 
established standard treatment will drastically lower the morbidity of mucocutaneous 
Candida infections and the high mortality associated with invasive candidiasis. New insights 
into the mechanisms of the anti-Candida host response have contributed to the design of 
novel immunotherapeutic approaches that have been proposed as adjuvant therapy in 
Candida infections. This review presents an overview of novel strategies in the prevention 
and treatment of Candida infections, with a special focus on adjuvant immunotherapy. 
Introduction 
Candida infections can be divided into local infections and invasive candidiasis. The various 
forms of mucosal Candida infections induce a significant burden of morbidity: vulvovaginal 
candidiasis (WC), oropharyngeal candidiasis (OPC) and chronic mucocutaneous candidiasis 
(CMC). WC, the most common form of mucosal candidiasis, is widespread and may affect up 
to 75% of women of child-bearing age (1). It is characterized by pruritus, irritation and 
dyspareunia often accompanied by increased vaginal discharge. WC can be divided into 
uncomplicated or complicated (2). Complicated WC is defined as severe or recurrent 
disease, infection due to Candida species other than C. albicans, or WC in an abnormal host 
(2). Recurrent forms of WC (RWC) are defined as four or more episodes of symptomatic 
WC within one year (3). Notably, in patients with RWC the associated costs of medical visits 
is high and their quality of life is significantly reduced (1). 
OPC is a relatively common local infection occurring in high-risk groups of patients such as 
dental wearers, diabetic patients, individuals treated with broad spectrum antibiotics, 
infants and patients infected with HIV. It has been reported that 84% of HIV-infected 
individuals are asymptomatically colonized with Candida spp. in the oral cavity, with 55% 
developing at least one episode of OPC with clinical signs (4). If left untreated these lesions 
contribute considerably to the morbidity associated with HIV infection (5). Importantly, 
oropharyngeal candidiasis can be complicated by esophageal candidiasis. Esophageal 
candidiasis is accompanied by more serious complaints and predisposes to the development 
of systemic candidiasis (6, 7). 
These mucosal manifestations of candidiasis may also be associated with primary 
immunodeficiencies. CMC represents a heterogeneous group of primary immunodeficiencies 
that are characterized by an inability to clear fungal infections. Consequently, persisting and 
recurrent infections of the skin and mucous membranes with C. albicans ensue (8). Some 
patients have autosomal recessive polyglandular autoimmune syndrome type I, also known 
as autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED) syndrome. 
This syndrome is caused by mutations in the autoimmune regulator (AIRE) gene and is 
characterized by CMC and endocrine disorders, such as hypoparathyroidism and Addison's 
disease (9). CMC also occurs without associated disorders and the genetic defect in these 
patients is not known (10). Another primary immunodeficiency accompanied by 
mucocutaneous candidiasis is the hyperimmunoglobulin E syndrome (HIES, Job's syndrome). 
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This disease is further characterized by recurrent staphylococcal skin abscesses, pulmonary 
infections, skeletal and dental abnormalities, and elevated serum immunoglobulin E 
concentrations (11,12). Recently, it has been demonstrated that in large number of patients 
with HIES, a dominant negative mutation in STAT3 is the underlying cause of disease (13). 
Disseminated candidiasis is a deep-seated organ infection with Candida spp. and/or 
candidemia. The clinical spectrum varies from minimal fever to severe sepsis with 
multiorgan failure (14). The microorganism gains access to the intravascular compartment 
either from the gastrointestinal tract or, less often, from the skin through the site of an 
indwelling intravascular catheter. Noteworthy, it has become apparent that health care 
workers' hands are commonly colonized with Candida spp. (15), and several studies have 
demonstrated that this is the main cause of the reported Candida parapsilosis outbreaks in 
pediatric ICU departments (16-18). Candida spp. has been reported as one of the most 
common pathogens that cause hospital acquired bloodstream infections in patients 
undergoing surgical or chemotherapeutic interventions and/or with underlying 
immunological deficiencies (19, 20). Importantly, nosocomial candidemia is associated with 
an unacceptable high mortality ranging between 30% and 50% (19, 21, 22). 
In this review we will discuss novel approaches such as vaccination, antibodies, cytokine 
therapy, and adoptive transfer of primed immune cells that have the potential to improve 
the clinical outcome of patients with Candida infections. 
Diagnosis and treatment of Candida infections 
Patients with invasive candidiasis should receive effective treatment as soon as possible, 
since delays in starting antifungal therapy in candidemia are correlated with increased 
mortality (14, 23, 24). Therefore, it is of utmost importance to identify candidemia in 
critically ill patients as soon as possible. Several clinical scores have been developed to 
identify patients who are at high risk for developing candidemia (25, 26). The golden 
standard for the diagnosis of disseminated candidiasis remains microbiological identification 
of the yeast in the blood or the organs. Unfortunately, the microbiological methods have a 
low sensitivity, and additional methods have been developed to improve early fungal 
detection. Non-invasive techniques, such as measurement of mannan and anti-mannan 
antibodies and the detection of the fungal cell wall component (l-3)-ß D-glucan (BDG) have 
the potential to be useful for early diagnosis of invasive candidiasis (27-29). Another 
promising technique is the use of polymerase chain reaction (PCR), which has been reported 
to have a high sensitivity and specificity and has good potential to provide species 
identification prior to blood culture positivity (30). Still, none of these techniques can 
definitively prove a Candida infection (31, 32). Since it remains difficult to establish a 
diagnosis of invasive candidiasis early in the course of infection, prophylactic therapy is 
often advocated. However, prophylactic treatment in high-risk groups, such as stem cell 
transplant recipients and high-risk populations in the ICU, is a controversial issue as outlined 
in the IDSA guidelines for the treatment of invasive candidiasis (24). 
Diagnosis of WC is usually made on the basis of clinical signs and symptoms (1), but since 
these are not specific it is wise to confirm it with a smear before starting antifungal therapy. 
Clinical signs and symptoms of oropharyngeal candidiasis in HIV patients are usually 
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suggestive of the diagnosis (33). However, in view of the differential diagnosis, frequent 
recurrence or persistence, microbiological culture to confirm the diagnosis of OPC, 
speciation and susceptibility testing are required. 
The current standard treatment of Candida infections consists of antifungal agents such as 
azoles, echinocandins and amphotericin Β compounds (Box 1). Despite these available 
antifungal agents the frequency of treatment failure is considerable, underscoring the 
necessity for new treatment strategies. In vitro experiments suggest that combinations of 
these antifungal agents might improve antifungal efficacy (34, 35). However, no clinical trial 
to date has demonstrated that combining antifungal agents results in additional efficacy for 
the treatment of invasive candidiasis. The lack of progress in terms of mortality due to 
disseminated Candida infections has led to the opinion among the experts that only a 
combination between standard antifungal treatment and the adjunctive immunotherapy will 
be able to decrease the mortality in Candida sepsis. A better understanding of the 
pathogenesis of host defense against Candida infections has made it possible to explore 
immunomodulatory interventions that might contribute to the standard clinical practice. 
Pathogenesis of host defense against Candida infection 
Host defense against Candida infection depends on intact mucosal and skin barriers, and 
adequate recognition of the fungus that subsequently triggers protective innate and 
adaptive antifungal defense mechanisms (36). The first line of defense is the skin and 
mucosa, which not only offers a mechanical barrier but also provides microbial antagonism 
with its associated normal flora. Once this first line of defense fails, protective innate and 
adaptive immune mechanisms will be activated that critically depend on appropriate 
pathogen recognition. Recognition of Candida is mediated by pattern recognition receptors 
(PRRs), which bind pathogen-associated molecular patterns (PAMPs). The most studied and 
well-known PAMPs of Candida are components of the fungal cell wall. The inner layer of the 
cell wall is composed of ß-(l,3)-glucan covalently linked to ß-(l,6)-glucan (37) and chitin, 
and an outer layer that consists of proteins that are heavily glycosylated by /V-linked (38) and 
O-linked mannosylation (39). All these components have been reported as ligands for one or 
more PRRs, among which two classes collaborate in Candida recognition: toll-like receptors 
(TLRs) such as TLR2 and TLR4, and the C-type lectin receptors (CLRs) such as dectin-1, dectin-
2, Mincie and mannose receptor (MR) (40-46). Some of these receptors exert a 
proinflammatory action (e.g., TLR4, dectin-1, MR), while others exert a more 
antiinflammatory effect (e.g., TLR2) (36). The type of response initiated by Candida depends 
on the complex interaction between the PRRs expressed by the different cell types present 
at the site of infection (47). Polymorphonuclear cells (PMNs), monocytes and macrophages 
are important for the main innate effector response: phagocytosis of Candida and the 
induction of reactive oxygen species (ROS) that can both damage and subsequently 
eliminate the fungus. 
Proinflammatory cytokines such as tumor necrosis factor α (TNFa) and interleukin (IL)-lß are 
crucial for proper activation of PMNs. TNFa is essential for ant\-Candida host defense 
through recruitment of neutrophils and phagocytosis, and deficiency results in higher 
mortality during experimental disseminated candidiasis (48). In addition, IFNy produced by 
CD4 Τ lymphocytes is also important for stimulation of antifungal activity of PMNs. IFNy 
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induces NO production by macrophages and Cond/do-specific immunoglobulin production 
(49). The central role of endogenous IFNy in the resistance against systemic candidiasis has 
been underscored by the observation that knock-out mice deficient in IFNy are highly 
susceptible to C. albicans infection (50, 51). Mice deficient in the cytokine IL-18, which plays 
a crucial role in the induction of IFNy, are also more susceptible to disseminated candidiasis 
(52). Thus, the pathogenesis of invasive candidiasis seems to be linked to defects in 
phagocytosis and killing of Candida and defects, leading to IFNy production. 
Another source for the production of pro-inflammatory cytokines in the mucosa are 
epithelial cells, and they have been advocated to play a central role in the protection against 
fungal pathogens (53, 54). Epithelial cells can produce IL-8 and GM-CSF in response to 
Candida spp. (55-57). Furthermore, oral epithelial cells can upregulate the anti-fungal 
activity of neutrophils in vitro, and this effect was partially dependent on IL-la (58). In 
addition, neutrophils can upregulate TLR4 expression on C. albicans infected human oral 
epithelium, and this was directly associated with protection against fungal invasion of the 
epithelium (59). 
The adaptive immune responses that are crucial for antifungal protection are elicited by 
CD4+ Τ helper (Th)l (IFNy-producing) cells and Thl7 (IL-17/IL-22-producing) cells. The 
Cond/do-specific Thl response is induced by antigen presentation in the presence of the 
cytokine IL-12 (60), while Thl7 responses are induced and maintained in the presence of IL-1 
and IL-23 (61). In patients with HIV who have low CD4 counts, the incidence of 
oropharyngeal candidiasis is high (62). This underscores the importance of the Τ helper cell 
in mucosal anti-Candida host defense. Notably, in the absence of CD4+ Τ cells, CD8+ Τ cells 
also appear to play an important role in anti-Conc//da host defense (63, 64). 
The recently discovered Τ helper subset Thl7 cells have provided important novel insights 
into the pathogenesis of mucosal Candida infections. Thl7 cells have been demonstrated to 
play a crucial role in host defense in experimental oropharyngeal Candida infection and 
disseminated candidiasis (65, 66). It has been shown that patients with HIES have a defect in 
the Candida- induced Thl7 response (67, 68). Furthermore, patients with CMC have been 
linked to a defect in their Thl7 response against Candida (69). A recent study shows that IL-
17A deficient mice were equally susceptible to disseminated candidiasis, but in the same 
study the Thl7 response induced by vaccination was associated with protection against 
disseminated candidiasis (70). However, Thl7 responses have also been suggested to be 
detrimental for the host during fungal infection. In an experimental fungal infection model, 
both inflammation and infection were exacerbated by the Thl7 response against Candida 
albicans and Aspergillus fumigatus (71). This is an important controversy that needs further 
investigation, since these observations will provide the rationale for choosing the correct 
adjuvant in fungal vaccine strategies. 
There has been quite some speculations over the years whether patients with vulvovaginal 
candidiasis (WC) have an underlying host defense defect (1). It has been reported that the 
increase of vaginal mannose binding lectin (MBL) levels in patients with WC may be an 
effective immune response against Candida albicans infection, and that women with 
recurrent WC have lower vaginal levels of MBL compared to controls (72). In addition, MBL 
polymorphisms have been associated with recurrent vulvovaginal candidiasis (73, 74). 
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Another polymorphism in the IL-4 (T-589) gene was found to correlate with a high 
prevalence of RWC (75). One study has reported a role for neutrophils in the inflammatory 
response during WC. Neutropenia in an experimental model of vaginal Candida infection 
had no effect on the fungal load during infection, but was significantly associated with 
decreased vaginal inflammation (76). Another study reported that symptoms of WC appear 
to be due to an aggressive innate response by PMN (77). 
Recently, new insights in the pathogenesis of RWC have emerged. A family in which four 
women were affected by either recurrent vulvovaginal candidiasis or onychomycosis were 
found to be dectin-1 deficient (78). It was demonstrated that dectin-1 deficiency resulted in 
lower IL-17 production in response to Candida albicans and this most probably accounts for 
the clinical picture seen in these patients. These observations were further strengthened by 
another report which describes a family that was deficient in CARD9, a downstream 
molecule in the signaling cascade of dectin-1 (79). Patients with CARD9 deficiency had an 
impaired Cond/cto-specific Thl7 response, and female patients had a long history or early 
onset of vaginal candidiasis. These data suggest that Thl7 responses are important for 
vaginal mucosal host defense. 
Novel immunotherapeutic strategies 
Insights into the ant\-Candida host defense mechanisms have contributed to the 
development of immune interventions that have the potential to lower the morbidity and 
mortality associated with Candida infections. Immunomodulatory strategies under 
investigation range from vaccination, to therapeutic antibodies and recombinant cytokines, 
and adoptive transfer of primed immune cells. 
Vaccination 
Among those with invasive Candida infection, immunocompromised patients have the 
highest morbidity and mortality. Since vaccination depends on an appropriate host defense 
mechanism to provide protection, active and passive immunization in immunocompromised 
patients remains a challenge. Currently, there are no Candida vaccines clinically available. 
Nevertheless, several active and passive fungal vaccine approaches look promising and could 
prove to be an effective and safe strategy. A preliminary phase II trial with the oral vaccine 
D.561 performed already two decades ago in 22 patients with frequent recurrences of 
vulvovaginal candidiasis (WC) showed promising results, but the true efficacy of the vaccine 
still has to be confirmed in a larger placebo-controlled trial (80). Several vaccine strategies 
have been tested in animal models with success. Diphtheria toxoid CRM197 conjugated with 
the algal antigen laminarin (Lam) was protective against both mucosal and systemic 
candidiasis in mice (81). Mannan protein conjugates induced protective antibody responses 
against experimental disseminated candidiasis and Candida vaginal infection (82). Vaccines 
based on the adhesins Alslp and Als3p were shown to cause a marked improvement in the 
fungal burden and survival of immunocompetent and immunocompromised mice with 
invasive and mucosal Candida infection (83-86). Furthermore, vaccination with live-
attenuated Candida or the low virulent CA2 strain have been reported to provide protection 
against hematogenous Candida re-infection in animal models (87). Although these different 
vaccination strategies provide promising results in animal models with experimental 
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infections, their clinical safety and efficacy remains to be assessed in humans with Candida 
infections. 
Important new insights have been gained in recent years regarding adjuvanticity. There are 
potent adjuvants that trigger the pattern recognition receptors (PRRs) of dendritic cells (DCs) 
which results in DC maturation. Different adjuvants induce different cytokine profiles, and 
dependent on this profile the immune response is shifted towards a Thl, Th2 or Thl7 
response. This enables to shape the kind of adaptive immune response elicited by the 
vaccine (Figure 1). Several adjuvants available act through PRRs or their pathways, such as 
the TLR9 agonist CpG DNA (88), the TLR4 agonist monophosphoryl lipid A (lipid A) (89), and 
alum which exerts its effects through cryopyrin (NALP3) (90). To improve the efficacy of 
current vaccines these insights should be exploited to specifically induce optimal defense 
against a pathogen. In candidiasis, this would mean that the adjuvant ideally facilitates a 
strong Thl response In case of disseminated candidiasis and a predominant Thl7 response 
during mucosal candidiasis. The dectin-1 ligand ß-glucan that has the potential to induce 
both a Thl and Thl7 response, would be a good candidate for a Candida vaccine adjuvant 
(91). Mannans from yeasts induce a Thl7 response through mannose receptor and/or 
dectin-2 are of potential interest for vaccination against mucosal Candida infections (40,46). 
A recent study has demonstrated that mice immunized with als3p vaccine plus alum as an 
adjuvant were protected against disseminated candidiasis (70). Vaccination primed Thl and 
Thl7 lymphocytes which resulted in neutrophil recruitment and activation at the site of 
infection and more effective clearance of Candida albicans from the tissues. 
Antibodies 
Anti-Candida antibodies artificially induced and administered to patients can be protective 
and might have the potential to be used as immunotherapy. This is evident from the 
literature that has investigated the use of antibodies directed against Candida in 
experimental models and patients with candidiasis. Since production of antibodies against the 
pathogen-specific heat shock protein 90 (Hsp90) is associated with recovery from invasive candidiasis 
in mice and also in patients, (92, 93), efungumab, a human recombinant shock protein 90 (Hsp90) is 
associated with recovery from invasive candidiasis in mice and also in patients, (92, 93), efungumab, 
a human recombinant antibody directed against the fungal Hsp90, has been developed. Efungumab 
was investigated in a double-blinded randomized multicentre study of 139 patients with invasive 
candidiasis (94). Treatment with liposomal amphotericin Β was compared with liposomal 
amphotericin Β in combination with efungumab. In patients with invasive candidiasis the combined 
therapy produced significantly better clinical and culture-confirmed outcome. However, questions 
were raised regarding the methodology (95) and additional studies are needed to establish its 
potential. Recently, pre-clinical data supporting synergy between efungumab and caspofungin in the 
treatment of invasive candidiasis has been reported (96). Other approaches include the use of 
monoclonal antibodies (mAb) and immune serum from mice that were vaccinated with Candida-
mannan containing liposomes, these provided protection in mice with disseminated candidiasis (97, 
98). Mice treated with recombinant anti-mannan human antibody were more resistant to 
disseminated candidiasis (99). The synthetic glycopeptide vaccines can induce protective antibodies 
in experimental systemic candidiasis in mice (100). In addition, it is reported that ß-glucan-conjugate 
vaccination results in anti-ß-glucan antibodies, which are effective against experimental murine 
vaginal candidiasis (101). 
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Another approach is the use of idiotypic antibodies. Candida albicans is highly susceptible to 
the so called yeast killer toxin (YKT). The monoclonal KT4 antibody neutralizes the effects of 
YKT. An idiotypic antibody that is directed against KT4 mAb appears to mimic the biological 
function of YKT (102), and exerts anti-candidal effects and protects against mucosal and 
systemic experimental candidiasis (102, 103). Treatment with such antibodies that are 
directly effective against Candida may become a therapy for the immunocompromised host. 
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Cytokine therapy 
Cytokines are able to enforce host defense and therefore may be useful for 
immunomodulation during infections. GM-CSF accelerates hemopoiesis of myeloid cells, 
resulting in production of monocytes and neutrophils (104), and in pharmacological doses it 
leads to monocytosis and neutrophilia. It enhances phagocytosis and the release of ROS by 
PMNs (105), and prolongs the survival of neutrophils by inhibition of programmed cell death 
(106). It also upregulates dectin-1 expression on macrophages (107) and promotes fungicidal 
activity via upregulation of chititriosidase, which cleaves chitin present in the inner cell wall 
of C. albicans (108). In neutropenic mice with disseminated candidiasis, GM-CSF was shown 
to reduce lung damage and mortality (109). In two small studies in patients, Vazquez et al. 
investigated the use of granulocyte macrophage-colony stimulating factor (GM-CSF) as an 
adjunctive drug for clinically refractory mucosal candidiasis in patients with advanced AIDS. 
GM-CSF in combination with antifungal therapy appeared to lead to clinical and mycological 
improvement without adverse events (110, 111). Anecdotal reports in the literature of 
patients with disseminated candidiasis showed a favorable response to addition of GM-CSF 
(112, 113). A case report of a patient with a 17-year history of severe chronic 
mucocutaneous candidiasis who was treated with GM-CSF had a favorable response (114). 
Unfortunately, the patient had a severe anaphylactic reaction, which is an uncommon side 
effect of GM-CSF, and GM-CSF was stopped (114). Although these studies indicate that GM-
CSF could be beneficial in the treatment of Candida infections, the experience is limited and 
controlled trials are lacking. 
G-CSF is a hematopoietic growth factor that selectively promotes the proliferation and 
differentiation of neutrophils. Incubation of PMNs from healthy volunteers in vitro with G-
CSF showed enhanced antifungal activity in damaging Candida pseudohyphae (115). G-CSF 
administered in humans also significantly enhanced PMN-mediated damage of Candida 
pseudohyphae (116). Furthermore, mice with disseminated candidiasis treated with 
recombinant G-CSF show significantly reduced mortality and lower fungal outgrowth (117-
119); this benefit was less obvious during subacute or chronic candidiasis (117). In chronic 
gastrointestinal candidiasis in mice, G-CSF in combination with fluconazole did not show 
additional benefit over fluconazole alone in reducing the fungal burden (120). The first 
randomized placebo controlled trial addressing adjunctive immunotherapy in non-
neutropenic patients with disseminated candidiasis, compared fluconazole alone with 
fluconazole and G-CSF. This phase 2 study indicated that administration of G-CSF is safe and 
showed a trend towards faster resolution of infection (121). 
IFNy is produced by Τ cells and NK cells and augments the cytotoxic function of macrophages 
and the killing of intracellular pathogens (122). IFNy is also known to have activity on other 
important non-immune cells important in host defense, such as endothelial cells, epithelial 
cells and fibroblasts (123). Clinical experience with IFNy therapy is greatest in patients with 
chronic granulomatous disease. In these patients it reduces the incidence of infections, 
including infections with Aspergillus (124). The effector mechanisms that are triggered by 
IFNy are elusive. Several in-vitro and in-vivo studies support that IFNy treatment is beneficial 
in the treatment of Candida infections. Various studies have shown that IFNy increases anti-
candidal function of macrophages (125-130). Other studies however were not able to show 
that IFNy enhanced the capacity of murine macrophages (Marcii, et al., 2002) or murine 
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pulmonary macrophages to kill Candida (131). Peritoneal and peripheral blood PMNs from 
IFNy-treated mice showed enhanced killing of Candida (132). Incubation of human PMNs 
with IFNy augments the capacity of PMNs to kill Candida (133). The administration of IFNy 
reduces the fungal burden in mice with disseminated candidiasis (132). However, IFNy failed 
to improve the efficacy of fluconazole in a murine model of experimental oral mucosal 
candidiasis (120). Although the literature is controversial regarding the role of IFNy in anti-
Candida host defense, a small study of three patients with disseminated candidiasis reported 
that additional IFNy therapy was beneficial (112). Furthermore, administration of IFNy in a 
HIV-infected patient with azole-resistent oropharyngeal candidiasis (OPC) resulted in a 
dramatic improvement (134). These case reports suggest that IFNy could be beneficial as 
adjuvant antifungal therapy, but clinical trials are urgently needed to establish whether IFNy 
is valuable in the treatment of Candida infections. 
Adoptive transfer of primed immune cells 
Another approach for antifungal immunotherapy would be the use of antigen primed 
dendritic cells (DCs) that are able to skew the adaptive immune response towards anti-
Candida effector functions (135). Dendritic cells could be primed ex-vivo with antigens that 
induce specific cytokine profiles, and thereafter infused in the patient with Candida infection 
(136). It has been shown that Thl dependent antifungal protection could be induced by DC 
vaccination in mice that received allogeneic bone marrow transplants (137). Furthermore, 
adoptive transfer of anti-Candida Τ cells has been proposed as potential immunotherapy in 
patients with Candida infection after hematopoietic stem cell transplantation (138). The 
generated human Τ cells were able to damage hyphal forms of Candida and significantly 
enhanced hyphal damage induced by human neutrophils. As the generated Τ cells do not 
seem to be affected by cryopreservation (138), there is the opportunity to generate anti-
Candida Τ cells before the patients reach an immunocompromised status, and adoptively 
transfer these cells during infection when patients are immunocomprimised. Such new 
approaches to modulate the immune response offer elegant opportunities to enforce the 
immune system at the core of its failing anti-Candida defense mechanisms. However, the 
efficacy and potential adverse effects still have to be assessed in both animal models with 
experimental Candida infections, and ultimately in the patients. 
Concluding remarks 
Candida infections account for a high burden of morbidity and mortality. New therapeutic 
approaches are urgently needed to improve the outcome of the patients, as the currently 
available treatment options have not reduced the mortality and morbidity associated with 
Candida infections over the recent years. One solution would be the use of immunotherapy, 
which aims at improving host defense against Candida. The increase in understanding the 
mechanisms that underlie the pathogenesis of Candida infection brings the development of 
efficient and feasible immunotherapeutic strategies closer. 
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Box 1. Standard treatment of Candida infections 
Invasive candidiasis 
• For neutropenic patients, patients with moderate to severe illness or hemodynamic instable 
patients, those with previous azole exposure, and/or patients that are at risk of infection by 
C glabrata or C krusei, echinocandins are recommended as primary treatment (24) Other 
patients may receive fluconazole treatment 
• Once the patient is clinically stable, the Candida species is identified and its susceptibility is 
known, echinocandins may be switched to fluconazole or voriconazole and conversion to oral 
therapy should be considered 
• Treatment should be continued for 2 weeks after the last positive blood culture If metastatic 
foci have occurred, treatment duration should be prolonged 
Vulvovaginal candidiasis 
• Successful treatment may be achieved with an oral or topical agent (2, 139), as these are 
equally effective (140) However, most often treatment does not prevent recurrences (1) 
• Repeated treatment might select and induce drug resistance and a shift towards more 
resistant Candida species (141,142) 
Oropharyngeal candidiasis 
• For mild disease topical therapy is recommended, for moderate to severe disease oral 
fluconazole is recommended (24) 
• In HIV-infected patients, chronic suppressive therapy is usually unnecessary The use of 
highly active anti-retroviral therapy (HAART) is recommended to reduce recurrent infections 
(24) 
Mucocutaneous candidiasis 
• Fluconazole should be used as first line treatment m patients with chronic mucocutaneous 
candidiasis or hyper-lgE syndrome and most patients require chronic suppressive antifungal 
therapy (24) This is due to the extensive skin or nail involvement and the many relapses 
often seen in these patients 
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Table 1. Advantages and limitations of Immunotherapeutic approaches. 
Vaccination 
Antibodies 
(Ab) 
Cytokines 
Adoptive 
transfer of 
primed 
immune 
cells 
- Broad 
spectrum 
activity 
- Low risk for 
the 
development of 
resistance 
- Long term 
effects 
- Can be directly 
fungicidal 
independent of 
host immune 
status 
- Very specific 
(e.g. strain 
specific) 
- Rapid effects 
- Could be used 
as monotherapy 
- Experience 
with efficacy 
and safety in 
patients 
- Already on the 
market 
- Rapid effects 
- Opportunity to 
develop 
immune cells 
before 
immunocompro 
mised status 
- Dependent on 
competence of host 
immune status; most 
patients with 
disseminated 
candidiasis are 
immune 
compromised 
- Might also induce 
disease-enhancing Ab 
- Relatively slow 
effects 
- May induce the 
development of anti-
antibodies 
- Potentially toxic 
- Mainly effective as 
adjunctive therapy 
- Might influence the 
pharmacokinetics and 
efficacy of the 
combined antifungal 
drug 
- Inflammation as a 
potential 
consequence 
-Risk for developing 
graft-versus-host 
disease after 
transplantation 
Ribosomal cell fraction 
(D.561) 
Diphtheria toxoid CRM 197 
conjugated with Lam 
Mannan protein conjugates 
Adhesins Alslp and Als3p 
Als3p conjugated with alum 
Live attenuated Candida 
strain CA2 
Recombinant Ab against heat 
shock protein 90 
(Efungumab) 
Anti-mannan Ab 
Anti-ß-glucan Ab 
Idiotypic antibodies (YKT 
neutralizing Ab KT4) 
GM-CSF 
G-CSF 
IFNy 
Adoptive transfer of anti-
Candida Τ cells or pulsed 
dendritic cells 
WC (80) 
WC; disseminated 
candidiasis (81) 
WC; disseminated 
candidiasis (82) 
Oropharyngeal candidiasis 
(84) ; disseminated 
candidiasis (85) 
Disseminated candidiasis 
(Lin, et al., 2009) 
Disseminated candidiasis 
(87) 
Invasive candidiasis (94, 96) 
WC (82); Disseminated 
candidiasis (82,97,143) 
WC (101); disseminated 
candidiasis (81) 
WC (103); disseminated 
candidiasis (102) 
Refractory mucosal 
candidiasis (110, 111, 114); 
disseminated candidiasis 
(112,113,144) 
Disseminated candidiasis 
(121,145,146) 
Oropharyngeal (in HIV) 
candidiasis (134); 
disseminated candidiasis 
(112,132) 
Disseminated candidiasis 
(136,138) 
Ab=antibody; WC=vulvovaginal candidiasis; G(M)-CSF=gronulocyte (macrophage)-colony stimulating factor; 
IFN=interferon; 
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Chapter 19 
Innate pattern recognition of Candida albicans 
The elementary function of the innate immune system is to recognize and eliminate 
pathogenic microorganisms. In Chapter 2, we gave an overview of the recognition of fungal 
pathogens by the innate immune system and proposed a model in which convergence and 
specificity shape the innate immune response. Fungal cell wall components are recognized 
by Toll like receptors (TLRs) and C-type lectin receptors (CLRs). Despite the fact that the 
signaling pathways of these receptors converge into a limited set of adaptor molecules and 
transcription factors, the innate immune response maintains its specificity by different 
mosaics of receptors that are stimulated by certain fungi, and by the complex interactions 
between the various pathways. In the end, this will lead to a tailored immune response to 
the invading microorganism. 
In Chapter 3 we have focused on the role of TLR9 in the host defense against Candida. TLR9 
recognizes unmethylated CpG dinucleotides that are common in microorganisms but not in 
vertebrate DNA (1). Several reports suggested that TLR9 can recognize fungal DNA (2, 3). 
When mice deficient in TLR9 were infected intravenously with Candida albicans, we did not 
observe differences in mortality and fungal growth in the organs compared to control mice. 
Interestingly, the cytokine response of peritoneal macrophages of TLR9 deficient mice 
exposed to Candida albicans differed from that of wild-type macrophages. Human 
peripheral blood mononuclear cells also demonstrated an altered cytokine profile in 
response to Candida albicans when TLR9 was blocked. Most strikingly, we observed that IL-
IO production was reduced in TLR9 deficient cells and TLR9 blocking, indicating that IL-10 
production induced by Candida albicans is at least in part dependent on TLR9. 
The fact that we found no significant difference susceptibility between TLR9 deficient mice 
and control mice does not necessarily imply that TLR9 is not important in anti-Candida host 
defense. This may be explanained by the presence of parallel signaling routes, as has been 
shown in studies with experimental M. tuberculosis and Tryposoma cruzii infections (4, 5). In 
these studies, TLR2 or TLR9 deficient mice were much less susceptible to experimental 
infection than mice deficient in both TLR2 and TLR9. This could also be the case for Candida 
infection, meaning that TLR9 deficiency may lead to a significantly increased susceptibility to 
Candida infection when there are additional immune defects. Since TLR9 in Candida 
infection is important for the anti-inflammatory cytokine IL-10, TLR9 deficiency combined 
with other defects might result in a strong pro-inflammatory condition during Candida 
infection that could be detrimental for the host. More research is needed to address these 
issues. 
TLR1 and TLR6 can form heterodimers with TLR2 and recognize specific molecular patterns. 
TLR2/1 heterodimers recognize bacterial triacyl lipopeptides (6) and TLR2/6 heterodimers 
recognize diacyl lipopeptides and lipoteichoic acid (7). Although the role of TLR2 for the 
recognition of Candida has been studied earlier, nothing is known about TLR1 and/or TLR6 in 
anti-Candida host defense. In Chapter 4 we investigated the role of TLR1 and TLR6 in anti-
Candida host defense. Splenocytes isolated from TLR6 deficient mice with disseminated 
candidiasis showed an increased IFNy production and a decreased IL-10 production in 
response to Candida albicans. In contrast, TLR1 deficiency did not result in a different 
cytokine profile. Although we observed a role for TLR6 in controlling the balance between 
Thl and Th2 balance during fungal infection, it was redundant during disseminated 
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candidiasis in mice. Furthermore, TLRl deficient mice were equally susceptible to 
disseminated candidiasis. However, because differences between murine and human TLRs 
are known to be present (8), our findings do not yet completely exclude a role of TLRl or 
TLR6 in innate immunity to Candida infections in humans. Notably, a recent study suggested 
an association between the susceptibility to invasive aspergillosis and TLR6 and TLRl 
polymorphisms (9). The potential role of TLRl and TLR6 is currently being investigated in a 
large cohort of patients with invasive candidiasis. 
The role of the inflammasome for the host defense against Candida albicans 
Stimulation and release of pro-inflammatory cytokines is an essential step for the activation 
of an effective innate host defense, and subsequently for the modulation of adaptive 
immune responses. Interleukin-lß (IL-lß) and IL-18 are important pro-inflammatory 
cytokines that play a critical role in fungal infection (10, 11). On the one hand they activate 
monocytes, macrophages, and neutrophils, and on the other hand they induce adaptive 
cellular responses. IL-lß and IL-18 are secreted as inactive precursors, and the processing of 
pro-IL-lß and pro-IL-18 depends on cleavage by proteases. One of the most important 
enzymes that cleaves these cytokines is the serine protease caspase-1, which in turn is 
activated by several protein platforms called the inflammasomes (12). 
In Chapter 5 we demonstrate the dichotomy in the capacity of cells of the mononuclear 
phagocyte lineage to release active IL-lß (Figure 1). Monocytes possess a constitutively 
activated caspase-1. Therefore, a single stimulatory event with a TLR ligand will lead to the 
release of active IL-lß. By contrast, macrophages need two distinct signals: one signal that 
induces transcription and translation, and a second signal that activates caspase-1. These 
two signals will finally result in IL-lß processing and secretion. The demonstration that 
monocytes have a constitutive activation of caspase-1, uncouples the necessity for human 
primary monocytes to activate caspase-1 by pathogen-associated molecular pattern 
recognition. This likely represents an adaptation of the monocyte and the macrophage to 
their respective environment. Circulating monocytes function in the surveillance of an 
essentially pathogen-free environment, i.e., the bloodstream, so they must respond 
promptly to any danger signal. Macrophages are confined to an environment (e.g. alveolar 
space, mucosal surfaces) in which they are constantly exposed to microbial stimuli and 
danger signals. A sensitive response to release IL-lß for each encounter with such stimuli 
would result in chronic deleterious inflammatory reactions. This can be prevented by the 
requirement of a second signal for the activation of the inflammasome and release of active 
IL-lß. Such a second signal would be available at sites of infection, trauma or necrosis, sites 
where ATP levels are elevated and trigger the P2X7 receptor. 
The pathways that are important for IL-lß production induced by Candida albicans were 
investigated in Chapter 6. We demonstrate that the mannose receptor pathway and the 
TLR2/dectin-l pathway, but not TLR4 or TLR9 are necessary for the induction of IL-lß 
production in response to Candida albicans. In our investigations into the role of the 
inflammasome, we confirmed that caspase-1 was crucial for IL-lß production in monocytes. 
But surprisingly, the enzyme was constitutively activated in monocytes. Next, we explored 
whether NLRs (Ipaf and Nlrp3) are important for IL-lß production induced by Candida 
albicans. We found no difference in IL-lß production between macrophages deficient in 
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either Nlrp3 or Ipaf when they were exposed to Candida albicans. Thus these data cast 
doubt on the role of the pathogen-mediated inflammasome activation in Candida infection. 
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Figure 1. Differential IL-Iß secretion pathways In monocytes and macrophages. 
Caspase-l is constitutively active in monocytes, and these cells release mature IL-Iß after single stimulation 
with a TLR ligand. In contrast, macrophages need two signals: one signal such as a TLR-ligand that induces 
transcription, and a second signal that induces Inflammasome activation, IL-Iß processing and secretion. 
Shortly after the data in Chapter 6 were published, additional studies appeared in the 
literature that suggested a protective role of the Nlrp3 inflammasome in Candida infection 
(13-16). These studies reported that Nlrp3 was essential for host defense against Candida. In 
Chapter 7 we addressed the role of Nlrp3 in a murine model of disseminated candidiasis. In 
contrast to the studies mentioned (13-16), we found no role for Nlrp3 in disseminated 
candidiasis. Notably, our observation that Nlrp3 is not essential during disseminated 
candidiasis underscores the argument that IL-Iß processing during disseminated Candida 
infection does not require pathogen-mediated inflammasome activation. It is of course 
possible that the use of Nlrp3 deficient mice generated in different institutes, and infection 
with different Candida strains could explain the contradictory observations found in our 
study and that of other studies. The discrepancy between these studies is not well 
understood and merits further investigation. 
In Chapter 8 we studied the inflammasome components ASC, caspase-l and P2X7 (the ATP 
receptor) in mice with disseminated candidiasis. Caspase-l and ASC, but not P2X7, were 
essential for anti-Cond/cto host defense. Mice with disseminated candidiasis that were 
deficient in caspase-l or ASC showed a reduced survival rate and higher fungal loads in the 
kidneys than infected control mice. Interestingly, we observed that caspase-l and ASC were 
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essential for protective Thl and Thl7 responses, which implies a novel role for the 
inflammasome. These results indicate that the innate immune system controls an important 
aspect of adaptive immunity by controlling the pro-inflammatory cytokines IL-lß and IL-18. 
The vaccine adjuvant alum activates the inflammasome and thereby caspase-1. Interestingly 
it was recently shown that vaccination with Als3p (a Candida antigen) together with alum as 
a vaccine adjuvant, induced protective adaptive immunity in mice with disseminated 
candidiasis through the induction of Thl and Thl7 responses (17). It is tempting to speculate 
that alum induces or boosts such protective Thl and Thl7 responses through the activation 
of caspase-1. The way of how alum is able to shape the antigen- induced adaptive immune 
response is currently under investigation. 
We observed an unexpected role for ASC in disseminated candidiasis. The kidneys of ASC-
deficient mice infected with Candida albicans displayed large numbers of infiltrating 
neutrophils, and this was neither observed in the other knockout mice nor in control mice. In 
addition, ASC-deficient splenocytes produced large amounts of TNF in response to Candida 
albicans. These findings suggest an important role for ASC in the control of TNF-mediated 
inflammation; apparently ASC also acts in an inflammasome-independent manner during 
infection, and this definitely needs further investigation. 
Thl7 and antifungal host defense 
The Thl7 lymphocyte subset is characterized by the production of IL-17 and thereby leads 
to the recruitment of neutrophils (18). The discovery of this subset has provided new 
insights into the pathogenesis of autoimmune diseases and host defense against infections. 
In Chapter 9 we describe the delicate balance between the protective and potentially 
harmful effects of Thl7 responses in infection. On the one hand, Thl7 cells provide 
protective host defense against bacterial and fungal infections by inducing production of 
defensins and recruitment of neutrophils to the site of infection. On the other hand, Thl7 
responses seem to contribute to viral persistence in viral infection and may be detrimental 
for the host in the chronic inflammation of parasitic infection. These insights need to be 
taken into account if one considers to exploit the Thl7 responses in immunomodulatory 
therapy. 
Chapter 10 describes the main pathways for the Thl7 response induced by Candida. We 
discovered that Candida albicans evokes a robust IL-17 response in human peripheral blood 
mononuclear cells and could demonstrate that interaction between the mannoproteins on 
the surface of Candida albicans and the mannose receptor on monocytes/macrophages is 
essential for the induction of IL-17. Stimulation of the TLR2/dectin-l pathway by itself does 
not lead to induction of IL-17. However, the TLR2 and dectin-1 pathways do have the 
capacity to amplify IL-17 production induced by the mannose receptor. These findings are in 
line with the results presented in Chapter 6, where we we demonstrate that the mannose 
receptor and TLR2/dectin-l pathways are needed for IL-lß production induced by Candida 
albicans. IL-lß in turn is required for the Thl7 response in humans. This study underscores 
the dominant role of saccharides (such as mannoproteins and glucans) and C-type lectins in 
initiating Thl7-mediated host defense and inflammation. To pull this further, we tend to 
hypothesize that the protein parts of the mannoproteins of Candida albicans are processed 
and presented at the surface of the antigen-presenting cells and subsequently trigger the Τ 
cell receptor and activate the Τ cell, while the mannan parts are responsible for inducing a 
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cytokine profile that polarizes the immune response towards a Thl7 response. We are 
currently investigating this hypothesis. 
Prostaglandin E2 (PGE2) contributes to Thl7 responses in experimental models of 
autoimmune disease (19). Since we found a robust IL-17 production in human cells exposed 
to Candida albicans, we explored the contribution of PGE2 to the Thl7 response induced by 
Candida (Chapter 11). The addition of a non-steroidal anti-inflammatory drug (NSAID) 
completely blocked PGE2 production and resulted in decreased IL-17 production when cells 
were stimulated with Candida albicans. Mannoproteins of Candida albicans and the 
mannose receptor appeared to have a prominent role in the production of PGE2. In addition, 
TLR2 synergizes with dectin-1 in the production of PGE2. Notably, IL-lß is not affected by 
blocking PGE2 and is probably responsible for the observed residual IL-17 production in the 
absence of PGE2. It is tempting to speculate that the use of an NSAID can reduce Thl7 
responses in patients, and in this way may ameliorate detrimental inflammation. This may 
be one explanation for the beneficial effects of NSAIDs in a chronic inflammatory disease 
such as rheumatoid arthritis. 
It has been suggested that the IL-17 response may be deleterious in fungal infection as it 
leads to an overwhelming neutrophil-mediated inflammation (20). Evidence for this was 
derived from experimental candidiasis and aspergillosis in animals (21). In other animal 
studies of mucosal and disseminated candidiasis a clear protective role of IL-17 responses 
was seen(22, 23). In Chapter 12, we addressed this controversy, and investigated the role of 
IL-17 in two different mouse models, namely one of invasive candidiasis and another of 
zymosan-mediated multi-organ failure. We observed that IL-17 receptor knockout animals 
were more susceptible to disseminated candidiasis than control mice and had equal survival 
rates to control mice in zymosan-induced multi-organ failure. These findings demonstrate 
that IL-17 does not contribute greatly to the inflammatory process that leads to organ failure 
in fungal sepsis, and support the concept that the IL-17 pathway is protective in antifungal 
host defense. 
In Chapter 13 we assessed the role of Thl7 responses in host defense against Aspergillus. In 
contrast to the high IL-17 production seen with human peripheral blood mononuclear cells 
stimulated with Candida albicans, we did not observe any IL-17 production when human 
cells were exposed to Aspergillus fumigatus. Furthermore, we found very low IL-17 
concentrations in the bronchoalveolar lavage fluid and serum of patients with invasive 
aspergillosis. This is in sharp contrast with the data obtained from the experimental 
Aspergillus infection models (20, 21). Interestingly, we observed that Aspergillus is a potent 
inducer of IFNy production, which is the prototypical cytokine of the Thl response. Since 
IFNy is known to suppress Thl7 responses (24), we explored whether the strong Thl 
responses induced by Aspergillus were responsible for the observed low IL-17 production. 
We found no difference in the capacity of Aspergillus to induce IL-17 when we blocked IFNy, 
making it unlikely that the low IL-17 is due to a strong Thl response. It has been suggested 
that the tryptophan metabolite L-kynurenine is able to dampen fungal 4sperg/7/us-induced 
IL-17 production (20). Interestingly, we found that Aspergillus itself is able to convert 
tryptophan into L-kynurenine, and that the supernatant of live Aspergillus has the capacity 
to decrease IL-17 production by mitogen-activated Τ cells. Altogether, it is likely that Thl7 
responses are not a major factor in host defense against Aspergillus infection. This is also in 
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line with the clinical picture of patients with hyper IgE syndrome who completely lack Thl7 
responses, yet they rarely display invasive infections with Aspergillus. 
The inflammasome/Thl7 axis in clinical syndromes 
Patients with chronic granulomatous disease (CGD) have a defect in the NADPH oxidase 
system and as a consequence cannot generate NADPH-dependent reactive oxygen species 
(ROS) (25). Interestingly, NADPH-dependent ROS are reported to be necessary for 
inflammasome activation (26). Therefore, the loss of ROS would theoretically result in 
defective inflammasome activation, decreased caspase-1 activation, less IL-lß processing 
and ultimately decreased IL-lß production. This would be in line with the generally assumed 
pro-inflammatory role of ROS. However, patients with CGD (as well as CGD mice) have a pro-
inflammatory status, which to date is still poorly understood (20, 27). To address the role of 
NADPH-dependent ROS in the activation of the inflammasome, we studied peripheral blood 
mononuclear cells isolated from patients with CGD in Chapter 14. Strikingly, we observed 
that cells isolated from CGD patients produced greater amounts of IL-lß in response to 
stimuli. When the caspase-1 status was assessed, it was found to be more activated in CGD 
cells than in control cells. In contrast to existing idea, these data show that the absence of 
NADPH-dependent ROS results in increased inflammasome activation and would explain 
why patients with CGD have an inflammatory phenotype. 
Β lymphocyte-depleting therapy with rituximab has been unexpectedly beneficial in Τ cell-
mediated autoimmune diseases such as multiple sclerosis (28). The efficacy of rituximab in 
rheumatoid arthritis also raised a lot of questions, since there was no clear effect on the 
presence of autoantibodies and the clinical beneficial effects were observed faster than one 
would expect from the rate of disappearance of antibodies (29). We realized that Thl7 cells 
have been implicated in the pathogenesis of multiple sclerosis and rheumatoid arthritis (30) 
and hypothesized that Β cells are important for the Thl7 response. An answer to this 
hypothesis is provided in Chapter 15. Twelve patients with rheumatoid arthritis were 
treated with rituximab. The treatment resulted in efficient Β cell depletion in vivo and led to 
a statistically clinical improvement in these patients. Before and 12 weeks after treatment 
we obtained synovial biopsies from affected knee joints. We were able to demonstrate that 
the Thl7 response was reduced after treatment with rituximab. Staining of IL-17 in the 
inflamed synovium was significantly decreased after treatment. We next addressed the 
question whether rituximab specifically inhibited the Thl7 response or inhibited all Τ cell 
responses. No effects on Thl or Treg responses were observed. In addition, we found no 
effect of rituximab on TNF responses indicating that the clinical improvement was not due to 
effects on TNF production. To obtain a better understanding of how rituximab inhibits the 
Thl7 response we used the in-vitro model of Candida albicans stimulation. Cells stimulated 
with Candida albicans produced significantly less IL-17 and IL-22 when rituximab was added 
to the culture. We entertained the possibility that rituximab could directly deplete Τ cells, 
since it has been reported that a subset of Τ cells expresses CD20 (31). We observed no 
CD20 expression on Τ cells that also expressed IL-17. Moreover, in cells isolated from 
patients with agammaglobulinemia, who do not have functional Β cells, the inhitory effect of 
rituximab on the Thl7 response was lost, supporting a direct effect of rituximab on Β cells. 
Thus we demonstrated an unexpected role for Β cells in the specific regulation of the Thl7 
response, and this may explain why rituximab works in multiple sclerosis and rheumatoid 
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arthritis. These findings may also have important Implications for the development, 
research, and treatment of Thl7 mediated diseases. 
Patients with hyper IgE syndrome (HIES) are particularly prone to infections with Candida 
albicans and Staphylococcus aureus (32). It is reported that some 60% of patients with HIES 
have mutations in STAT3 and as a consequence have a defective Thl7 response (33). In 
Chapter 16 we describe three patients with HIES from the same family with a STAT3 
mutation in the linker domain; interestingly these patients are phenotypically different from 
sporadic HIES patients. The most striking feature is that they are not highly susceptible to S. 
aureus pneumonia, which is a common feature in patients with HIES (34). We found that 
cells isolated from the patients of the HIES family had residual IL-17 production upon 
stimulation with S. aureus, which is in contrast with the absolute defect of IL-17 production 
in the sporadic HIES patients that were reported previously (33). These data suggest that the 
IL-17 response is particularly critical for host defense against 5. aureus at the level of the 
lung epithelium. In addition, all HIES patients with mucocutaneous candidiasis had defective 
IL-17 production in response to Candida albicans, underscoring the important role for Thl7 
cells in host defense against mucosal candidiasis. These HIES patients also suggest that 
different STAT3 mutations result in clinically variant phenotypes of HIES. Moreover, the 
mutation in the linker domain of STAT3, which has not been described before, resulted in 
normal intracellular levels of IL-17 after mitogenic stimulation demonstrated by FACS 
analysis, but ultimately lower IL-17 concentrations in the supernatants when cells were 
exposed to relevant microbial stimuli. These data underscore a direct relationship between 
the degree of the defect in the Thl7 response and the severity of the clinical picture in 
patients with hyper IgE syndrome. 
In Chapter 17, we demonstrate that autosomal dominant chronic mucocutaneous 
candidiasis (AD-CMC) is due to mutations in the CC domain of the STATI gene. We had 
found that CMC patients have a deficient production of Thl and Thl7 cytokines in response 
to Candida, and the IL-12 and IL-23 pathway are both functionally compromised in cells 
isolated from patients with CMC. With next-generation sequencing we analyzed genes that 
coded for the molecules shared by the IL-12 and IL-23 pathway and genes involved in the 
differentiation of the Thl7 response. Interestingly, all patients from 5 AD-CMC families from 
the Netherlands and the United Kingdom were positive for a mutation in the CC domain of 
STATI, whereas no mutations have been found in unaffected siblings and 162 healthy 
controls. Three families carried the A267V mutation (one Dutch and two UK families), and 
two families carried the R274W mutation (one Dutch and one from the UK). Interestingly, in 
the three families with A267V mutation, several patients with CMC also suffered from 
oral/oesophagal carcinoma indicating a role for STATI in the pathogenesis of 
oral/oesophagal carcinoma. This is in line with previous reports linking STATI deficiency to 
oesophageal carcinoma. Furthermore, the two families with the R274W mutation included 
CMC patients that also had autoimmune phenomena, such as autoimmune hepatitis and 
autoimmune haemolytic anemia. The role of STATI in the pathogenesis of oral and 
oesophageal cancer and autoimmune diseases merits further investigation. This study shows 
the power of next generation sequencing technologies combined with well-designed and 
robust functional assays to elucidate the pathogenesis of hereditary diseases. 
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It is unlikely that the current treatment options will significantly reduce the morbidity of 
mucosal Candida infection and the high mortality associated with disseminated candidiasis. 
This underscores the need to develop new treatment strategies in the fight against Candida 
infection. Chapter 18 discusses the present knowledge that has contributed to approaching 
alternatives such as vaccination, antibodies, cytokine therapy or adoptive transfer of primed 
immune cells, which all are promising, but yet have to be demonstrated to be safe and 
effective. It also points out that it is necessary to address controversies such as the role of 
the Thl7 response in antifungal host defense, since it is essential to know whether 
augmentation or inhibition of the Thl7 response would be more likely to be beneficial in 
patients with fungal infection. 
General conclusions 
By understanding the failing defense mechanisms that underlie the occurrence of a specific 
Candida infection, we are on the edge of developing immunotherapeutic strategies that will 
support standard treatment regiments in patients with candidiasis. The experiments 
performed in this thesis aim to contribute to the large and dynamic field of research in 
immunology that brought us where we are today. Many challenges lie ahead: understanding 
the molecular mechanisms by which mutations in the CC domain of STATI lead to Thl and 
Thl7 deficiency in autosomal dominant chronic mucocutaneous candidiasis or the reasons 
why patients with chronic granulomatous disease are especially susceptible to Aspergillus 
infection. These are but a few examples that will finally contribute to the understanding of 
antifungal host defense. Moreover, the role of the immune system stretches out far beyond 
host defense against infection into virtually every area of the medical sciences. By combining 
the knowledge of the different areas of research, we will move forward in our appreciation 
and understanding of the full magnitude of the importance of the immune system and its 
unknown functions. This will help us in the development of strategies that can modulate the 
immune response during health and disease in such a way that it will be valuable for a better 
prevention and treatment of infections in general, and fungal infections in particular. 
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Aangeboren afweer tegen Candida albicans 
Een elementaire functie van het aangeboren afweersysteem is het herkennen van 
ziekteverwekkende micro-organismen opdat ze vervolgens geëlimineerd kunnen worden. In 
hoofdstuk 2 geven we daarom een overzicht over hoe schimmels worden herkend door het 
aangeboren afweersysteem en beschrijven we een model dat verklaart hoe het aangeboren 
afweersysteem specifiek op een ziekteverwekker kan reageren. De celwand componenten 
van schimmels worden herkend door Toll-like receptoren (TLR's) en C-type lectine 
receptoren (CLR's). Ondanks het feit dat de signaalwegen van deze receptoren convergeren 
tot een beperkt aantal adapter moleculen en transcriptiefactoren, kan het aangeboren 
afweersysteem zijn specificiteit behouden doordat meerdere signaalwegen tegelijkertijd 
kunnen worden gestimuleerd en er complexe interacties zijn tussen deze verschillende 
signaalroutes. Uiteindelijk zal dit leiden tot een op maat gesneden afweerreactie gericht 
tegen het binnendringende micro-organisme. 
In hoofdstuk 3 hebben we de rol van TLR9 bij de herkenning van en de afweer tegen de 
schimmel Candida onderzocht. TLR9 herkent ongemethyleerde CpG dinucleotiden die 
voorkomen in DNA van micro-organismen, maar niet in de mens (1). Verschillende studies 
hebben gesuggereerd dat TLR9 het DNA van schimmels kan herkennen (2, 3). Om de rol van 
TLR9 in systemische Candida infecties te bestuderen hebben we TLR9 deficiënte muizen 
intraveneus geïnfecteerd met C. albicans. We zagen geen verschil in de vatbaarheid voor 
Candida infectie in TLR9 deficiënte muizen ten opzichte van de controle groep. Echter, de 
cytokine reactie van TLR9 deficiënte macrofagen die werden blootgesteld aan C. albicans 
verschilde wel van die van controle macrofagen. Humane perifere bloed mononucléaire 
cellen vertoonde ook een afwijkend cytokine profiel als ze gestimuleerd werden met C. 
albicans in de aanwezigheid van een TLR9 blokker. Het meest opvallende was dat de 
interleukine (IL)-IO productie was verminderd in TLR9 deficiënte cellen en in de humane 
cellen waarbij TLR9 was geblokkeerd. Dit geeft aan dat de IL-10 productie geïnduceerd door 
C. albicans ten minste gedeeltelijk afhankelijk is van TLR9. 
Het feit dat we geen significant verschil vonden in de gevoeligheid tussen TLR9 deficiënte 
muizen en controle muizen betekent niet noodzakelijkerwijs dat TLR9 niet belangrijk is voor 
een optimale afweerreactie tegen C. albicans. Dit kan worden verklaard door observaties die 
zijn beschreven in studies met experimentele Mycobacterium tuberculosis en Tryposoma 
cruzii infecties (4, 5). In deze studies waren TLR2 of TLR9 deficiënte muizen veel minder 
gevoelig voor een experimentele infectie dan muizen die deficiënt waren voor zowel TLR2 en 
TLR9. Dit zou ook kunnen gelden voor systemische Candida infecties, wat betekent dat een 
TLR9 tekort kan leiden tot een verhoogde gevoeligheid voor systemische Candida infecties 
mits er ook nog andere immunologische defecten bestaan. Omdat TLR9 belangrijk is voor de 
productie van het anti-inflammatoire cytokine IL-10, kan TLR9 deficiëntie, in combinatie met 
andere afwijkingen, leiden tot een sterke pro-inflammatoire reactie tijdens een systemische 
Candida infectie die uiteindelijk nadelig kan zijn voor de gastheer. Meer onderzoek is nodig 
om deze observaties verder te bestuderen. 
TLR1 en TLR6 kunnen heterodimeren vormen met TLR2. Deze heterodimeren herkennen 
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specifieke moleculaire patronen. TLR2/1 heterodimeren herkennen bacteriële triacyl 
lipopeptiden (6) en TLR2/6 heterodimeren herkennen diacyl lipopeptiden en 
lipoteichoïnezuur (7). De rol van TLR2 in de herkenning van Candida is al eerder onderzocht, 
echter er is niets bekend over de functies van TLR1 en/of TLR6 in de afweerreactie tegen 
Candida. In hoofdstuk 4 beschrijven we de rol van TLR1 en TLR6 in invasieve candidiasis. 
Miltcellen van TLR6 deficiënte muizen met een systemische Candida infectie vertoonden een 
toegenomen IFNy productie en een verminderde productie van IL-10 wanneer ze 
gestimuleerd werden met C. albicans. Miltcellen met een TLR1 deficiëntie vertoonden geen 
veranderd cytokine profiel na stimulatie met C. albicans. Alhoewel we vonden dat TLR6 een 
rol speelde in de beheersing van het evenwicht tussen Thl en Th2 reacties, bleek TLR6 
overbodig te zijn voor het herstel van muizen met een systemische Candida infectie. TLR1 
deficiënte muizen waren ook even vatbaar voor systemische candidiasis als controle muizen. 
Omdat er verschillen tussen muis en mens beschreven zijn met betrekking tot TLR functie in 
vivo (8), sluiten onze bevindingen niet uit dat TLR1 en TLR6 toch een belangrijke rol kunnen 
spelen in de aangeboren immuniteit gericht tegen Candida bij de mens. Een recente studie 
suggereerde een verband tussen de gevoeligheid voor invasieve aspergillose en TLR6 en 
TLR1 polymorfismen (9). De potentiële rol van TLR1 en TLR6 polymorfismen wordt 
momenteel onderzocht in een groot cohort van patiënten met invasieve candidiasis. 
De rol van het inflammasoom in de afweer tegen Candida albicans 
Pro-inflammatoire cytokinen spelen een belangrijke rol in de activering van de aangeboren 
afweerreactie, en zorgen tevens voor de modulatie van de verworven immuniteit. 
Interleukine-lß (IL-lß) en IL-18 zijn belangrijke pro-inflammatoire cytokinen voor de afweer 
tegen schimmelinfecties (10, 11). Enerzijds activeren ze monocyten, macrofagen, en 
neutrofielen, en anderzijds induceren ze een beschermende verworven cellulaire respons. 
IL-lß en IL-18 worden in eerste instantie geproduceerd als inactieve precursor pro-IL-lß en 
pro-IL-18. Om actief te kunnen worden, moeten deze percursor moleculen eerst "geknipt" 
worden. Deze splitsing van pro-IL-lß en pro-IL-18 is afhankelijk van Proteasen. Een van de 
belangrijkste enzymen die deze percursors splitst is het serine protease caspase-1, dat op 
zijn beurt weer geactiveerd wordt door een platvorm van eiwitten die tezamen het 
inflammasoom worden genoemd (12). 
In hoofdstuk 5 beschrijven we het verschil tussen monocyten en macrofagen met betrekking 
tot de activering van het inflammasoom en IL-lß productie (Figuur 1). Monocyten hebben 
een constitutief geactiveerd caspase-1. Daardoor kan een stimulatie met een enkelvoudig 
TLR ligand direct leiden tot het vrijkomen van actief IL-lß. Macrofagen hebben twee 
verschillende signalen nodig om actief IL-lß te produceren: een signaal dat de transcriptie 
van IL-lß induceert, en een tweede signaal (exogeen) dat leidt tot caspase-1 activering. 
Omdat monocyten een constitutief geactiveerd caspase-1 hebben, is in deze cellen 
activering van caspase-1 door exogene gevaar signalen niet nodig. Dit verschil tussen 
monocyten en macrofagen is te beschouwen als een vorm van aanpassing van deze cellen 
aan hun omgeving. Circulerende monocyten bevinden zich in de bloedbaan en bewaken zo 
een omgeving die in wezen vrij is van ziekteverwekkers. Monocyten moeten dus snel 
kunnen reageren op elk signaal van gevaar. Macrofagen komen in weefsel voor 
(bijvoorbeeld alveoli in de long, slijmvlies van het gastro-intestinale systeem) waar ze 
voortdurend worden blootgesteld aan microbiële stimuli en gevaar signalen. Als een 
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enkelvoudige prikkel in deze situatie direct zou leiden tot de productie van actief IL-lß zou 
dit kunnen resulteren in een schadelijke chronische ontstekingsreactie. De noodzaak van een 
tweede signaal om uiteindelijk actief IL-lß te kunnen produceren, is aldus een logisch 
veiligheidsmechanisme om chronische inflammatie te voorkomen. 
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Figuur 1. Inflammasoom activatle in monocyten en macrofagen. 
Caspase-1 is constitutief actief in monocyten, en actief IL-lß kan direct na een enkelvoudige stimulatie met een 
TLR ligand geproduceerd worden. Macrofagen hebben echter twee signalen nodig: een eerste signaal, zoals 
een TLR ligand dat de transcriptie van IL-lß induceert, en een tweede signaal dat leidt tot de activering van het 
inflammasoom en vervolgens IL-lß productie. 
Het onderzoek in hoofdstuk 6 beschrijft de routes die betrokken zijn bij de IL-lß productie 
die door C. albicans geïnduceerd wordt. We hebben aangetoond dat de mannose-receptor 
en de TLR2/dectln-l route, maar niet de TLR4 of TLR9 route, nodig zijn voor de inductie van 
IL-lß productie. Caspase-1 was belangrijk voor de IL-lß productie door monocyten en we 
vonden tevens dat caspase-1 constitutief geactiveerd was in monocyten. Vervolgens hebben 
we onderzocht of de Nod like receptoren (NLR's) (IPAF en NLRP3) van belang waren voor de 
IL-lß productie die wordt veroorzaakt door C albicans. We vonden geen verschil in IL-lß 
productie in macrofagen die deficiënt waren voor NLRP3 of IPAF als ze werden blootgesteld 
aan C. albicans. Deze gegevens werpen een nieuw licht op de rol van het inflammasoom 
tijdens infecties. 
Kort nadat de gegevens in hoofdstuk 6 werden gepubliceerd, verschenen er in de literatuur 
aanvullende studies die een beschermende rol van het NLRP3 inflammasoom in de afweer 
tegen C. albicans rapporteerden (13-16). Deze studies vonden dat NLRP3 essentieel was voor 
de afweer tegen experimentele Candida infectie in muizen. In hoofdstuk 7 hebben wij de rol 
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van NLRP3 daarom nader bestudeerd in een muismodel van systemische candidiasis. In 
tegenstelling tot de andere studies (13-16), vonden wij dat NLRP3 géén belangrijke rol had 
bij candidiasis. Dit ondersteunt het argument dat IL-lß tijdens systemische infecties niet 
geheel afhankelijk is van pathogeen geïnduceerde inflammasoom activering. Het is natuurlijk 
mogelijk dat deze tegenstrijdige waarnemingen verklaard kunnen worden door gebruik van 
NLRP3 deficiente muizen afkomstig van verschillende instituten, of door infecties met 
verschillende Candida stammen. Echter, de discrepantie tussen onze waarnemingen en de 
andere studies is niet goed opgehelderd en behoeft nader onderzoek. 
In hoofdstuk 8 onderzochten we hoe belangrijk de inflammasoom componenten ASC, 
caspase-1 en P2X7 (de ATP-receptor) zijn in de afweer tegen systemische Candida infecties. 
Caspase-1 en ASC, maar niet P2X7, waren essentieel voor een goede afweer tegen 
systemische candidiasis. Muizen die deficient waren in caspase-1 of ASC vertoonden een 
verhoogde vatbaarheid voor een systemische Candida infectie. We vonden dat caspase-1 en 
ASC belangrijk waren voor een beschermende reactie van het verworven afweersysteem 
door Thl en Thl7 cellen. Deze resultaten laten zien dat het aangeboren afweersysteem ook 
een belangrijke rol speelt in het moduleren van het verworven afweersysteem door middel 
van de regulatie van IL-lß en IL-18. 
Het vaccin adjuvant alum activeert het inflammasoom en dus caspase-1. Recentelijk is 
aangetoond dat vaccinatie met Als3p (een Cond/cfa-antigeen) samen met alum, 
beschermend werkt in muizen met een systemische Candida infectie. Deze beschermende 
afweerreactie was afhankelijk van een vaccin geïnduceerde Thl en Thl7 reactie (17). Het is 
verleidelijk om te speculeren dat alum deze beschermende Thl en Thl7 reacties induceert 
door caspase-1 te activeren. Het mechanisme hoe alum een verworven afweerreactie kan 
beïnvloeden wordt momenteel onderzocht. 
We vonden een onverwachte functie van ASC in muizen met een systemische candidiasis. De 
nieren van ASC deficiente muizen die geïnfecteerd waren met Candida vertoonden grote 
Infiltraten die bestonden uit neutrofielen. Dit werd niet waargenomen in de NALP3 en 
caspase-1 deficiënte muizen, noch in controle muizen. ASC deficiènte miltcellen 
produceerden bovendien grote hoeveelheden TNFa na stimulatie met C. albicans. Deze 
bevindingen suggereren dat ASC een belangrijke rol speelt in in de regulatie van TNFa 
afhankelijke ontstekingsreacties. Blijkbaar heeft ASC ook een inflammasoom onafhankelijke 
functie tijdens infectie en dit verdient zeker verder onderzoek. 
Thl7 en anti-schimmel afweer 
Thl7 lymfocyten worden gekenmerkt door de productie van IL-17 (18). De ontdekking van 
deze subgroep van Τ helper cellen heeft nieuwe inzichten gegeven in de Pathogenese van 
vele auto-immuunziekten en heeft bijgedragen aan een beter begrip van de afweer tegen 
bacteriele infecties en schimmelinfecties. In hoofdstuk 9 beschrijven we het delicate 
evenwicht tussen de beschermende en potentieel schadelijke effecten van Thl7 reacties 
tijdens een infectie. Aan de ene kant hebben Thl7 cellen een belangrijke rol in de afweer 
tegen bacteriele en schimmelinfecties door het induceren van defensines en de werving van 
neutrofielen naar de plaats van infectie. Aan de andere kant kunnen Thl7 cellen bijdragen 
aan het persisteren van virus infecties en kunnen ze schadelijk zijn voor de gastheer door het 
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in stand houden van chronische ontstekingen bij parasitaire infecties. Met deze inzichten 
moet rekening worden gehouden als men immunomodulatoire behandelingen wil 
ontwikkelen. 
Hoofdstuk 10 beschrijft de belangrijkste signaalroutes die betrokken zijn bij de Thl7 reactie 
die optreedt wanneer humane mononucléaire cellen gestimuleerd worden met C. albicans. 
We hebben ontdekt dat C. albicans een zeer uitgesproken IL-17 productie induceert. Dit 
blijkt te berusten op een interactie tussen de mannoproteïnen die zich bevinden op het 
celoppervlak van Candida albicans en de mannose receptor die zich bevindt op de 
celmembraan van de monocyt/macrofaag. Stimulatie van de TLR2/dectin-l route leidt op 
zichzelf niet tot de inductie van IL-17, echter de TLR2 en dectin-1 signaalroutes hebben wel 
het vermogen om de IL-17 productie door stimulatie van de mannose receptor te 
versterken. Deze bevindingen zijn in overeenstemming met de resultaten die zijn 
gepresenteerd in hoofdstuk 6, waar we aantonen we dat de mannose receptor en 
TLR2/dectin-l nodig zijn voor IL-lß productie; IL-lß is namelijk erg belangrijk voor het 
induceren van een Thl7 reactie. Deze studie onderstreept de dominante rol die suikers 
(zoals mannose structuren en glucanen) en de Calcium-afhankelijke suikerherkennende 
moleculen, de C-type lectines, spelen in het initiëren van Thl7 afweerreacties. We hebben 
een model voorgesteld waarin de eiwitstructuren van de mannoproteïnen van C. albicans 
belangrijk zijn voor Τ helper cel activering en de mannose structuren verantwoordelijk zijn 
voor het induceren van een cytokine profiel dat de Τ helper cel polariseert richting Thl7. We 
zijn deze hypothese momenteel aan het onderzoeken. 
Prostaglandine E2 (PGE2) speelt een belangrijke rol in de initiatie van Thl7 reacties in 
experimentele modellen van auto-immuunziekten (19). Omdat we een robuuste IL-17 
productie vonden in menselijke cellen die werden blootgesteld aan C. albicans, 
onderzochten we de rol van PGE2 in de Thl7 reactie die geïnduceerd wordt door Candida 
(hoofdstuk 11). De toevoeging van een niet-steroïdale anti-inflammatoire geneesmiddel 
(NSAID) blokkeerde de PGE2 productie volledig en resulteerde in een afname van IL-17 
productie door cellen die gestimuleerd werden met C. albicans. Mannoproteïnen van C. 
albicans en de mannose-receptor bleken een prominente rol te spelen in de productie van 
PGE2. Daarnaast versterkten de TLR2 en dectin-1 signaalroutes de productie van PGE2. 
Interessant genoeg werd IL-lß niet beïnvloed door het blokkeren van PGE2. Dit is 
waarschijnlijk de verklaring voor de resterende IL-17 productie na blokkade van PGE2. Deze 
observaties geven aan dat het gebruik van een NSAID Thl7 reacties zou kunnen 
verminderen in patiënten. Dit zou de reden kunnen zijn waarom NSAID's gunstige effecten 
hebben in chronische ontstekingsziekten, zoals reumatoïde arthritis. 
Er is gesuggereerd dat de IL-17 respons onwenselijk is tijdens schimmelinfecties, omdat het 
bijdraagt aan een ontstekingreactie die schadelijk is voor de gastheer (20). Deze suggestie is 
afgeleid van onderzoek dat is verricht in muizen met experimentele candidiasis en invasieve 
aspergillose (21). In andere dierstudies die experimentele Candida infecties hebben 
bestudeerd, heeft de Thl7 reactie duidelijk een beschermende functie (22, 23). In hoofdstuk 
12 hebben we geprobeerd deze controverse te onderzoeken door Thl7 reacties te 
bestuderen in twee verschillende muismodellen, namelijk invasieve candidiasis en zymosan-
gemedieerd multi-orgaanfalen. We zagen dat IL-17 receptor deficiënte (IL-17R-/-) dieren 
meer vatbaar waren voor systemische candidiasis dan controle muizen. Echter, IL-17R-/-
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muizen hadden gelijke overlevingskansen in het model van zymosan-gemduceerd multi-
orgaanfalen vergeleken met controle muizen Deze bevindingen tonen aan dat IL-17 met in 
grote mate bijdraagt aan schadelijke ontstekingsprocessen die leiden tot orgaanfalen tijdens 
mvasieve schimmelinfecties, maar ondersteunen juist het concept dat de IL-17 signaalroute 
beschermend is tijdens schimmelinfecties 
In hoofdstuk 13 hebben we de rol van de Th 17 reactie in de afweer tegen Aspergillus 
fumigatus onderzocht In tegenstelling tot de hoge IL-17 productie die wordt geïnduceerd 
door C albicans, vonden we een relatief lage IL-17 productie door humane mononucléaire 
cellen die werden blootgesteld aan Aspergillus fumigatus Bovendien vonden we zeer lage 
IL-17 concentraties in de bronchoalveolaire lavage vloeistof en serum van patiënten met 
mvasieve aspergillose. Dit staat in schril contrast met de gegevens die zijn verkregen uit 
experimentele Aspergillus infectie modellen (20, 21) Verder vonden WIJ dat Aspergillus een 
zeer krachtige interferon (IFN)y respons teweegbrengt m humane cellen ΙΡΝγ is het 
prototypische cytokine van een Thl respons Omdat het bekend is dat IFNy Thl7 reacties 
onderdrukt (24), hebben we onderzocht of de sterke Thl reactie verantwoordelijk was voor 
de lage IL-17 productie We vonden geen verschil in het vermogen van Aspergillus om IL-17 
te induceren wanneer we IFNy blokkeerden Deze observatie maakt het onwaarschijnlijk dat 
de lage IL-17 productie door Aspergillus te wijten is aan een sterke Thl respons Er is 
gesuggereerd dat L-kynurenme (een tryptofaan metaboliet) in staat is om Aspergillus 
geïnduceerde IL-17 productie te dempen (20) We hebben gevonden dat Aspergillus zelf in 
staat is om tryptofaan om te zetten in L-kynurenme, en dat het supernatant van levende 
Aspergillus de capaciteit heeft om de IL-17 productie van mitogeen geactiveerde T-cellen te 
verminderen Concluderend is het zeer waarschijnlijk dat Thl7 reacties met cruciaal zijn voor 
een optimale afweer tegen Aspergillus infecties Dit is ook in overeenstemming met het 
klinisch beeld van patiënten met het hyper-lgE syndroom Deze patiënten kunnen helemaal 
geen Thl7 reacties induceren, maar krijgen zelden mvasieve infecties met Aspergillus 
Het inflammasoom en Th 17 reacties in klinische syndromen 
Patienten met chronische granulomateuze ziekte (CGD) hebben een defect m het NADPH 
oxidase systeem en als gevolg daarvan kunnen ze geen zuurstof radicalen (reactive oxygen 
species, ROS) produceren (25) Het is beschreven dat NADPH afhankelijke ROS essentieel zijn 
voor de activering van het inflammasoom (26) Dit zou m overeenstemming zijn met de 
algemeen geaccepteerde gedachte dat ROS met name pro-mflammatoir zijn Echter, 
patiënten met CGD (evenals CGD muizen) hebben een pro-mflammatoire status, wat tot op 
heden nog steeds met goed is verklaard (20, 27) In hoofdstuk 14 hebben we de rol van 
NADPH afhankelijke ROS in de activering van het inflammasoom bestudeerd door cellen te 
isoleren van patiënten met CGD We vonden dat de CGD cellen grotere hoeveelheden IL-lß 
produceerden na stimulatie Tevens bleek caspase-1 meer geactiveerd te zijn in CGD cellen 
dan m controle cellen In tegenstelling tot het dogma dat ROS pro-mflammatoir zijn en 
essentieel zijn voor de activering van het inflammasoom, blijkt uit onze gegevens dat ROS 
deficiëntie uiteindelijk resulteert m een actiever inflammasoom en meer IL-lß productie Dit 
zou kunnen verklaren waarom patiënten met CGD een pro-mflammatoir fenotype hebben 
CD20 is een molecuul dat voorkomt op alle B-cellen Rituximab is een geneesmidel dat bindt 
aan CD20 waardoor B-cellen worden geëlimineerd Ziektes die worden veroorzaakt door B-
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cellen kunnen dan ook behandeld worden met rituximab. Echter, merkwaardigerwijs heeft 
rituximab ook een gunstig effect op sommige T-cel gemedieerde auto-immuunziekten zoals 
multiple sclerose (28). Ook de werkzaamheid van rituximab bij patiënten met reumatoïde 
artritis roept vragen op, immers er is geen effect van rituximab op de ziektegeassocieerde 
autoantilichamen en het gunstige effect treedt veel sneller op dan wat men zou 
verwachten bij het verdwijnen van autoantilichamen (29). Gezien het feit dat Thl7 cellen 
een prominente rol spelen in de Pathogenese van zowel multiple sclerose als reumatoïde 
artritis (30), formuleerden we de hypothese dat B-cellen een rol spelen bij de regulatie van 
de Th 17 reactie. Deze hypothese is uitgewerkt en bestudeerd in hoofdstuk 15. Twaalf 
patiënten met reumatoïde artritis werden behandeld met rituximab. De behandeling 
resulteerde in een efficiënte B-cel depletie en leidde tot een klinische verbetering bij deze 
patiënten. Vóór en 12 weken na de behandeling werden synoviale biopten genomen uit 
aangedane kniegewrichten. De Thl7 reactie in de aangedane gewrichten in deze patiënten 
was na behandeling met rituximab minder. Vervolgens stelden we ons de vraag of rituximab 
de Thl7 reactie specifiek remt of dat het meerdere T-cel reacties beïnvloed. We konden 
geen effect vinden van rituximab op Thl of Treg reacties. Bovendien vonden we geen effect 
op TN Fa, wat aangeeft dat de klinische verbetering niet te wijten was aan een verminderde 
TNFa productie. Om een beter begrip te krijgen hoe rituximab de Thl7 reactie remt hebben 
we een in-vitro model gebruikt met C. albicans stimulaties. Cellen die gestimuleerd werden 
met C. albicans produceerden aanzienlijk minder IL-17 en IL-22 als rituximab werd 
toegevoegd aan het kweekmedium. Wij hebben vervolgens de mogelijkheid overwogen dat 
rituximab rechtstreeks de Th 17 cellen zou kunnen depleteren, omdat er is gerapporteerd dat 
sommige T-cel subsets CD20 tot expressie kunnen brengen (31). Wij konden echter geen 
CD20 expressie op T-cellen aantonen die ook IL-17 produceerden. Bovendien vonden we dat 
rituximab geen effect had op de Thl7 reactie in cellen die geïsoleerd werden van patiënten 
met een X-linked agammaglobulinemie (deze patiënten hebben geen naiëve en geen mature 
B-cellen). Dit ondersteunt de hypothese dat het effect van rituximab op TH17 ectivatie toch 
verloopt via een direct effect op B-cellen. Concluderend beschrijft deze studie een rol voor 
B-cellen in de regulatie van de Thl7 reactie. Hiermee kan worden verklaard waarom 
rituximab effectief is in patiënten met multiple sclerose en reumatoïde artritis. Onze 
bevindingen kunnen belangrijke gevolgen hebben voor de ontwikkeling, het onderzoek en 
de behandeling van Th 17 gemedieerde ziekten. 
Patiënten met het hyper IgE syndroom (HIES; Job syndroom) zijn bijzonder gevoelig voor 
infecties met Candida albicans en Staphylococcus aureus (32). Het is beschreven dat circa 
60% van de HIES patiënten mutaties hebben in het STAT3 gen met als gevolg daarvan een 
deficiënte Th 17 reactie (33). In hoofdstuk 16 beschrijven we drie HIES patiënten afkomstig 
uit één gezin. Zij hebben allemaal dezelfde STAT3 mutatie in het linker-domein en hebben 
een fenotype dat interessant genoeg verschilt van dat bij patiënten met een sporadisch HIES. 
Het meest opvallende verschil is dat, in tegenstelling tot vrijwel alle andere HIES patiënten, 
onze patiënten niet extra vatbaar zijn voor 5. aureus longontstekingen (34). We vonden dat 
de cellen van HIES patiënten met een linker-domein mutatie weldegelijk IL-17 produceerden 
als ze gestimuleerd werden met S. aureus, terwijl de cellen van patiënten met een 
sporadisch HIES absoluut geen IL-17 produceerden (33). Deze gegevens suggereren dat de 
IL-17 respons bijzonder belangrijk is voor de afweer tegen 5. aureus op het niveau van 
longepitheel. De cellen van alle HIES patiënten die ook een mucocutane candidiasis hadden, 
vertoonden ook een defecte IL-17 productie na stimulatie met C. albicans. Dit benadrukt de 
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belangrijke beschermende rol van de Thl7 reactie in de afweer tegen mucosale Candida 
infecties. Deze studies suggereren verder dat verschillende STAT3 mutaties kunnen 
resulteren in verschillende klinische karakteristieken. Een interessante bevinding was dat de 
cellen met een mutatie in het linker-domein van STAT3 een normale intracellulaire productie 
van IL-17 lieten zien na mitogene stimulatie (aangetoond door FACS analyse), hoewel in de 
supernatanten duidelijk lagere concentraties IL-17 werden gevonden na mitogene 
stimulatie. Concluderend suggereert deze studie een directe relatie tussen de mate van 
Thl7 deficiëntie en de ernst van het klinische beeld bij patiënten met het hyper IgE 
syndroom en geeft ze aan dat IL-17 essentieel is voor de afweer tegen een S. aureus 
pneumonie. 
In hoofdstuk 17 hebben we aangetoond dat autosomaal dominant chronische mucocutane 
candidiasis (AD-CMC) veroorzaakt wordt door mutaties in het CC domein van het STATI gen. 
We hebben gevonden dat T-cellen van patiënten met CMC nauwelijks in staat zijn om 
karakteristieke Thl en Thl7 cytokinen te produceren als ze gestimuleerd worden met 
Candida. In deze cellen bleek er tevens een gestoorde respons te bestaan op de cytokinen IL-
12 en IL-23. Met next-generation sequencing analyseerden we de genen van de moleculen 
die gedeeld worden door de IL-12 en IL-23 signaalroutes en de genen die betrokken zijn bij 
de differentiatie van de Thl7 reactie. Alle patiënten van de 5 AD-CMC gezinnen afkomstig uit 
Nederland en Engeland hadden een mutatie in het CC domein van STATI, terwijl er geen 
mutaties werden gevonden in de niet aangedane broers en zussen en in 162 gezonde 
controles. Drie families droegen de A267V mutatie (een Nederlandse en twee Engelse 
families), en twee gezinnen droegen de R274W mutatie (een Nederlandse en een Engelse). 
De patiënten met een A267V mutatie bleken ook orale en oesofagale tumoren te hebben, 
wat wijst op een rol voor STATI in de Pathogenese van orale en oesofagale carcinomen. Dit 
is in overeenstemming met eerdere studies die hebben laten zien dat STATI gebreken 
geassocieerd zijn met slokdarmcarcinoom. Patiënten met een R274W mutatie hadden 
daarentegen geen carcinomen, maar een auto-immuun hepatitis of een auto-immuun 
hemolytische anemie. De rol van STATI in de Pathogenese van orale en slokdarmcarcinomen 
en auto-immuunziekten verdient nader onderzoek. Dit onderzoek toont aan dat next 
generation sequencing in combinatie met goed ontworpen functionele studies de potentie 
heeft om de Pathogenese van erfelijke ziekten op te helderen. 
Het is niet waarschijnlijk dat de huidige behandelmogelijkheden de morbiditeit van 
mucosale Candida infecties en de hoge sterftecijfers van systemische candidiasis nog verder 
zal doen afnemen. Het is dus nodig om nieuwe therapeutische strategieën te ontwikkelen 
om Candida infecties te bestrijden. In hoofdstuk 18 beschrijven we de huidige studies die 
hebben bijgedragen aan de ontwikkeling van vaccinatie, therapeutische antistoffen, cytokine 
therapieën als behandelingsopties voor Candida infecties. Deze benaderingen zijn allen 
veelbelovend, maar de effectiviteit en veiligheid van deze behandelmethoden moeten nog 
worden aangetoond. Ook beschrijven we dat als we immunomodulatoire therapieën willen 
ontwikkelen het noodzakelijk is om controverses aan te pakken, zoals bijvoorbeeld de rol 
van de Thl7 reactie tijdens schimmelinfecties. 
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Algemene conclusies 
Door de mechanismen te ontrafelen die ten grondslag liggen aan de vatbaarheid voor 
Candida infecties kunnen we nieuwe strategieën ontwikkelen die kunnen leiden tot een 
vermindering van de morbiditeit en mortaliteit van Candida infecties. De experimenten 
uitgevoerd in dit proefschrift hebben een bescheiden bijdrage kunnen leveren aan het 
omvangrijke en dynamische veld van immunologisch onderzoek. Vele uitdagingen liggen nog 
voor ons, waaronder bijvoorbeeld het begrijpen van de moleculaire mechanismen waardoor 
mutaties in het CC domein van STATI leiden tot Thl en Thl7 deficiëntie in autosomaal 
dominante chronische mucocutane candidiasis, of de reden waarom een patiënt met 
chronische granulomateuze ziekte vooral gevoelig is voor een Aspergillus infectie. 
De rol van het afweersysteem strekt zich uit tot vrijwel elk gebied van de medische 
wetenschap. Door de kennis van de verschillende gebieden van onderzoek te combineren, 
kunnen we een beter begrip krijgen van het afweersysteem en haar onbekende functies. Dit 
zal ons helpen bij de ontwikkeling van nieuwe strategieën die afweerreacties kunnen 
moduleren, zodat we in de toekomst beschikken over betere behandelingopties voor 
infecties in het algemeen en schimmelinfecties in het bijzonder. 
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Stellingen behorend bij het Proefschrift: 
The interplay between innate 
immunity and Thl7 responses 
in Candida infection 
1. Autosomaal dominante chronische mucocutane candidiasis wordt veroorzaakt door 
een mutatie in het CC domain van het STATI gen. 
2. Zuurstofradicalen hebben ook een anti-inflammatoire functie, wat betekent dat anti-
oxidanten met alleen onstekingsremmend werken zoals algemeen wordt 
aangenomen, maar juist kunnen bijdragen aan een schadelijke ontstekingsreactie. 
3. De Th l7 afweerreactie is essentieel voor de bescherming tegen mucocutane 
candidiasis en Staphyloccoccus aureus pneumonie. 
4. Candida albicans en S. aureus induceren een zeer uitgesproken Th l7 afweerreactie. 
5. De Th l7 afweerreactie wordt met name geïnduceerd door glycoprotemen die 
worden herkend door mannose bindende receptoren zoals de mannose receptor. 
6. NSAIDs werken in ontstekingsziekten zoals reumatoi'de artritis doordat ze de Th l7 
reactie onderdrukken. 
7. B-cellen spelen een belangrijke rol m het onderhouden van een pathologische Th l7 
respons. 
8. "Word geen archivarissen van feiten. Tracht hun ontstaan te doorgronden Zoek 
hardnekkig hun wetten." 
Ivan Petrovich Pavlov (1849-1936) 
9. "Het is een teken van een geschoolde geest als iemand kan nadenken over een 
gedachte zonder ze te aanvaarden." 
Aristoteles (384-322 v.C.) 
10. "Fantasie is belangrijker dan kennis." 
Albert Einstein (1879-1955) 
Frank Leo van de Veerdonk 



